<SEC-DOCUMENT>0000939767-20-000117.txt : 20200806
<SEC-HEADER>0000939767-20-000117.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806161354
ACCESSION NUMBER:		0000939767-20-000117
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20200703
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		201081783

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel2020063010-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:a6c929e163f444efba35cbf466b1e412,x:53788ab9a236433fb9ebe804a38a3e73-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:sheci="http://fasb.org/stm/sheci/2020-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2020-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2020-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2020-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2020-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2020-01-31" xmlns:equity="http://fasb.org/dis/equity/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ides="http://fasb.org/dis/ides/2020-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2020-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2020-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2020-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2020-01-31" xmlns:ei="http://fasb.org/dis/ei/2020-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2020-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2020-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2020-01-31" xmlns:srt-all="http://fasb.org/srt-all/2020-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2020-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2020-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2020-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2020-01-31" xmlns:se="http://fasb.org/dis/se/2020-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2020-01-31" xmlns:hco="http://fasb.org/dis/hco/2020-01-31" xmlns:soi="http://fasb.org/stm/soi/2020-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2020-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:debt="http://fasb.org/dis/debt/2020-01-31" xmlns:spc="http://fasb.org/stm/spc/2020-01-31" xmlns:ts="http://fasb.org/dis/ts/2020-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:rd="http://fasb.org/dis/rd/2020-01-31" xmlns:sr="http://fasb.org/dis/sr/2020-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2020-01-31" xmlns:guar="http://fasb.org/dis/guar/2020-01-31" xmlns:te="http://fasb.org/dis/te/2020-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:ni="http://fasb.org/dis/ni/2020-01-31" xmlns:dr="http://fasb.org/dis/dr/2020-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2020-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2020-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2020-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2020-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2020-01-31" xmlns:iago="http://fasb.org/dis/iago/2020-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2020-01-31" xmlns:con="http://fasb.org/dis/con/2020-01-31" xmlns:leas="http://fasb.org/dis/leas/2020-01-31" xmlns:com="http://fasb.org/stm/com/2020-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:inv="http://fasb.org/dis/inv/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2020-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2020-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2020-01-31" xmlns:oi="http://fasb.org/dis/oi/2020-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2020-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2020-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:cn-part="http://fasb.org/cn-part/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2020-01-31" xmlns:srt-std="http://fasb.org/srt-std/2020-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2020-01-31" xmlns:exel="http://www.exelixis.com/20200703" xmlns:re="http://fasb.org/dis/re/2020-01-31" xmlns:ir="http://fasb.org/dis/ir/2020-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2020-01-31" xmlns:soc="http://fasb.org/stm/soc/2020-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2020-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2020-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2020-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2020-01-31" xmlns:regop="http://fasb.org/dis/regop/2020-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2020-01-31" xmlns:ero="http://fasb.org/dis/ero/2020-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2020-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2020-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invco="http://fasb.org/dis/invco/2020-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2020-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2020-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2020-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2020-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2020-01-31" xmlns:aro="http://fasb.org/dis/aro/2020-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2020-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2020-01-31" xmlns:pay="http://fasb.org/dis/pay/2020-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2020-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2020-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2020-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2020-01-31" xmlns:eps="http://fasb.org/dis/eps/2020-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2020-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2020-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:crcrb="http://fasb.org/dis/crcrb/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2020-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2020-01-31" xmlns:lea="http://fasb.org/dis/lea/2020-01-31" xmlns:disops="http://fasb.org/dis/disops/2020-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2020-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2020-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2020-01-31" xmlns:nt="http://fasb.org/dis/nt/2020-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2020-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2020-01-31" xmlns:cce="http://fasb.org/dis/cce/2020-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2020-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2020-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2020-01-31" xmlns:acec="http://fasb.org/dis/acec/2020-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2020-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2020-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2020-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2020-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2020-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2020-01-31" xmlns:ru="http://fasb.org/dis/ru/2020-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2020-01-31" xmlns:foct="http://fasb.org/dis/foct/2020-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2020-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2020-01-31" xmlns:diha="http://fasb.org/dis/diha/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ap="http://fasb.org/dis/ap/2020-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:eui="http://fasb.org/dis/eui/2020-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:AmendmentFlag" id="Fact-592E148DB114A4BF026875FEE663A3D4-wk-Fact-592E148DB114A4BF026875FEE663A3D4" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-F06B931E75A14DD9818175FEE665E619-wk-Fact-F06B931E75A14DD9818175FEE665E619">--01-01</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-C04FCB626909C01E918875FEE663099A-wk-Fact-C04FCB626909C01E918875FEE663099A">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-A520564214F93E2E9F9275FEE664A22F-wk-Fact-A520564214F93E2E9F9275FEE664A22F">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-6BEF72363DD68747445375FEE66423AB-wk-Fact-6BEF72363DD68747445375FEE66423AB">0000939767</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" name="exel:MilestonePaymentsEarned" id="Fact-1DC56B6E8A351A0D24959691F738C998-wk-Fact-1DC56B6E8A351A0D24959691F738C998">18800000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" name="exel:MilestonePaymentsEarned" id="Fact-9DCE220A5A7F32CAB42196950977587E-wk-Fact-9DCE220A5A7F32CAB42196950977587E">23700000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-0C2FC794B7FA54E6F10275FEE6CFC241-wk-Fact-0C2FC794B7FA54E6F10275FEE6CFC241">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-5F64ABF82B7B30D622B575FEE6D28F65-wk-Fact-5F64ABF82B7B30D622B575FEE6D28F65">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-27AA9CB174B894767F9B75FEE6D0BF6F-wk-Fact-27AA9CB174B894767F9B75FEE6D0BF6F">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:CommonStockSharesAuthorized" id="Fact-268D10173B1BC33A61B775FEE6D24EC4-wk-Fact-268D10173B1BC33A61B775FEE6D24EC4">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-7A3DF061F3DB6F0EEF9F75FEE6D28DB9-wk-Fact-7A3DF061F3DB6F0EEF9F75FEE6D28DB9">304830706</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:CommonStockSharesIssued" id="Fact-E83BBD97B5576D19DE8475FEE6D0D7A2-wk-Fact-E83BBD97B5576D19DE8475FEE6D0D7A2">308886497</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-BC7624A493AD84016F9375FEE6CFA59F-wk-Fact-BC7624A493AD84016F9375FEE6CFA59F">304830706</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:CommonStockSharesOutstanding" id="Fact-0139DB16EC1BFA5056C175FEE6CE9520-wk-Fact-0139DB16EC1BFA5056C175FEE6CE9520">308886497</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2019Q2" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" id="Fact-3BBAC7B5E97D7505FF5E75FEE6D277FF-wk-Fact-3BBAC7B5E97D7505FF5E75FEE6D277FF">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-0D4C66312D469C8D741B75FEE6AE816D-wk-Fact-0D4C66312D469C8D741B75FEE6AE816D">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-442F61FE2B6FD5F7A68E75FEE672BB2D-wk-Fact-442F61FE2B6FD5F7A68E75FEE672BB2D">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q2QTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-1DBEF0613D1F9BBE22D075FEE6AA8D96-wk-Fact-1DBEF0613D1F9BBE22D075FEE6AA8D96">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-25C049D332909F59612675FEE6B7C23B-wk-Fact-25C049D332909F59612675FEE6B7C23B">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-80922E0FCC45C412175275FEE6A3F3C7-wk-Fact-80922E0FCC45C412175275FEE6A3F3C7">807000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-252CB8EF23D111C2926C9EFFDCD6066F-wk-Fact-252CB8EF23D111C2926C9EFFDCD6066F">413000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q2QTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-2732A943E99E432B688F75FEE6A3CDC9-wk-Fact-2732A943E99E432B688F75FEE6A3CDC9">1346000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q2YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-94ADE9270AE804525B1F75FEE66B0396-wk-Fact-94ADE9270AE804525B1F75FEE66B0396">2287000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-EDC2064FF1A46874E63E75FEE6D2CBFC-wk-Fact-EDC2064FF1A46874E63E75FEE6D2CBFC">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q2" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-11D3BE69EAEA4A93760C75FEE6D110A5-wk-Fact-11D3BE69EAEA4A93760C75FEE6D110A5">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-0E0E8B73370B39E5BEF575FEE6CED4AE-wk-Fact-0E0E8B73370B39E5BEF575FEE6CED4AE">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-F08091ECA925E51FEE2A75FEE6D266AB-wk-Fact-F08091ECA925E51FEE2A75FEE6D266AB">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-11BC3626CAF4F609F70D75FEE6CEE164-wk-Fact-11BC3626CAF4F609F70D75FEE6CEE164">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q2" name="us-gaap:PreferredStockSharesIssued" id="Fact-D16D710714A5464E7F6075FEE6D3D9B8-wk-Fact-D16D710714A5464E7F6075FEE6D3D9B8">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="exel-20200703.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:NewInformationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:NewInformationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-04-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_MajorCustomersAxis_exel_TakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MunicipalBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q2May20-May20">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-05-20</xbrli:startDate>
			<xbrli:endDate>2020-05-20</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-07-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-04-04</xbrli:startDate>
			<xbrli:endDate>2020-07-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="sA8536B80A6815B22AB8036898F685555"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:20px;text-align:left;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><span style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:266px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:133px;"></td><td style="width:133px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:right;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e417-wk-Fact-97A378DA99D33CBF574975FEE6C99C7C" name="dei:DocumentType" contextRef="FD2020Q2YTD">10-Q</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d682038e432-wk-Fact-8153E32E4695622263D875FEE6B79D6E" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">For the quarterly period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d682038e443-wk-Fact-F04EFFCBC4E1410E26E575FEE6B82387" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q2YTD" format="ixt:datemonthdayyearen">July 3, 2020</ix:nonNumeric></span></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">or</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d682038e463-wk-Fact-16B6CAC910788EA9CC1875FEE6980BA5" name="dei:DocumentTransitionReport" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d682038e473-wk-Fact-43D6C66160FB22FEA8A375FEE6890E3D" name="dei:EntityFileNumber" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;">000-30235</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:267px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:266px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo19q4a03.jpg" alt="exellogo19q4a03.jpg" style="height:64px;width:188px;"></img></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e495-wk-Fact-509928AF09A5FD9B1E3575FEE6AC3EDA" name="dei:EntityRegistrantName" contextRef="FD2020Q2YTD">EXELIXIS, INC.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e516-wk-Fact-A8A23BC723E01347380675FEE6D3B50A" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e521-wk-Fact-F689D07F834BFEE36CC975FEE6D3F6E1" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q2YTD">04-3257395</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(I.R.S. Employer Identification Number)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d682038e536-wk-Fact-51389F73B2BE1F8C6AAA75FEE67835CB" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">1851 Harbor Bay Parkway</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d682038e542-wk-Fact-DFF7BCA75BDB92E5D5CB75FEE6895C3B" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">Alameda,</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d682038e547-wk-Fact-38ECDA7B2C4777A6774F75FEE68E8EF5" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">CA</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d682038e552-wk-Fact-673E1D5F9724DFC6FF9E75FEE692181E" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">94502</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d682038e560-wk-Fact-FF4D3253E0698EF9F7B275FEE6B9BC85" name="dei:CityAreaCode" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">650</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d682038e565-wk-Fact-51BD7D0936C139A2020575FEE6BADD09" name="dei:LocalPhoneNumber" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">837-7000</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e606-wk-Fact-0369FC7F4F51AB35A89275FEE6C80220" name="dei:Security12bTitle" contextRef="FD2020Q2YTD">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e611-wk-Fact-517F6D14AB7E4E1E4C9175FEE6CA274B" name="dei:TradingSymbol" contextRef="FD2020Q2YTD">EXEL</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d682038e616-wk-Fact-B6F2AF48762C029F9C7675FEE6C85672" name="dei:SecurityExchangeName" contextRef="FD2020Q2YTD" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d682038e621-wk-Fact-1ECFF1A3F9967DCA52AC75FEE66A27F9" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d682038e635-wk-Fact-A50608FCA16FDE1F7DE375FEE6741497" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q2YTD"><span style="font-family:Calibri,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:26%;"></td><td style="width:4%;"></td><td style="width:20%;"></td><td style="width:27%;"></td><td style="width:3%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d682038e666-wk-Fact-AF41EFCDD72FE9B8998575FEE6B23103" name="dei:EntityFilerCategory" contextRef="FD2020Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d682038e717-wk-Fact-17AD38345726C198B73075FEE6B4F8EB" name="dei:EntitySmallBusiness" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d682038e733-wk-Fact-E94D7EA43E6BB0D20E7175FEE6B28DCE" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="font-family:Wingdings;font-size:10pt;">&#168;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d682038e764-wk-Fact-DA7EE7D81F61B2381A7075FEE670BAC3" name="dei:EntityShellCompany" contextRef="FD2020Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Wingdings;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;27, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d682038e780-wk-Fact-F9C6A1B6D1DC8ABD99A675FEE679D497" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2SharesOutstanding" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">308,995,819</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> shares of the registrant&#8217;s common stock outstanding. </span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sF49F8B6BF5635F81B9FD2CEB87EDF574"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s7EBF203EBA1C5AF386EF7D87CABA2D6B"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4E98CA0431705BB3A65336C0D1C78091"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4E98CA0431705BB3A65336C0D1C78091">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sEC3E41F8A1615F9094881CB6706C7ACC"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sEC3E41F8A1615F9094881CB6706C7ACC">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s960AA3BA85B855749A5B2A38A63643EF"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s960AA3BA85B855749A5B2A38A63643EF">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s13104C7D2611558AA5AA1F793AE2D2D3"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s13104C7D2611558AA5AA1F793AE2D2D3">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s02E228238C4A532FA8B0C36A12CB75D0"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s02E228238C4A532FA8B0C36A12CB75D0">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA34EDCEC197D51609FCBCDD863C886FC"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA34EDCEC197D51609FCBCDD863C886FC">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s863ABBC44F445EC6AD8BA33302186D70"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s863ABBC44F445EC6AD8BA33302186D70">8</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDE37327891A25A749DDCCEC2A4484EB0"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sDE37327891A25A749DDCCEC2A4484EB0">21</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s28E46A8B3EE9540189D98C957B5BEA51"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s28E46A8B3EE9540189D98C957B5BEA51">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s72B09ECCF6C6515EA9D64C7052618B30"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s72B09ECCF6C6515EA9D64C7052618B30">34</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sD3A0A824FF935F609BE2193A557D4794"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s583792048820564688F3B7727DC8A98B"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s583792048820564688F3B7727DC8A98B">35</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6E97F3A039435CF89644389568E05D92"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6E97F3A039435CF89644389568E05D92">35</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#se4ab3b2c975b48029eb5107107673971"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#se4ab3b2c975b48029eb5107107673971">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1fdf5d4fa34246199955d4e9db9b0a45"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1fdf5d4fa34246199955d4e9db9b0a45">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s914950cc57a84ff194e17745a51df2cf"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s914950cc57a84ff194e17745a51df2cf">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 5.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s127dad8d4c694cfa9e003cf6266c1295"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s127dad8d4c694cfa9e003cf6266c1295">57</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4BA46924F56D52F8943EEF35D81ABC31"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s4BA46924F56D52F8943EEF35D81ABC31">57</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s21AED4B1279A5ED499174A853CCAE9BE"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7EBF203EBA1C5AF386EF7D87CABA2D6B"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I - FINANCIAL INFORMATION</span></div><div><a id="s4E98CA0431705BB3A65336C0D1C78091"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> Item 1. Financial Statements</span></div><div><a id="sEC3E41F8A1615F9094881CB6706C7ACC"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e555-wk-Fact-A1BC98B7EF7C3CEC321D75FEE6A61235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">527,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e574-wk-Fact-7FE412FB8DEB8D023E2A75FEE68E25BF" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e589-wk-Fact-8EA9C968D0775E56EE9075FEE6AA88F7" name="us-gaap:ShortTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">685,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e608-wk-Fact-7D70645D98D7DF24306575FEE6A71499" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">585,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e628-wk-Fact-726D61C5B7AA39AF4F6C75FEE6983988" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">121,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e647-wk-Fact-D267F154A2367000C44B75FEE69B3AE6" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e667-wk-Fact-9E0ACE578A8CAFF5511075FEE69718F6" name="us-gaap:InventoryNet" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e686-wk-Fact-659D1063D874253CF9C775FEE6AAEA01" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e706-wk-Fact-9BEBE9EB865DA7731A9375FEE68F2F95" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e725-wk-Fact-33CB26723913E330830A75FEE6917841" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e745-wk-Fact-A56525C631E2A9DE7B6075FEE6992BD1" name="us-gaap:AssetsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,394,663</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e764-wk-Fact-962916F4D3A05E28A5FA75FEE6A6CBD2" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,011,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e784-wk-Fact-E99F48EF214B6EDB2D2775FEE694C2D2" name="us-gaap:LongTermInvestments" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">327,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e803-wk-Fact-123709BDA93A763239AD75FEE693F4F9" name="us-gaap:LongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">536,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e823-wk-Fact-3F16181B17AC2617D95B75FEE6A99C7E" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e842-wk-Fact-126DA19DE7968DD6BB4075FEE6968C69" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e863-wk-Fact-0017258F1EF9928801C375FEE6AE8AAD" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">148,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e882-wk-Fact-391D35AC6B9749C9457475FEE696F7C0" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e902-wk-Fact-EBEB69FCDD20547F03BA75FEE68E4EA3" name="us-gaap:Goodwill" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e921-wk-Fact-3031808366C2A59AB31775FEE69A3A6A" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e941-wk-Fact-056CE590EDDF7FA621F175FEE69849CD" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e960-wk-Fact-F6F6250876E1F16C133775FEE6A9439A" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e985-wk-Fact-1E08E820C252EE2AE0DA75FEE694B2FE" name="us-gaap:Assets" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,046,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1004-wk-Fact-324C8C7F81D535E8DCC375FEE6AB36BB" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,885,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1106-wk-Fact-3760C39ED3F86A42220175FEE68F448F" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1125-wk-Fact-37A7A0834A4B2442D5F475FEE6962BCD" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1140-wk-Fact-423BB5F65BBAA6C0633F75FEE69407F7" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1159-wk-Fact-484B2F7FFDD6045C957375FEE6AD3784" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1179-wk-Fact-EA22433E5A4FF56702B375FEE698AA64" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1198-wk-Fact-69E7B0F63573AC62CCB575FEE6AB53AE" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,777</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1218-wk-Fact-DD643177FF5977EB8F4E75FEE6913792" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,957</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1237-wk-Fact-21659537ED2F6B51D33C75FEE6A57CE0" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1257-wk-Fact-7A70E94CB4F70781F48875FEE69BC2A5" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1276-wk-Fact-E82A53BC12F4E0C7BF4275FEE6A33354" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1297-wk-Fact-838E447ACDB39F68B25275FEE68DE7E8" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,830</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1316-wk-Fact-00C652C57F4B0234EF6375FEE68C2456" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,449</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1336-wk-Fact-3B1997B750DF626E721C75FEE6990A5B" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1355-wk-Fact-946863AD77AC67770FF475FEE69C4294" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">142,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1375-wk-Fact-A93B787849B3E949D31F75FEE6940F9B" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1394-wk-Fact-6C8B22B96953215DDA0575FEE68C322B" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1414-wk-Fact-11EA854E2FC2A219A9C075FEE6962530" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1433-wk-Fact-CFA81AE458A42D0DB1DC75FEE6ACE3DD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1453-wk-Fact-B4E38DA5FC452561B80D75FEE6925F37" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1472-wk-Fact-85F9A7631F241144FCBB75FEE6A465A9" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1492-wk-Fact-F20AF102F9BF9F1120E075FEE6951E4E" name="us-gaap:Liabilities" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">213,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1511-wk-Fact-A852081931270495BA6875FEE696A711" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">199,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments and contingencies</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1531-wk-Fact-E9A8755E38B85F07B2C275FEE69ABD66" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q2" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1550-wk-Fact-3A18043265814EC1383375FEE6A1D0E5" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1611-wk-Fact-D566DAEA28C18D00B8D875FEE6A40F8E" name="us-gaap:PreferredStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1630-wk-Fact-E41C41AC20D42CB61D3575FEE6995EE3" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 308,886 and 304,831 at June 30, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1650-wk-Fact-6EB798595AE963D0B77575FEE6AC0917" name="us-gaap:CommonStockValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1669-wk-Fact-D84C1D33D7080277100D75FEE6A72524" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1689-wk-Fact-A675F4CB2955238197AB75FEE6A354DA" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,093</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1708-wk-Fact-63723B8BA9AA57909FB575FEE695A57E" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,241,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1729-wk-Fact-661E9F47367FD7AAB72975FEE690C909" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1748-wk-Fact-68D0EA26568360F9C02175FEE68AF2D1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d657361e1768-wk-Fact-74DB45FBA64E3D67553A75FEE6A22C3A" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">443,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d657361e1788-wk-Fact-15708CD2EF4E8CA781F275FEE6A8EECC" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">559,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1809-wk-Fact-405EB66828E2E3705C8975FEE68FA624" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1828-wk-Fact-7276C7CE657618237BF775FEE68C3A2B" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,685,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1853-wk-Fact-7F8719D4C919EFEB115675FEE6925125" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,046,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d657361e1872-wk-Fact-F74093144AF9AFE4866A75FEE6998805" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,885,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s960AA3BA85B855749A5B2A38A63643EF"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e684-wk-Fact-5A2214FE83685521E13275FEE66421F4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">178,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e703-wk-Fact-A72FA94CFA55F8922B2275FEE6756D0F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e722-wk-Fact-097C78DB144C18F7259275FEE691AFDD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">372,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e742-wk-Fact-699B1F7B1BA2FDD648FF75FEE68E5EDB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e757-wk-Fact-6497319F83CC3DF3C90C75FEE69CD50C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e776-wk-Fact-47C49EFE5D0D56E8685575FEE6630E63" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e795-wk-Fact-DB9618FDB1571E3C9A6C75FEE68A0242" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e815-wk-Fact-6128661D81D66A5B5C9375FEE6974202" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e835-wk-Fact-9B99F65872BA5239ABE07602BC70F963" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e854-wk-Fact-899A8C5BB40BE0001A397602BC1564A1" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e873-wk-Fact-FABE9E85A8ECD171D56A75FEE69330AA" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e893-wk-Fact-C4E1C3CC83C7DDABA2EF75FEE6927942" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e913-wk-Fact-44B7BE6FB321312F7E7D75FEE669CD36" name="us-gaap:Revenues" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e932-wk-Fact-3EFFF6A6BFF3B9030C2D75FEE6D03440" name="us-gaap:Revenues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e951-wk-Fact-4696CD3398156FF3047675FEE6878468" name="us-gaap:Revenues" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e971-wk-Fact-6B39914FAAEB56AC401A75FEE696E280" name="us-gaap:Revenues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1073-wk-Fact-9E27F2A0808CC315799F75FEE6A7866E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1092-wk-Fact-8622BF1E05F752B317E875FEE682C9FE" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,539</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1111-wk-Fact-625C07FCFC01125B6CB975FEE68F2955" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1131-wk-Fact-E83356C41307BE58712675FEE6894674" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1151-wk-Fact-7333C5FA493FCB1F77FE75FEE691024D" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">114,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1170-wk-Fact-675F905CB9B96736DF2875FEE6788ECB" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1189-wk-Fact-DC501452596C90F137C975FEE696699F" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">216,810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1209-wk-Fact-08DEBC41F956C6CFBE0B75FEE68810BF" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1229-wk-Fact-B2FE5F35811885D0B6AA75FEE67AA348" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1248-wk-Fact-263A5B76D209799EFBEE75FEE6B38F88" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1267-wk-Fact-239AE749398E97D75FCB75FEE68C0B3E" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1287-wk-Fact-6641CBDBC3058A0F984F75FEE688BDB7" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1308-wk-Fact-3006363C2CE6A9500A0475FEE66DB08B" name="us-gaap:CostsAndExpenses" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">183,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1327-wk-Fact-CF49A044B7BA64FE1A4F75FEE6C496E3" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">148,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1346-wk-Fact-119BD0C532682CC94DE875FEE68B6007" name="us-gaap:CostsAndExpenses" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">358,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1366-wk-Fact-441EE5DFFB2EE984B69075FEE68CFE02" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">279,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1386-wk-Fact-68379E13562CC39B45A875FEE688B677" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">75,534</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1405-wk-Fact-A17BCD475B3923AC655F75FEE6B50AC6" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1424-wk-Fact-5EAE4C597C7E377BB7D175FEE6917C5F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1444-wk-Fact-880CD5AE7F89A9F25FE175FEE6939619" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">176,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1464-wk-Fact-785AF6D3969505B038D575FEE6851F86" name="us-gaap:InterestIncomeOther" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1483-wk-Fact-A72E29C8EE1E6CF96B4075FEE66A8B9E" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1502-wk-Fact-ECCA051934A25BD46C0775FEE692197B" name="us-gaap:InterestIncomeOther" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1522-wk-Fact-011C16CC181C6067369F75FEE693E65B" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other income, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1542-wk-Fact-AB2CE9FBEF99724C556375FEE69B1D5C" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1561-wk-Fact-0C7C873D2145DF3AC32F75FEE6981B00" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1580-wk-Fact-070975B94B0C319114B575FEE6929B67" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1600-wk-Fact-DBC663AB684CFF36214D75FEE68F2AA1" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1620-wk-Fact-FA3B7009E9448606CEEC75FEE697D8AF" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1639-wk-Fact-5DF3282E546998A3A03275FEE6935A9D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,767</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1658-wk-Fact-300C48E7FC43A080E26275FEE69486CB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1678-wk-Fact-5EFFB8AE52851F00A18E75FEE6981051" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">190,438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1698-wk-Fact-7F0D96BDAFFF1885BDB375FEE6833EE9" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1717-wk-Fact-F70908986042DF91E8DF75FEE665A45D" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1736-wk-Fact-21B7AB002913FBF6C5B275FEE69330CD" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1756-wk-Fact-6C6FDB6E21072B966BC675FEE6975173" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1781-wk-Fact-B487DD23D99A668528F075FEE69990CC" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1800-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1819-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1839-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1941-wk-Fact-F04F7BABEA56FDB5117F75FEE6AF18A3" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1960-wk-Fact-566FD1EE1C16BA6A763575FEE69BA939" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1979-wk-Fact-C28F37DC2381E7E89D3B75FEE6957C17" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e1999-wk-Fact-0CBBC6463637620FE6C375FEE6880911" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2019-wk-Fact-31596066A1892C4DB17575FEE6844845" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2038-wk-Fact-A98347421B831C365EB575FEE68DED9E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2057-wk-Fact-CEB696DF869A2F41037E75FEE68AADD1" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2077-wk-Fact-CAB85F7EB403C6F9822C75FEE69349E8" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2175-wk-Fact-59033765D73556484CE675FEE68A2255" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">307,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2194-wk-Fact-1927675C729F464ED63A75FEE6BA1013" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2213-wk-Fact-D67C673E55257A7E629B75FEE68DC8AD" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">306,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2233-wk-Fact-1B7FF6816B05CF8C6D3375FEE695C60A" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2253-wk-Fact-FDB4E707E9E9AEF20F9075FEE6B71B34" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">318,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2272-wk-Fact-AA49B4BBB4C251F3D89B75FEE6935051" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2291-wk-Fact-A5A35B7E2FE8BFD7BE9375FEE69113AE" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">316,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661138e2311-wk-Fact-FE1018EC5634CAFA582475FEE6978CD0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">      </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div><a id="s13104C7D2611558AA5AA1F793AE2D2D3"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e611-wk-Fact-B487DD23D99A668528F075FEE69990CC" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e630-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e649-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e669-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net unrealized gains on available-for-sale debt securities, net of tax impact of $2,287, $413, $1,346 and $807, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e766-wk-Fact-C325A05E25FA49873E8175FEE664573A" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e785-wk-Fact-F789BDB1F0539B01D15375FEE679B796" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e804-wk-Fact-305CBE1D5242A6DB460275FEE6681873" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e824-wk-Fact-BA446023B0360A29E07B75FEE669989C" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e849-wk-Fact-86AADDF31698EC3FFC6475FEE67A2EB5" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e868-wk-Fact-7324A1B2D18D7859833A75FEE668BB5E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e887-wk-Fact-298FC67CD0C2D4AB5DFD75FEE668EBDB" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d686239e907-wk-Fact-6F8F6A5AF21ED8F0D88475FEE668208E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s02E228238C4A532FA8B0C36A12CB75D0"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Three Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e795-wk-Fact-B4C0B679A7B7426455FDB659D0305744" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">305,780</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e814-wk-Fact-0C8B8C5BFEB941225EEEB659D19D5726" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e833-wk-Fact-C0BB75657B31AD2FD51DB659D31D457B" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,258,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e853-wk-Fact-B9597F3572FAE2D4A0D7B659D48AF7EA" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e873-wk-Fact-D806E132FA81CAC6D16CB659D60BC94B" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">510,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e893-wk-Fact-258819F3C2722FAFFCA1B659D779C447" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,747,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e981-wk-Fact-56BD2266AFDAAFAA478BB65B0D3D77B1" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1000-wk-Fact-B487DD23D99A668528F075FEE69990CC" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1074-wk-Fact-6D1AE06B475D91D6F8B9B65B1250532B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1112-wk-Fact-D1FDA48D752AC68F0DC4B65B14B969C2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1133-wk-Fact-9F25E308761044CBBBDCB65B15605A82" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1147-wk-Fact-B38294F59DC3F293888BB65B16DE8BEE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1166-wk-Fact-C2B5455AC650ADD9F529B65B184D0369" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,780</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1224-wk-Fact-2115D271EA638DB7515DB65B1BC2C275" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock transactions associated with taxes withheld on equity awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1245-wk-Fact-4C8B44EA6DEEF1EADC7A9EE7CF212C1A" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1259-wk-Fact-8E1AD2F59669937AFF419EE7F873E437" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e1278-wk-Fact-009AC1632BBB135A97B99EE7F884A657" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e1337-wk-Fact-0C70DB5CD61A1E2C7B859EE7F85BDC5E" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1392-wk-Fact-0D9AE55490B5D4E8A9C4B65B1E5DB06A" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1450-wk-Fact-03625A2251369A11D339B65B21BD9796" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1471-wk-Fact-3D89C39D3A864657343775FEE6887E87" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">308,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1490-wk-Fact-FC5A742D21DEC7EE36F075FEE682BCA1" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1509-wk-Fact-7F3927A2BE560D1A923175FEE67A48E1" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,093</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1529-wk-Fact-E4281AB195516E124F8475FEE67A710A" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e1548-wk-Fact-DF3BD333F12A4B7156BE75FEE68A703A" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">443,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e1568-wk-Fact-405EB66828E2E3705C8975FEE68FA624" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e1970-wk-Fact-218D16037F1B3E8181E5B659FD3B7B9A" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e1989-wk-Fact-F56DCAA4B8574F43D935B659FEBB3339" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2008-wk-Fact-BA78C55E9180299F512BB65A0029FFE9" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,188,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2028-wk-Fact-511E863E0E7ADBEF2E92B65A01A7863B" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>(<ix:nonFraction id="d691634e2047-wk-Fact-70A348EA7E82AF20A00BB65A03168972" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">804,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2067-wk-Fact-41A07C2AC2CEA25D52F0B65A0498AF25" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,385,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2155-wk-Fact-3142823932FCE325C8D6B65B4A3C24D6" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2174-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2248-wk-Fact-B6E7E8A1CC192AEFC735B65B4F4186CF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2286-wk-Fact-BBE51ED4AA7E3E987220B65B51B9BF50" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2307-wk-Fact-35E2848AF6BA65E69C7EB65B5260DF32" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2321-wk-Fact-1E1377C11F37A4F5A5C9B65B53CF7278" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2340-wk-Fact-035C141CB9DA20C5DAF3B65B554F40C4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2398-wk-Fact-9D166AA500BDF049A144B65B58AFB3B6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock transactions associated with taxes withheld on equity awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e2419-wk-Fact-6CB68A99C8376082B1299EE7E2E716A2" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e2433-wk-Fact-485A07A121F13B53C29A9EE8193F55E0" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e2452-wk-Fact-357A548E93BDB23817BA9EE8193FD60B" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e2511-wk-Fact-49BBE17602BC9604D9149EE8193F720D" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2566-wk-Fact-AF05BF8F2FF8A5BB7D3BB65B5B4BFCA3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2624-wk-Fact-FFCA155468DA4C6FA5A3B65B5EC4E659" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2645-wk-Fact-E5115665AAAEDE9296E075FEE6B10BE8" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2664-wk-Fact-9B8AF0765E1D87F21B6975FEE6B8A98C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2683-wk-Fact-2A3D92C80FA735850DBC75FEE6AE3441" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,211,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2703-wk-Fact-EB9AB94CA6D92BF0BDD275FEE6B484D3" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>(<ix:nonFraction id="d691634e2722-wk-Fact-6306400E31582A2FED1C75FEE6B81248" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">725,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691634e2742-wk-Fact-1105B74DA3A2AD822BFD75FEE6B17D02" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Continued on next page</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional Paid-in Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Other Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total Stockholders&#8217; Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3158-wk-Fact-1C3B2610812AB3CE318775FEE681A350" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">304,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3177-wk-Fact-3D87CD4DE7CD8DBCD19675FEE6829032" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3196-wk-Fact-E577F76ED347B8629C3A75FEE688A9FD" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,241,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3216-wk-Fact-25E427EF73470D6CB0DC75FEE6867160" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e3235-wk-Fact-5BA18EF013E36644574275FEE687E145" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">559,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3255-wk-Fact-7276C7CE657618237BF775FEE68C3A2B" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,685,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3343-wk-Fact-B82192C24AC3A41B7E2E75FEE6897CC9" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3362-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3436-wk-Fact-02700DE730381EADD1D775FEE6855919" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3474-wk-Fact-A85282254684D990D90E75FEE686360A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3495-wk-Fact-B2DDE578212311C9D9C175FEE68543AD" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3509-wk-Fact-9B9C1BFBD4007AD78A9075FEE67CCD8A" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3528-wk-Fact-D7146D53383F37431B4F75FEE682D810" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3586-wk-Fact-05099D82C87FA23D3CA575FEE685C7B4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock transactions associated with taxes withheld on equity awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3607-wk-Fact-FA5F0ABE32011CB381509EE9217E0C01" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3621-wk-Fact-8A0C1FB852AD6BC30D939EE923664E65" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e3640-wk-Fact-E9FDBB9A72AFB14CFC679EE925602AE2" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e3699-wk-Fact-38F2389EA67A4125C4D79EE9293C2DE5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3754-wk-Fact-385EB6884712785BE5F175FEE678C668" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3812-wk-Fact-C54A906E7E2D8E17743875FEE684D8CD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3833-wk-Fact-3D89C39D3A864657343775FEE6887E87" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">308,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3852-wk-Fact-FC5A742D21DEC7EE36F075FEE682BCA1" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3871-wk-Fact-7F3927A2BE560D1A923175FEE67A48E1" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,093</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3891-wk-Fact-E4281AB195516E124F8475FEE67A710A" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e3910-wk-Fact-DF3BD333F12A4B7156BE75FEE68A703A" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">443,918</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e3930-wk-Fact-405EB66828E2E3705C8975FEE68FA624" name="us-gaap:StockholdersEquity" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional Paid-in Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Other Comprehensive Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total Stockholders&#8217; Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4332-wk-Fact-1BC96CA04031D1CFF45275FEE6AE9C13" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">299,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4351-wk-Fact-B234DBB445107B0D8A6175FEE6B4D7FE" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4370-wk-Fact-295FFE3155019E88E2E775FEE6B33867" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e4390-wk-Fact-BB2A01826E7DA494B81775FEE6B5D43F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e4410-wk-Fact-B57280CC7A1EED3D828575FEE6B6BA05" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4430-wk-Fact-E8B7D75A367A1A71EC2375FEE6B1AF5B" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4518-wk-Fact-AB75BED4FC69972EBC2375FEE6B66EB0" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4537-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4611-wk-Fact-4686E9A491BCAA41609D75FEE6B32C79" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4649-wk-Fact-541DC41C260972EFD16175FEE6B002C7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4670-wk-Fact-8236F8316BCD44CC6CCB75FEE6AF3E7A" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4684-wk-Fact-5AB4604EDB02A9FCE74975FEE6B4681E" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4703-wk-Fact-732AE455D54E231F72FF75FEE6AE8A1F" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4761-wk-Fact-0FA11B37558E207C03A375FEE6B03559" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock transactions associated with taxes withheld on equity awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4782-wk-Fact-125AEA6C263F523D62979EE9C43C541C" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4796-wk-Fact-71BE5E09C6C91EABF93E9EE9C626DE25" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e4815-wk-Fact-86709CE7D8D68FB725B09EE9C81C99E0" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e4874-wk-Fact-AA5C4579FD4719E85F8C9EE9CBFF0086" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4929-wk-Fact-B8B93AAF005A45CD366375FEE6B92BCF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e4987-wk-Fact-B37872B58E6399998EBB75FEE6B6C11B" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e5008-wk-Fact-E5115665AAAEDE9296E075FEE6B10BE8" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e5027-wk-Fact-9B8AF0765E1D87F21B6975FEE6B8A98C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e5046-wk-Fact-2A3D92C80FA735850DBC75FEE6AE3441" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,211,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e5066-wk-Fact-EB9AB94CA6D92BF0BDD275FEE6B484D3" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d691634e5085-wk-Fact-6306400E31582A2FED1C75FEE6B81248" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">725,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d691634e5105-wk-Fact-1105B74DA3A2AD822BFD75FEE6B17D02" name="us-gaap:StockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA34EDCEC197D51609FCBCDD863C886FC"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e513-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e532-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e588-wk-Fact-2867C45E0F7D32BA9A2275FEE6AD3B68" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e607-wk-Fact-72AE9A4E1ED39B055E0B75FEE6ADDF85" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e627-wk-Fact-84CD633465686252ABC975FEE6C49DF3" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e646-wk-Fact-EDCB7A8EEA52903BCB8875FEE6C33A78" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-cash lease expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e666-wk-Fact-B127A796D9184C3DDF4175FEE6B640DE" name="exel:NoncashLeaseExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e685-wk-Fact-B63118B38A666723131D75FEE6C770DF" name="exel:NoncashLeaseExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e705-wk-Fact-62E271D638856DD3B83375FEE6B0A894" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,793</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e724-wk-Fact-3E92D433FDDF4B1508EA75FEE6B4E3A6" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e744-wk-Fact-EA0357F0016266F1BC3D75FEE6B0C29B" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">726</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e763-wk-Fact-EB651914D0400B9C1F9875FEE6BAB97E" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e825-wk-Fact-681E3EB2D89B5788167A75FEE6BB7A93" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e845-wk-Fact-C81C1F12249EDCBF576075FEE6BD0135" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e866-wk-Fact-F2490184CE0585C2AA5F75FEE6B49A91" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e886-wk-Fact-AB4878DCC3FCE045CE5275FEE6B9F15B" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e907-wk-Fact-94C36D8D2BC2491A9F7775FEE6B2977B" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e927-wk-Fact-AD898E5268074456DB2475FEE6ABB86B" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e948-wk-Fact-F422F64CF4DB8271E99F75FEE6B51332" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e967-wk-Fact-EFF19C1CEB4A6FE2CE0075FEE6BA1922" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e987-wk-Fact-92906DE47483F15357E675FEE6B1BA2C" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1006-wk-Fact-06C348DE70749FEA6FDA75FEE6ADE1D3" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1026-wk-Fact-552353194C69765A7AD175FEE6C3D6AD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1045-wk-Fact-EA2EB4DFB70B0FF0773075FEE6B72986" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of property, equipment and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1106-wk-Fact-93080FAE74AE1DB9D2B575FEE6BA06AA" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1126-wk-Fact-6D5611278612A329A86A75FEE6B88077" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1147-wk-Fact-77804806D993831C079675FEE6B54562" name="us-gaap:PaymentsToAcquireInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">433,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1167-wk-Fact-11DB8924C128ED4887F775FEE6B8BDCC" name="us-gaap:PaymentsToAcquireInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">518,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from maturities and sales of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1188-wk-Fact-35C6563D3912C9A7707275FEE6AB016D" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">548,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1207-wk-Fact-F194CA637E6D4899AF4875FEE6C67FBC" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1227-wk-Fact-AD5A54CBBCB48DD2E61B75FEE6B33CC1" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,894</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1246-wk-Fact-F23066B63799EB104F5F75FEE6C41D77" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">250,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1309-wk-Fact-B3EFE5E5911E04384D7875FEE6AAE75A" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1328-wk-Fact-26123195C5ED29D9426775FEE6C213B4" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,735</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1348-wk-Fact-2E814D669175F3608CD375FEE6C53C2B" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1368-wk-Fact-9D0BB365892EC5B6BDE575FEE6BB6207" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1389-wk-Fact-8009644C420177F2B5C275FEE6AA88DB" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1408-wk-Fact-2276CAA793549BE3C4BE75FEE6B7B1A3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d661133e1429-wk-Fact-4471F5E935DEDFFF524775FEE6B9B10D" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1449-wk-Fact-D94EF118E322220ABEA575FEE6C37E05" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1469-wk-Fact-57544DA839DB28C3B3C375FEE6B90B9D" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">260,642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1488-wk-Fact-B7D88E01470A1E2B405D75FEE6B35EEF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1508-wk-Fact-8769E5B4758910A379EB75FEE6AF4BC1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1527-wk-Fact-60C7BA94A95E2D674C3075FEE6AFD6CE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1552-wk-Fact-894D15D3C93C47AB426A75FEE6B2B28C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d661133e1571-wk-Fact-E24C8F0479AF9D312D9C75FEE6C6CEF0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">370,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplemental cash flow disclosures:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661133e1632-wk-Fact-DCA8B3292C61567AC8A575FEE6B58F71" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661133e1651-wk-Fact-EE7BC74EF03E442D4A9875FEE6B0D0BA" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred for purchases of property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661133e1671-wk-Fact-FFE7FE04BA0A0478D98D75FEE6BCB3DA" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d661133e1690-wk-Fact-8911D45121336B390AE675FEE6ACF1F3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s863ABBC44F445EC6AD8BA33302186D70"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div><a id="sC91B084BC4D4598DA538C75AA3BDB724"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="TextSelection-E72D58CE998F817F398C75FEE6E37340-0-wk-Fact-FB8CF658B3E8F386A16975FEE67965A7" continuedAt="TextSelection-E72D58CE998F817F398C75FEE6E37340-1" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-E72D58CE998F817F398C75FEE6E37340-1" continuedAt="TextSelection-E72D58CE998F817F398C75FEE6E37340-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691997e438-wk-Fact-9C5CC1732F9F0614737E75FEE6774DF1" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691997e442-wk-Fact-3784B82218A19C9524E375FEE6740E97" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">Two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma and previously treated hepatocellular carcinoma; and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691997e449-wk-Fact-1A698DE9C304102A077B75FEE67655D0" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-B43C0B9BBBA3FB25235475FEE6E310AE-0-wk-Fact-DB0B7BEBFA3374C3C6EB75FEE67BEB14" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-2C7E747566A77499FC6B75FEE6E37F97-0-wk-Fact-79243E4F60C28E51FCFA75FEE67B9DD8" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FiscalPeriod" id="TextSelection-72C474DCEBBD9FBD33EF75FEE6E3AA1C-0-wk-Fact-36720F4A2C497AD73E9D75FEE679B2D7" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended July 3, 2020 and June 28, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended June 30, 2020 and June 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.</span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="TextSelection-8B8007B3123F17EA899175FEE6E35F3A-0-wk-Fact-219CDB6211F635D012FE75FEE677B23F" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Such reclassifications did not impact previously reported total revenues, i</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ncome from operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-E72D58CE998F817F398C75FEE6E37340-2" continuedAt="TextSelection-E72D58CE998F817F398C75FEE6E37340-3"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-1C5A2E293DA56F48C67675FEE6E3FEB8-0-wk-Fact-5BDB206604242C87ADB875FEE68316CF" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691997e563-wk-Fact-64E029CDD110273079E975FEE67B5A8E" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:UseOfEstimates" id="TextSelection-8559EF33B190F463711E75FEE6E33283-0-wk-Fact-C28E5E089C795F811CD875FEE677B993" continuedAt="TextSelection-8559EF33B190F463711E75FEE6E33283-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-8559EF33B190F463711E75FEE6E33283-1">In March 2020, we received the 2020 preliminary fee notice from the Internal Revenue Service for the Branded Prescription Drug Fee for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years.</ix:continuation> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accordingly, we recorded an adjustment to increase selling, general and administrative expenses and our accrual for these fees by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e607-wk-Fact-1B054492DA4DD702CB8175FEE675880F" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q1QTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the three months ended March 31, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. T</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">his adjustment resulted in a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e616-wk-Fact-1D65A425E4CB610BF9FE7D6FF0B2E54F" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q2YTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.02</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> decrease in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">basic and diluted earnings per share</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our total accrual for the Branded Prescription Drug Fee was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e637-wk-Fact-B8FFA6959C9F6232263275FEE677F626" name="exel:BrandedPrescriptionDrugFeeAccrual" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e641-wk-Fact-CAB34890CDA6827DB85175FEE674151B" name="exel:BrandedPrescriptionDrugFeeAccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e654-wk-Fact-56588E269F039B43358275FEE676EC68" name="exel:BrandedPrescriptionDrugFeeAccrualCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e658-wk-Fact-002E2771CDE0E27F247A75FEE67BEA46" name="exel:BrandedPrescriptionDrugFeeAccrualCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was recorded in other current liabilities, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e662-wk-Fact-F31E39E882E70FC4CA2C75FEE674DBA9" name="exel:BrandedPrescriptionDrugFeeAccrualNonCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d691997e666-wk-Fact-73D1050FAFCAFC195D8275FEE67A0030" name="exel:BrandedPrescriptionDrugFeeAccrualNonCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was recorded in other long-term liabilities. </span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-0-wk-Fact-7C353960A80A09DADB1E75FEE6732258" continuedAt="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Accounting Standards Update (ASU) No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Revenue from Contracts with Customers </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-1" continuedAt="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-2"><ix:continuation id="TextSelection-E72D58CE998F817F398C75FEE6E37340-3" continuedAt="TextSelection-E72D58CE998F817F398C75FEE6E37340-4"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investment Impairment</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#8217;s impairment </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">is due to credit-related factors or noncredit-related factors. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Credit-related impairments on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">debt securities available-for-sale </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">are recognized as an allowance for credit losses with a corresponding adjustment to o</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ther income, net in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Condensed Consolidated Statements of Income. The portion of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">impairment that is not credit-related is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded, net of applicable taxes, as a reduction of other comprehensive income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade receivables, net</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> contain amounts billed to our customers for product sales, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">amounts billed to our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration partners for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">development, regulatory and sales-based </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on the sale of licensed products</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">profit-sharing arrangements, development cost reimbursements, and payments for product supply services</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to estimate credit losses and consider our historical loss information, adjusted to account for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691997e968-wk-Fact-64E029CDD110273079E975FEE67B5A8E" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d691997e972-wk-Fact-46C10B37E848520AFF7D75FEE6725F2B" name="us-gaap:GoodwillImpairmentLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-2" continuedAt="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-3"><ix:continuation id="TextSelection-E72D58CE998F817F398C75FEE6E37340-4" continuedAt="TextSelection-E72D58CE998F817F398C75FEE6E37340-5"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which happens at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from non-refundable, up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit-sharing Arrangements: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Royalty and Sales-based Milestone Payments:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and clarifying and amending existing </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-3"><ix:continuation id="TextSelection-E72D58CE998F817F398C75FEE6E37340-5"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.</span></div></ix:continuation></ix:continuation><div><a id="s86BBCE65F49B5D3AA2F4948F9613827A"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-FC50726AF4826ADDE44875FEE6E45034-0-wk-Fact-8BFF7CE42D60DBBCF35075FEE68A44BC" continuedAt="TextSelection-FC50726AF4826ADDE44875FEE6E45034-1" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FC50726AF4826ADDE44875FEE6E45034-1" continuedAt="TextSelection-FC50726AF4826ADDE44875FEE6E45034-2"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-4429EF402FC218E899BA75FEE6E400E0-0-wk-Fact-D0D788419C6B7C881D3975FEE6624E26" continuedAt="TextSelection-D1E997EBA92738D3656B75FEE6E441A7-0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e689-wk-Fact-75E61E4155457B9DC64C75FEE69B34A3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">229,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e708-wk-Fact-42E7E3EEBEF51004554175FEE68959B1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e727-wk-Fact-5A2437E9F723431F06EC75FEE6678C7E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">482,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e747-wk-Fact-B87648C5D2A24F19289475FEE665F257" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">464,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e762-wk-Fact-0F9A4F27D1484F2E3B5475FEE668AE8D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">51,168</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e782-wk-Fact-0775568DC09851F9E65375FEE699D081" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">46,743</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e802-wk-Fact-AE57CEF1BB0D51041CFD75FEE666D129" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">109,854</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e823-wk-Fact-9715B9A42CB5D82101B875FEE66C6211" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,912</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e844-wk-Fact-5A2214FE83685521E13275FEE66421F4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">178,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e863-wk-Fact-A72FA94CFA55F8922B2275FEE6756D0F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e882-wk-Fact-097C78DB144C18F7259275FEE691AFDD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">372,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e902-wk-Fact-699B1F7B1BA2FDD648FF75FEE68E5EDB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1004-wk-Fact-6497319F83CC3DF3C90C75FEE69CD50C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1023-wk-Fact-47C49EFE5D0D56E8685575FEE6630E63" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1042-wk-Fact-DB9618FDB1571E3C9A6C75FEE68A0242" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1062-wk-Fact-6128661D81D66A5B5C9375FEE6974202" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1082-wk-Fact-9B99F65872BA5239ABE07602BC70F963" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1101-wk-Fact-899A8C5BB40BE0001A397602BC1564A1" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1120-wk-Fact-FABE9E85A8ECD171D56A75FEE69330AA" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1140-wk-Fact-C4E1C3CC83C7DDABA2EF75FEE6927942" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1160-wk-Fact-00F23BF2710148220E7075FEE6D15EB4" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1179-wk-Fact-5AF0D8107730A50AC5C075FEE678CE8C" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1198-wk-Fact-1CDB4277CFAC2A3C75BA75FEE66689C3" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">113,784</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1218-wk-Fact-CB45989127F561E2BCDF75FEE66ADCB5" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1243-wk-Fact-44B7BE6FB321312F7E7D75FEE669CD36" name="us-gaap:Revenues" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1262-wk-Fact-3EFFF6A6BFF3B9030C2D75FEE6D03440" name="us-gaap:Revenues" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1281-wk-Fact-4696CD3398156FF3047675FEE6878468" name="us-gaap:Revenues" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1301-wk-Fact-6B39914FAAEB56AC401A75FEE696E280" name="us-gaap:Revenues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:continuation id="TextSelection-08A4251D64E39CB3B1A675FEE6E4CB1B-0" continuedAt="TextSelection-D8419934250557BC4D0F75FEE6E48E7E-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.</span></div></ix:continuation><ix:continuation id="TextSelection-D1E997EBA92738D3656B75FEE6E441A7-0" continuedAt="TextSelection-D1E997EBA92738D3656B75FEE6E441A7-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1528-wk-Fact-C7291BDC3630B3E636E875FEE6B6B113" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">173,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1547-wk-Fact-608EB675A72BD98355DE75FEE6BBE1B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">189,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1566-wk-Fact-B3ED997AA6070DE474F475FEE69B5C5C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">362,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1586-wk-Fact-7B05A6D1DF4E8FC9C98275FEE6A4D3A9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">364,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1601-wk-Fact-0A4D89824AB9D3007F1A75FEE6AD0E17" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1620-wk-Fact-38DDBA319CE1E0513AD575FEE6B39348" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1639-wk-Fact-BADB79FD50BA1104E87575FEE6A4C355" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,784</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1659-wk-Fact-62C105BC4367E6AFE18375FEE69CC773" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1684-wk-Fact-5A2214FE83685521E13275FEE66421F4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">178,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1703-wk-Fact-A72FA94CFA55F8922B2275FEE6756D0F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1722-wk-Fact-097C78DB144C18F7259275FEE691AFDD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">372,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1742-wk-Fact-699B1F7B1BA2FDD648FF75FEE68E5EDB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:48%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen Pharma SAS (Ipsen)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1906-wk-Fact-73F4F9EC40D81B245F5CB6E621622607" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1921-wk-Fact-5A87E05E90D0F8DD8D5FB6E594293242" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1936-wk-Fact-992EB9D518267292FB9D75FEE66A7E05" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1951-wk-Fact-629862386B35A299BCFA75FEE66C0345" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of CVS Health Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1968-wk-Fact-7C41E6F3F433DECAB421B6E618084B85" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1983-wk-Fact-64D3DB69D4036A80073AB6E58BCB5ECD" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e1998-wk-Fact-17011D27505146DCA7F275FEE66AB6A3" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2013-wk-Fact-F2B147D8F15FC5F9AAB075FEE66E995C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2030-wk-Fact-C6F11659D7622EB4C412B6E61C9DE5F8" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2045-wk-Fact-24C57E65741E2669935FB6E590110263" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2060-wk-Fact-B40C04F4998C26C1DD9D75FEE66B4C4F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2075-wk-Fact-21530D242669368BA8B375FEE66B8BE2" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2092-wk-Fact-B02F2C735D1A2E13D99CB6E6264424D3" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2107-wk-Fact-034604E54968694AE36EB6E59929A280" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2122-wk-Fact-17C87D592ECE51A9532D75FEE66CBB37" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2137-wk-Fact-D7FFB89A07ABCEB83A1975FEE66EF5AB" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of Optum Specialty Pharmacy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2154-wk-Fact-226A55FA2D1C9054A9ADB6E62B3DC38E" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2169-wk-Fact-3011228E6ECB93D7CE83B6E59E11A966" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2184-wk-Fact-86627013F6F488312E0C75FEE66E1F14" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2199-wk-Fact-E914B700CB52FCF8EFB875FEE66DF0C7" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda Pharmaceutical Company Limited (Takeda)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2216-wk-Fact-2E27ACAA1DCE958559EC7127B40A5BDC" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2231-wk-Fact-0C46E8DB283DA678A1727127B939291A" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2246-wk-Fact-EB63B154536F992518837127BDF70F0B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2261-wk-Fact-73D87BD7444A314069F97127C32C0FFF" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2278-wk-Fact-491986CA0FB6D5FE5A7CB6E62F9A993F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2293-wk-Fact-59008AAD1210BC7B343CB6E5A2D0426A" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2308-wk-Fact-7728904BB5841AF33F0275FEE669152A" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2323-wk-Fact-5925AAB94F01AE3F29C375FEE66A097F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FC50726AF4826ADDE44875FEE6E45034-2" continuedAt="TextSelection-FC50726AF4826ADDE44875FEE6E45034-3"><ix:continuation id="TextSelection-D1E997EBA92738D3656B75FEE6E441A7-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2537-wk-Fact-802622B63D75BC86F0427602BC275A14" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2556-wk-Fact-E335AF4C229A771EDE757602BC78CF58" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">196,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2575-wk-Fact-CB53EEEA8D62B629A1DA75FEE6B934FC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">377,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2595-wk-Fact-8698FB9433CE2968B92975FEE6C51C7B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">378,473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2610-wk-Fact-42583925A711EBAFAB247602BC779FE5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2629-wk-Fact-0B47D60139C0F7244C3E7602BC72874F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2648-wk-Fact-953C134494B206A765E275FEE6C64ED1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2668-wk-Fact-6A36C21C6478349FABE575FEE6BBFB60" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2688-wk-Fact-E78BDE53A1E2E01465267602BC7106D7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2707-wk-Fact-9BFC4A3D44E7A13034537602BC23CD76" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2726-wk-Fact-C196CA27E2956B283DCE75FEE6B23111" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2746-wk-Fact-23B245A4374FE791348375FEE6BBCC6F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2771-wk-Fact-236CCC5F43B92BD94705B6E7A291E7BE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">259,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2790-wk-Fact-EFD8537590A7DAD43966B6E7A296CDC2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2809-wk-Fact-F61B0DC327BA39D1D716B6E7776BD6AA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2829-wk-Fact-CBEB745D5F61054F7843B6E7776F4C91" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><ix:continuation id="TextSelection-D8419934250557BC4D0F75FEE6E48E7E-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="TextSelection-D7F1FA9817065AEE5E9275FEE6E4DC89-0-wk-Fact-9E3CB1E3CB7397A3165575FEE6640823" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e2986-wk-Fact-4C33FA0B6F44D99A977D75FEE688DD58" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3005-wk-Fact-F8DB20A18B45811488DA75FEE678C699" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3024-wk-Fact-956C44DBC52F0650D9C675FEE6A4A664" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3044-wk-Fact-F30A7CB458CA47BB8C1475FEE6833337" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3141-wk-Fact-AF0586EF9D952068642375FEE67B2BF2" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3160-wk-Fact-FBF024E0017D4875C0A875FEE682DB46" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3179-wk-Fact-48470B330B8AF551CE0475FEE682E4FB" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3199-wk-Fact-6986BB2B477994842F7B75FEE685F690" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">109,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3219-wk-Fact-92CD814550C140EF98DC75FEE67664B9" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e3238-wk-Fact-FAEB27FDE4001533B40C75FEE678E8CE" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3258-wk-Fact-D397191DF0E6D703AD0675FEE69A3B46" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3278-wk-Fact-48F7B70CE4F1DDB6F08875FEE6784C0C" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e3298-wk-Fact-65C4463DF48EE688C77C75FEE698F929" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e3318-wk-Fact-DB7ADC8B8B06512E83F275FEE67B8493" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e3338-wk-Fact-78F1254141F8543F9C8075FEE6845AA5" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d672417e3359-wk-Fact-FAC6EDC04EFF5ACDA60C75FEE67AB6C7" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">110,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3385-wk-Fact-3B9D9EB536D5B082C2A675FEE6744954" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3404-wk-Fact-A343E52FFBBFB89CC07675FEE6875F6A" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3423-wk-Fact-02894ED3950D6EF07EDA75FEE6737386" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d672417e3443-wk-Fact-9AB781BD067B5554A2E775FEE6756C06" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-14D21D02B533E7C39F9C75FEE6E4F742-0-wk-Fact-C92EC76FF3DB2E67AE2175FEE686B4CA" continuedAt="TextSelection-08A4251D64E39CB3B1A675FEE6E4CB1B-0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3567-wk-Fact-AF23E46A4E7C9C8DB37575FEE68FC5BD" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3571-wk-Fact-77BCE6DAF10BF973718775FEE6D4C5C4" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3584-wk-Fact-051DAEBCD80A3B8208A275FEE690A87C" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3588-wk-Fact-ADA8FFC71BA8EDE6101A75FEE69045B2" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The current portion of the contract liabilities totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3600-wk-Fact-3931015A0044A1825C3775FEE6901E64" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3604-wk-Fact-8222D7D29C15113E983C75FEE68E943B" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanying Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Significant changes in contract assets during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> include the impact of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3632-wk-Fact-79B5D9AA426F6193E4D1713526BBAE4C" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> development milestone from Ipsen we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">determined was probable of achievement, which was offset by the impact of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3638-wk-Fact-A27FE51E00A2DDAAE58B75FEE68B3986" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2020Q2_srt_MajorCustomersAxis_exel_TakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone from Takeda which was recognized as revenues during the year ended December 31, 2019 and was achieved, invoiced and collected during the current period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3662-wk-Fact-7D871297CB30BDFFC03B75FEE692B52F" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3666-wk-Fact-95A5F89B7247B542AE5F75FEE68ED916" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FC50726AF4826ADDE44875FEE6E45034-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3681-wk-Fact-A4E20AD0A1DE7AB7B09BB6FF7B94FE70" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">62.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3685-wk-Fact-FB02B8E130BC88D1747075FEE68F7BE2" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues for performance obligations satisfied in previous periods as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3689-wk-Fact-F19C96A3D191E8B5494BB6FFA6CEA868" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3694-wk-Fact-AE55E14EE8D6124BB31275FEE68BEDB5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Such revenues primarily related to milestone and royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d672417e3709-wk-Fact-94336A19737899D6278075FEE695ABD0" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price was allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for information about the expected timing </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to satisfy these performance obligations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation><div><a id="s34B0B4821CAD5429A5BBA1F8FC714E7E"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-813C4703E5DED57EF68475FEE6E594B7-0-wk-Fact-93113978F0181E8FCC2175FEE698CB77" continuedAt="TextSelection-813C4703E5DED57EF68475FEE6E594B7-1" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-813C4703E5DED57EF68475FEE6E594B7-1" continuedAt="TextSelection-813C4703E5DED57EF68475FEE6E594B7-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib. Additionally, consistent with our business strategy prior to the commercialization of cabozantinib, we entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have also established multiple collaborations with smaller, discovery-focused biotechnology companies to expand our product pipeline. Under these collaborations, we may be required to make milestone and royalty payments, and for certain collaborations make payments for development cost reimbursements and/or option exercise fees. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a description of each of our collaboration agreements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. During the second quarter of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2020, Ipsen opted into and is now co-funding the development costs for CONTACT-01 and CONTACT-02, two phase 3 pivotal trials of cabozantinib in combination with atezolizumab in patients with previously treated, metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively, and the four remaining cohorts of COSMIC-021 it had not previously opted into.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-7F2A7A999A3A402563E475FEE6E565A0-0-wk-Fact-CC59790D422FCE6DA2F975FEE6A4E250" continuedAt="TextSelection-5CA0C82564EBD78E528D75FEE6E5D3B5-0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e638-wk-Fact-236F4CD7C50BF08900E7B733B2565510" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e657-wk-Fact-E9C12EFBE451B2E5CA5AB733D544993C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e676-wk-Fact-97233F1C6784D56BF8DB75FEE6CAF7B4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e696-wk-Fact-4348C8FC48872EB376E475FEE6CF0832" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e711-wk-Fact-E8BEE20B3434CDFD10A8B733B521618E" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e730-wk-Fact-BD006F0DC9B1E0A5A00CB733D81173DD" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e749-wk-Fact-A67B020A145596D6D78F75FEE6CA5DA6" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e769-wk-Fact-DCF4118497FE7209D96F75FEE6CB92DD" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e794-wk-Fact-CB1AE47A1FEFA1B8426CB733B84F4270" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e813-wk-Fact-488E6C9DD40914687CB1B733DBA59952" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e832-wk-Fact-098BEA423A0767D1F04375FEE6CC26E7" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e852-wk-Fact-D58292963F600DFBE23F75FEE6CAF4E9" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for both the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e954-wk-Fact-2664B31718BB44FE1E88713DBEB70CDD" name="exel:MilestonePaymentsEarned" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenues recognized in connection with a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e958-wk-Fact-79B5D9AA426F6193E4D1713526BBAE4C" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> development milestone from Ipsen we determined was probable of achievement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e969-wk-Fact-9C225FB6B01EA36ECC6B75FEE6BB86F6" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">46.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-813C4703E5DED57EF68475FEE6E594B7-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration agreement with Takeda. Under this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><ix:continuation id="TextSelection-1E0F6F380E3843C9933D75FEE6E58043-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1192-wk-Fact-070652DFABB9D3B000A8B735CAF63CD9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1211-wk-Fact-F927F2D3C3403A793A19B735F06565F3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1230-wk-Fact-5115172E19E1139DEA5375FEE6AD461E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1250-wk-Fact-4C6385FE23D3E0867C8275FEE6ABA1F6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1265-wk-Fact-0821F0E7BEBC77113983B735CE68B0F6" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1284-wk-Fact-C01FACEEE068E24B8674B735F4348A06" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1303-wk-Fact-B612B993545C92F473DC75FEE6ACC097" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1323-wk-Fact-ABC63BC52127D185094B75FEE6AB0593" name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1348-wk-Fact-3AA94C98BBD9F24123DAB735D15E1E13" name="us-gaap:Revenues" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1367-wk-Fact-37BF683D908401969BE3B735F8159904" name="us-gaap:Revenues" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1386-wk-Fact-AD688E69561EEE8C08E275FEE6BCF812" name="us-gaap:Revenues" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1406-wk-Fact-8FD3AC0A737A995406AE75FEE6A98524" name="us-gaap:Revenues" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for both the three and six months ended June&#160;30, 2020 included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1500-wk-Fact-836A51E6DDE5F0540E2394579215BBD6" name="exel:MilestonePaymentsEarned" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">23.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenues recognized in connection with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1504-wk-Fact-B84DCEB143503652D249945F27D4540C" name="exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones we achieved upon Takeda&#8217;s first commercial sale of CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma in Japan, as well as royalties earned related to sales of cabozantinib in Japan. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1515-wk-Fact-E1D193D86111CB838D8275FEE6CBE5A7" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. We are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d671000e1534-wk-Fact-FFCBE57EB6DE16A8452475FEE6C23818" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1538-wk-Fact-C3DB37C4ACE5C379BF9EB7373B47FA63" name="us-gaap:RoyaltyExpense" contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1542-wk-Fact-FDBA1E4750D1B4587D5875FEE6C928E6" name="us-gaap:RoyaltyExpense" contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1555-wk-Fact-7E20911B4AE9D8FE3BDFB7376DF5D69C" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d671000e1559-wk-Fact-2C6311766A03F8F380D075FEE6BCF063" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with Zelboraf and Tecentriq (atezolizumab) as a treatment for BRAF V600-mutation positive advanced melanoma in previously untreated patients. <ix:continuation id="TextSelection-5CA0C82564EBD78E528D75FEE6E5D3B5-0" continuedAt="TextSelection-5CA0C82564EBD78E528D75FEE6E5D3B5-1">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</ix:continuation></span></div><ix:continuation id="TextSelection-5CA0C82564EBD78E528D75FEE6E5D3B5-1" continuedAt="TextSelection-1E0F6F380E3843C9933D75FEE6E58043-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1787-wk-Fact-2C5B94634F128DB4465175FEE6C7F5EA" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1806-wk-Fact-AF5C10BE8DCD35C4416875FEE66923E2" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1825-wk-Fact-7DC52CD6A38341BEB70975FEE6C98853" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1845-wk-Fact-478A121F079D8B7F82E875FEE6C423D0" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1865-wk-Fact-A1387856281B23C89A4B75FEE6674BBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1884-wk-Fact-412ADF46147D0C06674775FEE6D4D715" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1903-wk-Fact-80D14B879D0E64134CA175FEE6BDBAB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d671000e1923-wk-Fact-29AD9E28F3F4F8B3418475FEE6CA5EE7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</span></div></div><hr style="page-break-after:always"></hr><div><a id="s727A29D9BE675401BEB2927BED47E344"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. <ix:nonNumeric contextRef="FD2020Q2YTD" name="exel:CashCashEquivalentsAndInvestmentsTextBlock" id="TextSelection-6F622559253FBC73838975FEE6E50CB2-0-wk-Fact-ACBD627D7970321673E375FEE6A644AE" continuedAt="TextSelection-6F622559253FBC73838975FEE6E50CB2-1" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6F622559253FBC73838975FEE6E50CB2-1" continuedAt="TextSelection-6F622559253FBC73838975FEE6E50CB2-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-72B5EA6D9452E6D9BB2175FEE6E58B1C-0-wk-Fact-474B42617C7BDACBC56975FEE6A88447" continuedAt="TextSelection-72B5EA6D9452E6D9BB2175FEE6E58B1C-1" escape="true"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-C55BFE0AE9248AD788E375FEE6E589CE-0-wk-Fact-DCA608C1BC1F3223123A75FEE6A4A019" continuedAt="TextSelection-C55BFE0AE9248AD788E375FEE6E589CE-1" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-72B5EA6D9452E6D9BB2175FEE6E58B1C-1"><ix:continuation id="TextSelection-C55BFE0AE9248AD788E375FEE6E589CE-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e489-wk-Fact-A1BC98B7EF7C3CEC321D75FEE6A61235" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">527,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e508-wk-Fact-7FE412FB8DEB8D023E2A75FEE68E25BF" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e523-wk-Fact-6315AEEC1175E1B551CC75FEE66753AD" name="us-gaap:RestrictedCashEquivalentsNoncurrent" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e542-wk-Fact-01EEDAED8C68CD6B172875FEE66B14F8" name="us-gaap:RestrictedCashEquivalentsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e567-wk-Fact-894D15D3C93C47AB426A75FEE6B2B28C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528,779</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e586-wk-Fact-8769E5B4758910A379EB75FEE6AF4BC1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">long-term </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">classification of restricted cash </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents is based </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon the remaining term of the underlying restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-9F8D83C8086EB7A2D38575FEE6E6D907-0-wk-Fact-5CF740AF1BD7925998A575FEE6A67C72" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e912-wk-Fact-522319E133BEFB42A34275FEE6D46867" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e931-wk-Fact-2FDFC0A79414F3015A7D75FEE6CC3AD2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e950-wk-Fact-526A594F51DE740DCD7C75FEE6C6CD35" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e970-wk-Fact-A9289102402F99BBD8FC75FEE6D287B0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e985-wk-Fact-D1A191D0DBF126F9395675FEE6C61F0A" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">663,491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1004-wk-Fact-609F3016527D90BF439A75FEE6CCBA69" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e1023-wk-Fact-8D3E7D5281419F153BBC75FEE6CE7F80" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1044-wk-Fact-F864CE890E543E5D356E75FEE6C7791A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">672,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1064-wk-Fact-8E434C861C3724B0594E75FEE6D373F1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">89,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1083-wk-Fact-C62B7925DF1C9E7B021F75FEE6C937C0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1102-wk-Fact-D4F1C1F5C7BE1462416775FEE6CB9025" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1122-wk-Fact-6B916479768C857B084975FEE6CBD745" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1142-wk-Fact-AD9D9FC35CA82786238275FEE6D1A08D" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1161-wk-Fact-20F8CF00BAC242D2834175FEE6CB3A3F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e1180-wk-Fact-83A37DF8166B4AAA47BA75FEE6CFBEFD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1201-wk-Fact-51AFEF564A2F2C64983F75FEE6CA8FC7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1221-wk-Fact-24361C94A361CB748C8A75FEE6C51006" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,021,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1240-wk-Fact-779F1992EEEC7861261775FEE6D0C8EB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e1259-wk-Fact-893951962E32BE8AA7F475FEE6C9B8FA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1280-wk-Fact-CBDF93617CF02EC0310B75FEE6C46ECF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,031,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1300-wk-Fact-9C8120DDAB01467C86EA75FEE6CBD4DF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1319-wk-Fact-4025C9BA6044667C982875FEE65D4ED4" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1338-wk-Fact-7B7E2BB280260F833FD575FEE6CD922A" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1358-wk-Fact-0B978933754D9005F5C975FEE6CFEC6E" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1378-wk-Fact-5638AFEDA9FC1947E80875FEE6D0BE99" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1397-wk-Fact-724D6570DEC463C8089175FEE6CD3CCF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1416-wk-Fact-C5F22A645179C190AD1175FEE6C9AA42" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1436-wk-Fact-87A97E1FC14D82524CE675FEE6CE82FE" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1456-wk-Fact-208CD45C8B650A2ABA0075FEE6CDD683" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1475-wk-Fact-60AB8C6C821B2255302475FEE6CB28B7" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1494-wk-Fact-846CC78D18B633711FEE75FEE6C485BB" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1514-wk-Fact-B39C6E6E332DBD04F71275FEE6C34EC2" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1540-wk-Fact-E3DAD595D38E376B4E6975FEE6CF5621" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,529,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1559-wk-Fact-ED6DFE1107D6002210E475FEE6C76E61" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e1578-wk-Fact-27B857BF84BFD62FAB9575FEE6CEEF62" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1599-wk-Fact-50AADC7571B677170AF975FEE6C8D039" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,540,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1890-wk-Fact-BE5DFE01A9F0F4BDE1B975FEE6ACFCE1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1909-wk-Fact-85BE5F5E344F56DE712475FEE6705688" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1928-wk-Fact-492917F91EE9FC4DC65C75FEE674DD30" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1948-wk-Fact-608C28D4C198B91A279275FEE6714490" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1963-wk-Fact-E6D71E200005A7F3E90475FEE6A827DC" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">752,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e1982-wk-Fact-D1A6C2F458D59606B50F75FEE6B6AB05" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2001-wk-Fact-82A47A2197C40469FA8A75FEE6B27A2F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2022-wk-Fact-B330E7B6AF4FCE3AD75D75FEE66ED0C1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">756,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2042-wk-Fact-1E5BAB7E975018F1097E75FEE675AFDF" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2061-wk-Fact-9BD712EFC41785EC4D5275FEE6B45BF9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2080-wk-Fact-C070A0CC46FA79D8CB3075FEE6B894B4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2101-wk-Fact-3D065C56B42EB437494775FEE6A67AE4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2121-wk-Fact-DD4A4B26EC4806DBD7C075FEE68563D3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,308,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2140-wk-Fact-E1A5DFE664CBEB8F823375FEE66F6B10" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2159-wk-Fact-4D4E82AAE923E302229F75FEE6B58C31" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2180-wk-Fact-D262D005796EFBBAE4FF75FEE6D2519D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2200-wk-Fact-C895ED58202C82F3D5C275FEE6723B92" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2219-wk-Fact-C94B1BEF441EFDE0F7E075FEE6AAD45E" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2238-wk-Fact-2ED04B3BBB3BA7752FA3B7449F9DC9FB" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2258-wk-Fact-8E6760AB9067DE2081E575FEE6735E35" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2278-wk-Fact-CA3F66DEBBFD1B6632A475FEE6A405FF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2297-wk-Fact-B94C8449ECAEBBAE8D4FB7449FC5BF31" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2316-wk-Fact-8D0D881263380CB8F17875FEE6B1F72E" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2336-wk-Fact-EA73B8314FC1D183E63775FEE686B658" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2356-wk-Fact-4D2F41E1F1653617E97175FEE6ABACBC" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2375-wk-Fact-74BBDB6A392F2B7A2B8775FEE6AF31C1" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2394-wk-Fact-4E5531F7AED76CC282F675FEE6ACD50D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2414-wk-Fact-6C3CAA0539565CA81EE875FEE6AD436D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2439-wk-Fact-73273A70EE388A9C48E875FEE6A7871C" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,384,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2458-wk-Fact-5DA3DCB03553435904FD75FEE6726762" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2477-wk-Fact-0640331C6C335518AF9975FEE6B2899A" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2498-wk-Fact-695F3CBC631EB1B2146575FEE6BB107E" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,388,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Interest receivable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d666062e2510-wk-Fact-A00F9C87F7650FF141D375FEE6A8AE3F" name="us-gaap:InterestReceivable" contextRef="FI2020Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d666062e2514-wk-Fact-71B0079E6F0878E93B8C75FEE6A3A851" name="us-gaap:InterestReceivable" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-6F622559253FBC73838975FEE6E50CB2-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Realized gains and losses on the sales of investments were insignificant during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="TextSelection-C05F5F5A88BB450AEDDE75FEE6E6C3A7-0-wk-Fact-40BCD2CB9ED99DE7B2E175FEE6A7B12C" continuedAt="TextSelection-C05F5F5A88BB450AEDDE75FEE6E6C3A7-1" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C05F5F5A88BB450AEDDE75FEE6E6C3A7-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2662-wk-Fact-ECDA02EE5E2AED64853775FEE699A15D" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2681-wk-Fact-94E7FE489585CE0E98B675FEE687667D" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2697-wk-Fact-C8D0841065C2977EFEA375FEE689C374" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2716-wk-Fact-9F2FD1B22C2540A2D33FA5A44C0D343A" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2736-wk-Fact-DB027AC591108761DE0C6CA39DA73425" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MunicipalBondsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2755-wk-Fact-3B593206F6A55C2089FC6CA3E2D2C082" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MunicipalBondsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2781-wk-Fact-A09D3FDD7561C74BEC6F75FEE6A8F3F8" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2800-wk-Fact-CB242F77ED5B9ECF8F8175FEE6AA3A6C" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2917-wk-Fact-A5557C7EB3CEEA2AD0C975FEE6D38A01" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2936-wk-Fact-EEB2C1B70061D493F27F75FEE6D3831F" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2952-wk-Fact-1CDD464FF29C3DAD026575FEE65D2411" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e2971-wk-Fact-7EBAA6779541C97F482275FEE6CF8A91" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e2997-wk-Fact-AA5BABF804E923AC245F75FEE6645FAF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d666062e3016-wk-Fact-DF6A8B8F4A75FDBBAFC275FEE6D0270F" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All securities presented have been in an unrealized loss position less than 12 months. There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d666062e3032-wk-Fact-09AF54E7B491B6819D4575FEE6A4A914" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2020Q2" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">17</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d666062e3036-wk-Fact-7B2E081106AB6D160EB075FEE6A75091" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2019Q4" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">9</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d666062e3061-wk-Fact-35BF21AF06F6C41D8B7875FEE6A5F8B1" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" contextRef="FI2020Q2" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-44BC1A95F65F002E272575FEE6E50C27-0-wk-Fact-20CE14E41C04EE186F6075FEE6A33F57" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e3179-wk-Fact-83FE0C0ABB89050C5F3F75FEE6CC4E7E" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">720,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e3198-wk-Fact-D40D400B1EDCA3AA826375FEE6CD289F" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">789,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e3213-wk-Fact-BA73B5A9D7D362829A8375FEE6CCAB79" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e3232-wk-Fact-B51294B9051F1D2DFFCC75FEE6CE6034" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">522,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e3257-wk-Fact-CBDF93617CF02EC0310B75FEE6C46ECF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,031,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666062e3276-wk-Fact-D262D005796EFBBAE4FF75FEE6D2519D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s7CD3876047A654A39D867C4700FE0D23"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-CF5FC8BC1AAF9DF36C3675FEE6E6A406-0-wk-Fact-9F1E5CB48DC847C25A3675FEE66391A8" continuedAt="TextSelection-CF5FC8BC1AAF9DF36C3675FEE6E6A406-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CF5FC8BC1AAF9DF36C3675FEE6E6A406-1" continuedAt="TextSelection-CF5FC8BC1AAF9DF36C3675FEE6E6A406-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-CF5FC8BC1AAF9DF36C3675FEE6E6A406-2"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-0AEF4FE31E0DC582C97C75FEE6E69B3C-0-wk-Fact-F346AB19B3D3573D35D175FEE66A6AFF" continuedAt="TextSelection-0AEF4FE31E0DC582C97C75FEE6E69B3C-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e592-wk-Fact-FBA3730362021F175EE875FEE6743A35" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e611-wk-Fact-217BAB2D3FB9F82E6EA975FEE6A738F1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e630-wk-Fact-991AE4FAE1C81744A16275FEE67A1B4A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e646-wk-Fact-41382F81375D635FF23C75FEE678DD31" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e665-wk-Fact-59A7E6F192AFED6DF71075FEE672EC0B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">672,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e684-wk-Fact-9F85996B929B619A241075FEE665CAAF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">672,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e705-wk-Fact-957B3417FFD97B6A721475FEE6730A74" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e724-wk-Fact-E5BD91EE03AE7CC4B3E075FEE66D0505" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e743-wk-Fact-524DE3EE3FA03A981F5575FEE674E99E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e764-wk-Fact-F18EE73CF8D28A02B5EB75FEE6729A32" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e783-wk-Fact-0F7B538091424A947D3C75FEE67713F9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e802-wk-Fact-55A6BD2DE1C733DDD4C475FEE69A73AA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e823-wk-Fact-846FA02778A45020A3B675FEE69B8118" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e842-wk-Fact-E7D296C81D8D1451E4B875FEE66DDE1B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,031,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e861-wk-Fact-91DF7F8BD29700E78BA875FEE66E7E55" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,031,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e882-wk-Fact-5A3311DD9A4B1171074975FEE6AA60A5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e901-wk-Fact-B2338375F149F905908875FEE665145A" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e920-wk-Fact-2B6649E6DFF13969599C75FEE667502B" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e941-wk-Fact-C999D1340B443C70CCC675FEE69B6B37" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e960-wk-Fact-A7B2ECF20443DC233B9E75FEE677A1BF" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e979-wk-Fact-A849D1DDA04A8BD6098375FEE678A91C" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1005-wk-Fact-E92575B29AF2FC3E044975FEE6A53B2D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1024-wk-Fact-330B015285238FD7AF0F75FEE6A1A95B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,083,813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1043-wk-Fact-9C5B4EC9062BEBB51D5775FEE675C0DF" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1269-wk-Fact-D3E35149A5453AA2AC9375FEE668F5BB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1288-wk-Fact-DD1E70CF50A64C419D1875FEE66632E0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1307-wk-Fact-B650C507BFC0D22F3A8A75FEE6676121" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">389,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1323-wk-Fact-5663214468CA148FED1775FEE66BFCFC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1342-wk-Fact-382B2C1225137C212A8F75FEE6B0FAF5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">756,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1361-wk-Fact-60C3F07ED9CBAAB06E1175FEE65DB390" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">756,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1382-wk-Fact-2232F6ADBB069CE5776875FEE66A9230" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1401-wk-Fact-B96B213267C510A7810C75FEE66475E0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1420-wk-Fact-E3036C46B25C388E280B75FEE66C1BF8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1441-wk-Fact-D19A1AE3F80DD4030EAA75FEE6719219" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1460-wk-Fact-F2150D2F6432AACF1DC475FEE66E6F52" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1479-wk-Fact-E2C2AD428866AFC0B60675FEE65D89FD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,312,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1500-wk-Fact-4CBC4BEB7AEEAB6744CA75FEE66AE43A" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1519-wk-Fact-38AD9C580B3BF901606175FEE6666692" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1538-wk-Fact-BDE2CE7BD1341B99DE2F75FEE668CEE4" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1559-wk-Fact-B7AC88D92D4A95C416AA75FEE669FCFE" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1578-wk-Fact-FD828F0DB5F9328D38E7B757D43B95B0" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1597-wk-Fact-FA3CC24B4CD7727E8B3E75FEE6B16D25" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1623-wk-Fact-64B264FE4E92DE12EC5F75FEE6D30444" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1642-wk-Fact-5BBBB3B11A07E359821175FEE6678C4E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,345,197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d662808e1661-wk-Fact-3DD47DFA974B0CC5F3D675FEE6706488" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,347,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-0AEF4FE31E0DC582C97C75FEE6E69B3C-1"></ix:continuation>When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div></ix:continuation><div><a id="sDAB067DEAFEA59228D95DF4FBE410FE9"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-08480ABB0B373849A4FF75FEE6E6B37B-0-wk-Fact-FAF156D68E16C90A17C375FEE6C4D50B" continuedAt="TextSelection-08480ABB0B373849A4FF75FEE6E6B37B-1" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="TextSelection-08480ABB0B373849A4FF75FEE6E6B37B-1"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-E1EFC0655D560DBE63CB75FEE6E669BB-0-wk-Fact-7B656871401920BCE5F975FEE6B71BFD" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e493-wk-Fact-3A07B3959FCD48891A0175FEE6715001" name="us-gaap:InventoryRawMaterials" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e512-wk-Fact-9CC01F0F7082CA3D4B3675FEE667629A" name="us-gaap:InventoryRawMaterials" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e527-wk-Fact-DCB91F09B342EE00993A75FEE66E9EFB" name="us-gaap:InventoryWorkInProcess" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e546-wk-Fact-1EA81E3131047A513EC675FEE66CAE56" name="us-gaap:InventoryWorkInProcess" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e566-wk-Fact-FC9F58DF0A74B591654675FEE684152E" name="us-gaap:InventoryFinishedGoods" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e585-wk-Fact-6255D2AE2B449C0A2B2A75FEE6825E11" name="us-gaap:InventoryFinishedGoods" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e610-wk-Fact-9BD5C314F7A28689FDAF75FEE686265D" name="us-gaap:InventoryGross" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e629-wk-Fact-574B21D606C0F130D38975FEE67BC4D1" name="us-gaap:InventoryGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e690-wk-Fact-FBA75F3963AE7DFE494C75FEE67A6817" name="us-gaap:InventoryGross" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e709-wk-Fact-0F78892AA805ABF0720475FEE682125B" name="us-gaap:InventoryGross" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e724-wk-Fact-62DB2C29A725FA51AD1975FEE6764809" name="us-gaap:InventoryGross" contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,629</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e743-wk-Fact-9F4BAA84BB0C7E708EC275FEE67AA7CA" name="us-gaap:InventoryGross" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e768-wk-Fact-9BD5C314F7A28689FDAF75FEE686265D" name="us-gaap:InventoryGross" contextRef="FI2020Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d666504e787-wk-Fact-574B21D606C0F130D38975FEE67BC4D1" name="us-gaap:InventoryGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">excess and expiring inventory were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d666504e804-wk-Fact-F63B735B9D5A211DA8FF7602BC05B29D" name="us-gaap:InventoryWriteDown" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d666504e808-wk-Fact-417B36FD2579903FD7D27602BC057029" name="us-gaap:InventoryWriteDown" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB75E5FEAC6A857A0B9DE4752E7279060"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-82719FCA92319853ACAD75FEE6E6A24A-0-wk-Fact-B8D7E0041F077D2C88E675FEE68671C5" continuedAt="TextSelection-82719FCA92319853ACAD75FEE6E6A24A-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="TextSelection-82719FCA92319853ACAD75FEE6E6A24A-1"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-C6AD1E98381ADCBF1ABF75FEE6E66902-0-wk-Fact-56D735F1F79ED8463A6475FEE68D6CB1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e618-wk-Fact-65E58CF88A0998C7491C75FEE6BA7417" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e637-wk-Fact-9587BB59E8B50646AE0075FEE6B37789" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e656-wk-Fact-BE68106A723F728B0C0375FEE666481A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e676-wk-Fact-80118899E2371525F70675FEE665022C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e691-wk-Fact-7ED48AADEA2D5AD6995E75FEE6B03EB7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e710-wk-Fact-0EEB62A3EF06F9ACF8E975FEE6C43447" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e729-wk-Fact-B249BD08CBCDEB10E35375FEE6B63D3F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e749-wk-Fact-9B66E76EA68AB7846EC175FEE6B4D2A3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e774-wk-Fact-D25B80EC9080863D585075FEE6BB1ABE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e793-wk-Fact-5ACB6E99A5B073C6942B75FEE6B0DC25" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e812-wk-Fact-2B88BA7C117BE0CC098975FEE6BD04F4" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d667668e832-wk-Fact-5347209DC38252E73DC675FEE66436D0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonFraction id="d667668e858-wk-Fact-189C0A55FD4710CCC7117602BC886F37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2020Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,749,356</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e862-wk-Fact-8500CD7AD98CD0354214714BBE9323CF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> share for each share issued pursuant to a stock option or stock appreciation award and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e866-wk-Fact-D78721E0C429A57DAC6F714CC88ACD14" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares for full value awards granted in the form of restricted stock units (RSUs). On May&#160;20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e870-wk-Fact-8076BE195FB5B6795343BBFBC950D7B4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="D2020Q2May20-May20" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">21,000,000</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (the Additional Shares)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Additional Shares will be registered on a Form S-8 prior to grant</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e894-wk-Fact-CC4705F6D458C04FA0A275FEE68B0C88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">839,318</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> stock options with a weighted average exercise price of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e898-wk-Fact-0B968784B8E9EE3CB98775FEE683E26F" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.40</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share and a weighted average grant&#160;date fair&#160;value of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e902-wk-Fact-9FAF301FD6204C9A9ABB75FEE6896455" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.74</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e911-wk-Fact-A46C846BBA9CC0A7B34775FEE68A07EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2020Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">16,655,274</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> stock options outstanding and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e915-wk-Fact-3D4D2433AA02308B681F75FEE6894675" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> unrecognized compensation expense. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e930-wk-Fact-DF4847989CDA7BF655C675FEE68447B5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">889,023</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs with a weighted average grant&#160;date fair&#160;value of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e934-wk-Fact-A15D92602F7A76707E5475FEE685FA8B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.43</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e943-wk-Fact-28DAE5087FF6A203952375FEE6757145" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,774,852</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs outstanding and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e947-wk-Fact-6648BA04E87099E5BE2C75FEE6838A92" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> unrecognized compensation expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock options and RSUs granted to employees during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have vesting conditions and contractual lives of a similar nature to those described in &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Note 8. Employee Benefit Plans&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e1050-wk-Fact-491F01DC44A6631698E67602BC5BF7EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">308,365</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> performance-based stock options (PSOs) to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of our Common Stock is equal to or greater than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e1054-wk-Fact-FF4223E6E2378F069D227602BC67AF89" name="exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">125</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the three months ended June&#160;30, 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e1065-wk-Fact-34B3AEE8E214A35F0C5A4761B58DCDE8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,343,852</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> performance-based restricted stock units (PSUs) outstanding with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e1069-wk-Fact-E49C7C84240546B7A60E71663A4F6E5F" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">79.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. Of the outstanding PSUs, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e1073-wk-Fact-0BC1D6BBE60620B72ED47165B7FB12E8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">237,945</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> relate to awards for which we achieved the performance target during 2019 or had determined during 2019 that it was probable that we would achieve the performance target during 2020. During the three months ended June&#160;30, 2020, we determined that it had become probable that we would achieve an additional performance target for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d667668e1077-wk-Fact-2A89C4AB55E6496DCFFA716A8945E80B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">98,653</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional PSUs granted during 2018 resulting in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d667668e1082-wk-Fact-2189ABB5E339AA87ED817602BC510A89" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense during the period. For more information about our PSUs, see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Note 8. Employee Benefit Plans&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div></ix:continuation><div><a id="sDD44A097002E52F399F5579F00BF325F"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-23CEF12B4BB978669A9175FEE6E6C1D5-0-wk-Fact-53B6C221B82C3871533375FEE69062AD" continuedAt="TextSelection-23CEF12B4BB978669A9175FEE6E6C1D5-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-23CEF12B4BB978669A9175FEE6E6C1D5-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d671637e409-wk-Fact-352A482271A9B1D8E2ECB75D0DB287B3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">17.2</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d671637e413-wk-Fact-F0472657DDE5E9D7B9CF75FEE68F043E" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2020Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.0</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d671637e427-wk-Fact-E5583659DD831C57581DB75D35AB173D" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.8</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d671637e432-wk-Fact-E6B2E9E59D1C241DD3DD75FEE6870BA5" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.7</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparable </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> differed from the U.S. federal statutory rate of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d671637e461-wk-Fact-F3DF6470589172FC3B0B75FEE679059B" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2020Q2YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;primarily due to excess tax benefits related to the exercise of certain stock options during the periods.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7D01F0F804745BE496EC0717CBFC0AA9"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-58EC83A226D55110680275FEE6E66A35-0-wk-Fact-5791CBC86BCE4AAD577175FEE68CEC31" continuedAt="TextSelection-58EC83A226D55110680275FEE6E66A35-1" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="TextSelection-58EC83A226D55110680275FEE6E66A35-1"><ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-662D20F65E54626B555475FEE6E7F935-0-wk-Fact-79F364EA440FBB5288C675FEE686A376" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e699-wk-Fact-B487DD23D99A668528F075FEE69990CC" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66,821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e718-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e737-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,433</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e757-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e854-wk-Fact-59033765D73556484CE675FEE68A2255" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">307,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e873-wk-Fact-1927675C729F464ED63A75FEE6BA1013" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e892-wk-Fact-D67C673E55257A7E629B75FEE68DC8AD" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">306,598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e912-wk-Fact-1B7FF6816B05CF8C6D3375FEE695C60A" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e932-wk-Fact-850D667D436AC0D5043175FEE6734D32" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e951-wk-Fact-0CBE8B0943D10CB66B3375FEE671FE85" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e970-wk-Fact-CC684BE0DB67ED87D59375FEE6B990AD" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e990-wk-Fact-68DEEABC2496D31B657175FEE6B49E3C" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">13,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1010-wk-Fact-FDB4E707E9E9AEF20F9075FEE6B71B34" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">318,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1029-wk-Fact-AA49B4BBB4C251F3D89B75FEE6935051" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1048-wk-Fact-A5A35B7E2FE8BFD7BE9375FEE69113AE" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">316,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1068-wk-Fact-FE1018EC5634CAFA582475FEE6978CD0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1093-wk-Fact-F04F7BABEA56FDB5117F75FEE6AF18A3" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1112-wk-Fact-566FD1EE1C16BA6A763575FEE69BA939" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1131-wk-Fact-C28F37DC2381E7E89D3B75FEE6957C17" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1151-wk-Fact-0CBBC6463637620FE6C375FEE6880911" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1171-wk-Fact-31596066A1892C4DB17575FEE6844845" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1190-wk-Fact-A98347421B831C365EB575FEE68DED9E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1209-wk-Fact-CEB696DF869A2F41037E75FEE68AADD1" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1229-wk-Fact-CAB85F7EB403C6F9822C75FEE69349E8" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities included stock options, RSUs, PSUs and ESPP contributions. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSOs and PSUs for which the contingent vesting condition had not been achieved. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-8CA8D5E7B9185639DD0F75FEE6E7CDAC-0-wk-Fact-FEC7702D1B48562C243875FEE68C4A3F" continuedAt="TextSelection-8CA8D5E7B9185639DD0F75FEE6E7CDAC-1" escape="true">These excluded potential common shares were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8CA8D5E7B9185639DD0F75FEE6E7CDAC-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:48%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Anti-dilutive securities and contingently issuable shares excluded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1496-wk-Fact-9DC9A83B8D4B74D4FE42B7625625E65E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">8,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1510-wk-Fact-E77FD60FC27D3DF65452B76256291C68" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1524-wk-Fact-9748BFEA7DA37B2B20CD75FEE6D081CF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d673815e1538-wk-Fact-E71148913890CB91990D75FEE6C2FDEC" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="sf23d6da2ad2e43e6acf4ff90544645e7"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. <ix:nonNumeric contextRef="FD2020Q2YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-73C6235F7931B31A6488F0A6A056ECB2-0-wk-Fact-6CD2338B0EBE87975DE5F0AB209A1586" continuedAt="TextSelection-73C6235F7931B31A6488F0A6A056ECB2-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-73C6235F7931B31A6488F0A6A056ECB2-1" continuedAt="TextSelection-73C6235F7931B31A6488F0A6A056ECB2-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-73C6235F7931B31A6488F0A6A056ECB2-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div><a id="sDE37327891A25A749DDCCEC2A4484EB0"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> filed with the Securities and Exchange Commission (SEC) on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Two are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care. The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. Food and Drug Administration (FDA) first approved CABOMETYX for previously treated patients with advanced RCC in April 2016, and in December 2017 the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda). We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. With respect to the Japanese market, Takeda has achieved important milestones in 2020, including receipt of Manufacturing and Marketing Approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) and first commercial sales of CABOMETYX as a treatment for patients with curatively unresectable or metastatic RCC, and the submission of its application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX as a treatment for patients with unresectable HCC who progressed after prior systemic therapy.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine.&#160;We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising&#160;over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator-sponsored trial program. Informed by the available data from these clinical trials, we continue to advance cabozantinib&#8217;s development program with potentially label-enabling trials. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after up to two VEGF receptor-targeted therapies. We plan to conduct an analysis in these first 100 patients enrolled in COSMIC-311 for the co-primary endpoint of objective response rate (ORR), and an interim analysis of progression-free survival (PFS) in the second half of 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are particularly interested in examining cabozantinib&#8217;s potential in combination with immune checkpoint inhibitors (ICIs) to determine if such combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. Furthest advanced is our evaluation of cabozantinib in combination with Bristol-Myers Squibb Company&#8217;s (BMS) nivolumab as a treatment for patients with previously untreated advanced or metastatic RCC, for which we plan to submit a supplemental New Drug Application (sNDA) for use of the combination in this indication to the FDA during the third quarter of 2020. The data in support of this filing will be derived from CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC, for which we and our collaboration partner BMS announced positive top-line results in April 2020. CheckMate -9ER met its primary endpoint of PFS at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis and ORR. The results, which will be presented as part of the Presidential Symposium II at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 in September 2020, showed that the combination of cabozantinib with nivolumab significantly reduced the risk of disease progression or death compared with sunitinib (hazard ratio [HR]=0.51, p&lt;0.0001) and also significantly improved OS compared to sunitinib (HR=0.60, p&lt;0.001). We have also collaborated with BMS on CheckMate 040, a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">multi-cohort </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, for which initial clinically meaningful results were presented at American Society of Clinical Oncology&#8217;s (ASCO&#8217;s) Gastrointestinal Cancers Symposium in January 2020, and COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. We expect to complete enrollment for COSMIC-313 in early 2021 and to report top-line results of the event-driven analyses from the trial in the 2022 time frame. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In an effort to diversify our exploration of combinations with ICIs, we have also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche&#8217;s) ICI, atezolizumab, including COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, for which we announced in August 2020 that enrollment was completed, and COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. COSMIC-021 is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion phase, which is ongoing. Findings from the dose-escalation stage of COSMIC-021 demonstrated that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. The expansion phase of COSMIC-021 comprises 24 total cohorts, with 20 cohorts evaluating the combination of cabozantinib and atezolizumab and four cohorts evaluating cabozantinib or atezolizumab as single-agent therapies. Based on continuing encouraging efficacy and safety data certain cohorts have been or may be further expanded, including the cohorts of patients with non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue. We anticipate enrolling up to 1,732 patients in the trial in late 2020, which timing is subject to the initiation of additional cohorts or expansion of selected existing cohorts, as well as potential delays resulting from the COVID-19 pandemic. Since its initiation, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the recent initiation of three phase 3 pivotal trials in collaboration with Roche evaluating the combination of cabozantinib with </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">atezolizumab. The first, CONTACT-01, focuses on patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy; the second, CONTACT-02, focuses on patients with mCRPC who have been previously treated with one novel hormonal therapy; and the third, CONTACT-03, focuses on patients with inoperable, locally advanced or metastatic RCC who have progressed during or following treatment with an ICI as the immediate preceding therapy. Encouraging results from interim analyses of the mCRPC and NSCLC cohorts of COSMIC-021 were presented at ASCO&#8217;s Genitourinary Cancer Symposium in February 2020 and the 2020 ASCO Virtual Scientific Program in May 2020, respectively. Based on regulatory feedback from the FDA, and if supported by the clinical data, we intend to file with the FDA for accelerated approval in an mCRPC indication as early as 2021.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. Notably, these efforts are led by some of the same experienced scientists that led the efforts to discover cabozantinib, cobimetinib and esaxerenone, which have been approved for commercialization. Using our expertise in medicinal chemistry, tumor biology and pharmacology and supported by our partners, we are advancing drug candidates across approximately 20 ongoing discovery programs toward and through preclinical development, with plans for up to three new compounds to reach Investigational New Drug (IND) filing status before the end of 2020. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The first compounds to advance from our recent internal drug discovery efforts include XL092, a next-generation oral tyrosine kinase inhibitor that is currently in a phase 1 clinical trial in patients with advanced solid malignancies for which we anticipate that dose expansion cohorts and potential combination cohorts with ICIs will begin enrolling in 2020, and XL265, a TAM kinase-focused kinase inhibitor for which we anticipate filing an IND in 2020. We augment our internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. In furtherance of this strategy, in 2019, we entered into collaboration and license agreements with&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene Discovery Technologies Limited (Aurigene), which is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on the discovery and development of novel small molecules as therapies for cancer, and Iconic Therapeutics, Inc. (Iconic), which is focused on the advancement of a next-generation antibody-drug conjugate (ADC) program targeting tissue factor in solid tumors. Both the lead Aurigene program targeting CDK7 and the tissue factor ADC program with Iconic are in preclinical development and could result in IND filings in 2020. We have also made progress under our 2018 collaborations with Invenra, Inc., which is focused on the discovery and development of multispecific antibodies for the treatment of cancer, and StemSynergy Therapeutics, Inc., which is focused on the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1 alpha</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To further enhance our early-stage pipeline, we expect to enter into additional, external collaborative relationships around assets and technologies that complement our internal drug discovery and development efforts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">COVID-19 Update</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of the date of this Quarterly Report, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Clinical Trials</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To varying degrees and at different rates across our clinical trials being conducted in regions impacted by COVID-19, we have experienced declines in screening and enrollment activity, delays in new site activations, and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. However, we recently began to see an increase in screening and enrollment activity, and overall, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful in preventing material delays to our ongoing and planned clinical trials. We have done this through ongoing assessment of the pandemic&#8217;s impact and, wherever possible, taking proactive steps in compliance with guidance issued by the FDA, European Medicines Agency (EMA) and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may be further slowed due to the COVID-19 pandemic, especially if it continues to grow in severity. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Drug Discovery and Preclinical Development</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have partially resumed internal drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">this temporary suspension did not result in any significant changes to the timelines for our late-stage discovery work, we did experience modest delays in the advancement of certain of our early-stage programs</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. However, those service providers have resumed discovery work and are meeting their contractual obligations in accordance with planned </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">timelines. Prior to the COVID-19 pandemic, we largely outsourced preclinical development work to third-party contractors, and that work has continued without substantial delay or interference resulting from the COVID-19 pandemic. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">While we continue to utilize our resources effectively to move new product candidates toward the clinic, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines due to the COVID-19 pandemic, especially if it continues to grow in severity.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Commercial Activities</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although our field employees have limited their in person promotional activities, they remain engaged with healthcare professionals and are available to them as an informational resource. Nevertheless, with healthcare professionals acutely focused on the COVID-19 pandemic and patient access to healthcare professionals limited due to shelter in place orders, we experienced a decrease in demand for CABOMETYX during the quarter ended June 30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also observed fluctuations in CABOMETYX ordering, and we believe that this effect could continue depending on developments related to the COVID-19 pandemic. Overall, despite the challenges posed by the pandemic, our commercial business has only experienced a small impact. We believe this is the case largely because of the gravity of the cancer conditions that our products are indicated to treat and the fact that CABOMETYX has been available as an orally administrable cancer treatment in the U.S. since 2016, thereby establishing a safety and efficacy profile that is well known to healthcare professionals. It remains possible, however, that over a longer period, changes to our standard sales and marketing practices resulting from the COVID-19 pandemic, including the shift from in-person to primarily telephonic and virtual interactions with healthcare professionals, along with</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> obstacles to patient access to healthcare professionals</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, could diminish sales of our marketed products</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Supply Chain</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.&#160; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have not experienced production delays or seen any significant impact to our clinical or commercial supply chain as a result of the COVID-19 pandemic. In addition, we have substantial safety stock inventories for both our commercial drug substance and drug products, which should be sufficient to maintain robust long-term supply. We continue to work closely with our third-party contract manufacturers, suppliers, comparator drug sourcing vendors and collaboration partners to&#160;safeguard both the timely production and delivery of our products. If the COVID-19 pandemic becomes more severe, however, we are prepared to modify our manufacturing and supply chain operations as appropriate in response</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">General Business Operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Most of our Alameda-based employees began working remotely on March 16, 2020, while a small number of employees have continued to work on-site in order to maintain critical operational activities. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Beginning in June 2020, we started permitting some of our employees to return to our Alameda headquarters under enhanced safety and social distancing protocols. Although having most of our employees continue to work remotely has required that we devise new ways of working and collaborating, to date we have not experienced any material reduction in productivity or interruptions in our general business operations. If the COVID-19 pandemic becomes more severe, however, we may find it more challenging to maintain that level of productivity, to grow the company as we have anticipated, and to execute on our long-term business plans.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The circumstances surrounding the COVID-19 pandemic are volatile and subject to rapid change. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout 2020, and potentially in future years should the adverse effects of the COVID-19 pandemic continue indefinitely.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Second Quarter 2020 Business Updates and Financial Highlights</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the second quarter of 2020, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Updates</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2020, Takeda, our partner responsible for the clinical development and commercialization of CABOMETYX in Japan, received approval from the Japanese MHLW to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic RCC. During the second quarter of 2020, Takeda launched CABOMETYX in Japan, triggering  $31.0 million in milestone payments from Takeda upon the first commercial sale of CABOMETYX, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$23.7 million </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was recognized as revenue in this quarter.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2020, we announced that CheckMate -9ER, BMS&#8217; phase 3 pivotal trial evaluating</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> the combination of cabozantinib and nivolumab in previously untreated advanced or metastatic RCC, met its primary endpoint of significantly improving PFS, as well as the secondary endpoints of OS and ORR, versus sunitinib. More detailed results of CheckMate -9ER will be presented as part of the Presidential Symposium II at the upcoming ESMO Virtual Congress 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2020, cabozantinib was the subject of 12 presentations at the 2020 ASCO Annual Meeting. Data presentations included results from NSCLC, mCRPC and urothelial carcinoma cohorts of COSMIC-021, as well as updates from other externally sponsored studies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2020, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">filed a second complaint in our patent infringement lawsuit against</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> MSN Pharmaceuticals, Inc. (MSN), </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">following receipt of notice from MSN</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> that it had amended its Abbreviated New Drug Application (ANDA), originally filed with the FDA in September 2019, to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of t</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">wo previously-unasserted CABOMETYX patents listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">: U.S. Patent No. 7,579,473, the composition of matter patent, and U.S. Patent No. 8,497,284, a method of use patent.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284, and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents.&#160;For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June 2020, we announced the initiation of CONTACT-01, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic NSCLC who have been previously treated with an ICI and platinum-containing chemotherapy. The primary endpoint of the trial is OS, and the secondary endpoints include PFS, ORR and duration of response (DOR)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June 2020, we announced the initiation of CONTACT-02, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with mCRPC who have been previously treated with one novel hormonal therapy. The co-primary endpoints of the trial are PFS and OS, and the secondary endpoints include ORR, prostate-specific antigen response rate and DOR</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">July 2020, we announced the initiation of CONTACT-03, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab in patients with inoperable, locally advanced or metastatic RCC who progressed during or following treatment with an ICI as the immediate preceding therapy. The co-primary endpoints of the trial are PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 as assessed by independent review and OS, and the secondary endpoints include PFS, ORR and DOR as assessed by the investigators</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2020, we completed patient enrollment in EXAMINER, the phase 4 trial evaluating the safety and efficacy of the 60 mg tablet formulation of cabozantinib compared with the 140 mg capsule formulation, which is marketed as COMETRIQ, for the treatment of patients with progressive, metastatic MTC. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">EXAMINER is a post-marketing requirement from the FDA and the European Commission. The trial was designed to enroll up to 250 patients, and top-line results from the trial are anticipated later in 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2020, the FDA approved the supplemental Biologics License Application submitted by Genentech for atezolizumab plus cobimetinib and vemurafenib for the treatment of BRAF V600-mutation positive advanced melanoma in previously untreated patients. The approval is based on positive results from IMspire150, a phase 3 pivotal trial that demonstrated that adding atezolizumab to cobimetinib and vemurafenib helped to reduce the risk of disease worsening or death, compared to placebo plus cobimetinib and vemurafenib. This is the second FDA approval for a regimen including cobimetinib, which we discovered and is now being developed by Genentech as part of a worldwide collaboration agreement between the two companies</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2020, we announced </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the completion of patient enrollment in COSMIC-312, a global phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, providing the patient population for the event-driven analyses of the study&#8217;s endpoints. Separately, patient enrollment remains open in China with a focus on enrolling the necessary patient number to enable local registration, if supported by the clinical data. The co-primary endpoints of the trial are PFS and OS. Based on current event rates, we anticipate announcing top-line results in&#160;the first half of&#160;2021.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Financial Highlights</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues for the second quarter of 2020 were </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$178.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$193.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for the second quarter of 2020 were </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$259.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$240.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses for the second quarter of 2020 were </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$114.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$81.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses for the second quarter of 2020 were </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$59.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$58.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for the second quarter of 2020 was </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$13.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$20.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income for the second quarter of 2020 was </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$66.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.22</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.21</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, diluted, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$79.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.26</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.25</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share diluted, for the second quarter of 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments were </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1.5 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1.4 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to the challenges and risks imposed by the COVID-19 pandemic and described under &#8220;&#8212;COVID-19 Update&#8221; above, we will also continue to face challenges and risks that may impact our ability to execute on our 2020 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and possibly for other indications for which cabozantinib is being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from such trials. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Achievement of our 2020 business objectives and the continued success of CABOMETYX will also depend on the success of our development and commercialization strategies to navigate increased competition, including that from, but not limited to, the use of therapies that combine an ICI with another targeted agent to treat cancer. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of CABOMETYX tablets that is the subject of an ANDA submitted to the FDA by MSN, which if approved, could result in significant decreases in the revenue derived from the U.S. sales of CABOMETYX and thereby materially harm our business and financial condition. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with internal drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. Moreover, as described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal Year Convention</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the three months ended July 3, 2020 and June 28, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the three months ended June 30, 2020 and June 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. </span></div><div><a id="s20A48847310654FDA264597F1EC2F758"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">178,730</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,675</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(8</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">372,610</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">373,256</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">0</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">59,234</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">37,742</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">57</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">80,113</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">63,306</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">27</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21,515</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,858</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">143</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33,671</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">19,200</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">75</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">259,479</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">240,275</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">486,394</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">455,762</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">229,898</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">240,418</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">482,464</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">464,168</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(51,168</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(46,743</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(109,854</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(90,912</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">178,730</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,675</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">372,610</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">373,256</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">173,610</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">189,015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">362,826</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">364,905</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,120</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,660</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,784</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,351</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">178,730</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,675</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">372,610</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">373,256</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in product revenues for CABOMETYX for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were due to decreases in the number of units of CABOMETYX sold, which were partially offset by increases in the average net selling price of the product. We partially attribute these decreases in the number of units of CABOMETYX sold to factors related to the COVID-19 pandemic, including obstacles to patient access to healthcare professionals and fluctuations in product ordering patterns. The increases in product revenues for COMETRIQ for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were due to increases in the number of units of COMETRIQ sold and increases in the average net selling price of the product.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our net product revenues for the remainder of 2020 to remain in-line with 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in discounts and allowances for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was primarily the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">result of increases in Public Health Service hospital utilization. We do not expect our discounts and allowances as a percentage of gross revenues to change significantly during the remainder of 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">License Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and the profit on the U.S. commercialization of COTELLIC from Genentech. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $43.5 million and $43.6 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $20.4 million and $30.5 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Milestone revenues by period included the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> $23.7 million in revenues recognized in connection with $31.0 million in milestones</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we achieved upon Takeda&#8217;s first commercial sale of CABOMETYX as a treatment for patients with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">curatively </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unresectable or metastatic RCC in Japan and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$18.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenues recognized in connection with a </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$20.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> development milestone from Ipsen </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we determined was probable of achievement</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included recognition of a $20.0 million milestone from Daiich</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">i Sankyo for the launch of MINNEBRO tablets as a treatment for patients with hypertension in Japan. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> also included $9.5 million in revenues recognized in connection with a $16.0 million milestone from Takeda for the submission in April 2019 of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese MHLW.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Royalties increased primarily as a result of increases in royalties earned on Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$16.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and $34.2 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, compared to $14.9 million and $28.9 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to increased demand of CABOMETYX, which, as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, is approved in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> countries outside of the U.S. Royalties also increased due to the commercial launch of CABOMETYX as a treatment for patients with curatively unresectable or metastatic RCC in Japan by Takeda during the three months ended June 30, 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our license revenues to decrease during the remainder of 2020, as compared to the same period in 2019, as a result of a decrease in milestones expected to be achieved during the year.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Services Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration services revenues include the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales by Ipsen of products containing cabozantinib.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements were $19.6 million and $34.0 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $10.2 million and $20.5 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases in development cost reimbursements were primarily a result of reimbursements from Ipsen for their share of the increase in spending on the COSMIC-312, COSMIC-021 and CONTACT-02 studies.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration services revenues were reduced by $2.3 million and $4.7 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GSK on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, compared to $2.0 million and $3.9 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As royalty generating sales of cabozantinib by Ipsen have increased as described above, our royalty payments to GSK have also increased.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect collaboration services revenues to increase during the remainder of 2020, as compared to the same period in 2019, as a result of higher development cost reimbursements earned under our collaboration agreements including in particular the impact of CONTACT-01 and CONTACT-02.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,221</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,539</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">22</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18,510</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,040</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">95</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">95</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty payable to GSK on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increases in cost of goods sold for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily the result of increases in write-downs of inventory and certain period costs. We do not expect our gross margin to change significantly during the remainder of 2020.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">114,933</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">81,932</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">40</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">216,810</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,221</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">49</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial costs, personnel expenses, license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs, stock-based compensation, and consulting and outside services. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in clinical trial costs, personnel expenses, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs, which were partially offset by decreases in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs and the impact of development cost reimbursements. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparator drug purchases</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$34.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$59.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases in clinical trial costs were primarily due to costs associated with the expanding clinical trial program for cabozantinib, which includes COSMIC-312, COSMIC-313, CONTACT-02 and COSMIC-021. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$6.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount to support our expanding discovery and development efforts. License and other collaboration costs decreased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily as a result of upfront license fee payments we made in 2019, offset in part by an increase in payments for our research funding commitments. Research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> were reduced by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as a result of development cost reimbursements </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">connection with our December 2019 collaboration arrangement with Roche; there were no such reimbursements during the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened research and development expenses on a project-by-project basis.&#160;We group our research and development expenses into three categories: 1) development; 2) drug discovery; and 3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses by category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">62,606</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28,369</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">115,950</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">56,556</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20,610</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,526</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">40,898</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,113</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,811</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,089</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,055</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,801</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,194</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,935</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,935</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,069</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">92,221</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">51,919</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">173,838</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">100,539</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License and other collaboration costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,239</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14,975</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,252</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17,481</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other drug discovery</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,407</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,440</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,141</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,974</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total drug discovery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,646</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21,415</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">25,393</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28,455</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,066</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,598</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17,579</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">16,227</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">114,933</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">81,932</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">216,810</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,221</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation, the allocation of general corporate costs to research and development, and development cost reimbursements in connection with our December 2019 collaboration arrangement with Roche.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we expect that a significant portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">100</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. Notable company-sponsored studies resulting from this program include: COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; CONTACT-02 for which Roche is sharing in the development costs including the provision of atezolizumab free of charge; and COSMIC-311. In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC led to the ongoing EXAMINER study in that indication.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we conduct internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Subject to the impact of the COVID-19 pandemic on our research and development efforts described under &#8220;&#8212;COVID-19 Update&#8221; above, we expect our research and development expenses to continue to increase over the remainder of 2020 as a result of the expected initiation and completion of numerous late-stage and other potentially label-enabling cabozantinib trials. In addition, our research and development expenses may further increase as we enter into business development transactions to augment our internal drug discovery efforts.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses were as follows (dollars in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">59,791</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">58,815</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">122,731</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">118,953</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs, and certain other administrative costs. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in selling, general and administrative expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to the increases in personnel expenses and the Branded Prescription Drug Fee, which were offset by decreases in marketing costs. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in administrative headcount to support our commercial and research and development organizations. The Branded Prescription Drug Fee increased $0.5 million and $5.8 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to a change in estimate for such fees related to 2018 and 2019 sales following our receipt of the 2020 preliminary fee notice from the Internal Revenue Service for the 2018 sales year. Marketing costs decreased $2.9 million and $6.4 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our selling, general and administrative expenses to continue to increase during the remainder of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in support of our continued commercial investment in CABOMETYX and the growth of the broader organization.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Non-operating Income</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Items of non-operating income were as follows (dollars in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,162</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,975</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(26</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,382</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,062</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">803</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">828</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(99</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in interest income for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were the result of lower interest rates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Provision for Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The provision for income taxes and effective income tax rates were as follows (dollars in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent Change</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,875</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20,725</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">25,298</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">35,621</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(29</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Effective income tax rate</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17.2</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20.8</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in the provision for income taxes for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to decreases in pre-tax income. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> differed from the U.S. federal statutory rate of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;primarily due to excess tax benefits related to the exercise of certain stock options during the periods.</span></div><div><a id="sAE723BE52B10524DB01074E9C4D5F765"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments, compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect to continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations. The COVID-19 pandemic has caused volatility in the U.S. and global financial markets and a downturn in the U.S. and global economy, which may adversely impact our rates of return for our invested cash resources, the availability and cost of credit, as well as our ability to&#160;raise additional funds in the capital markets. Among other things, our inability to access additional funds could in the future inhibit our ability to engage in larger-scale strategic transactions or investments</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flow activities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">157,751</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">293,321</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by (used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">105,894</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(250,586</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash (used in) provided by financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(3,003</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,279</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income, the most significant of which may include the timing of milestones payments from our collaboration partners. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factors that contributed to the decrease in cash provided by operating activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were an increase in cash paid for operating expenses as a result of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$78.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in operating expenses, a $33.0 million decrease in milestone payments received, and other net changes in operating assets and liabilities described above.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included cash provided by the maturities and sales of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$549.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$433.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and purchases of property, equipment and other of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$518.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and property and equipment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturities and sales of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$271.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements of equity awards, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$17.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive and stock purchase plans.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive and stock purchase plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements of equity awards.</span></div><div><a id="s3E3AF2ED8AE958E78B3F3A0CA384F7CB"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no material changes outside of the ordinary course of business in our contractual obligations as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from those disclosed in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div><a id="sD125FC7AFDBC574E8057A15D9D896D03"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been no significant changes in our critical accounting policies and estimates during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div><a id="s28E46A8B3EE9540189D98C957B5BEA51"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our market risks as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><a id="s72B09ECCF6C6515EA9D64C7052618B30"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Controls and Procedures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the effectiveness of controls.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in internal control over financial reporting. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD3A0A824FF935F609BE2193A557D4794"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II. OTHER INFORMATION</span></div><div><a id="s583792048820564688F3B7727DC8A98B"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div><a id="s6E97F3A039435CF89644389568E05D92"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the risks discussed elsewhere in this report, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and possibly for other indications for which cabozantinib is being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from such trials. In this regard, part of our strategy is to pursue additional indications for cabozantinib to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we fail to achieve anticipated product royalties and collaboration milestones, whether as a result of the COVID-19 pandemic or otherwise, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If the COVID-19 pandemic becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">&#160;&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business could be materially and adversely impacted by the ongoing COVID-19 pandemic, a disease caused by a novel coronavirus, SARS-CoV-2, which has spread globally. The COVID-19 pandemic continues to have a modest impact on our business operations, in particular on our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials being conducted in regions impacted by COVID-19, we experienced declines in screening and enrollment activity, delays in new site activations, and restrictions on access to treatment sites that is necessary to monitor clinical study progress and initiation. As the COVID-19 pandemic continues to surge in various parts of the world, the impact on our clinical development operations could grow more severe. We anticipate that a prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing COSMIC-311, COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02 and CONTACT-03 clinical trials. Disruptions to medical and administrative operations at clinical trial sites and the implementation of crisis management initiatives have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could delay our clinical trial plans or require certain trials to be temporarily suspended. Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also interfere with and potentially negatively impact clinical trial results. In addition, new and increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in administering those clinical trials to increase considerably. Specifically, with respect to our clinical trials evaluating cabozantinib in combination with therapies that must be administered via professional intravenous infusion, such as COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02 and CONTACT-03, limited patient movement or interrupted healthcare services at medical institutions have delayed in some instances and may continue to delay or prevent on-site infusion of the therapies being evaluated in combination with cabozantinib. If a sizable portion of patients in our combination studies are unable or unwilling to receive all components of the combination therapy being tested in accordance with the applicable clinical trial protocol, those studies could be delayed, suspended or prevented from producing statistically significant results.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depending upon the severity of the COVID-19 pandemic, we could also experience delays in the commencement of new clinical trials of cabozantinib, or our earlier-stage investigative product candidates. The COVID-19 pandemic could also impede internal clinical operations and delay our planning and preparation timelines for new clinical trials, as well as adversely affect our ability to obtain regulatory approval for clinical protocols and increase the operating expenses connected with these new clinical trials.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, the COVID-19 pandemic caused us to suspend internal drug discovery work in our laboratories temporarily while we observed the shelter in place orders issued by the State of California and Alameda County. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. While both internal drug discovery work in our laboratories and outsourced drug discovery activities have since partially resumed, we may be unable to maximize the potential of these programs due to reduced staffing and the imposition of increased safety protocols, and should the COVID-19 pandemic continue to grow in severity, we may have to further  scale back activities in the future. For example, as a result of spikes or surges in infection, positivity or hospitalization rates, we may choose or be required to suspend work in our laboratories, which will once again impede our internal drug discovery efforts. Prior to the COVID-19 pandemic, we had largely outsourced preclinical development work, as well as certain drug discovery activities, to third-party contractors, and although to date that work has continued without substantial delay or interference, the COVID-19 pandemic could impede these third parties from providing timely deliverables to us in the future. As a result of the COVID-19 pandemic, especially if it continues to grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, while we believe that our commercial business has only experienced a small impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including the shift from in-person to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although as of the date of this Quarterly Report, we have substantial safety stock inventories for both our commercial drug substance and drug products and, to our knowledge, we have not yet experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers may experience delays, facility closures and other hardships due to COVID-19, which could potentially impact our supply chain and cause delays or disruption in our commercial or clinical supply of our products or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product candidates. These potential delays or disruptions to our supply chain could be exacerbated if the COVID-19 pandemic begins to impact essential mail distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues.  </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of the date of this Quarterly Report, we have taken temporary precautions to help mitigate the risk of transmission of the virus, including: initially requiring Alameda-based employees to work remotely beginning on March 16, 2020, with rare exceptions to maintain critical operational activities, and then beginning in June 2020, permitting some of our employees to return to our Alameda headquarters under enhanced safety and social distancing protocols; suspending all non-essential business travel for our employees; and limiting the circumstances under which our field employees may engage in in-person promotional activities with healthcare professionals. Over a longer period, all of these measures could negatively affect our business operations and prospects in both foreseeable and unforeseeable ways. For instance, requiring employees to work remotely while we adhered to shelter in place orders limited our internal drug discovery activities, and although we have begun to allow our employees to return to our Alameda headquarters under enhanced safety and social distancing protocols, if we are forced to, or determine that we should, resume shelter in place restrictions for an extended period of time, this would eventually cause substantial delays and otherwise negatively impact the effectiveness of these programs and delay our ability to execute on our long-term business plans. Further, extended periods of remote work could impede the focused attention of management or reduce the productivity of teams that would otherwise be working closely together.&#160;The COVID-19 pandemic has also caused volatility in the U.S. and global financial markets and a downturn in the U.S. and global economy, which may adversely impact our rates of return for our invested cash resources, the availability and cost of credit, as well as our ability to&#160;raise additional funds in the capital markets. Among other things, our inability to access additional funds could in the future inhibit our ability to engage in larger scale strategic transactions or investments</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact arising from the COVID-19 pandemic to our business and our financial results, as well as to the value of and market for our common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease.  These effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, as further explained in the risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.  In addition, to the extent the ongoing COVID-19 pandemic adversely impacts our business and financial results, it may also have the effect of exacerbating many of these other risks and uncertainties inherent to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their foreign sales of CABOMETYX, could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or otherwise. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">medical community. Market acceptance for CABOMETYX could depend on numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts, the impact to healthcare systems and our ability to successfully communicate product information to healthcare professionals resulting from the COVID-19 pandemic, and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by constant technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy following the advent of ICIs. While we have adapted our cabozantinib development strategy to address the use of therapies that combine ICIs with other targeted agents in indications for which CABOMETYX is approved, we cannot ensure that our ongoing or planned clinical trials will show efficacy in comparison to competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or increase our internal sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and pre-commercial-stage oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical and biotechnology organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to maintain primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to enter into or maintain agreements with third parties to store, distribute and commercialize our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize our products successfully will depend, in part, on the adequacy of our distribution of those products to eligible patients. We currently rely on third-party providers for storage and distribution and on collaboration partners for ongoing commercialization and distribution of CABOMETYX and COMETRIQ in their respective </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply CABOMETYX and COMETRIQ on a timely and competitive basis. The services provided by these third parties may not be effective or timely, which risks may be increased as a result of the COVID-19 pandemic. In such cases, we may be unable to maintain, improve or renew our arrangements with these third parties or enter into new, alternative arrangements with other service providers, on acceptable terms or at all. If we are unable to contract successfully for effective third-party services on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">th</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">e Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Open Payments program of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (PPACA), which was created under the Physician Payments Sunshine Act and its implementing regulations and requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians (as defined by such law) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities, as well as state and local laws requiring the registration of pharmaceutical sales representatives; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state pharmaceutical price and price reporting laws and regulations that require us to provide notice of price increases or the introduction of new high-cost products, and/or file complex ancillary reports concerning prices and pricing and discount practices.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. Under the False Claims Act, these individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the civil False Claims Act, or settles a lawsuit brought pursuant to the False Claims Act to avoid further prosecution, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, if any such action is brought against us, our business may be impaired, even if we are ultimately successful in our defense</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We face related uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. Notably, in December 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the penalty enforcing the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Then, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld this District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well. While the U.S. Supreme Court has agreed to review an appeal of the 5th Circuit&#8217;s decision in 2020, it is unclear how this decision, future decisions, subsequent appeals and other efforts will impact the PPACA. Additionally, the 2020 federal spending package permanently repealed, effective January 1, 2020, the PPACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device taxes, and, effective January 1, 2021, also eliminates the health insurer tax. There is no assurance that the repeal or modification of some or all of the provisions of the PPACA in the future, will not have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the healthcare industry. It is also possible that additional governmental actions will be taken to address the ongoing COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of these developments and trends, third-party payers are increasingly attempting to contain healthcare costs by limiting coverage and the level of reimbursement of new drugs. Insurers are also pursuing means of contracting for pharmaceutical &#8220;value&#8221; or &#8220;outcomes.&#8221; These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of value-based contracting, which could adversely affect product sales. Furthermore, the expansion of the 340B Drug Discount Program has increased the number of purchasers eligible for significant discounts on branded drugs, including our marketed products. Due to the volatility in the current regulatory and market dynamics, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, any such measures could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as Executive Orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients; reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; revise rebate payments for prescription drugs under Medicaid and the methodologies to calculate average manufacturer price and best price; and facilitate the importation of certain lower-cost drugs from other countries. While we cannot know the final form of any such legislative, regulatory and/or administrative measures, some of the pending legislative proposals, such as those incorporating International Pricing Index models, if enacted, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with its evaluation of proposals concerning the pricing of, and access to, pharmaceutical products, many companies in our industry have received governmental requests for documents and information relating to drug pricing and patient support programs. We could receive a similar request, which would require us to incur significant expense and divert the attention of management. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, these findings could further harm our business, reputation and/or prospects.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For example, California adopted SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide advance notice of price increases above a defined threshold to certain purchasers and related reports to the government. Such obligations to provide notices of price increases to purchasers may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of drug pricing transparency regulations, and our associated compliance obligations, may increase general and administrative costs and/or diminish our revenues as a result of the imposition of caps on pricing and price increases. Therefore, the implementation of these cost-containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products resulting in a decrease in revenue.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Outside the U.S., particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner Ipsen may also be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and Ipsen might establish for CABOMETYX, which would result in lower license revenues to us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">A significant and prolonged economic downturn, whether globally or just within the U.S., could have a substantial impact on our revenues and financial condition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our revenues are substantially dependent on the net pricing that we ultimately realize in payment for our marketed products, and commercial third-party payers do not receive the same degree of discounts and allowances that we provide to government payers. In the event of a significant and prolonged economic downturn, the number of patients enrolled in commercial health insurance programs is likely to decrease, particularly in the U.S. where workforce reductions could cause widespread loss of the private health insurance coverage typically provided by employers, and a commensurate shift of eligible individuals to government insurance programs or to the circumstance of lacking health insurance coverage altogether. The effects of the COVID-19 pandemic, among other catalysts, have already caused a downturn in the U.S. and global economy and significant levels of unemployment, and the duration and severity of this economic downturn are not yet known. Depending on the severity of the COVID-19 pandemic, as well as other factors, we could experience a substantial decrease in revenues as a result of the increase in gross-to-net discounting applied to the price of our products due to a substantial shift from private health insurance coverage to government insurance coverage, and also a significant increase in demand for our patient assistance and/or free drug program, all or any of which would adversely affect our product revenues.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The U.S. Department of Health and Human Services Office of Inspector General established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are deemed not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities.  Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare professional.&#160; For manufacturers of specialty </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pharmaceuticals</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Regardless of whether we have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection continues to evolve globally and in the U.S. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation on January 1, 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. Similar legislative proposals being advanced in other states and Congress is also considering federal privacy legislation. In addition, most healthcare providers are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly encourage, assist or otherwise facilitate a HIPAA-covered entity (or its business associate) to use or disclose </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also restricts transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA and GDPR, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Legislation and regulatory action designed to facilitate the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the commercial potential of our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in whole or in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail under &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 25, 2020. In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our marketed products prior to the expiry of one or more our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs and divert the attention of management, and could have an adverse impact on our stock price. For example, we received Paragraph IV certification notice letters from MSN concerning the ANDA that it had filed with the FDA seeking approval to market a generic version of CABOMETYX tablets. It is possible that MSN or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which reauthorized the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which applicants for such products partially pay for the FDA&#8217;s pre-market review of their product candidates and pay other specified fees. The legislation also includes, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. In addition, the FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act of 2019, signed into law as part of the 2019 year-end federal spending package, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing generic manufacturers access to branded drug samples. While we cannot predict the specific outcome or impact on our business of such regulatory actions or legislation, they do have the potential to facilitate the development and future approval of generic versions of our products, or otherwise limit or reduce the term for our market exclusivity, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of cabozantinib for new indications, or of new potential product candidates, is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of that product for a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib (or of other product candidates) in new indications, and in some cases, as described in the risk factor titled, &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">If the COVID-19 pandemic becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such developments to occur. These may include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of acceptable efficacy or a tolerable safety profile;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, including as a result of the COVID-19 pandemic, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of cabozantinib or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to pursue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable authorities in other countries. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual additional indications. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-approval studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. For example, based on the regulatory feedback from the FDA, and if supported by the clinical data from COSMIC-021, we intend to file with the FDA for accelerated approval of cabozantinib in an mCRPC indication as early as 2021. We expect that as a condition of any potential approval under the FDA's accelerated approval pathway, the FDA will require us to perform confirmatory post-marketing clinical trials to confirm the clinical benefit, if any, of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, such as mCRPC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in any additional indications. Further, these regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply successfully with regulatory requirements, including withdrawal of product approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, on March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in response to the COVID-19 pandemic. Amongst other provisions, the CARES Act made a number of changes to the FDCA aimed at preventing drug shortages. While we are still evaluating these and other CARES Act changes, these changes could impact our business. For example, in light of the COVID-19 pandemic, the FDA has issued a number of guidance documents describing the agency&#8217;s expectations for how drug manufacturers should comply with various FDA requirements during the pandemic, including with respect to conducting clinical trials, distributing drug samples, and reporting post-marketing adverse events. In addition, as a result of the COVID-19 pandemic, there has been increasing political and regulatory scrutiny of foreign-sourced drugs and foreign drug supply chains, resulting in proposed legislative and executive actions to incentivize or compel drug manufacturing operations to relocate to the United States. These political and regulatory developments and any further guidance documents issued by FDA that impact the requirements to which we are subject, as well as any equivalent federal or state legislative or regulatory initiatives, or similar measures outside of the United States, could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding such investment, we temporarily suspended internal drug discovery in our laboratories due to the COVID-19 pandemic, among other limitations to our programs described in the risk factor titled, &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">If the COVID-19 pandemic becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;  While we have since partially resumed our drug discovery operations, even assuming we successfully return these operations to full capacity in the future, many programs that may have initially shown promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product candidates to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160;We may also be unable to in-license or acquire additional product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If our internal drug discovery or business development efforts do not result in suitable product candidates, our business and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although we do not intend to disclose material, nonpublic information through these means. Despite our efforts to monitor social media communications, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may result in violations of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements, Accounting and Financial Results</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our profitability could be negatively impacted by our extensive clinical development, business development and commercialization activities for cabozantinib and pipeline expansion efforts relative to the revenues we generate.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$115.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and $321.0 million for the year ended December 31, 2019, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; other collaboration revenues; and the level of our expenses, including for development and commercialization activities for cabozantinib and for any pipeline expansion efforts. We expect to continue to spend substantial amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of additional partnerships through business development activities or strategic transactions that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial outlook may not be realized.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">From time to time, in press releases and otherwise, we may publish estimates, forecasts or other forward-looking statements regarding our future financial or operating results, including estimated revenues, expenses and earnings. Any forecast of our future performance reflects various assumptions. These assumptions are subject to significant risks and uncertainties, and as a matter of course, any number of them may prove to be incorrect. Further, the achievement of any </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">forecast depends on numerous assumptions and other factors (including those described in this discussion), many of which are beyond our control. Moreover, the impact of the COVID-19 pandemic on our profitability, especially if it continues to grow in severity, is difficult to predict. As a result, we cannot be certain that our performance will be consistent with any management estimates or forecasts or that the variation from such estimates or forecasts will not be material and adverse. Current and potential stockholders are cautioned not to base their entire analysis of our business and prospects upon isolated estimates or forecasts, but instead are encouraged to utilize our entire publicly available mix of historical and forward-looking information, as well as other available information regarding us, our products, the competitive landscape for our products, our commercialization, development and regulatory efforts, as well as those of our collaboration partners, and the biotechnology and pharmaceutical industry generally when evaluating our prospective financial or operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Our business operations grew substantially during 2019 and the first six months of 2020. In order to maintain business growth during the remainder of 2020, we plan to continue to execute on our U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib and our other product candidates, internal discovery activities, and the execution of strategic transactions. Our ability to achieve these business objectives will depend on many factors including but not limited to: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impact </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the COVID-19 pandemic on our ability to conduct critical business operations, including internal drug discovery activities, clinical trials and commercial operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number and size of clinical trials we conduct and the cost of drug supply for such clinical trials evaluating our products with other therapeutic agents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib and increasing internal drug discovery activities, as well as through the execution of strategic transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including disruptions that have resulted and may continue to result from the COVID-19 pandemic and the related downturn in the U.S. and global economy, as well as future potential U.S. federal government shutdowns, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise additional funds in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160;In particular, our inability to access additional funds, whether due to the COVID-19 pandemic or otherwise, could in the future inhibit our ability to engage in larger scale strategic transactions or investments</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We do not know whether </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory, stock-based compensation and income taxes reflect the more significant estimates and judgments used in the preparation of our Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements from the Financial Accounting Standards Board and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and, as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, our other results of operations or our current financial position.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to income tax in the U.S. as well as numerous U.S. states and territories, municipalities, and other local jurisdictions. As a result, our effective tax rate is derived from various factors including the mix of forecast and actual earnings and applicable tax rates in the various places that we operate, the accounting for stock options and stock-based awards, and research and development spending. In preparing our financial statements, we estimate the amount of tax that will become payable in each jurisdiction. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in tax laws, changes in the mix of our earnings from state to state, the results of examinations and audits of our tax filings, or our inability to secure or sustain acceptable agreements with tax authorities. Any of these factors could cause our effective tax rate to fluctuate.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses and tax credits to offset future taxable income may be subject to limitations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2019, we had federal and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to the recent California franchise tax law change affecting California state net operating losses mentioned below, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state net operating loss carryforwards of approximately $675 million. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Portions of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2035 for federal income tax purposes and 2020 for state income tax purposes. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Portions of these</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code (the Code) and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a portion of our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">net operating losses and credit carryforwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2019, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses is conditioned upon our maintaining profitability and generating U.S. federal taxable income. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, at the state level, there may be periods during which the use of net operating losses is suspended or otherwise limited. For example, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">California recently imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The United Kingdom&#8217;s (UK&#8217;s) withdrawal from the EU&#160;may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Following the ratification of the Withdrawal Agreement by the European Parliament and UK Parliament, the UK left the EU on January 31, 2020 (commonly referred to as &#8220;Brexit&#8221;). The Withdrawal Agreement provides for a transition period until December 31, 2020, during which the UK remains in the single market and customs union and the free movement of goods, services, people and capital will continue, in order to ensure frictionless trade and business continuity until a long-term relationship is agreed. At the end of transition, the UK&#8217;s relationship with the EU will be determined by the new agreements it has entered into on trade and other areas of cooperation. The new agreements must be reached before the transition period ends. If not, the UK would have to rely on previous international conventions for security cooperation and would trade with the EU on World Trade Organization terms. The exception is Northern Ireland, whose trade in goods with the EU would be covered by the provisions in the Northern Ireland Protocol. As a result of the COVID-19 pandemic, planned negotiating rounds for the UK&#8217;s future relationship with the EU have not been progressing at a pace that would facilitate a final agreement on trade and cooperation between the UK and the EU prior to December 31, 2020. Under these circumstances, it is uncertain whether the UK and EU would agree to extend the transition period beyond December 31, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications Brexit will have and how it might affect us. For example, we rely on third-party contract manufacturing organization facilities located in the UK, responsible for packaging, labeling, storing and subsequently distributing supplies of our product to the EU. Any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the UK and the EU that ultimately result from Brexit may have an adverse impact on this part of our supply chain. Trade restrictions, changes to the regulatory approval or drug cost reimbursement systems, and additional administrative costs may impede the ability of our collaboration partner Ipsen to market our products in Europe. Furthermore, the initial announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations; therefore, the Brexit transition may continue to adversely affect European and global economic and market conditions, which may cause third-party payers, including governmental organizations, to closely monitor their costs and reduce their spending budgets, and which could contribute to instability in the global financial and foreign exchange markets. Any of these effects of Brexit could have a material adverse impact on our business, financial condition and results of operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subject us to a number of risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies, including, Ipsen, Takeda, Roche and Genentech, BMS and Daiichi Sankyo, for the development and ultimate commercialization of our products. Our dependence on our relationships with collaboration partners for the development and commercialization of compounds subjects us to, a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the amount and timing of resources that our collaboration partners or potential future collaboration partners will devote to the development or commercialization of drug candidates or to their marketing and distribution</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaboration partners may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial (including as a result of the COVID-19 pandemic), deliver product that fails to meet appropriate quality and regulatory standards and results in a market recall or withdrawal, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes that may arise between us and our collaboration partners that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaboration partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaboration partners&#8217; lack of success in their efforts to obtain regulatory approvals in a timely manner, or at all;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaboration partners&#8217; failure to comply with the terms of our collaboration agreements and related ancillary agreements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaboration partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice, Good Clinical Practice, Good Distribution Practice and Good Pharmacovigilance Practice;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaboration partners could independently move forward with competing drug candidates, developed either independently or in collaboration with others, including our competitors</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to enter into additional collaboration arrangements with third parties in an area or field of exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that future collaboration partners may require us to relinquish some important rights, such as marketing and distribution rights; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of, development of our drug candidates.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations and our product development efforts could be delayed, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, whether as a result of the COVID-19 pandemic or otherwise, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our internal drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce materials required for certain preclinical activities and produce our products for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture preclinical, clinical and commercial supplies of our products. As our operations continue to grow in these areas, we continue to appropriately expand our supply chain through secondary third-party contract manufacturers and suppliers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although as of the date of this Quarterly Report, we have substantial safety stock inventories for both our commercial drug substance and drug products and, to our knowledge, have not yet experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers may experience delays, facility closures and other hardships due to COVID-19, which could potentially impact our supply chain and cause delays or disruption in our commercial or clinical supply of our products or product candidates. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude our ability to meet our commercial product supply requirements, or our product supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the supply of CABOMETYX and COMETRIQ for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our partners&#8217; ability to successfully develop and commercialize CABOMETYX and COMETRIQ and generate revenues to which we are entitled under the collaborations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in internal drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by external factors, as we experienced in the early stages of the COVID-19 pandemic. If we have or may continue to experience delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Information Technology, Data Privacy and Intellectual Property</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches, cyber attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber attack. Such vulnerabilities may be further exacerbated by the fact that </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our workforce is operating remotely as we comply with shelter in place orders and the recent rise in COVID-19 phishing attacks targeting remote workers. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous companies have been subject to a wide variety of security incidents, cyber attacks (including through use of ransomware) and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber attacks on our operations and financial condition has not been material to date, we and our third-party vendors have frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack, and such threats can also vary in motive (including corporate espionage). Cyber attacks continue to become more prevalent and much harder to detect and defend against, and it is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information (or sensitive business information of our collaboration partners, which may lead to significant liability for us). A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter partes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN concerning the ANDA that it had filed with the FDA seeking approval to market a generic version of CABOMETYX tablets. Should MSN or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert the attention of management. If we fail in defending such claims, in addition to paying damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">develop or commercialize certain product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for cabozantinib and our other product candidates, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Similarly, the COVID-19 pandemic could negatively impact the health of key personnel or make it difficult to recruit qualified personnel for critical positions. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our headquarters in Alameda, California is located in the San Francisco Bay Area, and therefore our facilities are vulnerable to damage from earthquakes. Our earthquake insurance may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fires and floods, which have become a significant danger in California during recent years, as well as power loss, communications failures, aircraft disasters (due to the proximity of our headquarters to a major international airport), terrorism and similar events, and any insurance we may maintain may be inadequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired, causing significant delays in our programs and making it difficult for us to recover due to the unique nature of our research activities. Accordingly, an earthquake or other disaster could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability or otherwise have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials, and such liability may exceed our insurance coverage and our total assets. In addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, healthcare providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the biotechnology, biopharmaceutical and pharmaceutical industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for cabozantinib or any of our other programs or product candidates</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to make future investments in the expansion of our pipeline through internal drug discovery and business development activities</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products or clinical trial data by our competitors;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications, such as MSN&#8217;s ANDA, seeking approval of generic versions of our marketed products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel or board members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the disposition of any of our technologies or compounds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, such as the impact of the COVID-19 pandemic on financial markets.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, including the effects of the COVID-19 pandemic, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><a id="se4ab3b2c975b48029eb5107107673971"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s1fdf5d4fa34246199955d4e9db9b0a45"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Defaults Upon Senior Securities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s914950cc57a84ff194e17745a51df2cf"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s127dad8d4c694cfa9e003cf6266c1295"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Other Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s4BA46924F56D52F8943EEF35D81ABC31"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Exhibits</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5/25/2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/23/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit32amendedandrestate.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2/20/2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specimen Common Stock Certificate</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">S-1,</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as amended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">333-96335</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4/7/2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2014 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2016 Inducement Award Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit104.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit105.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit106.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Form of Restricted Stock Unit Agreement (Non-Employee Director) under the Exelixis, Inc. 2017 Equity Incentive Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.7*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit107.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated May 7, 2020, to the Supplement to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and among Exelixis, Inc., Bristol-Myers Squibb Company and Ipsen Pharma SAS.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit311.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit312.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32.1&#8225;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20200630exhibit321.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Instance Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cover Page Interactive Data File</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Formatted as Inline XBRL and contained in Exhibit 101.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8225;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</span></div></div><hr style="page-break-after:always"></hr><div><a id="s21AED4B1279A5ED499174A853CCAE9BE"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#sF49F8B6BF5635F81B9FD2CEB87EDF574"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">E</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">I</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">NC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">August&#160;6, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief&#160;Financial&#160;Officer </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel20200630exhibit101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB5964AB97C5E2D749027A6499A2294CB"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2014 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  FEBRUARY 28, 2014</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE: APRIL 14, 2014</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">APPROVED BY THE STOCKHOLDERS:  MAY 28, 2014</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY: APRIL 12, 2018</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE: DECEMBER 6, 2018</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE: MAY 6, 2020</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Successor to and Continuation of Prior Plans.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan is intended as the successor to and continuation of the Exelixis, Inc. 2011 Equity Incentive Plan and the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Following the Effective Date, no additional stock awards may be granted under the Prior Plans.  Any unallocated shares remaining available for grant under the Prior Plans as of 12:01 a.m. Pacific time on the Effective Date (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Available Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will cease to be available under the Prior Plans at such time and will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan.  In addition, from and after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date, all outstanding stock awards granted under the Prior Plans, the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or the Exelixis, Inc. 2010 Inducement Award Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Inducement Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will remain subject to the terms of the Prior Plans, the 2000 Plan or the Inducement Plan, as applicable; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any shares subject to outstanding stock awards granted under the Prior Plans, the 2000 Plan or the Inducement Plan that (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding options and stock appreciation rights granted under the Prior Plans, the 2000 Plan or the Inducement Plan with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Appreciation Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder.  All Awards granted on or after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date will be subject to the terms of this Plan, as amended from time to time.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Employees, Directors and Consultants are eligible to receive Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common Stock may be issued).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  However, if required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E)&#160;materially expands the types of Awards available for issuance under the Plan.  Except as provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C)&#160;to clarify the manner of exemption from, or </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Section 162(m) and Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Delegation to an Officer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate to one or more Officers the authority to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.  Any such Stock Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation authority.  The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Repricing; Cancellation and Re-Grant of Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Stock Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Share Reserve.  </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 13,564,602 shares (which number is the sum of (i) the number of shares (1,564,602) subject to the Prior Plans&#8217; Available Reserve and (ii) an additional 12,000,000 new shares) plus (B) the Prior Plans&#8217; Returning Shares, if any, which become available for grant under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A) one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B) 1.55 shares for each share of Common Stock issued pursuant to a Full Value Award.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If (A) any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  For each (1) 2014 Plan Returning Share subject to a Full Value Award or (2) Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by 1.55 shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award will no longer be available for issuance under the Plan, including any shares subject to a Stock Award that are not delivered to a Participant because such Stock Award is exercised through a reduction of shares subject to such Stock Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;).  In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Incentive Stock Option Limit.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 66,000,000 shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Section 162(m) Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, at such time as the Company may be subject to the applicable provisions of Section 162(m) of the Code, the following limitations will apply.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">of the Fair Market Value on the date any such Stock Award is granted may be granted to any one Participant during any one calendar year.  Notwithstanding the foregoing, if any additional Options, SARs or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is granted are granted to any Participant during any calendar year, compensation attributable to the exercise of such additional Stock Awards will not satisfy the requirements to be considered &#8220;qualified performance-based compensation&#8221; under Section 162(m) of the Code unless such additional Stock Award is approved by the Company&#8217;s stockholders.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of $10,000,000 subject to Performance Cash Awards may be granted to any one Participant during any one calendar year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligibility for Specific Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code).  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; provided, however, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Ten Percent Stockholders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option.  If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option.  The provisions of separate Options or SARs need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  The Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2).  If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Non-Exempt Employees.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;PROVISIONS OF STOCK AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividends.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.  At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board.  Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Performance Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Performance Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d)(ii)) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Performance Cash Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d)(iii)) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Cash Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  The length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Committee and Board Discretion.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Section 162(m) Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless otherwise permitted in compliance with Section 162(m) of the Code with respect to an Award intended to qualify as &#8220;performance-based compensation&#8221; thereunder, the Committee will establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (A) the date 90 days after the commencement of the applicable Performance Period, and (B) the date on which 25% of the Performance Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain.  Prior to the payment of any compensation under an Award intended to qualify as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where the Performance Goals relate solely to the increase in the value of the Common Stock).  Notwithstanding satisfaction or any completion of any Performance Goals, shares subject to Options, cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of any further considerations as the Committee, in its sole discretion, will determine.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Other Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Corporate Action Constituting Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Change in Time Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Incentive Stock Option Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award, provided that notwithstanding anything to the contrary in the terms of an Award Agreement, the Company will have the discretion to determine the basis upon which the number of shares to be withheld will be calculated; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that notwithstanding anything to the contrary in the terms of an Award Agreement, no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Electronic Delivery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code. Consistent with </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Compliance with Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent that the Board determines that any Award granted hereunder is subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code.  To the extent applicable, the Plan and Award Agreements will be interpreted in accordance with Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Clawback/Recovery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Capitalization Adjustments.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Section 3(d), and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Dissolution or Liquidation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the Stock Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(c) will apply to Stock Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Stock Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue the Stock Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Stock Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Payment for Stock Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Stock Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(d) will apply to Stock Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of a Stock Award. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Stock Awards as if such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">280G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then any such 280G Payment (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Pro Rata Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest  economic benefit for the Participant as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Participant receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Board may suspend or terminate the Plan at any time.  No Incentive Stock Option will be granted after</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;No Impairment of Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan will become effective on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award or a Performance Cash Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">mean, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;Control Acquisition&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Covered Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; will have the meaning provided in Section 162(m)(3) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant,  the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2014, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Full Value Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if: (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an option granted pursuant to Section 5 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 that does not qualify as an Incentive Stock Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Outside Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Director who either (i) is not a current employee of the Company or an &#8220;affiliated corporation&#8221; (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an &#8220;affiliated corporation&#8221; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an &#8220;affiliated corporation,&#8221; and does not receive remuneration from the Company or an &#8220;affiliated corporation,&#8221; either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an &#8220;outside director&#8221; for purposes of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Cash Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Criteria</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the one or more criteria that the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee (or Board, if applicable): (1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, depreciation and amortization; (4) total stockholder return; (5) return on equity or average stockholder&#8217;s equity; (6) return on assets, investment, or capital employed; (7) stock price; (8) margin (including gross margin); (9) income (before or after taxes); (10) operating income; (11) operating income after taxes; (12) pre-tax profit; (13) operating cash flow; (14) sales or revenue targets; (15) increases in revenue or product revenue; (16) expenses and cost reduction goals; (17) improvement in or attainment of working capital levels; (18) economic value added (or an equivalent metric); (19) market share; (20) cash flow; (21) cash flow per share; (22) share price performance; (23) debt reduction; (24) implementation or completion of projects or processes; (25) customer satisfaction; (26) stockholders&#8217; equity; (27) capital expenditures; (28) debt levels; (29) operating profit or net operating profit; (30) workforce diversity; (31) growth of net income or operating income; (32) billings; and (33) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Committee or Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Goals</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, for a Performance Period, the one or more goals established by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Committee (or Board, if applicable) will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; and (5) to exclude the effects of any &#8220;extraordinary items&#8221; as determined under generally accepted accounting principles.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the period of time selected by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Performance Stock Award or a Performance Cash Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Committee (or Board, if applicable).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2014 Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(tt)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(uu)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ww)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 405</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(xx)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(yy)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(zz)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aaa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bbb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ccc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ddd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ten Percent Stockholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.&#160;&#160;&#160;&#160;</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exel20200630exhibit102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1C9C1F28F6E27FC533A4A65E8D9837C3"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2016 INDUCEMENT AWARD PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  NOVEMBER 18, 2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY:  APRIL 12, 2018</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE:  DECEMBER 6, 2018</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE:  MAY 6, 2020</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Awards under the Plan may only be granted to Employees who satisfy the standards for inducement grants under Rule 5635(c)(4) of the NASDAQ Listing Rules.  A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a bona fide period of non-employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following types of Awards: (i) Nonstatutory Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock Awards, (iv) Restricted Stock Unit Awards, and (v) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide an inducement material for such persons to enter into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).  However, notwithstanding the foregoing or anything in the Plan to the contrary, the grant of Awards will be approved by the Company&#8217;s independent compensation committee or a majority of the Company&#8217;s independent directors (as defined in Rule 5605(a)(2) of the NASDAQ Listing Rules) in order to comply with the exemption from the stockholder approval requirement for &#8220;inducement grants&#8221; provided under Rule 5635(c)(4) of the NASDAQ Listing Rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common Stock may be issued).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  If required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan.  Except as provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A)&#160;the Company requests the consent of the affected Participant, and (B)&#160;such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A) to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code or (B) to comply with other applicable laws or listing requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Repricing; Cancellation and Re-Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Share Reserve.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards from and after the Effective Date will not exceed 1,500,000 shares (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If (A) any shares of Common Stock subject to an Award are not issued because such Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Award having been issued or is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to an Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of an Award will no longer be available for issuance under the Plan, including any shares subject to an Award that are not delivered to a Participant because such Award is exercised through a reduction of shares subject to such Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;).  In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right will no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligibility for Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Awards may only be granted to persons who are Employees described in Section 1(a), where the Award is an inducement material to the individual&#8217;s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules.  For clarity, Awards may not be granted to (1) Consultants or Directors, for service in such capacities, or (2) any individual who was previously an Employee or Director, other than following a bona fide period of non-employment.  Notwithstanding the foregoing, Awards may not be granted to Employees who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Awards are otherwise exempt from or alternatively comply with the distribution requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Approval Requirements.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards must be granted either by a majority of the Company&#8217;s independent directors or by the Company&#8217;s compensation committee comprised of independent directors within the meaning of Rule 5605(a)(2) of the NASDAQ Listing Rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or SAR will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be Nonstatutory Stock Options.  The provisions of separate Options or SARs need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A)&#160;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the following restrictions on the transferability of Options and SARs will apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  The Board may permit transfer of the Option or SAR in a manner that is not prohibited by </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">applicable tax and securities laws.  Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of performance goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Non-Exempt Employees.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Corporate Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Awards and are hereby incorporated by reference into such Award Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;PROVISIONS OF AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company or (B) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividends.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.  At the sole discretion of the Board, such dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such manner as determined by the Board.  Any additional shares covered by the Restricted Stock Unit Award credited by reason of such dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement to which they relate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Other Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., options or stock appreciation rights with an exercise price or strike price less than 100% of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan, the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking will not require the Company to register under the Securities </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising an Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock issued pursuant to Awards will constitute general funds of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Corporate Action Constituting Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Change in Time Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">shares upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii)&#160;withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award, provided that notwithstanding anything to the contrary in the terms of an Award Agreement, the Company will have the discretion to determine the basis upon which the number of shares to be withheld will be calculated; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that notwithstanding anything to the contrary in the terms of an Award Agreement, no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of the Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Electronic Delivery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code.  Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Compliance with Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To the extent that the Board determines that any Award granted hereunder is subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code.  To the extent applicable, the Plan and Award Agreements will be interpreted in accordance with Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Clawback/Recovery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Capitalization Adjustments.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a) and </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii) the class(es) and number of securities and price per share of stock subject to outstanding Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Dissolution or Liquidation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board may, in its sole discretion, cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Corporate Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(c) will apply to Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar stock awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar stock award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar stock awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;Current Participants&#8221;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Awards that are held by Current Participants, the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar stock awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the effective time of the Corporate Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Payment for Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Award immediately prior to the effective time of the Corporate Transaction (including, at the discretion of the Board, any unvested portion of such Award), over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Company&#8217;s Common Stock in connection with the Corporate Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(d) will apply to Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company or unless otherwise expressly provided by the Board at the time of grant of an Award. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Awards as if such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">280G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then any such 280G Payment (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Pro Rata Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest economic benefit for the Participant as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Participant receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Board may suspend or terminate the Plan at any time.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;No Impairment of Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan will become effective on the Effective Date.  All Awards granted on or after the Effective Date will be subject to the terms of this Plan, as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any right to receive Common Stock granted under the Plan, including a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, or any Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of two or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.  Consultants are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;Control Acquisition&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.  Directors are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date this Plan is approved by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Full Value Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if: (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 that does not qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2016 Inducement Award Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 405</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exel20200630exhibit103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7A58E9EBAC41960509C4A66089C8AF9D"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.3</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2017 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS:  FEBRUARY 23, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE:  MARCH 22, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;APPROVED BY THE STOCKHOLDERS:  MAY 24, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPANY:  DECEMBER 18, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDED BY THE COMPENSATION COMMITTEE:  MARCH 18, 2020</font></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;APPROVED BY THE STOCKHOLDERS:  MAY 20, 2020</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GENERAL.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Successor to and Continuation of 2014 Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan is intended as the successor to and continuation of the Exelixis, Inc. 2014 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Following the Effective Date, no additional stock awards may be granted under the 2014 Plan.  Any unallocated shares remaining available for grant under the 2014 Plan as of 12:01 a.m. Pacific time on the Effective Date (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2014 Plan&#8217;s Available Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will cease to be available under the 2014 Plan at such time and will be added to the Share Reserve (as further described in Section 3(a) below) and be then immediately available for grant and issuance pursuant to Stock Awards granted under the Plan.  In addition, from and after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date, all outstanding stock awards granted under the 2014 Plan, the Exelixis, Inc. 2000 Equity Incentive Plan, as amended and restated (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), the Exelixis, Inc. 2000 Non-Employee Directors&#8217; Stock Option Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2000 Non-Employee Directors&#8217; Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), the Exelixis, Inc. 2011 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2011 Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and the Exelixis, Inc. 2016 Inducement Award Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2016 Inducement Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will remain subject to the terms of the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan, as applicable; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any shares subject to outstanding stock awards granted under the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan that (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding options and stock appreciation rights granted under the 2014 Plan, the 2000 Plan, the 2000 Nonemployee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan with respect to which the exercise or strike price is at least one hundred percent (100%) of the Fair Market Value of the Common Stock subject to the option or stock appreciation right on the date of grant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Appreciation Awards</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when such shares become Prior Plans&#8217; Returning Shares and become available for issuance pursuant to Awards granted hereunder.  All Awards granted on or after 12:01 a.m. Pacific time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">on the Effective Date will be subject to the terms of this Plan, as amended from time to time.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Eligible Award Recipients.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to Section 4, Employees, Directors and Consultants are eligible to receive Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Available Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan provides for the grant of the following types of Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Stock Appreciation Rights, (iv) Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Purpose.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Plan, through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and provide a means by which the eligible recipients may benefit from increases in value of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;ADMINISTRATION.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Administration by Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will administer the Plan.  The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Powers of Board.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To determine (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted; (D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award; and (F) the Fair Market Value applicable to a Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards.  The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To settle all controversies regarding the Plan and Awards granted under it.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common Stock may be issued in settlement thereof).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To suspend or terminate the Plan at any time.  Except as otherwise provided in the Plan or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#8217;s rights under his or her then-outstanding Award without his or her written consent except as provided in subsection (viii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or exempt from or compliant with the requirements for nonqualified deferred compensation under Section 409A of the Code, subject to the limitations, if any, of applicable law.  However, if required by applicable law or listing requirements, and except as provided in Section&#160;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&#160;materially increases the number of shares of Common Stock available for issuance under the Plan, (B)&#160;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&#160;materially increases the benefits accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased under the Plan, or (E) materially expands the types of Awards available for issuance under the Plan.  Except as otherwise provided in the Plan (including Section 2(b)(viii)) or an Award Agreement, no amendment of the Plan will materially impair a Participant&#8217;s rights under an outstanding Award without the Participant&#8217;s written consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding incentive stock options or (C) Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(viii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that a Participant&#8217;s rights under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant, and (B) such Participant consents in writing.  Notwithstanding the foregoing, (1) a Participant&#8217;s rights will not be deemed to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#8217;s rights, and (2) subject to the limitations of applicable law, if any, the Board may amend the terms of any one or more Awards without the affected Participant&#8217;s consent (A)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (C)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with, Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ix)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">To adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Delegation to Committee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;General.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate some or all of the administration of the Plan to a Committee or Committees.  If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable).  Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable).  The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee.  The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Section 162(m) and Rule 16b-3 Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee may consist solely of two or more Outside Directors, in accordance with Section 162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Delegation to an Officer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may delegate to one or more Officers the authority to do one or both of the following: (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards, and (ii) determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.  Any such Stock Awards will be granted on the form of Award Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation of authority.  The Board may not delegate authority to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant to Section 13(w)(iii) below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Effect of Board&#8217;s Decision.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Repricing; Cancellation and Re-Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Neither the Board nor any Committee will have the authority to (i) reduce the exercise, purchase or strike price of any outstanding Option or SAR under the Plan, or (ii) cancel any outstanding Option or SAR that has an exercise price or strike price greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Minimum Vesting Requirements.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Award may vest until at least twelve (12) months following the date of grant of the Award; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that shares of Common Stock up to five percent (5%) of the Share Reserve (as defined in Section 3(a)) may be issued pursuant to Awards which do not meet such vesting requirement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Dividends and Dividend Equivalents.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and contained in the applicable Award Agreement; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that (i) no dividends or dividend equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Award Agreement, (ii) any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions), and (iii) any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;SHARES SUBJECT TO THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Share Reserve. </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Sections 3(b)(i) and 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date will not exceed (A) 45,453,064 shares (which number is the sum of (i) the number of shares (453,064) subject to the 2014 Plan&#8217;s Available Reserve, (ii) an additional 24,000,000 shares that were approved at the annual meeting of stockholders of the Company held in 2017, and (iii) an additional 21,000,000 shares that were approved at the annual meeting of stockholders of the Company held in 2020), </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">plus</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(B) the Prior Plans&#8217; Returning Shares, if any, which become available for issuance under this Plan from time to time (such aggregate number of shares described in (A) and (B) above, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Reserve</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, the Share Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan.  Accordingly, this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a).  Shares may be issued in connection with a merger or acquisition as permitted by Nasdaq Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section 303A.08, AMEX Company Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by: (A) one share for each share of Common Stock issued pursuant to an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant; and (B) 1.5 shares for each share of Common Stock issued pursuant to a Full Value Award. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Reversion of Shares to the Share Reserve.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Shares Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If (A) any shares of Common Stock subject to a Stock Award are not issued because such Stock Award or any portion thereof expires or otherwise terminates without all of the shares covered by such Stock Award having been issued or is settled in cash (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Participant receives cash rather than stock), (B) any shares of Common Stock issued pursuant to a Stock Award are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (C) with respect to a Full Value Award, any shares of Common Stock are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with such Full Value Award, such shares will again become available for issuance under the Plan (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">2017 Plan Returning Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  For each (1) 2017 Plan Returning Share subject to a Full Value Award or (2) Prior Plans&#8217; Returning Share subject to a stock award other than a Prior Plans&#8217; Appreciation Award, the number of shares of Common Stock available for issuance under the Plan will increase by 1.5 shares.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Shares Not Available For Subsequent Issuance.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares of Common Stock reacquired or withheld (or not issued) by the Company to satisfy the exercise or purchase price of a Stock Award or a Prior Plans&#8217; Award will no longer be available for issuance under the Plan, including any shares subject to a Stock Award or a Prior Plans&#8217; Award that are not delivered to a Participant because such Stock Award or Prior Plans&#8217; Award is exercised through a reduction of shares subject to such Stock Award or Prior Plans&#8217; Award (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., &#8220;net exercised&#8221;).  In addition, any shares reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award, or any shares repurchased by the Company on the open market with the proceeds of the exercise or strike price of an Option or Stock Appreciation Right or a Prior Plans&#8217; Appreciation Award will no longer be available for issuance under the Plan.  In the event that a Stock Appreciation Right or a Prior Plans&#8217; Award that is a stock appreciation right is settled in shares of Common Stock, the gross number of shares of Common Stock subject to such award will no longer be available for issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Incentive Stock Option Limit.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 50,000,000 shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Individual Award Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the Share Reserve and Section 9(a) relating to Capitalization Adjustments:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date any such Stock Award is granted may be granted to any one Participant during any one calendar year.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of 5,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the Performance Goals).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A maximum of $10,000,000 subject to Performance Cash Awards may be granted to any one Participant during any one calendar year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Limitation on Grants to Non-Employee Directors.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">The (i) maximum number of shares of Common Stock subject to Stock Awards granted under the Plan or otherwise during any one calendar year (beginning with the 2017 calendar year) to any Non-Employee Director, taken together with the (ii) cash fees paid by the Company to such Non-Employee Director during such calendar year, and in both cases for service on the Board, will not exceed $750,000 in total value (calculating the value of any such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to the calendar year in which a Non-Employee Director is first appointed or elected to the Board, $1,500,000.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Source of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;ELIGIBILITY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Eligibility for Specific Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Incentive Stock Options may be granted only to employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code).  Stock Awards other than Incentive Stock Options may be granted to Employees, Directors and Consultants; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that Stock Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405, unless (i) the stock underlying such Stock Awards is treated as &#8220;service recipient stock&#8221; under Section 409A of the Code (for example, because the Stock Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii) the Company, in consultation with its legal counsel, has determined that such Stock Awards are otherwise exempt from or alternatively comply with the requirements of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Ten Percent Stockholders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Ten Percent Stockholder will not be granted an Incentive Stock Option unless the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration of five years from the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;PROVISIONS RELATING TO OPTIONS AND STOCK APPRECIATION RIGHTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Option or Stock Appreciation Right Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option.  If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option.  The provisions of separate Option or Stock Appreciation Right Agreements need not be identical; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Term.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Exercise Price.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the provisions of Section 4(b) regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award is granted.  Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value of the Common Stock subject to the Award on the date the Award is granted if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of Section 409A of the Code and, if applicable, Section 424(a) of the Code.  Each SAR will be denominated in shares of Common Stock equivalents.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Purchase Price for Options.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment set forth below.  The Board will have the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use a particular method of payment.  The permitted methods of payment are as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by cash, check, bank draft or money order payable to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if an Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that the Company will accept a cash or other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued.  Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">in any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exercise and Payment of a SAR.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR.  The appreciation distribution payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B) the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is exercising the SAR on such date.  The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such SAR.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Transferability of Options and SARs.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs as the Board will determine.  In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section 5(e) on the transferability of Options and SARs will apply.  Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Restrictions on Transfer.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;An Option or SAR will not be transferable except by will or by the laws of descent and distribution (and pursuant to Sections 5(e)(ii) and 5(e)(iii) below) and will be exercisable during the lifetime of the Participant only by the Participant.  Subject to the foregoing paragraph, the Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws.  Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2).  If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant&#8217;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.  However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Vesting Generally.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic installments that may or may not be equal.  The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board may deem appropriate.  The vesting provisions of individual Options or SARs may vary.  The provisions of this Section 5(f) are subject to Section 2(g) and any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Termination of Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates (other than for Cause and other than upon the Participant&#8217;s death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Extension of Termination Date.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause and other than upon the Participant&#8217;s death or Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the exercise of the Option or SAR would not be in violation of such registration requirements, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.  In addition, unless otherwise provided in a Participant&#8217;s Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if the sale of any Common Stock received upon exercise of an Option or SAR following the termination of the Participant&#8217;s Continuous Service (other than for Cause) would violate the Company&#8217;s insider trading policy, then the Option or SAR will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#8217;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be in violation of the Company&#8217;s insider trading policy, or (ii) the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Disability of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&#160;the expiration of the term of the Option or SAR as set forth in the Award Agreement.  If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Death of Participant.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the applicable Award Agreement or other written agreement between the Participant and the Company or an Affiliate, if (i) a Participant&#8217;s Continuous Service terminates as a result of the Participant&#8217;s death, or (ii) the Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#8217;s Continuous Service (for a reason other than death), then the Participant&#8217;s Option or SAR may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#8217;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&#8217;s death, but only within such period of time ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the Award Agreement), and (ii) the expiration of the term of such Option or SAR as set forth in the Award Agreement.  If, after the </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Participant&#8217;s death, the Option or SAR (as applicable) is not exercised within the applicable time frame, the Option or SAR (as applicable) will terminate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Termination for Cause.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as explicitly provided otherwise in a Participant&#8217;s Award Agreement or other individual written agreement between the Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Option or SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Non-Exempt Employees.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of grant of the Option or SAR (although the Award may vest prior to such date).  Consistent with the provisions of the Worker Economic Opportunity Act, (i) if such non-exempt employee dies or suffers a Disability, (ii) upon a Transaction in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&#8217;s retirement (as such term may be defined in the Participant&#8217;s Award Agreement, in another written agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#8217;s or Affiliate&#8217;s then current employment policies and guidelines), the vested portion of any Options and SARs may be exercised earlier than six&#160;months following the date of grant.  The foregoing provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.  To the extent permitted and/or required for compliance with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise, vesting or issuance of any shares under any other Stock Award will be exempt from the employee&#8217;s regular rate of pay, the provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;PROVISIONS OF AWARDS OTHER THAN OPTIONS AND SARS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Restricted Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  To the extent consistent with the Company&#8217;s bylaws, at the Board&#8217;s election, shares of Common Stock underlying a Restricted Stock Award may be (i) held in book entry form subject to the Company&#8217;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board.  The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Award Agreements need not be identical. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Award Agreement will conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 2(g), shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance with a vesting schedule to be determined by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If a Participant&#8217;s Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of such termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Transferability.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement.  Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no Restricted Stock Award may be transferred to any financial institution without prior stockholder approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Restricted Stock Unit Awards.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate.  The terms and conditions of Restricted Stock Unit Award </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Agreements may change from time to time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical.  Each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise) the substance of each of the following provisions:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Consideration.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award.  The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Vesting.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to Section 2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Payment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Additional Restrictions.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Termination of Participant&#8217;s Continuous Service.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or other written agreement between the Participant and the Company or an Affiliate, such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&#8217;s termination of Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Performance Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Performance Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section 3(d)(ii)) that is payable (including that may be granted, vest or be exercised) contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Stock Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Performance Cash Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d)(iii)) that is payable contingent upon the attainment during a Performance Period of certain Performance Goals.  A Performance Cash Award may, but need not, require the Participant&#8217;s completion of a specified period of Continuous Service.  Subject to Section 2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee), in its sole discretion.  The Board may specify the form of payment of Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Committee and Board Discretion.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Section 162(m) Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless otherwise permitted in compliance with Section 162(m) of the Code with respect to an Award intended to qualify as &#8220;performance-based compensation&#8221; thereunder, the Committee will establish the Performance Goals applicable to, and the formula for calculating the amount payable under, the Award no later </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">than the earlier of (A) the date 90 days after the commencement of the applicable Performance Period, and (B) the date on which 25% of the Performance Period has elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain.  Prior to the payment of any compensation under an Award intended to qualify as &#8220;performance-based compensation&#8221; under Section&#160;162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such Award have been satisfied (other than in cases where the Performance Goals relate solely to the increase in the value of the Common Stock).  Notwithstanding satisfaction or any completion of any Performance Goals, shares subject to Options, cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance Goals may be reduced by the Committee on the basis of any further considerations as the Committee, in its sole discretion, will determine.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Section 162(m) Transition Relief.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding anything in the Plan to the contrary, any provision in the Plan that refers to &#8220;performance-based compensation&#8221; under Section 162(m) of the Code will only apply to any Award that is intended to qualify, and is eligible to qualify, as &#8220;performance-based compensation&#8221; under Section 162(m) of the Code pursuant to the transition relief provided by the Tax Cuts and Jobs Act (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">TCJA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) for remuneration provided pursuant to a written binding contract which was in effect on November 2, 2017 and which was not modified in any material respect on or after such date, as determined by the Board, in its sole discretion, in accordance with the TCJA and any applicable guidance, rulings or regulations issued by the U.S. Department of the Treasury, the Internal Revenue Service or any other governmental authority.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Other Stock Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock may be granted either alone or in addition to Stock Awards granted under Section 5 and this Section 6.  Subject to the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)), the Board will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all other terms and conditions of such Other Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;COVENANTS OF THE COMPANY.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Availability of Shares.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy then-outstanding Stock Awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Securities Law Compliance.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan the authority required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock Awards; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that this undertaking will not require the Company to register under the Securities Act the Plan, any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award.  If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.  A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any applicable securities law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;No Obligation to Notify or Minimize Taxes.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising a Stock Award.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.  The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Use of Proceeds from Sales of Common Stock.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from the sale of shares of Common Stock issued pursuant to Stock Awards will constitute general funds of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Corporate Action Constituting Grant of Awards.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant.  In the event that the corporate records (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., Board consents, resolutions or minutes) </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">documenting the corporate action constituting the grant contain terms (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect terms in the Award Agreement or related grant documents.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Stockholder Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to such Award has been entered into the books and records of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;No Employment or Other Service Rights.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;Change in Time Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event a Participant&#8217;s regular level of time commitment in the performance of his or her services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award.  In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;Incentive Stock Option Limitations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Investment Assurances.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i) to give written assurances satisfactory to the Company as to the Participant&#8217;s knowledge and experience in financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the Participant&#8217;s own account and not with any present intention of selling or otherwise distributing the Common Stock.  The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under the Stock Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws.  The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;Withholding Obligations.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Stock Award, provided that notwithstanding anything to the contrary in the terms of an Award Agreement, the Company will have the discretion to determine the basis upon which the number of shares to be withheld will be calculated; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">withheld by law (or such other amount as may be permitted while still avoiding classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as may be set forth in the Award Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Electronic Delivery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Any reference herein to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;Deferrals.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made in accordance with Section 409A of the Code.  Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate.  The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&#8217;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;Compliance with Section 409A of the Code.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code.  To the extent that the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and, to the extent applicable, the Plan and Award Agreements will be interpreted in accordance with the requirements of Section 409A of the Code.  Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded and a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section 409A of the Code is a &#8220;specified employee&#8221; for purposes of Section 409A of the Code, no distribution or payment of any amount will be made upon a &#8220;separation from service&#8221; before a date that is six&#160;months following the date of such Participant&#8217;s &#8220;separation from service&#8221; (as defined in Section 409A of the Code without regard to alternative definitions thereunder) or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment may be made in a manner that complies with Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;Clawback/Recovery.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law, and any other clawback policy that the Company adopts.  In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or &#8220;constructive termination&#8221; (or similar term) under any agreement with the Company or an Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Capitalization Adjustments.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es) and maximum number of securities that may be awarded to any person pursuant to Section 3(d), and (iv) the class(es) and number of securities and price per share of stock subject to outstanding Stock Awards.  The Board will make such adjustments, and its determination will be final, binding and conclusive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Dissolution or Liquidation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Except as otherwise provided in the Stock Award Agreement or any other written agreement between the Company or any Affiliate and the Participant, in the event of a dissolution or liquidation of the Company, all outstanding Stock Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the Company&#8217;s repurchase rights or subject to a </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Transaction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(c) will apply to Stock Awards in the event of a Transaction unless otherwise provided in the instrument evidencing the Stock Award or any other written arrangement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;Stock Awards May Be Assumed.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Stock Awards outstanding under the Plan or may substitute similar stock awards for Stock Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Stock Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Transaction.  A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of a Stock Award or substitute a similar stock award for only a portion of a Stock Award, or may choose to assume or continue, or substitute similar stock awards for, the Stock Awards held by some, but not all Participants.  The terms of any assumption, continuation or substitution will be set by the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Current Participants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full (and with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of such Transaction (contingent upon the effectiveness of the Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such Stock Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Transaction).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;Stock Awards Held by Current Participants in Certain Control Acquisitions.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Control Acquisition that was not approved by the Board prior to the consummation of such transaction, then with respect to Stock Awards that are held by Current Participants, the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in full (and with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting will be deemed to be satisfied at the target level of performance) to a date prior to the effective time of such Control Acquisition (contingent upon the effectiveness of the Control Acquisition) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Control Acquisition) and any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will lapse (contingent upon the effectiveness of the Control Acquisition).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;Stock Awards Held by Persons other than Current Participants.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;In the event of a Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Stock Awards or substitute similar stock awards for such outstanding Stock Awards, then with respect to Stock Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Stock Awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that any reacquisition or repurchase rights held by the Company with respect to such Stock Awards will not terminate and may continue to be exercised notwithstanding the Transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;Payment for Stock Awards in Lieu of Exercise.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Notwithstanding the foregoing, in the event a Stock Award will terminate if not exercised prior to the effective time of a Transaction, the Board may provide that the holder of such Stock Award may not exercise such Stock Award but instead will receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&#160;the value of the property the Participant would have received upon the exercise of the Stock Award immediately prior to the effective time of the Transaction, over (B)&#160;any exercise price payable by such holder in connection with such exercise.  For clarity, this payment may be zero if the value of the property is equal to or less than the exercise price.  Payments under this provision may be delayed to the same extent that payment of consideration to the holders </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">of the Company&#8217;s Common Stock in connection with the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Change in Control.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The provisions of this Section 9(d) will apply to Stock Awards in the event of a Change in Control unless otherwise provided in the instrument evidencing the Stock Award or any other written arrangement between the Company or any Affiliate and the Participant or in any director compensation policy of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Change in Control occurs and within one month before, as of, or within thirteen months after, the effective time of such Change in Control a Participant&#8217;s Continuous Service terminates due to an involuntary termination (not including death or Disability) without Cause or due to a voluntary termination with Good Reason, then the vesting of such Stock Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Stock Awards may be exercised) will be accelerated in accordance with the vesting schedule applicable to such Stock Awards as if (A) with respect to any such Stock Awards that are subject to vesting conditions or requirements based solely on such Participant&#8217;s Continuous Service, such Participant&#8217;s Continuous Service had continued for twelve months following the date of termination of Continuous Service, and (B) with respect to any such Stock Awards that are subject to performance-based vesting conditions or requirements, vesting has been satisfied at the target level of performance.  Such vesting acceleration will occur on the date of termination of such Participant&#8217;s Continuous Service, or if later, the effective date of the Change in Control (if the Participant&#8217;s termination of Continuous Service occurs prior to the Change in Control).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If any payment or benefit a Participant will or may receive from the Company or otherwise (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">280G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Excise Tax</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then any such 280G Payment (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be equal to the Reduced Amount.  The &#8220;Reduced Amount&#8221; will be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#8217;s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that results in the greatest economic benefit for the Participant.  If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Pro Rata Reduction Method</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding any provision of the foregoing paragraph to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A of the Code as follows: (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest  economic benefit for the Participant as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., being terminated without Cause), will be reduced (or eliminated) before Payments that are not contingent on future events; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If a Participant receives a Payment for which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 9(d)(ii) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, the Participant agrees to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 9(d)(ii)) so that no portion of the remaining Payment is subject to the Excise Tax.  For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of the first paragraph of this Section 9(d)(ii), the Participant will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the Participant and the Company agree on an alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations.  If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">or law firm to make the determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will use commercially reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#8217;s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by the Participant or the Company) or such other time as requested by the Participant or the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;TERMINATION OR SUSPENSION OF THE PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Termination or Suspension.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The Board may suspend or terminate the Plan at any time.  No Incentive Stock Option will be granted after</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0070c0;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the tenth anniversary of the earlier of (i) the date the Plan is adopted by the Board, or (ii) the date the Plan is approved by the stockholders of the Company.  No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;No Impairment of Rights.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suspension or termination of the Plan will not materially impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;EFFECTIVE DATE OF PLAN.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Plan will become effective on the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;CHOICE OF LAW.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The laws of the State of California will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#8217;s conflict of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;DEFINITIONS.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405.  The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award or a Performance Cash Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Board of Directors of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Capitalization Adjustment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Stock Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto).  Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">will have the meaning ascribed to such term in any written agreement between the Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term will mean, with respect to a Participant, the occurrence of any of the following events: (i) such Participant&#8217;s conviction of, or plea of no contest with respect to, any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant&#8217;s attempted commission of or participation in a fraud or act of dishonesty against the Company or an Affiliate that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate; (iii) such Participant&#8217;s intentional, material violation of any </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">contract or agreement between the Participant and the Company or an Affiliate, or any statutory duty the Participant owes to the Company or an Affiliate; or (iv) such Participant&#8217;s conduct that constitutes gross misconduct, insubordination, incompetence or habitual neglect of duties and that results in (or might have reasonably resulted in) material harm to the business of the Company or an Affiliate.  The determination that a termination of a Participant&#8217;s Continuous Service is for Cause will not be made unless and until there will have been delivered to such Participant a copy of a resolution duly adopted by the affirmative vote of at least a majority of the Board at a meeting of the Board called and held for such purpose (after reasonable notice to such Participant and an opportunity for such Participant, together with such Participant&#8217;s counsel, to be heard before the Board), finding that in the good faith opinion of the Board, such Participant was guilty of the conduct constituting &#8220;Cause&#8221; and specifying the particulars.  Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or an Affiliate or such Participant for any other purpose.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors other than by virtue of a merger, consolidation or similar transaction;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the term Change in Control will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(h)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(j)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(k)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Exelixis, Inc., a Delaware corporation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(l)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Consultant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services.  However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(m)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Continuous Service</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated.  A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate.  For example, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service.  To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors.  Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in a Stock Award only to such extent as may be provided in the Company&#8217;s or Affiliate&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(n)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a sale, lease or other disposition of all or substantially all of the assets of the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">an acquisition by any Exchange Act Person of the beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act, or comparable successor rule) of securities of the Company representing at least 50% of the combined voting power entitled to vote in the election of Directors (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Control Acquisition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a merger, consolidation or similar transaction in which the Company is not the surviving corporation; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a reverse merger, consolidation or similar transaction in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing definition or any other provision of this Plan, the terms Corporate Transaction and Control Acquisition will not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(o)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Covered Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; will have the meaning provided in Section 162(m)(3) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(p)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a member of the Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(q)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(r)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the effective date of this Plan document, which is the date of the annual meeting of stockholders of the Company held in 2017, provided this Plan is approved by the Company&#8217;s stockholders at such meeting.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(s)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any person employed by the Company or an Affiliate.  However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(t)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Entity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a corporation, partnership, limited liability company or other entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(u)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act Person</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Entity or &#8220;group&#8221; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(w)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, as of any date, the value of the Common Stock determined as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(x)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Full Value Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award that is not an Option or SAR with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date of grant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(y)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Good Reason</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that one or more of the following are undertaken by the Company or an Affiliate without the Participant&#8217;s express written consent:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">reduction of such Participant&#8217;s rate of compensation as in effect immediately prior to a Change in Control by greater than 10%, except to the extent the compensation of other similarly situated persons are accordingly reduced;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure to provide a package of welfare benefit plans that, taken as a whole, provide substantially similar benefits to those in which such Participant is entitled to participate immediately prior to a Change in Control (except that such Participant&#8217;s contributions may be raised to the extent of any cost increases imposed by third parties) or any action by the Company or an Affiliate that would adversely affect such Participant&#8217;s participation or reduce such Participant&#8217;s benefits under any of such plans;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a change in such Participant&#8217;s responsibilities, authority, titles or offices resulting in diminution of position, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith that is remedied by the Company or an Affiliate promptly after notice thereof is given by such person;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a request that such Participant relocate to a worksite that is more than 50 miles from such Participant&#8217;s prior worksite, unless such person accepts such relocation opportunity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material reduction in duties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vi)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a failure or refusal of any successor company to assume the obligations of the Company or an Affiliate under an agreement with such Participant; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a material breach by the Company or an Affiliate of any of the material provisions of an agreement with such Participant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, a Participant will have &#8220;Good Reason&#8221; for his or her resignation only if: (a)&#160;such Participant notifies the Company in writing, within 30&#160;days after the occurrence of one of the foregoing event(s), specifying the event(s) constituting Good Reason and that he or she intends to terminate his or her employment no earlier than 30 days after providing such notice; (b)&#160;the Company does not cure such condition within 30&#160;days following its receipt of such notice or states unequivocally in writing that it does not intend to attempt to cure such condition; and (c)&#160;the Participant resigns from employment within 30&#160;days following the end of the period within which the Company was entitled to remedy the condition constituting Good Reason but failed to do so.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(z)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an option granted pursuant to Section 5 that is intended to be, and that qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Employee Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulation S-K</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii) is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonstatutory Stock Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any option granted pursuant to Section 5 that does not qualify as an Incentive Stock Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(cc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(dd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and an Optionholder evidencing the terms and conditions of an Option grant.  Each Option Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Optionholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(gg)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of Section 6(d).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(hh)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant.  Each Other Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Outside Director</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Director who either (i) is not a current employee of the Company or an &#8220;affiliated corporation&#8221; (within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company or an &#8220;affiliated corporation&#8221; who receives compensation for prior services (other than benefits under a tax-qualified retirement plan) during the taxable year, has not been an officer of the Company or an &#8220;affiliated corporation,&#8221; and does not receive remuneration from the Company or an &#8220;affiliated corporation,&#8221; either directly or indirectly, in any capacity other than as a Director, or (ii) is otherwise considered an &#8220;outside director&#8221; for purposes of Section 162(m) of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(jj)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Own,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owned,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Owner,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ownership</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(kk)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ll)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Cash Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(mm)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Criteria</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the one or more criteria that the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) will select for purposes of establishing the Performance Goals for a Performance Period.  The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Committee (or Board, if applicable): (1) earnings (including earnings per share and net earnings); (2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, </font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">depreciation and amortization; (4) total stockholder return; (5) return on equity or average stockholder&#8217;s equity; (6) return on assets, investment, or capital employed; (7) stock price; (8) margin (including gross margin); (9) income (before or after taxes); (10) operating income; (11) operating income after taxes; (12) pre-tax profit; (13) operating cash flow; (14) sales or revenue targets; (15) increases in revenue or product revenue; (16) expenses and cost reduction goals; (17) improvement in or attainment of working capital levels; (18) economic value added (or an equivalent metric); (19) market share; (20) cash flow; (21) cash flow per share; (22) share price performance; (23) debt reduction; (24) implementation or completion of projects or processes; (25) customer satisfaction; (26) stockholders&#8217; equity; (27) capital expenditures; (28) debt levels; (29) operating profit or net operating profit; (30) workforce diversity; (31) growth of net income or operating income; (32) billings; and (33) to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance selected by the Committee or Board.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(nn)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Goals</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, for a Performance Period, the one or more goals established by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) for the Performance Period based upon the Performance Criteria.  Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices.  Unless specified otherwise by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Committee (or Board, if applicable) will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects, as applicable, for non-U.S. dollar denominated Performance Goals; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; and (5) to exclude the effects of any items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles.    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(oo)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the period of time selected by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board or the Committee) over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to and the payment of a Performance Stock Award or a Performance Cash Award.  Performance Periods may be of varying and overlapping duration, at the sole discretion of the Committee (or Board, if applicable).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(pp)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(qq)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means this Exelixis, Inc. 2017 Equity Incentive Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(rr)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Prior Plans&#8217; Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any stock award granted under the 2014 Plan, the 2000 Plan, the 2000 Non-Employee Directors&#8217; Plan, the 2011 Plan or the 2016 Inducement Plan, in each case that was outstanding as of the Effective Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ss)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(a).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(tt)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant.  Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(uu)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section 6(b).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(vv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a written agreement between the Company and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant.  Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ww)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 16b-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.&#160;&#160;&#160;&#160;</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(xx)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Rule 405</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means Rule 405 promulgated under the Securities Act.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(yy)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Securities Act</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(zz)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 5.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(aaa)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a holder of a Stock Appreciation Right evidencing the terms and conditions of a Stock Appreciation Right grant.  Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(bbb)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ccc)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Award Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a written agreement between the Company and a Participant evidencing the terms and conditions of a Stock Award grant.  Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ddd)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(eee)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ten Percent Stockholder</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(fff)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Transaction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a Corporate Transaction or a Change in Control.</font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.&#160;&#160;&#160;&#160;</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exel20200630exhibit104.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s18D5347A5A8EBB10A037A684F2C53EE5"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.4</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC. <br>2017 EQUITY INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">OPTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to your Notice of Grant of Stock Option (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Option Agreement and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has granted you an option under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. Your option is granted to you effective as of the Date of Grant set forth in the Grant Notice. This Option Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Grant Notice to which it is attached. Capitalized terms not explicitly defined in this Option Agreement shall have the same meanings given to them in the Plan. In the event of any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan shall control. The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your option will vest as provided in your Grant Notice, provided that vesting will cease upon the termination of your Continuous Service. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;NUMBER OF SHARES AND EXERCISE PRICE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The number of shares of Common Stock subject to your option and your exercise price per share referenced in your Grant Notice may be adjusted from time to time for Capitalization Adjustments. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;EXERCISE RESTRICTION FOR NON-EXEMPT EMPLOYEES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event that you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (i.e., a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Non-Exempt Employee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant specified in your Grant Notice, notwithstanding any other provision of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;METHOD OF PAYMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Payment of the exercise price is due in full upon exercise of all or any part of your option. You may elect to make payment of the exercise price in cash or by check or by any of the following methods</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;unless prohibited by your Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the aggregate exercise price. You must pay any remaining balance of the aggregate exercise price not satisfied by such delivery in cash or other permitted form of payment. Notwithstanding the foregoing, you may not exercise your option by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#8217;s stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;WHOLE SHARES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You may exercise your option only for whole shares of Common Stock. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;TERM</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. You may not exercise your option before the commencement or after the expiration of its term. The term of your option commences on the Date of Grant and expires upon the earliest of the following: </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">immediately upon the termination of your Continuous Service for Cause; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">three (3) months after the termination of your Continuous Service for any reason other than Cause, Disability or death, provided that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the section above relating to &#8220;Securities Law Compliance,&#8221; your option shall not expire until the earlier of the expiration date indicated in your Grant Notice (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or until it shall have been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service; and provided further that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant specified in your Grant Notice, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option shall not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant specified in your Grant Notice or (B) the date that is three (3) months after the termination of your Continuous Service, or (y) the Expiration Date; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">twelve (12) months after the termination of your Continuous Service due to your Disability; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">eighteen (18) months after your death if you die during your Continuous Service; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Expiration Date indicated in your Grant Notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, if you die during the period provided in Section 7(b) or 7(c) above, the term of your option shall not expire until the earlier of eighteen (18) months after your death or the Expiration Date indicated in your Grant Notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If your option is an Incentive Stock Option, note that to obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your option and ending on the day three (3) months before the date of your option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. The Company has provided for extended exercisability of your option under certain circumstances for your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;EXERCISE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You may exercise the vested portion of your option during its term by delivering a notice (in a form designated by the Company) or taking such other action as the Company may require together with delivering the exercise price to the Secretary of the Company, or to such other person as the Company may designate (such as any broker designated by the Company to effect option exercises) during regular business hours, together with such additional documents as the Company may then require. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By exercising your option you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company or any Affiliate of any tax withholding obligation of the Company or any Affiliate arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the date of your option grant or within one (1) year after such shares of Common Stock are transferred upon exercise of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;TRANSFERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Certain Trusts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">of the Code and applicable state law) while the option is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Domestic Relations Orders</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument. If this option is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Beneficiary Designation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company and any broker designated by the Company to effect option exercises, you may designate a third party who, in the event of your death, shall thereafter be entitled to exercise this option and receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate shall be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;OPTION NOT A SERVICE CONTRACT. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice. Nothing in this Option Agreement (including, but not limited to, the vesting of your option pursuant to the schedule set forth in Section 1 herein or the issuance of the shares upon exercise of your option), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Option Agreement or the Plan shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Option Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Option Agreement or Plan; or (iv) deprive the Company or an Affiliate of the right to terminate you at will and without regard to any future vesting opportunity that you may have. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By accepting this option, you acknowledge and agree that the right to continue vesting in the option pursuant to the schedule set forth in Section 1 is earned only by continuing as an employee, director or consultant at the will of the Company or an Affiliate (not through the act of being hired, being granted this option or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;). You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Option Agreement, including but not limited to, the termination of the right to continue vesting in the option. You further acknowledge and agree that this Option Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Option Agreement, for any period, or at all, and shall not interfere in any way with your right or the Company&#8217;s or an Affiliate&#8217;s right to terminate your Continuous Service at any time, with or without cause and with or without notice. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">At the time you exercise your option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with the exercise of your option (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Withholding Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your option by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company or an Affiliate; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the exercise of your option </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">with a Fair Market Value equal to the amount of such Withholding Taxes; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your option as a liability for financial accounting purposes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to this Section 11 shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock unless such obligations are satisfied. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;TAX CONSEQUENCES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You shall not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#8220;fair market value&#8221; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notices provided for in your option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company. Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of your option and those of the Plan, the provisions of the Plan shall control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus. In addition, you acknowledge receipt of the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;MISCELLANEOUS. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your option shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns. Your rights and obligations under your option may only be assigned with the prior written consent of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Option Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Option Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;EFFECT ON OTHER EMPLOYEE BENEFIT PLANS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The value of the option subject to this Option Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the Employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Option Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">20.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to Section 21(g), this Option Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company. Notwithstanding the foregoing, this Option Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Option Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent, except as otherwise provided in Section 21(g). Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Option Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of your option which is then subject to restrictions as provided herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">21.&#160;&#160;&#160;&#160;CLAWBACK/RECOVERY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You acknowledge and agree that, notwithstanding anything to the contrary in this Option Agreement or the Grant Notice but subject to applicable law, to the extent that any Clawback Policy (as defined below) is applicable to your option:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your option, any shares issued (or issuable) or other compensation paid (or payable) pursuant to your option, and any gains you realize with respect to the sale of any shares issued pursuant to your option (in an amount determined by the Board in its discretion) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Option Gains</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) are subject to recoupment in accordance with the following (each of which will be considered a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Clawback Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; for purposes of this Option Agreement): (i) the Exelixis, Inc. Policy for Recoupment of Variable Compensation, adopted by the Board on February 28, 2019 and as may be amended from time to time (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Variable Compensation Clawback Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); and (ii) any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For purposes of any Clawback Policy, your option, any shares issued (or issuable) or other compensation paid (or payable) pursuant to your option, and any Option Gains are not earned until no longer subject to recoupment in accordance with such Clawback Policy;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As a condition to the grant of your option:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You expressly agree and consent to the Company&#8217;s application, implementation and enforcement of any Clawback Policy and any provision of applicable law relating to cancellation, recoupment, rescission or payback of compensation;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You expressly agree that the Company may take such actions as are necessary or appropriate to effectuate any Clawback Policy or applicable law without any further consent or action being required by you; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For purposes of the foregoing, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold any shares issued pursuant to your option and any other amounts acquired pursuant to your option and/or to re-convey, transfer or otherwise return such shares and/or other amounts to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company has provided you with a copy of the Variable Compensation Clawback Policy;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event of any conflict between the terms of your option (including this Section 21) and any Clawback Policy, the terms of such Clawback Policy will control;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event that your option is subject to more than one Clawback Policy, the Clawback Policy with the most restrictive recoupment provisions (as applied to your option) will control; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Option Agreement may be unilaterally amended by the Board (without your consent) at any time to comply with any Clawback Policy, as it may be amended from time to time. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>6
<FILENAME>exel20200630exhibit105.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEC89AFE3A051381EC37EA688019405F6"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC. <br>2017 EQUITY INCENTIVE PLAN </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;<br>RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to the Restricted Stock Unit Grant Notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Restricted Stock Unit Agreement and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has awarded you a Restricted Stock Unit Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award.  This Restricted Stock Unit Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Restricted Stock Unit Grant Notice to which it is attached.  Capitalized terms not explicitly defined in this Restricted Stock Unit Agreement shall have the same meanings given to them in the Plan.  In the event of any conflict between the terms in this Restricted Stock Unit Agreement and the Plan, the terms of the Plan shall control.  The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GRANT OF THE AWARD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Award represents the right to be issued on a future date the number of shares of the Company&#8217;s Common Stock as indicated in the Grant Notice.  As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Account</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) the number of shares of Common Stock subject to the Award.  Except as otherwise provided herein, you will not be required to make any payment to the Company or an Affiliate (other than past and future services to the Company or an Affiliate) with respect to your receipt of the Award, the vesting of the shares or the delivery of the underlying Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.  Upon such termination of your Continuous Service, the shares credited to the Account that were not vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;NUMBER OF SHARES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other shares covered by your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3.  The Board shall, in its discretion, determine an equivalent benefit for any fractional shares or fractional shares that might be created by the adjustments referred to in this Section 3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not be issued any shares under your Award unless the shares of Common Stock subject to your Award are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Your Award also must comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;TRANSFERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in this Section 5, your Award is not transferable, except by will or by the laws of descent and distribution.  In addition to any other limitation on transfer created by applicable securities laws, you agree not to assign, hypothecate, donate, encumber or otherwise dispose of any interest in any of the shares of Common Stock subject to the Award until the shares are issued to you in accordance with Section 6 of this Restricted Stock Unit Agreement.  After the shares have been issued to you, you are free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein and applicable securities laws.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Certain Trusts.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, you may transfer your Award to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the Award is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your Award pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.  You are encouraged to discuss the proposed terms of any division of this Award with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death pursuant to this Restricted Stock Unit Agreement.  In the absence of such a designation, your executor or administrator of your estate shall be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;DATE OF ISSUANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will deliver to you a number of shares of the Company&#8217;s Common Stock equal to the number of vested shares subject to your Award, including any additional shares received pursuant to Section 3 above that relate to those vested shares on the applicable vesting date(s).  However, if a scheduled delivery date falls on a date that is not a business day, such delivery date shall instead fall on the next following business day.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, in the event that (i) you are subject to the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time (collectively the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), you are subject to a lock-up agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with one or more underwriters or placement agents in connection with an offering or other placement of securities by the Company, or you are otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the public market and any shares covered by your Award are scheduled to be delivered on a day (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Original Distribution Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that (A) does not occur during an open &#8220;window period&#8221; applicable to you or a day on which you are permitted to sell shares of the Company&#8217;s common stock covered by your Award pursuant to a written plan that meets the requirements of Rule 10b5-1 under the Exchange Act, as determined by the Company in accordance with the Policy, (B) occurs within a period during which transactions in Company securities by you are prohibited under the terms of a Lock-Up Agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or (C) does not occur on a date when you are otherwise permitted to sell shares of the Company&#8217;s common stock on the open market, and (ii) the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original Distribution Date and shall instead be delivered, as applicable, on (X) the first business day of the next occurring open &#8220;window period&#8221; applicable to you pursuant to the Policy (regardless of whether you are still providing Continuous Service at such time), (Y) the first business day immediately following the end of the Lock-Up Period, or (Z) the next business day on which you are not otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the open market, but in no event later than the fifteenth (15th) day of the third calendar month of the calendar year following the calendar year in which the Original Distribution Date occurs.  The form of such delivery (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;DIVIDENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;RESTRICTIVE LEGENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;AWARD NOT A SERVICE CONTRACT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice.  Nothing in this Restricted Stock Unit Agreement (including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 herein or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Restricted Stock Unit Agreement or the Plan shall: (i) confer upon you any right to continue in the employ of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or affiliation; (iii) confer any right or benefit under this Restricted Stock Unit Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Restricted Stock Unit Agreement or Plan; or (iv)&#160;deprive the Company or an Affiliate of the right to terminate you at will and without regard to any future vesting opportunity that you may have.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award pursuant to the schedule set forth in Section 2 is earned only by continuing as an employee, director or consultant at the will of the Company or an Affiliate (not through the act of being hired, being granted this Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;).  You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Restricted Stock Unit Agreement, including but not limited to, the termination of the right to continue vesting in the Award.  You further acknowledge and agree that this Restricted Stock Unit Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee or consultant for the term of this Restricted Stock Unit Agreement, for any period, or at all, and shall not interfere in any way with your right or the Company&#8217;s or an Affiliate&#8217;s right to terminate your Continuous Service at any time, with or without cause and with or without notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">On or before the time you receive a distribution of the shares subject to your Award, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with your Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Withholding Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company or an Affiliate; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair Market Value equal to the amount of such Withholding Taxes; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your Award as a liability for financial accounting purposes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any shares of Common Stock subject to your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event the Company&#8217;s or an Affiliate&#8217;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Company&#8217;s or Affiliate&#8217;s withholding obligation was greater than the amount withheld by the Company or Affiliate, you agree to indemnify and hold the Company and Affiliate harmless from any failure by the Company or Affiliate to withhold the proper amount.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;UNSECURED OBLIGATION</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue shares pursuant to this Restricted Stock Unit Agreement.  You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Restricted Stock Unit Agreement until such shares are issued to you pursuant to Section 6 of this Restricted Stock Unit Agreement.  Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company.  Nothing contained in this Restricted Stock Unit Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or an Affiliate or any other person.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.  In addition, you acknowledge receipt of the Policy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.  Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to request your consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;MISCELLANEOUS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns.  Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Restricted Stock Unit Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Restricted Stock Unit Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Restricted Stock Unit Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Restricted Stock Unit Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Restricted Stock Unit Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;EFFECT ON OTHER EMPLOYEE BENEFIT PLANS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The value of the Award subject to this Restricted Stock Unit Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the Employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Restricted Stock Unit Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to Section 20(g), this Restricted Stock Unit Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company.  Notwithstanding the foregoing, this Restricted Stock Unit Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Restricted Stock Unit Agreement, so long as a copy of such amendment is delivered </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent, except as otherwise provided in Section 20(g).  Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Restricted Stock Unit Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">20.&#160;&#160;&#160;&#160;CLAWBACK/RECOVERY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You acknowledge and agree that, notwithstanding anything to the contrary in this Restricted Stock Unit Agreement or the Grant Notice but subject to applicable law, to the extent that any Clawback Policy (as defined below) is applicable to your Award:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Award, any shares issued (or issuable) or other compensation paid (or payable) pursuant to your Award, and any gains you realize with respect to the sale of any shares issued pursuant to your Award (in an amount determined by the Board in its discretion) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Gains</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) are subject to recoupment in accordance with the following (each of which will be considered a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Clawback Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; for purposes of this Restricted Stock Unit Agreement): (i) the Exelixis, Inc. Policy for Recoupment of Variable Compensation, adopted by the Board on February 28, 2019 and as may be amended from time to time (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Variable Compensation Clawback Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); and (ii) any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For purposes of any Clawback Policy, your Award, any shares issued (or issuable) or other compensation paid (or payable) pursuant to your Award, and any Award Gains are not earned until no longer subject to recoupment in accordance with such Clawback Policy;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">As a condition to the grant of your Award:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You expressly agree and consent to the Company&#8217;s application, implementation and enforcement of any Clawback Policy and any provision of applicable law relating to cancellation, recoupment, rescission or payback of compensation;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You expressly agree that the Company may take such actions as are necessary or appropriate to effectuate any Clawback Policy or applicable law without any further consent or action being required by you; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For purposes of the foregoing, you expressly and explicitly authorize the Company to issue instructions, on your behalf, to any brokerage firm and/or third party administrator engaged by the Company to hold any shares issued pursuant to your Award and any other amounts acquired pursuant to your Award and/or to re-convey, transfer or otherwise return such shares and/or other amounts to the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company has provided you with a copy of the Variable Compensation Clawback Policy;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event of any conflict between the terms of your Award (including this Section 20) and any Clawback Policy, the terms of such Clawback Policy will control;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event that your Award is subject to more than one Clawback Policy, the Clawback Policy with the most restrictive recoupment provisions (as applied to your Award) will control; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Restricted Stock Unit Agreement may be unilaterally amended by the Board (without your consent) at any time to comply with any Clawback Policy, as it may be amended from time to time.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>exel20200630exhibit106.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBF0CA9BBFB9874848A5AA696A82BFDF7"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.6</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:32px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC. <br>2017 EQUITY INCENTIVE PLAN </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;<br>RESTRICTED STOCK UNIT AGREEMENT (NON-EMPLOYEE DIRECTORS)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to the Restricted Stock Unit Grant Notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Grant Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and this Restricted Stock Unit Agreement (Non-Employee Directors) and in consideration of your services, Exelixis, Inc. (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) has awarded you a Restricted Stock Unit Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) under its 2017 Equity Incentive Plan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Your Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this Award.  This Restricted Stock Unit Agreement shall be deemed to be agreed to by the Company and you upon the signing or electronically accepting by you of the Restricted Stock Unit Grant Notice to which it is attached.  Capitalized terms not explicitly defined in this Restricted Stock Unit Agreement shall have the same meanings given to them in the Plan.  In the event of any conflict between the terms in this Restricted Stock Unit Agreement and the Plan, the terms of the Plan shall control.  The details of your Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;GRANT OF THE AWARD</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Award represents the right to be issued on a future date the number of shares of the Company&#8217;s Common Stock as indicated in the Grant Notice.  As of the Date of Grant, the Company will credit to a bookkeeping account maintained by the Company for your benefit (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Account</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) the number of shares of Common Stock subject to the Award.  Except as otherwise provided herein, you will not be required to make any payment to the Company (other than past and future services to the Company) with respect to your receipt of the Award, the vesting of the shares or the delivery of the underlying Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;VESTING</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the limitations contained herein, your Award will vest, if at all, in accordance with the vesting schedule provided in the Grant Notice, provided that vesting will cease upon the termination of your Continuous Service.  Upon such termination of your Continuous Service, the shares credited to the Account that were not vested on the date of such termination will be forfeited at no cost to the Company and you will have no further right, title or interest in or to such underlying shares of Common Stock.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;NUMBER OF SHARES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The number of shares subject to your Award may be adjusted from time to time for Capitalization Adjustments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Any shares, cash or other property that becomes subject to the Award pursuant to this Section 3, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other shares covered by your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the provisions of this Section 3, no fractional shares or rights for fractional shares of Common Stock shall be created pursuant to this Section 3.  The Board shall, in its discretion, determine an equivalent benefit for any fractional shares or fractional shares that might be created by the adjustments referred to in this Section 3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;SECURITIES LAW COMPLIANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained herein, you may not be issued any shares under your Award unless the shares of Common Stock subject to your Award are then registered under the Securities Act or, if such shares of Common Stock are not then so registered, the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Your Award also must comply with other applicable laws and regulations governing the Award, and you will not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;TRANSFERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as otherwise provided in this Section 5, your Award is not transferable, except by will or by the laws of descent and distribution.  In addition to any other limitation on transfer created by applicable securities laws, you agree not to assign, hypothecate, donate, encumber or otherwise dispose of any interest in any of the shares of Common Stock subject to the Award until the shares are issued to you in accordance with Section 6 of this Restricted Stock Unit Agreement.  After the shares have been issued to you, you are free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein and applicable securities laws.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Certain Trusts.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, you may transfer your Award to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the Award is held in the trust, provided that you and the trustee enter into transfer and other agreements required by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;Domestic Relations Orders.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your Award pursuant to a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.  You are encouraged to discuss the proposed terms of any division of this Award with the Company prior to finalizing the domestic relations order, official marital settlement agreement or other divorce or separation instrument to help ensure the required information is contained within the domestic relations order, official marital settlement agreement or other divorce or separation instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;Beneficiary Designation.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;By delivering written notice to the Company, in a form provided by or otherwise satisfactory to the Company, you may designate a third party who, in the event of your death, shall thereafter be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death pursuant to this Restricted Stock Unit Agreement.  In the absence of such a designation, your executor or administrator of your estate shall be entitled to receive any distribution of Common Stock to which you were entitled at the time of your death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;DATE OF ISSUANCE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Company will deliver to you a number of shares of the Company&#8217;s Common Stock equal to the number of vested shares subject to your Award, including any additional shares received pursuant to Section 3 above that relate to those vested shares on the applicable vesting date(s).  However, if a scheduled delivery date falls on a date that is not a business day, such delivery date shall instead fall on the next following business day.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, in the event that (i) Withholding Taxes apply to the distribution of the shares subject to your Award, (ii) you are subject to the Company&#8217;s insider trading policy, including the policy permitting officers and directors to sell shares only during certain &#8220;window&#8221; periods, in effect from time to time (collectively the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Policy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), you are subject to a lock-up agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with one or more underwriters or placement agents in connection with an offering or other placement of securities by the Company, or you are otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the public market and any shares covered by your Award are scheduled to be delivered on a day (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Original Distribution Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) that (A) does not occur during an open &#8220;window period&#8221; applicable to you or a day on which you are permitted to sell shares of the Company&#8217;s common stock covered by your Award pursuant to a written plan that meets the requirements of Rule 10b5-1 under the Exchange Act, as determined by the Company in accordance with the Policy, (B) occurs within a period during which transactions in Company securities by you are prohibited under the terms of a Lock-Up Agreement (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Lock-Up Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) or (C) does not occur on a date when you are otherwise permitted to sell shares of the Company&#8217;s common stock on the open market, and (iii) the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original Distribution Date and shall instead be delivered, as applicable, on (X) the first business day of the next occurring open &#8220;window period&#8221; applicable to you pursuant to the Policy (regardless of whether you are still providing Continuous Service at such time), (Y) the first business day immediately following the end of the Lock-Up Period, or (Z) the next business day on which you are not otherwise prohibited from selling shares of the Company&#8217;s Common Stock in the open market, but in no event later than the fifteenth (15th) day of the third calendar month of the calendar year following the calendar year in which the Original Distribution Date occurs.  The form of such delivery (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;DIVIDENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You shall receive no benefit or adjustment to your Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your Award after such shares have been delivered to you.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;RESTRICTIVE LEGENDS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The shares issued under your Award shall be endorsed with appropriate legends determined by the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;AWARD NOT A SERVICE CONTRACT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Your Continuous Service with the Company or an Affiliate is not for any specified term and may be terminated by you or by the Company or an Affiliate at any time, for any reason, with or without cause and with or without notice.  Nothing in this Restricted Stock Unit Agreement (including, but not limited to, the vesting of your Award pursuant to the schedule set forth in Section 2 herein or the issuance of the shares subject to your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit in this Restricted Stock Unit Agreement or the Plan shall: (i) confer upon you any right to continue in the service of, or affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of service or affiliation; (iii) confer any right or benefit under this Restricted Stock Unit Agreement or the Plan unless such right or benefit has specifically accrued under the terms of this Restricted Stock Unit Agreement or Plan; or (iv)&#160;deprive the Company of the right to terminate you at will and without regard to any future vesting opportunity that you may have.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">By accepting this Award, you acknowledge and agree that the right to continue vesting in the Award pursuant to the schedule set forth in Section 2 is earned only by continuing as an employee, director or consultant at the will of the Company (not through the act of being hired, being granted this Award or any other award or benefit) and that the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its businesses or Affiliates at any time or from time to time, as it deems appropriate (a &#8220;reorganization&#8221;).  You further acknowledge and agree that such a reorganization could result in the termination of your Continuous Service, or the termination of Affiliate status of your employer and the loss of benefits available to you under this Restricted Stock Unit Agreement, including but not limited to, the termination of the right to continue vesting in the Award.  You further acknowledge and agree that this Restricted Stock Unit Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth herein or any covenant of good faith and fair dealing that may be found implicit in any of them do not constitute an express or implied promise of continued engagement as an employee, director or consultant for the term of this Restricted Stock Unit Agreement, for any period, or at all.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;WITHHOLDING OBLIGATIONS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">On or before the time you receive a distribution of the shares subject to your Award, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Stock issuable to you and/or otherwise agree to make adequate provision in cash for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any Affiliate which arise in connection with your Award (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Withholding Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Additionally, the Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to your Award by any of the following means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you in connection with the Award with a Fair Market Value equal to the amount of such Withholding Taxes; provided, however, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax that may be required to be withheld by law (or such other amount as may be permitted while still avoiding classification of your Award as a liability for financial accounting purposes).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Unless the tax withholding obligations of the Company and/or any Affiliate are satisfied, the Company shall have no obligation to deliver to you any shares of Common Stock subject to your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event the Company&#8217;s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Company&#8217;s withholding obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;UNSECURED OBLIGATION</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is unfunded, and as a holder of a vested Award, you shall be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue shares pursuant to this Restricted Stock Unit Agreement.  You shall not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant to this Restricted Stock Unit Agreement until such shares are issued to you pursuant to Section 6 of this Restricted Stock Unit Agreement.  Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company.  Nothing contained in this Restricted Stock Unit Agreement, and no action taken pursuant to its provisions, shall create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;OTHER DOCUMENTS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  You hereby acknowledge receipt or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Plan prospectus.  In addition, you acknowledge receipt of the Policy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;NOTICES</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.  Notwithstanding the foregoing, the Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Award by electronic means or to request your consent to participate in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;MISCELLANEOUS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The rights and obligations of the Company under your Award shall be transferable to any one or more persons or entities, and all covenants and agreements hereunder shall inure to the benefit of, and be enforceable by, the Company&#8217;s successors and assigns.  Your rights and obligations under your Award may only be assigned with the prior written consent of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award, and fully understand all provisions of your Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Restricted Stock Unit Agreement shall be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All obligations of the Company under the Plan and this Restricted Stock Unit Agreement shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and/or assets of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;GOVERNING PLAN DOCUMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  Except as expressly provided herein, in the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan shall control.  In addition, your Award (and any compensation paid or shares issued under your Award) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;SEVERABILITY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If all or any part of this Restricted Stock Unit Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of this Restricted Stock Unit Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Restricted Stock Unit Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;EFFECT ON OTHER EMPLOYEE BENEFIT PLANS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event that you become an Employee, the value of the Award subject to this Restricted Stock Unit Agreement shall not be included as compensation, earnings, salaries, or other similar terms used when calculating the your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;CHOICE OF LAW</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The interpretation, performance and enforcement of this Restricted Stock Unit Agreement will be governed by the law of the state of California without regard to such state&#8217;s conflicts of laws rules.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;AMENDMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Restricted Stock Unit Agreement may not be modified, amended or terminated except by an instrument in writing, signed by you and by a duly authorized representative of the Company.  Notwithstanding the foregoing, this Restricted Stock Unit Agreement may be amended solely by the Board by a writing which specifically states that it is amending this Restricted Stock Unit Agreement, so long as a copy of such amendment is delivered to you, and provided that no such amendment materially impairing your rights hereunder may be made without your written consent.  Without limiting the foregoing, the Board reserves the right to change, by written notice to you, the provisions of this Restricted Stock Unit Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision, provided that any such change shall be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>exel20200630exhibit107.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC4DB571BCDF814DD4E20A69ACA190541"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div style="line-height:120%;text-align:right;text-indent:672px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.7</font></div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT NO. 2 TO THE</font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IPSEN SUPPLEMENT AGREEMENT </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Amendment No. 2 (this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment No. 2 &#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) is effective as of the date signed by the last Party (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Amendment No. 2 Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) and is made and entered into by and among Exelixis, Inc., a Delaware corporation, located at 210 East Grand Avenue, South San Francisco, CA 94080 (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">), Bristol-Myers Squibb Company, a Delaware corporation, a place of business at Route 206 &amp; Province Line Road, Princeton, New Jersey 08543-4000 (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">BMS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and Ipsen Pharma SAS, a French Corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ipsen</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with regards to the Supplement To The Clinical Trial Collaboration Agreement effective February 24, 2017 entered into by Exelixis, BMS and Ipsen (the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Ipsen Supplement Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#0000ff;font-weight:bold;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and BMS entered into that certain Clinical Trial Collaboration Agreement dated February 24, 2017 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to enable them to collaborate with each other to sponsor one or more clinical trials of a combination therapy using Exelixis&#8217;s tyrosine kinase inhibitor known as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Cabozantinib&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, certain rights to which are licensed by Exelixis to, and shared by Exelixis with  Takeda and Ipsen, and BMS&#8217; human monoclonal antibody that binds PD-1 known as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Nivolumab&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, certain rights to which are licensed by BMS from, and shared by BMS with, Ono Pharmaceutical Co. Ltd. (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ono</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), with or without BMS&#8217;s CTLA-4 monoclonal antibody known as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ipilimumab</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and Ipsen entered into a Collaboration and License Agreement dated February 29, 2016 (such agreement, as amended from time to time, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;Ipsen-Exelixis Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), as amended</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">wherein Exelixis and Ipsen formed a collaboration for the continued development of and commercialization of Cabozantinib and wherein Exelixis granted to Ipsen certain exclusive rights to develop and commercialize Cabozantinib worldwide, with the exception of the United States and Japan (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Ipsen Territory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;);</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis, Ipsen and BMS want to amend the Ipsen Supplement Agreement.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of the foregoing premises and the mutual promises and covenants contained herein, Exelixis, BMS and Ipsen agree as follows: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Definitions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The terms in this Amendment No. 2 with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth herein, or if not defined herein, as set forth in the Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Approval</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean any and all approvals (including supplements, amendments, variations, label expansion, indication extensions, pre- and post-approvals, NDA or BLA approvals, and their foreign equivalents such as MAA approvals), licenses, registrations or authorizations (including marketing and labelling authorizations) of any national, supra-national (e.g., the European Union), regional, state or local Regulatory Authority, department, bureau, commission, council or other governmental entity, that are necessary for the commercial manufacture, commercial use, or sale of a product in a given jurisdiction.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Parties hereby amend the Agreement to add the following sections in Article 8.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.8&#160;&#160;&#160;&#160;NDAs and BLAs and their foreign equivalents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding either Party&#8217;s ownership of (i) a Combined Therapy IND as set forth in Section 2.1(a) or (ii) Regulatory Documentation associated with a Combined Therapy IND, unless otherwise agreed by the JDC and reflected in the mutually agreed JDC minutes, and pursuant to a regulatory submission strategy:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;The sponsor of record shall prepare all Regulatory Documentation for any new or supplemental BLA or NDA and its foreign equivalent to be filed for a Combined Therapy in the Field arising from a Combined Therapy Trial.  The sponsor of record shall have primary responsiblity, and shall have the first right but not the obligation, to file and maintain (directly or through its designee) all such Regulatory Documentation for each Regulatory Authority (i.e., for each country or region) for such NDA or BLA and its foreign equivalent to be filed for a Combined Therapy in the Field for its respective Compound and all Regulatory Approvals related thereto; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided that</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(x) the other Party shall have the right to review and </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">comment on all such regulatory filings prior to such filing, as well as communications with Regulatory Authorities through the JCS-WG, as required under Section 2.4(b)(iv) above, (y) shall receive a complete, final copy of such Regulatory Documentation prior to such filing, and (z) shall have the right but not the obligation to file all such Regulatory Documentation on its own behalf concurrently or at any time thereafter;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;The Parties agree that Exelixis and BMS (including their respective Affiliates and licensees) shall each have all necessary Right of Cross-Reference and other rights to support such new or supplemental BLA or NDA filings and their foreign equivalents, including through the rights set forth in the Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.9&#160;&#160;&#160;&#160;Cooperation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party (including their respective Affiliates and licensees) shall provide reasonable consultation and assistance to the other Party, in each case, for purposes of supporting the preparation, filing and submission by the other Party of Regulatory Documentation for Combined Therapies and shall continue to provide consultation and assistance during the period of regulatory review.  Notwithstanding Section 8.3 above, the Parties (including their respective Affiliates and licensees) through the JDC will enter into good faith discussions to determine a regulatory submission strategy agreeable to both Parties for the applicable Combined Therapy indication.  If the Parties do not agree on a regulatory submission strategy for the Combined Therapy indication, such dispute will be referred to the Executive Officers for resolution in accordance with the timelines at Section 13.3(a).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">With respect to filings within the United States only, if agreement on a regulatory submission strategy is not reached after such escalation, then if a Party desires to submit the Regulatory Documentation prepared in accordance with Section 8.8(a) above, or update its label for its respective Compound in the Combined Therapy based on the results of the Study, such Party shall notify the other Party, and each Party and its Affiliates shall cooperate to take all steps reasonably necessary to enable such submission.  For clarity, with respect to filings within the United States only, each Party agrees to: (a) provide to the other Party prompt, reasonable consultation and assistance with the preparation, filing and submission of Regulatory Documentation with the Regulatory Authorities, including providing access to all reasonably requested documentation under each Party&#8217;s or its Affiliates&#8217; control that may be necessary or useful for the preparation of such Regulatory Documentation (including single-agent clinical data as reasonably required); and (b) complete all documents requested by the other Party reasonably required for such Regulatory Documentation, all in accordance with the timelines provided in this Agreement or otherwise agreed by the JDC, and in any event such that final Regulatory Documentation is ready for filing with the applicable Regulatory Authority within [ * ].  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For clarity, outside of the United States, the Parties (including their respective Affiliates and licensees) must agree on a regulatory submission strategy.  Where such agreement is to file, the Parties (including Affiliates and licensees) shall cooperate to take all steps reasonably necessary to enable such submission.  Outside of the United States and more specifically in the Ipsen Territory, the Parties hereby agree that regulatory submission strategy discussions shall occur through the JCS-WG or at </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">ad hoc </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">meetings as may be agreed by the Parties and Ipsen.  For clarity, with respect to filings within the Ipsen Territory, each Party and Ipsen agree to: (a) provide prompt, reasonable consultation and assistance with the preparation, filing and submission of Regulatory Documentation with the Regulatory Authorities, including providing access to all reasonably requested documentation under each Party&#8217;s or its licnesee&#8217;s or Affiliates&#8217; control that may be necessary or useful for the preparation of such Regulatory Documentation (including single-agent clinical data as reasonably required); and (b) complete all documents requested as reasonably required for such Regulatory Documentation, all in accordance with the timelines provided in this Agreement or otherwise agreed by the JCS-WG.   The Parties also agree that notwithstanding Section 8.3 above, with respect to filings in the Ipsen Territory, BMS shall provide Ipsen direct access to and Ipsen will provide BMS direct access to all reasonably requested Regulatory Documentation and other documents under each of BMS&#8217;, Ipsen&#8217;s and their respective Affiliates&#8217; control that may be necessary or useful for Ipsen&#8217;s or BMS&#8217; preparation of the Regulatory Documentation in the Ipsen Territory. Such exchanges of Regulatory Documentation and other documents shall occur through the JCS-WG, or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">ad hoc</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;as may be agreed  by the Parties and Ipsen.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.10&#160;&#160;&#160;&#160;Timelines.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Each Party shall review, comment and approve (if applicable) any and all documentation provided by one Party to the other Party pursuant to Sections 8.8 and 8.9 above within [ * ], or if more time is reasonably requested by a Party, such longer period as reasonably agreed by the Parties.  Further, subject to Sections 8.8 and 8.9 above, each Party shall provide the requested reasonable consultation and assistance, including, but not limited to, providing any reasonably requested documentation to the other Party, within [ * ] from such request, or if more time is reasonably requested by a Party, such longer period as reasonably agreed by the Parties.   </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.11&#160;&#160;&#160;&#160;Regulatory</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Authority Inspection</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Each Party shall promptly notify the other Party in writing within [ * ] inspections by any Regulatory Authority directly related to the Combined Therapy and/or the other Party&#8217;s Compound, and within [ * ] regulatory inspection with respect to the other Party&#8217;s Compound or Combined Therapy development activities. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;The first sentence of Section 9.7(b) is hereby deleted and replaced with the following:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Exelixis and BMS agree to collaborate to publicly disclose, publish or present (1) top-line results from each Combined Therapy Trial and joint global regulatory strategy, limited if possible to avoid jeopardizing the future publication of the Study Data at a scientific conference or in a scientific journal, solely for the purpose of disclosing, as soon as reasonably practicable after such data is first available to the Controlling Party, the safety or efficacy results and conclusions that are material to any Party under applicable securities laws, and (2) the conclusions and outcomes (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Results</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) of each Combined Therapy Trial at a scientific conference as soon as reasonably practicable following the completion of such Combined Therapy Trial, subject in the case of (2) to the following conditions.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;The Parties hereby agree that Sections 8.8 to 8.11 will survive any termination or expiration of the Agreement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;Ipsen, BMS and Exelixis hereby agree that each Party will provide reasonable assistance to the other Party in the cooperation and compliance of its own licensees with respect to all conduct carried out under this Amendment.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;Except as expressly set forth herein, all provisions of the Agreement shall remain unchanged and in full force and effect.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;This Amendment No. 2 shall be governed and construed in accordance with the internal laws of the State of New York, USA, excluding any choice of law rules that may direct the application of the laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;This Amendment No. 2 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument.  This Amendment No. 2 may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each party hereto as if they were original signatures. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signature page follows]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;IN WITNESS WHEREOF, Ipsen, Exelixis and BMS, intending to be legally bound hereby, have caused this Amendment No. 2 to be executed by their duly authorized representatives as of the date(s) below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:6%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:    /s/ Gisela Schwab      </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:    /s/ Nancy Forrest      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Gisela M. Schwab, M.D.      </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Nancy Forrest      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: President, Product Development &amp; Medical Affairs, Chief Medical Officer</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date:   5/5/2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:   Vice President, Development &amp; Commercial Alliances</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date:  5/7/2020</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.89682539682539%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Pharma SAS</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:    /s/ Francois Garnier      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Francois Garnier      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  EVP General Counsel</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date:   5/5/2020      </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signature Page to Amendment No. 2]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>exel20200630exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2A843807CE13584C9F4C0E2495419EC3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">August&#160;6, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>exel20200630exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s97CD239722D15097A68E0101222B5021"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">August&#160;6, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>exel20200630exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1ED0248E7CB15E3A981AF8457A2A7E95"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;3, 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">6th</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">August 2020</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>exel-20200703.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20200703" xmlns:exel="http://www.exelixis.com/20200703" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200703_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200703_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200703_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20200703_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2104100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails">
        <link:definition>2404405 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails">
        <link:definition>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInvestmentsBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails">
        <link:definition>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2404404 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2304301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsGskDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsGskDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.exelixis.com/role/CommitmentsAndContingencies">
        <link:definition>2111100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2105100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2405402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2305301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesDetails">
        <link:definition>2408401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2106100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2406402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2306301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2110100 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails">
        <link:definition>2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails">
        <link:definition>2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2310301 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2102100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails">
        <link:definition>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsAndLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails">
        <link:definition>2402407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedByProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails">
        <link:definition>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails">
        <link:definition>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails">
        <link:definition>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails">
        <link:definition>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2302301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AchievedMember" name="AchievedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesOfAmerisourceBergenCorporationMember" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofCVSHealthCorporationMember" name="AffiliatesofCVSHealthCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofOptumSpecialtyPharmacyMember" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForProductRebatesMember" name="AllowanceForProductRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_BrandedPrescriptionDrugFeeAccrual" name="BrandedPrescriptionDrugFeeAccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_BrandedPrescriptionDrugFeeAccrualCurrent" name="BrandedPrescriptionDrugFeeAccrualCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_BrandedPrescriptionDrugFeeAccrualNonCurrent" name="BrandedPrescriptionDrugFeeAccrualNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsAndInvestmentsTextBlock" name="CashCashEquivalentsAndInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ChargebacksAndDiscountsForPromptPaymentMember" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationMember" name="CollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CotellicMember" name="CotellicMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareDenominatorAbstract" name="EarningsPerShareDenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareNumeratorAbstract" name="EarningsPerShareNumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" name="EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_MilestonePaymentsEarned" name="MilestonePaymentsEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_NewInformationMember" name="NewInformationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceShareOptionsPSOMember" name="PerformanceShareOptionsPSOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProbableMember" name="ProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductGrossMember" name="ProductGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductSalesDiscountsAndAllowancesMember" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedFromCabozantinibMember" name="ProductsDerivedFromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedFromOtherCompoundsMember" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ResultingFromDiscoveryEffortsMember" name="ResultingFromDiscoveryEffortsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusAxis" name="StatusAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusDomain" name="StatusDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_TakedaMember" name="TakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>exel-20200703_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20200703.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20200703.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20200703.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGskDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20200703.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingencies" xlink:href="exel-20200703.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20200703.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20200703.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20200703.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20200703.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20200703.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20200703.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20200703.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20200703.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20200703.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20200703.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20200703.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20200703.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20200703.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20200703.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20200703.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20200703.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20200703.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails" xlink:href="exel-20200703.xsd#RevenuesContractAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20200703.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20200703.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20200703.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20200703.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20200703.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20200703.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637161ae-edda-4795-a48b-e7fc200f1f64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_637161ae-edda-4795-a48b-e7fc200f1f64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5dc3180f-9781-8308-f5f8-40f910129f38" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5dc3180f-9781-8308-f5f8-40f910129f38" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a837b31e-1400-d592-c167-ead1d80d260e" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a837b31e-1400-d592-c167-ead1d80d260e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ef772ef-d0a5-977b-06d1-931f4da1f4a0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7ef772ef-d0a5-977b-06d1-931f4da1f4a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8eb340c5-931d-6039-6a0a-c6ca66e2f0f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_907f932c-4028-78a7-797b-75fef8e1c674" xlink:type="locator" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_23ab1222-0bab-b43d-9c55-75fef8fe7734" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_907f932c-4028-78a7-797b-75fef8e1c674" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_23ab1222-0bab-b43d-9c55-75fef8fe7734" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_a13c4d80-ba4e-2256-7611-75fef94351cb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_907f932c-4028-78a7-797b-75fef8e1c674" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_a13c4d80-ba4e-2256-7611-75fef94351cb" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_9c76cc35-f7e8-3cf6-d2bc-75fef915dc84" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_907f932c-4028-78a7-797b-75fef8e1c674" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_9c76cc35-f7e8-3cf6-d2bc-75fef915dc84" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1ec2d36f-0116-a649-3e1a-75fef9b20d5f" xlink:type="locator" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45db371a-10e0-a52c-144d-75fef8e497f3" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1ec2d36f-0116-a649-3e1a-75fef9b20d5f" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_45db371a-10e0-a52c-144d-75fef8e497f3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd59665b-8c5e-370e-8a91-75fefa15ca37" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1ec2d36f-0116-a649-3e1a-75fef9b20d5f" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_cd59665b-8c5e-370e-8a91-75fefa15ca37" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a59f59ae-c39f-4085-bddc-75fef93fb763" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_1ec2d36f-0116-a649-3e1a-75fef9b20d5f" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a59f59ae-c39f-4085-bddc-75fef93fb763" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8ffc7e1-866c-6a43-467c-5cfa8ba6296f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8ffc7e1-866c-6a43-467c-5cfa8ba6296f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_b2cef9de-b2d2-c3f3-772b-2ec7db5b141e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8ffc7e1-866c-6a43-467c-5cfa8ba6296f" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_b2cef9de-b2d2-c3f3-772b-2ec7db5b141e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_95fe5c6d-e90e-6d2c-8e9a-8339666be1b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_AccountsPayableCurrent_95fe5c6d-e90e-6d2c-8e9a-8339666be1b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_9746a712-2516-2b22-a7be-3a89f7517db6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_9746a712-2516-2b22-a7be-3a89f7517db6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_3eabdaf8-0799-3862-7f86-75fef905730a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_3eabdaf8-0799-3862-7f86-75fef905730a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_33db0297-d8dd-91fa-7762-dc203c65a33f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_33db0297-d8dd-91fa-7762-dc203c65a33f" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_bab9b9c9-5725-b55c-c311-75fef8f6f52c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_bab9b9c9-5725-b55c-c311-75fef8f6f52c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_13159f86-b20a-f641-5cfd-65a0553fc694" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_723c74a6-b3c0-ab21-b11a-8bd4ce4806f0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_13159f86-b20a-f641-5cfd-65a0553fc694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c26fd986-9c22-6850-c06e-2e4754d9df6f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_c26fd986-9c22-6850-c06e-2e4754d9df6f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_44e41183-ff71-8a5d-6bae-236dd27ab6c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a0e4a1b3-b018-392a-9b7d-09729b37d6a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7098604a-0754-f0ec-28b7-b5aa73ca65d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c8c1ef7d-82ef-ec40-66d0-45806fc53a6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c8c1ef7d-82ef-ec40-66d0-45806fc53a6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae7d1998-6654-2677-8e9f-f36b62210000" xlink:to="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_844e7c43-dfe0-790d-4f5e-8b1150390e12" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_PreferredStockValue_844e7c43-dfe0-790d-4f5e-8b1150390e12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_CommonStockValue_130b8997-2f7a-8192-a853-ff9fb4629d95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26982214-e3a4-a834-1e73-cd58ba2d5ac9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_355fc088-038d-3905-0784-91db0d020a77" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_355fc088-038d-3905-0784-91db0d020a77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_444cfce6-fc59-0d4d-1ade-0fdec3499b08" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18ff0284-4873-6ef0-806f-4fb76051c01f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26247a2d-7bac-8834-3dc5-06c993b10b2c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_ShortTermInvestments_eecfbaaa-c976-c575-7b2f-92db01e55182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_02eb9f27-cc70-d84a-60be-0ebfa9ad27e5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_02eb9f27-cc70-d84a-60be-0ebfa9ad27e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_InventoryNet_aa7cc103-d668-cf3b-6875-81c99ffeac19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33b4d214-779b-2177-f7ba-19f0abb03b76" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bceb5e86-dcaf-e940-c004-d20dda9b81f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33b4d214-779b-2177-f7ba-19f0abb03b76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_30a7f09e-9bdf-f419-115d-3a4521db1baa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_LongTermInvestments_30a7f09e-9bdf-f419-115d-3a4521db1baa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf545d72-755b-f46c-4176-2eeaac0328d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_657ba5b9-6efd-7796-881d-42495ee333b2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_657ba5b9-6efd-7796-881d-42495ee333b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_Goodwill_57088d99-3f43-6bbf-c330-0bf0e1b35b0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d88b9019-0bd3-d7de-96eb-5cd69c504c2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_17a41c51-6fe7-c037-64c3-3ef6c9692a94" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_fb4a1534-3ea3-3150-f601-42486b71bc63" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_fb4a1534-3ea3-3150-f601-42486b71bc63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_ShareBasedCompensation_8e70545b-e41a-5c88-3aeb-15f273c05266" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_NoncashLeaseExpense" xlink:label="loc_exel_NoncashLeaseExpense_897e143a-fe41-32fd-13da-75fef9118329" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_exel_NoncashLeaseExpense_897e143a-fe41-32fd-13da-75fef9118329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85778726-2976-db5c-852c-dbc4adac60a9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_85778726-2976-db5c-852c-dbc4adac60a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0f2b9828-5f8e-5896-c7bd-f8b6ab4926af" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0f2b9828-5f8e-5896-c7bd-f8b6ab4926af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_753ca67e-e0b1-89f6-0f4c-664d01a2b0f7" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_753ca67e-e0b1-89f6-0f4c-664d01a2b0f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_660d037d-5031-2fde-c0d3-d2b6978292ac" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_660d037d-5031-2fde-c0d3-d2b6978292ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a606b8-7e33-f76c-e640-a59fba42c06a" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_30a606b8-7e33-f76c-e640-a59fba42c06a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_afeb5653-dd4e-f1f9-0e15-665d77599c63" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_afeb5653-dd4e-f1f9-0e15-665d77599c63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1aefa3b7-6b7a-d481-5bdc-6b8b587c627e" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13d5d34e-e391-ca89-d84d-71b1e1c2a78c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1aefa3b7-6b7a-d481-5bdc-6b8b587c627e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca48a49a-2cde-cf3d-6904-e8f08b6e1fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_fa7a25d7-7510-4a32-f462-4117022ba713" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_fa7a25d7-7510-4a32-f462-4117022ba713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6c5680ad-5464-f400-8095-cd1e8fafccd5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2794b8a8-762d-d243-a2f5-a00d52d74432" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_6c5680ad-5464-f400-8095-cd1e8fafccd5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e98a0be-51ae-18d0-54bf-b32eca8c5c1d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a919e86d-0b1f-2f4b-24ba-d39230d49e92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a919e86d-0b1f-2f4b-24ba-d39230d49e92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1280953b-4e55-e1d6-0c4b-6dfd4307a698" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1280953b-4e55-e1d6-0c4b-6dfd4307a698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6af9b322-bd28-b53c-6ab5-52bafd228259" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a7e00ec-a1a5-81e8-5255-8844ac6fe87f" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6af9b322-bd28-b53c-6ab5-52bafd228259" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:to="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21e78629-41be-59b9-6de7-6a506ab18f9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_61cff5eb-6380-0a99-0b9f-2aa494c88658" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21e78629-41be-59b9-6de7-6a506ab18f9f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0bbe8f4f-d085-9302-fa93-9512411ebfc0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:to="loc_us-gaap_Revenues_0bbe8f4f-d085-9302-fa93-9512411ebfc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0bbe8f4f-d085-9302-fa93-9512411ebfc0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ff0f538-863f-dffc-da3e-5378e55a2439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_4637d214-404c-0950-dcc6-952c72e38d5a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_0bbe8f4f-d085-9302-fa93-9512411ebfc0" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_4637d214-404c-0950-dcc6-952c72e38d5a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0595bf0b-6881-370e-2cc3-29f72f729fac" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_86cfb7da-c050-ac7c-919e-7f811affb4ae" xlink:to="loc_us-gaap_CostsAndExpenses_0595bf0b-6881-370e-2cc3-29f72f729fac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_01f4f849-ade5-f04f-1204-64d74a0c2886" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0595bf0b-6881-370e-2cc3-29f72f729fac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_01f4f849-ade5-f04f-1204-64d74a0c2886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_922daf79-4589-2010-458b-2bc250462d25" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0595bf0b-6881-370e-2cc3-29f72f729fac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_922daf79-4589-2010-458b-2bc250462d25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89404ae6-0808-876c-4ac7-0c429ea9ed38" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0595bf0b-6881-370e-2cc3-29f72f729fac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89404ae6-0808-876c-4ac7-0c429ea9ed38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_fb1da450-b187-3ff7-5004-3eb80bfc2a0e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_InterestIncomeOther_fb1da450-b187-3ff7-5004-3eb80bfc2a0e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3b4fb19e-0ab3-73fa-6824-0c5022a00349" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_497f98e6-8a11-3c53-7076-ee6aaae664ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_aaf4fade-f652-62f8-cf02-c59447905641" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6a75c878-dfaf-e368-936e-ce293fe86f6f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17e567b0-4e77-385a-6ce4-0f470bbb70c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_88da5cea-7ea1-ec46-7d8e-822e6c2e193d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f6e033ad-7025-b6e1-c62b-b572fe209bf1" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_88da5cea-7ea1-ec46-7d8e-822e6c2e193d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_80b2cab3-30ae-20d1-0cea-6c990f5012bd" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:to="loc_us-gaap_InventoryRawMaterials_80b2cab3-30ae-20d1-0cea-6c990f5012bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_c2b6624f-4172-33cb-87ca-3e23d17f2460" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:to="loc_us-gaap_InventoryWorkInProcess_c2b6624f-4172-33cb-87ca-3e23d17f2460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_b4994565-276e-19f8-ba9d-e3a584b51998" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_94fef42f-79e8-6ba5-8b50-111a59f6360d" xlink:to="loc_us-gaap_InventoryFinishedGoods_b4994565-276e-19f8-ba9d-e3a584b51998" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4f95d0-4de5-2b2f-e2ec-91daf63ca50c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f60858b4-cb31-daa2-3699-140a0e3df912" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4f95d0-4de5-2b2f-e2ec-91daf63ca50c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f60858b4-cb31-daa2-3699-140a0e3df912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7595492d-e98c-ec24-3583-0c7237508f48" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b4f95d0-4de5-2b2f-e2ec-91daf63ca50c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7595492d-e98c-ec24-3583-0c7237508f48" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>exel-20200703_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20200703.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20200703.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20200703.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGskDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20200703.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingencies" xlink:href="exel-20200703.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20200703.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20200703.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20200703.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20200703.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20200703.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20200703.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20200703.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20200703.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20200703.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20200703.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20200703.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20200703.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20200703.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20200703.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20200703.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20200703.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20200703.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails" xlink:href="exel-20200703.xsd#RevenuesContractAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20200703.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20200703.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20200703.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20200703.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20200703.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20200703.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5F17D8935E577B21FD24BA4187D13363" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5F17D8935E577B21FD24BA4187D13363" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_18E55933F5B9D8E42AB4BA4187D05E28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_18E55933F5B9D8E42AB4BA4187D05E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F2B2A69FFD669B90AD1BBA4187D01632" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F2B2A69FFD669B90AD1BBA4187D01632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:label="loc_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:to="loc_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5F17D8935E577B21FD24BA4187D13363" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:to="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_085E834CA4A7A6692669B6610C774BB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CommercialPaperMember_085E834CA4A7A6692669B6610C774BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_4793BE5EF55D119ED5A5B6610C77E5FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_4793BE5EF55D119ED5A5B6610C77E5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0CC815AD89848A71DD52B6610C77B77E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0CC815AD89848A71DD52B6610C77B77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_F7FDC9E839C07BE48AF3B6610C772897" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_F7FDC9E839C07BE48AF3B6610C772897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_15DD1DBA4D988E66C6B4B6610C785C1A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_MoneyMarketFundsMember_15DD1DBA4D988E66C6B4B6610C785C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_88A1F1D91760BD857E2CB6610C785FAC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CertificatesOfDepositMember_88A1F1D91760BD857E2CB6610C785FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:to="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:to="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:to="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:to="loc_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:to="loc_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:to="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:to="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:to="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_86D1D6F859EE233E485EB6610CF05CE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:to="loc_us-gaap_LicenseMember_86D1D6F859EE233E485EB6610CF05CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_4BAA2435B1BB89C0F18BB6610CF068DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:to="loc_us-gaap_ServiceMember_4BAA2435B1BB89C0F18BB6610CF068DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4C15576F7BCA721719A9B6610CF18E3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4C15576F7BCA721719A9B6610CF18E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_6B5BA3885EAE9D7C91AFB6610CF2755F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_6B5BA3885EAE9D7C91AFB6610CF2755F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5062446A008195C06D15B6610CF2F456" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_Revenues_5062446A008195C06D15B6610CF2F456" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:to="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:to="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:to="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F" xlink:to="loc_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:to="loc_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_21D062012DA397B67052BA77822C37DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_21D062012DA397B67052BA77822C37DF" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:to="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:to="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:to="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A" xlink:to="loc_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_130ED3012B497852C0079692687318A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_130ED3012B497852C0079692687318A6" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_1880D7C13C5E0DD812A6969268741A68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_exel_MilestonePaymentsEarned_1880D7C13C5E0DD812A6969268741A68" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6BFB55D0B28DB28CC5E196926879BD34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6BFB55D0B28DB28CC5E196926879BD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D6399096E86D7018680A969268799E5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D6399096E86D7018680A969268799E5A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:to="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:to="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:to="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:to="loc_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_8540CF7AAA61C8C5A222AE19B2D410C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:to="loc_us-gaap_LicenseMember_8540CF7AAA61C8C5A222AE19B2D410C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_B5282CC8B8D5556882C9AE19B2D4C511" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:to="loc_us-gaap_ServiceMember_B5282CC8B8D5556882C9AE19B2D4C511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF081833DF6980D4FC70AE19B2D54BD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF081833DF6980D4FC70AE19B2D54BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_FBE091E73554ECAF5C83AE19B2D578B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_FBE091E73554ECAF5C83AE19B2D578B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:to="loc_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:to="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:to="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:to="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C3EB145F5199CF39D78CB4328A8E6653" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_NetIncomeLoss_C3EB145F5199CF39D78CB4328A8E6653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:to="loc_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:to="loc_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:to="loc_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20200703.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:type="locator" />
    <link:loc xlink:href="exel-20200703.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_NewInformationMember" xlink:label="loc_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:to="loc_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:to="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:to="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:to="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductsDerivedFromOtherCompoundsMember" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9AB99FE6870382F7834A941BB8162515" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9AB99FE6870382F7834A941BB8162515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrual" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrualCurrent" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrualNonCurrent" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="loc_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:to="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:to="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:to="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:to="loc_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_TakedaMember" xlink:label="loc_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:to="loc_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1A0572EFDBE3AC22BB54A578CD33D275" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1A0572EFDBE3AC22BB54A578CD33D275" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:to="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:to="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:to="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A" xlink:to="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:to="loc_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:to="loc_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:to="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:to="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:to="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:to="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:to="loc_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductSalesDiscountsAndAllowancesMember" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:to="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:to="loc_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_28E45D646D32C8CF7908B6610D50B90C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:to="loc_us-gaap_ServiceMember_28E45D646D32C8CF7908B6610D50B90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4AA5961DD1459D89833FB6610D51093D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4AA5961DD1459D89833FB6610D51093D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_A8A4FC7818C0AF6A2F27B6D5A62FC274" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_A8A4FC7818C0AF6A2F27B6D5A62FC274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D618AD9F8C1C52F0A036B6610D5145FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_Revenues_D618AD9F8C1C52F0A036B6610D5145FC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3905C0BA68599C86C06EB6610D30FC3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3905C0BA68599C86C06EB6610D30FC3F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:to="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:to="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:to="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="loc_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="loc_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:label="loc_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="loc_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_542939CD8204C8BCAB77B6610D30CC10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3905C0BA68599C86C06EB6610D30FC3F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_542939CD8204C8BCAB77B6610D30CC10" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:to="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:to="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofCVSHealthCorporationMember" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_TakedaMember" xlink:label="loc_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:to="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:to="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:to="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:to="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:to="loc_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:to="loc_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>exel-20200703_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1" xlink:to="lab_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:to="lab_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:to="lab_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:to="lab_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:to="lab_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:to="lab_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5_label_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5_documentation_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:to="lab_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:to="lab_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F_label_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F_documentation_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:to="lab_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:to="lab_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:to="lab_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F_label_en-US" xlink:label="lab_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:to="lab_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="lab_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:to="lab_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:to="lab_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:to="lab_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:to="lab_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA" xlink:to="lab_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains on available-for-sale debt securities, net of tax impact of $2,287, $413, $1,346 and $807, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:to="lab_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:to="lab_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081_label_en-US" xlink:label="lab_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:to="lab_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A_label_en-US" xlink:label="lab_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:to="lab_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:to="lab_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue not from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6_label_en-US" xlink:label="lab_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:to="lab_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2_label_en-US" xlink:label="lab_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="lab_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380_terseLabel_en-US" xlink:label="lab_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380_label_en-US" xlink:label="lab_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:to="lab_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:to="lab_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:to="lab_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:to="lab_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C_label_en-US" xlink:label="lab_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:to="lab_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD_label_en-US" xlink:label="lab_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:to="lab_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:to="lab_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:to="lab_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:to="lab_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:to="lab_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:to="lab_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62_label_en-US" xlink:label="lab_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:to="lab_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:to="lab_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6_label_en-US" xlink:label="lab_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:to="lab_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7_label_en-US" xlink:label="lab_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:to="lab_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7_label_en-US" xlink:label="lab_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:to="lab_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:to="lab_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:to="lab_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC_label_en-US" xlink:label="lab_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:to="lab_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:to="lab_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:to="lab_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8_label_en-US" xlink:label="lab_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:to="lab_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B_label_en-US" xlink:label="lab_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:to="lab_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:to="lab_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:to="lab_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:to="lab_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:to="lab_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:to="lab_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:type="arc" />
    <link:label id="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_NoncashLeaseExpense" xlink:label="loc_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:to="lab_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:to="lab_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:to="lab_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:to="lab_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="lab_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:to="lab_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:to="lab_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:to="lab_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50_label_en-US" xlink:label="lab_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:to="lab_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:to="lab_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377" xlink:to="lab_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05_label_en-US" xlink:label="lab_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:to="lab_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:to="lab_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="lab_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:to="lab_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:to="lab_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:to="lab_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:to="lab_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:to="lab_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:to="lab_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:to="lab_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:to="lab_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:to="lab_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on available-for-sale securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:to="lab_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="lab_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen Pharma SAS (Ipsen)</link:label>
    <link:label id="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748_label_en-US" xlink:label="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748_documentation_en-US" xlink:label="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:to="lab_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofCVSHealthCorporationMember" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:type="arc" />
    <link:label id="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44_terseLabel_en-US" xlink:label="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited (Takeda)</link:label>
    <link:label id="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44_label_en-US" xlink:label="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44_documentation_en-US" xlink:label="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_TakedaMember" xlink:label="loc_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:to="lab_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:to="lab_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138_label_en-US" xlink:label="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138_documentation_en-US" xlink:label="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:to="lab_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9_label_en-US" xlink:label="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9_documentation_en-US" xlink:label="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:to="lab_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90_label_en-US" xlink:label="lab_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:to="lab_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:to="lab_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:type="arc" />
    <link:label id="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163_label_en-US" xlink:label="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163_documentation_en-US" xlink:label="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:to="lab_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:type="arc" />
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductSalesDiscountsAndAllowancesMember" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420_label_en-US" xlink:label="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420_documentation_en-US" xlink:label="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:to="lab_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:to="lab_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068_label_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:to="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21_label_en-US" xlink:label="lab_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:to="lab_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Investments, available-for-sale, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale, fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:to="lab_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:to="lab_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:to="lab_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:type="arc" />
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:to="lab_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2019</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at June 30, 2020</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:to="lab_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:to="lab_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E_terseLabel_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO)</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E_label_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:label id="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E_documentation_en-US" xlink:label="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Share Options (PSO) [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:to="lab_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:to="lab_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:type="arc" />
    <link:label id="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8_terseLabel_en-US" xlink:label="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8_label_en-US" xlink:label="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8_documentation_en-US" xlink:label="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:to="lab_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:type="arc" />
    <link:label id="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566_terseLabel_en-US" xlink:label="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566_label_en-US" xlink:label="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566_documentation_en-US" xlink:label="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:to="lab_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:type="arc" />
    <link:label id="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631_terseLabel_en-US" xlink:label="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631_label_en-US" xlink:label="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631_documentation_en-US" xlink:label="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:to="lab_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:type="arc" />
    <link:label id="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6_terseLabel_en-US" xlink:label="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6_label_en-US" xlink:label="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6_documentation_en-US" xlink:label="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:to="lab_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in share reserve under 2017 plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, percent of common stock share price triggering PSO exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:type="arc" />
    <link:label id="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9_terseLabel_en-US" xlink:label="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New information</link:label>
    <link:label id="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9_label_en-US" xlink:label="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Information [Member]</link:label>
    <link:label id="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9_documentation_en-US" xlink:label="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Information [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_NewInformationMember" xlink:label="loc_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:to="lab_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:type="arc" />
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products derived from cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductsDerivedFromOtherCompoundsMember" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:to="lab_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:to="lab_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in earnings per share due to change in accounting estimate (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:type="arc" />
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9_terseLabel_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Branded prescription drug fee, accrual</link:label>
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9_label_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Branded Prescription Drug Fee, Accrual</link:label>
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9_documentation_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Branded Prescription Drug Fee, Accrual</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrual" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:to="lab_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:type="arc" />
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C_terseLabel_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Branded prescription drug fee, accrual, current</link:label>
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C_label_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Branded Prescription Drug Fee, Accrual, Current</link:label>
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C_documentation_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Branded Prescription Drug Fee, Accrual, Current</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrualCurrent" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:to="lab_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:type="arc" />
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95_terseLabel_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Branded prescription drug fee, accrual, noncurrent</link:label>
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95_label_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Branded Prescription Drug Fee, Accrual, Non-Current</link:label>
    <link:label id="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95_documentation_en-US" xlink:label="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Branded Prescription Drug Fee, Accrual, Non-Current</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrualNonCurrent" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:to="lab_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="lab_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="lab_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:to="lab_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:to="lab_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA_label_en-US" xlink:label="lab_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:to="lab_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:to="lab_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:to="lab_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F_label_en-US" xlink:label="lab_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:to="lab_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265_label_en-US" xlink:label="lab_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:to="lab_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:to="lab_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:to="lab_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6_label_en-US" xlink:label="lab_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:to="lab_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:to="lab_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:to="lab_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 308,886 and 304,831 at June 30, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:to="lab_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:to="lab_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12" xlink:to="lab_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:type="arc" />
    <link:label id="lab_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:label="loc_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:to="lab_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:type="arc" />
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:to="lab_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:to="lab_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:to="lab_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="lab_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:type="arc" />
    <link:label id="lab_country_US_179D4E6E341A4A97C255B6610D29FAFE_terseLabel_en-US" xlink:label="lab_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_179D4E6E341A4A97C255B6610D29FAFE_label_en-US" xlink:label="lab_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:to="lab_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C_label_en-US" xlink:label="lab_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:to="lab_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:type="arc" />
    <link:label id="lab_country_JP_2D2201C54820C669DCDEB6610D30AC3A_terseLabel_en-US" xlink:label="lab_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_2D2201C54820C669DCDEB6610D30AC3A_label_en-US" xlink:label="lab_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:label="loc_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:to="lab_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:type="arc" />
    <link:label id="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF_terseLabel_en-US" xlink:label="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF_label_en-US" xlink:label="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF_documentation_en-US" xlink:label="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:to="lab_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7" xlink:type="arc" />
    <link:label id="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623_terseLabel_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623_label_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623_documentation_en-US" xlink:label="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:to="lab_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:type="arc" />
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47_verboseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47_label_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47_documentation_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash equivalents included in long-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731_verboseLabel_en-US" xlink:label="lab_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ipsen</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:to="lab_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:type="arc" />
    <link:label id="lab_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB_verboseLabel_en-US" xlink:label="lab_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_TakedaMember" xlink:label="loc_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:to="lab_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:to="lab_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:type="arc" />
    <link:label id="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB_terseLabel_en-US" xlink:label="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction related to a milestone</link:label>
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:to="lab_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>exel-20200703_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20200703.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20200703.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20200703.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20200703.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsGskDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20200703.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20200703.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsAndContingencies" xlink:href="exel-20200703.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20200703.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20200703.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20200703.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20200703.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20200703.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20200703.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20200703.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20200703.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20200703.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20200703.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20200703.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20200703.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20200703.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20200703.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20200703.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20200703.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20200703.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20200703.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20200703.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails" xlink:href="exel-20200703.xsd#RevenuesContractAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20200703.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20200703.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20200703.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20200703.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20200703.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20200703.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20200703.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9A8CFCC55BE4FD358B2975FF5ED4EB2A" xlink:type="locator" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9A8CFCC55BE4FD358B2975FF5ED4EB2A" xlink:to="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_524ADEDB1F1D01CF00DD75FF5ED4F068" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59C9AD55B04B018C7D00BA4187CF592D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59C9AD55B04B018C7D00BA4187CF592D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A05B00400B6753747ED2BA4187CF7D7F" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_18E55933F5B9D8E42AB4BA4187D05E28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_18E55933F5B9D8E42AB4BA4187D05E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F2B2A69FFD669B90AD1BBA4187D01632" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F2B2A69FFD669B90AD1BBA4187D01632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MunicipalBondsMember" xlink:label="loc_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_AD5DB05E009F1ED2B410BA4187D07345" xlink:to="loc_us-gaap_MunicipalBondsMember_508164E0AC1643F02AC4BA4187D0FE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5F17D8935E577B21FD24BA4187D13363" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5DAC4FC5F858B9CDE1D5BA4187CFE1B3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5F17D8935E577B21FD24BA4187D13363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5F17D8935E577B21FD24BA4187D13363" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_52DF6029D1514E539497BA4187D12B38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_36C79CFF08455B397FA8BA4187D1AC3B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_EC737C9ACE76F080B288BA4187D19AAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1B76675B88C086247FB875FF5FC14361" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1B76675B88C086247FB875FF5FC14361" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4B2EA6588B1AE43249F675FF5FC15BF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1B76675B88C086247FB875FF5FC14361" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7023611A8323A49CF9AF75FF5FC20B1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1B76675B88C086247FB875FF5FC14361" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_F8C2EFEE256894A2DB8475FF5FC214C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B4FBFDE337019DE85296B6610C7699AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B4FBFDE337019DE85296B6610C7699AA" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:to="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_AD271BF65AD15CDBE5EFB6610C762A2B" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_085E834CA4A7A6692669B6610C774BB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CommercialPaperMember_085E834CA4A7A6692669B6610C774BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_4793BE5EF55D119ED5A5B6610C77E5FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_4793BE5EF55D119ED5A5B6610C77E5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0CC815AD89848A71DD52B6610C77B77E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0CC815AD89848A71DD52B6610C77B77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_F7FDC9E839C07BE48AF3B6610C772897" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_F7FDC9E839C07BE48AF3B6610C772897" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CashMember_84DBD2A22C5F572A0597B6610C789E21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_15DD1DBA4D988E66C6B4B6610C785C1A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_MoneyMarketFundsMember_15DD1DBA4D988E66C6B4B6610C785C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_88A1F1D91760BD857E2CB6610C785FAC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05CCB9DD030DA425161AB6610C771E87" xlink:to="loc_us-gaap_CertificatesOfDepositMember_88A1F1D91760BD857E2CB6610C785FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_D907CFBFA4BAB5956E4FB6610C76BB52" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_939F16900DC93163F70BB6610C78A451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6868FD6C7C384A06E1C0B6610C7E5396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7DBC0C1E4672108F55C4B6610C7E8396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_69023235E3445ED30C71B6610C7E6798" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_10E42BB7D6E0BAF881F8B6610C7E5C06" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_EF2F41FF3308FD51D144B6610C7ED830" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_8750385AADF05F157CC5B6610C7F226E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1F5B21966B41750F06E3B6610C7F5683" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_F0727D6312443FD7173CB6610C7F09EE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2314DFB54D07B0B48A73B6610C7F5371" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_E2456389291523FDEC33B6610C7F642C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_91280AA57D9B4ED9CB52B6610C7876F3" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_20CDEC536138B720C405B6610C7FF733" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:to="loc_us-gaap_InterestReceivable_E80908F6D51C61857E6A75FF5FE0AA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_B63291FBA86753F1F6C775FF5FE1950F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_582B1D967A2FF1260B4175FF5FE19442" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9B4364478F377025A17D75FF5FE06D8D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_911CE30B0953F29679EA75FF5FE184F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D7A35FAFF8A8DA9E52DBAE19B2377704" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_D7A35FAFF8A8DA9E52DBAE19B2377704" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_437ED0383AEEFD384339AE19B2373086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_6CF3C3EB6D9354F215E4AE19B23746D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_29DC55EBD0A1CC1F5B28AE19B2374E0F" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_033836107C67F9907E6EAE19B2377353" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_658487330C8431B1C8C4B6610C8C1856" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_658487330C8431B1C8C4B6610C8C1856" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0159C754813A7A0D35FFB6610C8C02E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_658487330C8431B1C8C4B6610C8C1856" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_BC6B4B03E685E1D47503B6610C8D81E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_658487330C8431B1C8C4B6610C8C1856" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_3D24A61D99765175FC0DB6610C8D9E00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_658487330C8431B1C8C4B6610C8C1856" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_5481DBA28A6681A44D19B6610C8D99E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_658487330C8431B1C8C4B6610C8C1856" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DE4F870EF67AD71F7AABB6610C8D2716" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62A5315122CF60254A9975FF5EA2E9FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62A5315122CF60254A9975FF5EA2E9FF" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9EDF5857AA07EBA2026875FF5EA2DDCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D00425C4E48810CEF449B6610D0360AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D00425C4E48810CEF449B6610D0360AE" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:to="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2BAB52E22DFCB0A39901B6610D042F47" xlink:to="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:to="loc_us-gaap_LicenseMember_6E75FC8C605428EFFD31B6610D040081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1249370E6B2213D36891B6610D0471D2" xlink:to="loc_us-gaap_ServiceMember_C23E19349BF81CB6DDD4B6610D04A13A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_030FB9E8ED58081533B7B6610D05B1B9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_938C937CB99D843F9206B6610D05A1FB" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_7B0F42A8790C7BC87206B6610D05F3BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F94E033EFAC44FFF7D5BB6610D03E56F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7986BC5A49F7ED21CB18B6610D05F9C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_46C4384CE4811562634CB6610D06A03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_93338FB321CF25C2AA20B6610D05130F" xlink:to="loc_us-gaap_Revenues_01D6CAF9A457450DF4F3B6610D06B8E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5E1C7F7B39919E2C9731B6610CEF5AAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5E1C7F7B39919E2C9731B6610CEF5AAC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:to="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B601B73BD85BD231DF95B6610CF01C4E" xlink:to="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_86D1D6F859EE233E485EB6610CF05CE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:to="loc_us-gaap_LicenseMember_86D1D6F859EE233E485EB6610CF05CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_4BAA2435B1BB89C0F18BB6610CF068DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EEA54E7D8FF547EAAE3AB6610CF0BB08" xlink:to="loc_us-gaap_ServiceMember_4BAA2435B1BB89C0F18BB6610CF068DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C85E9529F33D4B5C5A94B6610CF1DDE2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3F1A15A0CAEE9E7E5B7DB6610CF15556" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_3BD09F5CA244DF9C6D4CB6610CF13A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_99B72F06C0A0106FEFADB6610CEF73AC" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4C15576F7BCA721719A9B6610CF18E3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4C15576F7BCA721719A9B6610CF18E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_6B5BA3885EAE9D7C91AFB6610CF2755F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_6B5BA3885EAE9D7C91AFB6610CF2755F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5062446A008195C06D15B6610CF2F456" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_437233FD9B647F0F33F4B6610CF1EDA9" xlink:to="loc_us-gaap_Revenues_5062446A008195C06D15B6610CF2F456" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_305668E00FA7D971FFEE71283456696D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_305668E00FA7D971FFEE71283456696D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:to="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9FADE8A43B745907C40B712834575726" xlink:to="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B6868513B6D4356128A771283457723F" xlink:to="loc_exel_GlaxoSmithKlineMember_9D935E7991121F169EE371283457EB7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_E136481F085A4257D0187128345819F7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_C422E4714743A10CB7C8712834580FE1" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_859A040E1BA624AEDC28712834582EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E8F641A33CB9C1237C8171283456E6CF" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_D6F2B295FC458633557D71283459BCD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_833E619E2D8C3EF2CCDC71283458542A" xlink:to="loc_us-gaap_RoyaltyExpense_3BEF1CE290293E6391567128345943E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65526A1058D4383FCD62BA77822B1E99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65526A1058D4383FCD62BA77822B1E99" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C56A396661C207628785BA77822C794B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_21D062012DA397B67052BA77822C37DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_F87046F98AAF4DC2D4D0BA77822CA68B" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_21D062012DA397B67052BA77822C37DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7666BC9E7F04A839B45CBA77822B0DB3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_exel_MilestonePaymentsEarned_A6815DE959C15BEB45DFBA77822D8623" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_7C294815EFAAC0539217BA77822DBB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_44ABF97846342A7DCFD0BA77822CF4C2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_5FC87FA344CE742A1CB4BA77822E9F54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2B2ADBA6A313F7CA33C4B6610CD168C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2B2ADBA6A313F7CA33C4B6610CD168C4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:to="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_72905A6754CCF9619AB4B6610CD270EE" xlink:to="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CotellicMember" xlink:label="loc_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5468CA023B13680925B9B6610CD24C0A" xlink:to="loc_exel_CotellicMember_C4E8F58B4223FC4179B3B6610CD2EBAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_33123547876F0612D4BFB6610CD2F2B1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2BBA3DBB1D299B5B0731B6610CD3DB13" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_60C8347449B5FE6A775FB6610CD3E77E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E3891532D47016F7C7EBB6610CD12A3C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_59186E947B174F93A40BB6610CD3BB91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5B0BD5EAA004C8DE831FB6610CD33E30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_DB32367257E9A0C210CAB6610CD40106" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DAAAA73DCBD7E6743E8175FF5FEA0C5B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_89C443B7065F1477581275FF5FEA83AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04EFE836A9DD3815115696926872BB66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_04EFE836A9DD3815115696926872BB66" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F0542EF7B2116CF7AE04969268732DE5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_130ED3012B497852C0079692687318A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_BB8D4FA40D9B45904C20969268736456" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_130ED3012B497852C0079692687318A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EA466C402655E3F01F2096926872D2BD" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_MilestonePaymentsEarned" xlink:label="loc_exel_MilestonePaymentsEarned_1880D7C13C5E0DD812A6969268741A68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_exel_MilestonePaymentsEarned_1880D7C13C5E0DD812A6969268741A68" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6BFB55D0B28DB28CC5E196926879BD34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_6BFB55D0B28DB28CC5E196926879BD34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_D6399096E86D7018680A969268799E5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5805E440D5DB13380A0896926874A750" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_D6399096E86D7018680A969268799E5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_026E090CB390BC8F596AF493A26C959C" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_904B554B5885EBC4C504F493A26CCA72" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_45FC0F4CFBC3E1142100941AD659FA29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_45FC0F4CFBC3E1142100941AD659FA29" xlink:to="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_460E7A199974A8367B3C941AD65F8D38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="loc_us-gaap_ShortTermInvestments_A029408D5D2063962361941AD65F76A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="loc_us-gaap_ReceivablesNetCurrent_29DFA58FF2DBA7059F28941AD65FC2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="loc_us-gaap_InventoryNet_C7CA5B5ED7A08DEF7D67941AD6602EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B1BF5CE72C1AAB193589941AD6604CEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3A93CA1A184C31E824BE941AD65EFF68" xlink:to="loc_us-gaap_AssetsCurrent_36A69A6FF8224056A1EE941AD660E1F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_LongTermInvestments_D29569464CEEF6945C55941AD6607C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_CF110E045C2575B92507941AD660BAFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_1FD01164165C664AE298941AD661861B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_Goodwill_4F33992E41F44B85E265941AD6615D0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A1E9245E086BE769A959941AD6617595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_C4FAF46020CD2E535F01941AD65CCE74" xlink:to="loc_us-gaap_Assets_E03ABCC1597BE16B5424941AD6611265" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_45FC0F4CFBC3E1142100941AD659FA29" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_us-gaap_AccountsPayableCurrent_EC363F865BA7C7B0509E941AD662A748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_04227BBB3FDCD51BE4D2941AD662D705" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_23B0BF43B730B07D461D941AD6624D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_1F39819573031759EC33941AD6628D07" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_D59D2E1C09F1A5F47396941AD66237D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_96088962F4987D09366C941AD663E2C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_B07C222B57B498886E79941AD661DEEA" xlink:to="loc_us-gaap_LiabilitiesCurrent_165D2691195522875CA6941AD663537F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_CD3B066A1ED7E8FB8AFF941AD6636FDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_357FAF5B07C77F8CBCAE941AD663BE32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_39B111C77FFA6C5717AC941AD663F3B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_Liabilities_044041A090C36B4D3C3E941AD66406B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_CA8CB66F4C24B94BD161941AD664539D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:to="loc_us-gaap_PreferredStockValue_804619CB2D74BFCA381F941AD6642191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:to="loc_us-gaap_CommonStockValue_E6132ED3FE548D7C8A1F941AD6643C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3928C8B60C18550510ED941AD66471C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7FAE9D69555C0DB3DCD4941AD66573BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_797BE058DDEC1AAA79BA941AD6656B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4F9D7BDAC097A6DF674F941AD664EF56" xlink:to="loc_us-gaap_StockholdersEquity_02777E5AD9D758E7D417941AD665FC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5DD24D708ECCC13DA672941AD66158A6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3470BE4E5ECD83CC08D0941AD6654385" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_81EFED100416005C0DDB75FF5EE00372" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_FD3A46923A8F9A817B5975FF5EE09E9E" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_40E1502E5EB404D3F06D75FF5EE149CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B36D76BEB75BBCDB021575FF5EE15A86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_4D00105C6AACBF2E9B6675FF5EE11A4A" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3E4703112FC533FB8F1E75FF5EE179DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8117FEFFA5E397AFF53875FF5EE0EF18" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_EAA8109668356F4AA8DE75FF5EE27BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6D9B11DCDB2B37AC0E3C75FF5EE2D72A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:to="loc_us-gaap_CommonStockSharesIssued_5221C7229F97889D750375FF5EE2387C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_CAAD4B505EBAC402B76575FF5EE18DF2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_25F9262B88FC1E0B9A5A75FF5EE2BFFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2F2A3E14F34B9B462B48941BB8453604" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_NetIncomeLoss_2F2A3E14F34B9B462B48941BB8453604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0E1E5AE4B84AB89A3D3F941BB8463CDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="loc_us-gaap_ShareBasedCompensation_48795CDD6313D98E4DE7941BB8461AD9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_NoncashLeaseExpense" xlink:label="loc_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="loc_exel_NoncashLeaseExpense_9AFD1D1C092A49B9FE2D941BB8469350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1C5FAE28E403A00353CC941BB8467773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_BD8788E9F74896437196941BB8462386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9D5EA27B5CC059A0F831941BB845B56E" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5608A41548B9EFE8C350941BB847616A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_A16497CF8947EE076491941BB847D19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_D16B6A3E20B4B0414E43941BB84825B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_23389E47FD6FD2E314AC941BB84805A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_514FD6E7E35971223EBB941BB847523F" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_F54D0D0078394FC58454941BB848E6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_DCEA940BE391E4F2DD71941BB848C39D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91BC7C90F71D8C7BBF4F941BB8489CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5F7BCAE2585BC22E0B19941BB849933A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_9AB48E63DE38BFC4FA6A941BB8495A77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C4850E392C27A6C73126941BB8482337" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_37E32060FC5C77B54E16941BB849B9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7A73287DE6683C158DDB941BB8493CC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1D207B81981246FAA212941BB849C318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_973783AE27FBB37F8DE4941BB84F1CA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_AC9A31174635ECE5F483941BB849D6DA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB3DE3F2333DC5E21845941BB84F01D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_C8D9F98C601807209007941BB84F8712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF7B11A477F0ED4CDF80941BB84F65DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_E83963D4EC121ACBD619941BB84F04D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_73A9E85A3E801A93D5D6941BB845DE38" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_809537AABB173FF0BFBF941BB850D3B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_EFEE39AAF27B1E1854F0941BB8505F3E" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_2D739608B2B4564493CE941BB850F108" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_011603AB9E69FE0CE06F85FAA627B0F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:to="loc_us-gaap_NetIncomeLoss_011603AB9E69FE0CE06F85FAA627B0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_A1F5FE154E670D3C5D8585FAA627F62C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7570BE881A854A8473F185FAA627E98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7F0B993D521123AD789A85FAA627BE1F" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3CE0C9B340C7580CE27685FAA627AC26" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_FB0870C0625E8111D58ABA7782B60E90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_618557AC93701581CA29BA7782B7A77A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_FB0870C0625E8111D58ABA7782B60E90" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_618557AC93701581CA29BA7782B7A77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_618557AC93701581CA29BA7782B7A77A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8E224DCECF62A86B80CBBA7782B77253" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_56B6B42705A0D4B893A8AE19B2D36377" xlink:to="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:to="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0409677F97DBE549E358AE19B2D47D0E" xlink:to="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:to="loc_us-gaap_ProductMember_277584DF235CF0057976AE19B2D4DD05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_8540CF7AAA61C8C5A222AE19B2D410C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:to="loc_us-gaap_LicenseMember_8540CF7AAA61C8C5A222AE19B2D410C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_B5282CC8B8D5556882C9AE19B2D4C511" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D01198C1F6D0E01ED38BAE19B2D4FE03" xlink:to="loc_us-gaap_ServiceMember_B5282CC8B8D5556882C9AE19B2D4C511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EEA39268A36F40D7EF3CAE19B2D33826" xlink:to="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF081833DF6980D4FC70AE19B2D54BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EF081833DF6980D4FC70AE19B2D54BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_FBE091E73554ECAF5C83AE19B2D578B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_FBE091E73554ECAF5C83AE19B2D578B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_Revenues_C4D2DAD4DA7B15CDCE79AE19B2D571FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1EFB08C95000CCAA9D7DAE19B2D6BBF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_E3B4A6994A762DC1794EAE19B2D6184B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A8078D01F81FBE2C4AAE19B2D68AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_41D4041428B41B38E90DAE19B2D520F3" xlink:to="loc_us-gaap_CostsAndExpenses_5AE38D7E0E9F1B3B81A4AE19B2D64F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_OperatingIncomeLoss_D3E292F926B91F2A74F5AE19B2D67716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_InterestIncomeOther_B6BE9AF51393E5CB03B5AE19B2D6340D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_935C54F4582FABD8C201AE19B2D75B19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49BBFC4C4112E5E52F83AE19B2D71947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_B3ED5D87FE829C12370AAE19B2D7890A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_NetIncomeLoss_47C2879D1EF2C9757C45AE19B2D794CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:to="loc_us-gaap_EarningsPerShareBasic_E02295511666C27DA8DCAE19B2D75E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C65F995F7E20B88A5FE9AE19B2D7282C" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C98A3901853B451994E5AE19B2D831BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_F194D31E540D3F8E7896AE19B2D5BD5F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_309A2C5DF02AFF2B5836AE19B2D81E72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_FD0A1502FDFBC63D3B35AE19B2D8970F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CC8C82DA59B575816EC4AE19B2D8FC4B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0B476DD0BBC783AA0A36B4328A86B004" xlink:to="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F3C9B3ABF010D666D357B4328A8A8706" xlink:to="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_CommonStockMember_CAD0C7D98F9B0DE4BBDFB4328A8B83AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6C29D874C6AB240592B6B4328A8D76E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87EDC09672A29091482AB4328A8DD674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5F4A711131DE98F0C3C7B4328A8AF1E5" xlink:to="loc_us-gaap_RetainedEarningsMember_354C8E232EE4290F493AB4328A8D5DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_82458F50FDCD50F5AD47B4328A89262F" xlink:to="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8103D833FB3659DF69C7B4328A8D7F99" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1F02AB4EFEDE3139B541B4328A8EB3B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockholdersEquity_68BD3CDD05A564C74924B4328A8E40E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C3EB145F5199CF39D78CB4328A8E6653" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_NetIncomeLoss_C3EB145F5199CF39D78CB4328A8E6653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_663389E1C8DA83A6DE0CB4328A8E64F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_249A804C581C412A253CB4328A8EBD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0EC6F868FAC34DB5B0A6B4328A8FF6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_EBEB891A01012983C16CB4328A8FB564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1F3567F704552D5E8284B4328A8FC911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC6E9F459E674F74FCBDB4328A8F2022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26DE602AFD4BD3367C0AB4328A8FD892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_EF0F08F3565424B05CA8B4328A8D3596" xlink:to="loc_us-gaap_StockholdersEquity_05192B99D5FB438C8880B4328A8FFFBA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_DocumentType_C603E508EDC5B3C82FCFAE19B2F7C380" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_DocumentQuarterlyReport_0435D1D8D5A19AC8A818AE19B2F7BFE0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_DocumentPeriodEndDate_DBC1971037FA21D8A413AE19B2F77FF3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_DocumentTransitionReport_7943C5870A45BED53649AE19B2F72368" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityFileNumber_0AFA18967FE582B60DEDAE19B2F8710C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityRegistrantName_108E56F34F5C985BFBD9AE19B2F8DEAD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0B1A217E60D13417CB86AE19B2F8D1B0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityTaxIdentificationNumber_2257EA8998BEB86BC858AE19B2F8760F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityAddressAddressLine1_7A58D790582288E4F830AE19B2F88DAD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityAddressCityOrTown_AF549146384091003D59AE19B2F89246" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityAddressStateOrProvince_284A024B4F3F415863D9AE19B2F90BBC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityAddressPostalZipCode_2A2C14B015622EF9F294AE19B2F99484" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_CityAreaCode_4387C97D37EF00EE46AAAE19B2F95C62" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_LocalPhoneNumber_923B7A65E9828CFF1551AE19B2F961E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_Security12bTitle_6AB1827D44A31EEE19AEAE19B2F9BFF6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_TradingSymbol_8B6799EEC2314D7AA544AE19B2F924E7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_SecurityExchangeName_8D94DBD774AE4C2C9247AE19B2F914F7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityCurrentReportingStatus_9560AAAD73F95760EB7DAE19B2FAF686" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityInteractiveDataCurrent_C430AE19CF0A32AAEAE5AE19B2FADF0E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityFilerCategory_FF8E923E5486CBEF7754AE19B2FA5DFC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntitySmallBusiness_BB282C9DF681AE361028AE19B2FA358B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityEmergingGrowthCompany_C43EC3EC4671F9129AE9AE19B2FAC8AC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityShellCompany_1323325B8A30D5BEA0DDAE19B2FA5BD8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_DF18C0E513C955E91AEFAE19B2FAC194" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_AmendmentFlag_464E6F06876A9578ACD7AE19B2FB734B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_DocumentFiscalYearFocus_CD46835E202BBCF6019EAE19B2FBA15C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_C28CFE9C8E50BA166531AE19B2FB69D0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_EntityCentralIndexKey_EC835D2F4B6E0FBECAA8AE19B2FBB35C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F0941CE4568996B1DD09AE19B2F77AD2" xlink:to="loc_dei_CurrentFiscalYearEndDate_F045C23291C86C891B2EAE19B2FB7B05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_21B5985BD738CE48FDD175FF5F0BE56D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_21B5985BD738CE48FDD175FF5F0BE56D" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_CE07B445E7158757BEA875FF5F0C1FB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4EDC633E033E7992D093B6610C46FEEA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ABAB593635E633E3DD74B6610C47EBA0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_CommercialPaperMember_A2762F7FE41F90947307B6610C4867FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_F2506D63D8D02AB25256B6610C48545C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_EF16862CF2227BBC07E1B6610C48B90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_C827090BF46D468346BCB6610C48A2F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E7F9117161F1E2EC0799B6610C484F5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_64291D02F3FD8F191140B6610C47F8C6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4BBCDE2D4F13732DC847B6610C4856FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BECF798406EF1A5A0B97B6610C49090D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_548D81BE54A2F2267668B6610C4956CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_B9A09AACCE93E84D8E66B6610C49EDA8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_E08AD3D4C96CCE2D8246B6610C49F4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5DF876F648E3D600ADE0B6610C4993D0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_1098CA1CDDFEF2E000CEB6610C490AEE" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2A5C90797819294A56CBB6610C4A8DE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_BEF00520EB09628DEB2CB6610C47871D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_10558A29E20BADA87AEFB6610C4AB678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_19C0F57B57D24839867BB6610C4B106D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_33000634E7BA420BD5C5B6610C4A9184" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7408477C509C613ABC16B6610C4BE2B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D7EB4B7613CEB024F80CB6610C4EA932" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D7EB4B7613CEB024F80CB6610C4EA932" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_058E6217BA4BE116C7C9B6610C4E8EA6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_56850A119E95DBB2DD9E75FF5EB6BC09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56850A119E95DBB2DD9E75FF5EB6BC09" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3196FD506FF068CDE3D175FF5EB6B687" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_59BA5260D5C989FF7729B6610BD33AE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F21A26CE35BDE7270997B6610BD38B29" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_330E2D037CB02F92826EB6610BD4022D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_17574349DE24CE7A5BA075FF5EA69966" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_17574349DE24CE7A5BA075FF5EA69966" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_CE33202D582803D5F07A75FF5EA63ABF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_49CC901F3580FF4FB4557291092E85F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_49CC901F3580FF4FB4557291092E85F9" xlink:to="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_42E04B81F5781696F7867291092E7181" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:to="loc_us-gaap_InventoriesMember_844910394432BCA1D7017291092F76BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3FFD79AB6B3228653D1A7291092F80CD" xlink:to="loc_exel_OtherLongtermAssetsMember_59871034E2B9806CE3C07291092F5A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_7A21177B0A4B51B58B617291092E26A4" xlink:to="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryRawMaterials_3B4D297C8AB6627E29BC729109303D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryWorkInProcess_9CF927988D19D35A65C072910930F837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryFinishedGoods_292210BAAFDEBF89DEEA7291093038AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_F3DEE689FC4FACA593A57291092F111B" xlink:to="loc_us-gaap_InventoryGross_C2B74A59590DD4B64F48729109305D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_49CC901F3580FF4FB4557291092E85F9" xlink:to="loc_us-gaap_InventoryWriteDown_86F5F4253DD3A046E4B072910930A71A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_EC00B655604EF2E8828D75FF5F5C0BFB" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3D16240B08F1244C894C75FF5F5C734A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1B2269278BB81134628F75FF5E6892BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1B2269278BB81134628F75FF5E6892BA" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_D9922BF1B7BCF760BBC175FF5E6839E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BB0CB58157B4B07BDFE3E9A7F54B83AF" xlink:type="locator" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB0CB58157B4B07BDFE3E9A7F54B83AF" xlink:to="loc_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_D013EA4567AE383AEE2AE9A7F54B04A5" xlink:to="loc_us-gaap_NetIncomeLoss_C9E09A0D0D7C23D21C8EE9A7F54B69F9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB0CB58157B4B07BDFE3E9A7F54B83AF" xlink:to="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19B3F6DC9C9BB1E90AFAE9A7F54C3BE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9E8AC8B2E23C17181C0DE9A7F54C9412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FB7CF0EDC1F6FDFC8F6CE9A7F54B574F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_522B1C98B26AD8EE365FE9A7F54CA26F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB0CB58157B4B07BDFE3E9A7F54B83AF" xlink:to="loc_us-gaap_EarningsPerShareBasic_662C261EA62FB01916DEE9A7F54CD251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BB0CB58157B4B07BDFE3E9A7F54B83AF" xlink:to="loc_us-gaap_EarningsPerShareDiluted_EF89E2FE49D240D9486EE9A7F54C5E4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_602D9E0311BDE1CF726975FF5EF92CC1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AE31EF5CFF3D2F5EFB3775FF5EFA0564" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_F7706D94DA1D71C22ABD75FF5EFADDA0" xlink:to="loc_us-gaap_StockCompensationPlanMember_0F0BF451E2AC1B29C6F875FF5EFB3B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A05C1602506EDCFDB8AB75FF5EF93DE4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9535FED39A80354DEA9175FF5EFBA813" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_58E1341E6BE24D6DCD0D75FF5EFBC068" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_FC9814E720E14B35BE68B6610BCA32DC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FC9814E720E14B35BE68B6610BCA32DC" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_84C08A5A9B25DE23F07AB6610BCA1B79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_FC9814E720E14B35BE68B6610BCA32DC" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3923834E027867211E63B6610BCA457A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C73ED01F6A70146EDE75FF5E89ABD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56C73ED01F6A70146EDE75FF5E89ABD3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_047AAE8A3C6DBCA881AC75FF5E899FED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E2C830B625D34084A66941BB813F4BA" xlink:type="locator" />
    <link:loc xlink:href="exel-20200703.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4E2C830B625D34084A66941BB813F4BA" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_D09ED10DF1CE1945876E941BB81433BA" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_NewInformationMember" xlink:label="loc_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5163D6B81D7C6EBEF573941BB814ECC4" xlink:to="loc_exel_NewInformationMember_FB7449F52F9F27D41B54941BB81446D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:to="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B1E895139F697B62A8CB941BB8147F16" xlink:to="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_0E79A87A89E6DBA0BB20941BB815FF60" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_CCE18AC06B952B1B194F941BB815F41F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductsDerivedFromOtherCompoundsMember" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5676A93032A9E9D5F52F941BB814EA8D" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_5F5414FC272F06348F6C941BB8152488" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_E4468DA415E872C44A1D941BB8133573" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_NumberofProductsinCommercialMarket_9C5EDE44712DE7BAB995941BB8160B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3309D60ECC17DAFC6F4A941BB8167550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9AB99FE6870382F7834A941BB8162515" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9AB99FE6870382F7834A941BB8162515" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_29393CCE96A81881F6F3941BB816568D" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrual" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_BrandedPrescriptionDrugFeeAccrual_50C0D30B51A3ECF19588941BB81782C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrualCurrent" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_BrandedPrescriptionDrugFeeAccrualCurrent_77F09F134D6517C020E6941BB817AE1C" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_BrandedPrescriptionDrugFeeAccrualNonCurrent" xlink:label="loc_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent_826488DE6553C658FE29941BB8170E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_F9F7F057EAE8183C4E85941BB81571DF" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_208D73DD60D0C501C49D941BB817866F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_CC29E45C3F785453901375FF5F52517D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_01895690D90E903DAB6A75FF5F523EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_FiscalPeriod_9CCB477FB1AD7BAF8D7A75FF5F5265A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_EDCADD0010BA6829E62C75FF5F53C6BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7D7DAA69DCB20CECA5DF75FF5F53234F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_UseOfEstimates_515FF683AECC2F8DA39575FF5F53C528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_E11785304F5634BD8B7675FF5F539306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73E4DFB983DF3394D82375FF5F517CB6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9AED449DBD29E10F848075FF5F53E322" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7A8037867EEE23B5D1A775FF5FEFC62E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_272019DE266599B3623575FF5FEFF4CB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CD047BC11192B0AAF01BAE19B2843EE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_CD047BC11192B0AAF01BAE19B2843EE4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_634A3233B27ABBDE0BDCAE19B2841647" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_120A71D3EEE77F1A81FEAE19B285EDD7" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_0FF24A42CACD40356715AE19B2859F94" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_C757CAA0F78619FCDB7FAE19B28492B9" xlink:to="loc_exel_AllowanceForProductRebatesMember_70F07F10BA9E2615B761AE19B285B211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_7C88D65D1018DEDD58E0AE19B284A644" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0E15C3D6CBE3F0BF2CB3AE19B2853EF4" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_DDE1BB6217177FB92575AE19B286DACC" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CCBCA787FAE7FFE5F760AE19B286DFD3" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_FBC7530CEC5AEE721722AE19B286A09F" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_66A94CAC9BDACAD0C368AE19B286D806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F6B4BA10A1487787B487AE19B286C01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_CBD86626C33FCD8E7DC7AE19B285F383" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_23097F9C3A84311178FAAE19B287409B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6158B60918F5A0A4373CA578CD30A34C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6158B60918F5A0A4373CA578CD30A34C" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:to="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_9ACB0318DDF4600B1AF3A578CD31FED3" xlink:to="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:to="loc_exel_IpsenMember_AA4F857A678779EC4CF0A578CD31C731" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_TakedaMember" xlink:label="loc_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_289EDBD9A61153049842A578CD3126FB" xlink:to="loc_exel_TakedaMember_5CC9D76C31B8B0FA1F0BA578CD32D8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3C8756F61523484E1955A578CD306395" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5CA105C7AEFA1E56E592A578CD32D2F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerLiability_3590D55E6E92FC7399BDA578CD32BBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_45EA4EE9DDD68971AC86A578CD325889" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement" xlink:label="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement_844EB108574C8F641035A578CD33CDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_7BF02A5F96307B3B8C88A578CD3360FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D660386A7ED19B4B27C0A578CD336979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_1A0572EFDBE3AC22BB54A578CD33D275" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_879C9ED0EE9760FD75F6A578CD326896" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_1A0572EFDBE3AC22BB54A578CD33D275" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3CB6C86CAB9FF221F9C375FF5ECC2A3B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3CB6C86CAB9FF221F9C375FF5ECC2A3B" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:to="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_A51686B5CCA220E7EBA375FF5ECDA94E" xlink:to="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_14B8824CB064FA318C7875FF5ECDD21A" xlink:to="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:to="loc_exel_CabometyxMember_AF8345B70B00DB4772F175FF5ECF3138" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_66AC79DA254D391D195075FF5ECE75AE" xlink:to="loc_exel_CometriqMember_83088FCE33C421BE4B3D75FF5ECF09E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EF84F32ABA408856A9C375FF5ECCBF3A" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3C57A43FD8EB39198D3E75FF5ED05165" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EADC90E48F130032A27975FF5ED0209F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1457C1E54F0D24E3B92DB6610D4F43D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1457C1E54F0D24E3B92DB6610D4F43D2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:to="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_45A7BABA48111EFD98BDB6610D4F6B59" xlink:to="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:to="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:to="loc_exel_ProductGrossMember_52E7087C869964E4E86DB6610D4FF163" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProductSalesDiscountsAndAllowancesMember" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_9D96A362F9203F70A1B5B6610D4F56C5" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_9A4EAFB23E44B022CF2CB6D8C3757E3A" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46E941138F0D6484CD89B6610D4F1E10" xlink:to="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:to="loc_us-gaap_LicenseMember_F4EB50D4350C6EEEBED3B6610D50A944" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_28E45D646D32C8CF7908B6610D50B90C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_C437A11ECA9EE500A525B6610D50E420" xlink:to="loc_us-gaap_ServiceMember_28E45D646D32C8CF7908B6610D50B90C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_FF5C3A2B6454E2C83C14B6610D4F45A9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4AA5961DD1459D89833FB6610D51093D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4AA5961DD1459D89833FB6610D51093D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_A8A4FC7818C0AF6A2F27B6D5A62FC274" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_A8A4FC7818C0AF6A2F27B6D5A62FC274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D618AD9F8C1C52F0A036B6610D5145FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_270BAE4DDE14184BEF59B6610D50C960" xlink:to="loc_us-gaap_Revenues_D618AD9F8C1C52F0A036B6610D5145FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_098D75772CDB2F532048B6610D28CD47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_098D75772CDB2F532048B6610D28CD47" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:to="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9656D970F669FFB41A5DB6610D281C6F" xlink:to="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="loc_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="loc_country_US_179D4E6E341A4A97C255B6610D29FAFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="loc_srt_EuropeMember_58247523BD603BD5257DB6610D2FA47C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP" xlink:label="loc_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_589EBF877C7657BB8998B6610D29BDC1" xlink:to="loc_country_JP_2D2201C54820C669DCDEB6610D30AC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_3905C0BA68599C86C06EB6610D30FC3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_EC4C133BEE1CF76026AFB6610D282377" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_3905C0BA68599C86C06EB6610D30FC3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_542939CD8204C8BCAB77B6610D30CC10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_3905C0BA68599C86C06EB6610D30FC3F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_542939CD8204C8BCAB77B6610D30CC10" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3B1B21635D5D95BEA853712612A38C50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3B1B21635D5D95BEA853712612A38C50" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_8821EBDD2CBE428BD71C712612A524E1" xlink:to="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_IpsenMember_D0F40B219313483FAC7E712612A9F748" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofCVSHealthCorporationMember" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_45D271135C87EDDF4B8A712612A649C5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_82135A225E6B559AE09C712612A86E62" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_20C7B62527B9D95B5B1F712612A9F963" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_BBD770CBB54FF22A122D712612A93953" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_TakedaMember" xlink:label="loc_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_TakedaMember_24C61E722CFD6B2C3510712778006E44" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B153B86D9E30471C2C1B712612A6388E" xlink:to="loc_exel_AccredoHealthIncorporatedMember_85EEE636D826549E3AD5712612A9533A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_336A439A4D113B5C1CEA712612A95CD3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_02183174AD5802A53F29712612A96C03" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_0D3C6325F4CF6803C51E712612A968DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1C73831E31100F71DE5B712612AA235C" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_50F3C538432E846795BC712612AA6DC8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_5F86D2B9B246F6E0FC1A712612AA214C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_D2566F0977068F2D8141712612A48684" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_516BE82B568F20838716712612AA6FFC" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_9890A29F4A07DDD8B0A3712612AB4A4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8EBDDC9FEFB7A98EBE5FB6610D535051" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8EBDDC9FEFB7A98EBE5FB6610D535051" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_99C90928AF457285C71BB6610D53EB42" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8EBDDC9FEFB7A98EBE5FB6610D535051" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_27FB79EADCA8EF314760B6610D549FCF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D6B640E6221CB79E668175FF5EDBF8EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D6B640E6221CB79E668175FF5EDBF8EC" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93AFDC129F1943AE53AA75FF5EDB8858" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64AC03C448858AAA8D3FE9A7F580D04E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6789C258E52A96BDD94CE9A7F58104FB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F0861155E2F345A0E6EE9A7F581D277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4353AC5FD6F63BAC3858E9A7F581A9BE" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_E27965E45615B932ADF3E9A7F582461E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E9C27ABAA0321D8881E2E9A7F58066E3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_BEF21D28378E2A748F4EE9A7F58235A8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_F980A9CB8254C04455C8E9A7F582146C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8B304CFDEBEA87756AFCC0E538F33134" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8B304CFDEBEA87756AFCC0E538F33134" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:to="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_39DAACFAB9ECA39E5BF1C0E538F5F681" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B2A1790EE9B71F9C4993C0E538F5EC31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_FCD23C036BAB28BCAD43C0E538F5A8E9" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_PerformanceShareOptionsPSOMember" xlink:label="loc_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_exel_PerformanceShareOptionsPSOMember_B81A529EA38F024D2910C0E538F6ED0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6A252A7FFDE7A07573ABC0E538F56C48" xlink:to="loc_us-gaap_PerformanceSharesMember_BC638FEE044E4845DECAC0E538F6D60F" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:to="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_3003B42443BC35EC7FAAC0E538F690A8" xlink:to="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:to="loc_exel_AchievedMember_12552EF20976D7375E48C0E538F7A631" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_431D1734EF063669B43DC0E538F64566" xlink:to="loc_exel_ProbableMember_8D61EB552A56A016BC98C0E538F7C4E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_55ED29AD38BE6515AC6BC0E538F3F6E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_14A0AFF8EE367DBBEE2BC0E538F7FAF8" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_66EB52D142A42FF2729FC0E538F8BF44" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_BCF274D71874BC5A6754C0E538F8CB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_D7F353AD77B45FE7BA87C0E538F8C0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_BF55E9C2E9A307342646C0E538F9C927" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BB21A87402518FE7526AC0E538F9CDB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7E976BB5C63393A13CA2C0E538F97173" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_096D6505BD5C5C1C1F2FC0E538F99184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AFC082EC3A1B97E75F9AC0E538F9AF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A7D3616DC103F0F94291C0E538FAC0FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0E60B349CD998E937BC2C0E538FA3352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2D3439F02E7E7918DC83C0E538FA4ED5" xlink:type="arc" />
    <link:loc xlink:href="exel-20200703.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises_3FAF67EF041C1F6F562FC0E538FACE49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A742E337C3C7538E8A1BC0E538F7D600" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_84AA0C82C1AD2203EF25C0E538FB41C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4720D2DC175F856CE9E975FF5FF65165" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4720D2DC175F856CE9E975FF5FF65165" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C185689186B49769A68475FF5FF6DE1D" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exellogo19q4a03.jpg
<TEXT>
begin 644 exellogo19q4a03.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
MTYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'
MS>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z
M/J***Y3H"BBB@ HHHH **** "BBB@ HHHH **** "OS:_P""RW[(7_"/Z[#\
M5]!M=MEJ;):Z_'&N!#<<+%<?2081N -RJ>2YK]):QO'_ ($TOXG>"M4\.ZU:
MK>:5K%L]K<PM_$C#''HPZ@CD$ CI7S'&'#=+/,LG@:FDMX/^62V?IT?DV?;^
M'O&E?A?.Z69TKN'PU(_S0?Q+U6CC_>2Z'\_E%>A?M1?L^:I^S#\;-8\(ZGND
M6RD\RSN2N%O;9^8Y1]1P0.C*P[5Y[7\18O"U<+6GAZ\>6<6TT^C6C/\ 37+\
M?0QN&IXS"R4J=1*46MFFKIA1117.=@4444 %%%% &EX/\7:CX!\5Z=K>DW4E
MEJFDW"75K/&?FBD1@RG\QTZ$5^WG[(O[26G_ +5/P-TGQ59^7#>2+]GU.T4Y
M^QW: >8G^Z<AE/=77OD5^&->F? 3]K+QG^S;H'BK3_"NHFRB\660M9V_BMG!
MXGB/\,H4NH;MOSU52/T7P[XX?#^+FJ]Y49KWDM^9+W6O/H_)WZ(_'O&#PQ7%
MN IO"M1Q-)KED]$XMI2BVM;)>\M]59?$SZL_X*S_ +>__"3WUY\*_!]XW]G6
MLGE^(;Z%^+J53S:*1_ I WG^)AMZ*=WP/3B=QR?F+=33:^9XEXBQ6=X^6.Q3
MU>B72,>D5Z?B[OJ?;<%\'X'AK*J>5X%:1UE+K.3WD_-]%T226B"BBBO /JPH
MHHH **** "OL_P#X(Z?LJ_\ "T/BQ-\0M6M]^A^#90MB'7Y;G4",J1_UQ4A_
M9FC/8U\D?#_P)J7Q.\;Z5X=T:W:ZU36;I+2VB'\3N<#/HHZD]  3VK]S/V=/
M@=IG[.7P8T/P?I2JT.DVX6:<+@W<[?-+,WNSDG'88 X K]9\)>%/[2S/Z]75
MZ5"S\G/[*^7Q/T2>Y^!^/_'G]BY)_9>%E:OBDXZ;QI_;?ES?"O636L3N****
M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?S\_\% _^3W/BK_V,U]_Z-:O(/F]
MJ]?_ ."@?_)[GQ5_[&:^_P#1K5Y!\WM75'8YP^;VH^;VH^;VH^;VI@'S>U'S
M>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S
M>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1
M\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U>R_L?_ +"WCS]L[Q>E
MGX;L&M=%@D"ZAKEVC+96*\9&[_EI)@\1KR<@G:N6"O8#H_\ @F9^QS<_M??M
M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
M^;VH^;VH]F@YV?K_ /\ $0!\&_\ H6?B9_X+K'_Y+H_XB /@W_T+/Q,_\%UC
M_P#)=?D!\WM1\WM1[-!SL_7_ /XB /@W_P!"S\3/_!=8_P#R77LG[&W_  4A
M\#_MP>)M9TKPGI7BO3[C0[5+N=M6MK>%'1FV@*8YI"3GU XK\'/F]J_0O_@W
MH_Y++\1/^P+;_P#H\U,H)(<9.Y^K5%%%9&@4444 %%%% !1110 V658(VDD9
M41 69F. H'4DU^,__!6[_@H6W[4GQ#/@WPK>,?A_X9N"/-C;Y=;NURIG/K$G
M(C'?+/SN4+]#?\%H?^"B'_"%:3=?!_P7?8UC4(MOB6]A?FR@89%HI'_+212"
MY_A0A>2YV_E=\WM6U./5F<Y= ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@
M ^;VH^;VH^;VH^;VH /F]J/F]J/F]JZCX+?!S7OC_P#%#1_"/AFS:]UC6IQ#
M"@^[&.K2.?X41068]@IH ]+_ & ?V*=6_;9^-D&BQ>?9^&M+VW6NZB@_X]8,
M\1H3QYLA!51ST9L$*:_=SP'X%TGX9>#-+\/Z#8PZ;H^CVZ6MI;1#"PQJ, >I
M/<DY))).22:X/]CW]E/0/V._@GIWA'0U6:9?](U._*;9-2NF #RMZ#@*JY.U
M54<\D^I5S2E<VC&P4445)04444 %%%% !7YF_P#!:?\ X)X;A>?&;P78<_?\
M564"?^3RJ/REQ[/_ ,]&K],JAO;*'5+*:WN(8KBWN$:.6*1 R2H1@JP/!!!P
M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!_/S_P4#_Y/<^*O_8S7W_HUJ\@^;VKU_P#X*!_\GN?%7_L9K[_T
M:U>0?-[5U1V.</F]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4
M?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>
MU'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>
MU'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?H7_P &]'_)9?B)
M_P!@6W_]'FOST^;VK]#_ /@WGM)'^+7Q&G"GR8](M8V;T9IF('X[6_*HJ;%1
MW/U6HHHKG-@HHHH **** "OF?_@IE^WM9_L5_"'R]-D@N?'?B-'AT:T;YOLR
M]'NY!_<3/R@_?? Y <KZU^TU^T=X=_94^#>K>,_$DVVST]=D%NC 3:A<-GRX
M(@>KL0?95#,<*I(_!#]H[]H+Q#^U!\7]6\9>)KCS-0U*3Y(D)\FSA'$<,8/1
M%''J3DG)))N$;ZDRE8Y#7-;O/$VM7>HZA=37E_?S/<7%Q,Y>2>1R69V)Y)))
M)/J:K?-[4?-[4?-[5T&(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\
MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
MEW!]?*<OL]4O>T]V^U9V<.F6<-O;PQ6]O;HL<44:!4B0# 50.  !@ <8J:BB
MOZN225D?P8VV[L****!!1110 4444 %%%% !1110 4444 %%%% %;5-,MM;T
MRXLKR"&ZL[R)H)X95#1S(PVLK \$$$@@^M?BM^WC^RK<?LF?'B^T>)97\/:G
MF^T6=OFWV[,?W9;N\9RI[XVMQN%?ME7AW[?O[*$'[67P&O=+MXX_^$FT?=?Z
M),<*1.!S"6/1)5^4Y. =C'.T5^=^)/"*SO+&Z*_?TKRAW?>/SZ>:7F?L'@OX
M@OAG.U'$R_V:O:-3M'^6?_;K>O\ =;ZV/Q4HJ:_L9M+OIK6YADM[BW=HI8I%
M*O&ZG!4@\@@@C%0U_'#33LS_ $8335T%%%%( HHHH **** /</V OVKY_P!D
MWX]6>J7$DA\,ZQML=<A7)'D$\3!1U>)OF&!DKO48W&OVEL;Z'5+*&ZMIH[BW
MN$66*2-@R2HPR&!'!!!!!K^>JOTW_P"".7[7W_"<^"I/A?KEUNU;P]$9M&>1
MN;FS!^:$>K1$\#KL8 <(:_=_!OC#V%9Y'BG[LW>FWTEUC_V]NO[U^LC^6?I&
M>'OUK#+B? Q]^FE&JEUATGZPV?\ =:>T3[EHHHK^E3^+0HHHH **** "OF7_
M (+%?\HX_B-_W#?_ $YVE?35?,O_  6*_P"4<?Q&_P"X;_Z<[2JCN@/PT^;V
MH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K_
M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
M?-[5Z]^P)\,YOBY^V;\-]%AC\Y&UVWO;A<9!@MV^T39_[9Q/^??I7D/S>U?I
M[_P09_9&N=)M-6^+VMVOE+J$3Z3X>$B_,\>X?:+@>Q91&I'/RR]B,Q)V14=6
M?I11117.;!1110 4444 %%%% &'\2/AIH/Q?\%WWAWQ/I-GK6B:E'Y=S:72;
MD<=01W5@<$,I#*0""" :_)_]O'_@B]XD^"<EYXF^&4=]XL\)KF6;3<>9J>EK
MWPH'[^,>JC>!U4@%Z_7RBJC)H3C<_F:9=IP?E(X(/:CYO:OW"_;0_P""4?P[
M_:V^U:Q;1?\ "'^-)LM_:UA"#'=O_P!/,.0LG^\"K],L0,5^5G[5?_!/3XG?
MLAWTTGB30Y+S05;$6NZ:&N+"0'IN; ,3'IMD"DG.,CD[1FF9.+1XA\WM1\WM
M1\WM1\WM5DA\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>
MU !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\
MWM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM6CX/\ !^J?
M$#Q18Z+H>GW>JZMJ<P@M;2UC,DL[GH%4<_X 5Z%^RS^QGX^_; \6_P!F^#](
M>:UA<+>:I<YBL+ ?]-),'YL$$(H9SV4C)'['?L-_\$Y_!?[$WA\36*#7/&%U
M'LOM=N8@LA!ZQP+SY,?L"6;^)FP (E)(J,6S@?\ @F1_P3 L/V0]%C\5>+([
M34_B/?1$;E(DAT.-A@Q0GH9".'D'8E5^7<7^PJ**P;N;;!1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
MXS1S(.5GQ9\WM1\WM7VWIO\ P0.^-5]*RRZO\/;-5P=TNI7+!OILMV_7%>M?
M"'_@WLCAO8Y_'GQ ,UNK O9Z%:;6<?\ 7>;./^_1I<Z#E9^<_P -/AAX@^,G
MC2Q\.^%](O=<UK47\N"UM8]SMZDGHJCJ68A5 )) !-?M'_P32_X)R:?^Q-X+
MFU35VM=4^(&N0A+^\C&8["+AOLL)/50P!9\ N0.RK7K_ .SO^RAX _97\.-I
MO@?P[::2LP N;HYEN[PCO),V7;GD#.T9X KT:LI3OH:1C8****@H**** "OF
M7_@L5_RCC^(W_<-_].=I7TU7C7_!0'X#:Y^TW^R+XN\#^&VL8]:UO[']G:\E
M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>exel2020063010-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:exel="http://www.exelixis.com/20200703"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20200703.xsd" xlink:type="simple"/>
    <context id="FD2020Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="I2020Q2SharesOutstanding">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-07-27</instant>
        </period>
    </context>
    <context id="FI2020Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:NewInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">exel:NewInformationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q2_srt_MajorCustomersAxis_exel_TakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MunicipalBondsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FI2020Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="D2020Q2May20-May20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-05-20</startDate>
            <endDate>2020-05-20</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceShareOptionsPSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FI2020Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2020Q2YTD"
      id="Fact-592E148DB114A4BF026875FEE663A3D4-wk-Fact-592E148DB114A4BF026875FEE663A3D4">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q2YTD"
      id="Fact-F06B931E75A14DD9818175FEE665E619-wk-Fact-F06B931E75A14DD9818175FEE665E619">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q2YTD"
      id="Fact-C04FCB626909C01E918875FEE663099A-wk-Fact-C04FCB626909C01E918875FEE663099A">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q2YTD"
      id="Fact-A520564214F93E2E9F9275FEE664A22F-wk-Fact-A520564214F93E2E9F9275FEE664A22F">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q2YTD"
      id="Fact-6BEF72363DD68747445375FEE66423AB-wk-Fact-6BEF72363DD68747445375FEE66423AB">0000939767</dei:EntityCentralIndexKey>
    <exel:MilestonePaymentsEarned
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="Fact-1DC56B6E8A351A0D24959691F738C998-wk-Fact-1DC56B6E8A351A0D24959691F738C998"
      unitRef="usd">18800000</exel:MilestonePaymentsEarned>
    <exel:MilestonePaymentsEarned
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="Fact-9DCE220A5A7F32CAB42196950977587E-wk-Fact-9DCE220A5A7F32CAB42196950977587E"
      unitRef="usd">23700000</exel:MilestonePaymentsEarned>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0C2FC794B7FA54E6F10275FEE6CFC241-wk-Fact-0C2FC794B7FA54E6F10275FEE6CFC241"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-5F64ABF82B7B30D622B575FEE6D28F65-wk-Fact-5F64ABF82B7B30D622B575FEE6D28F65"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-27AA9CB174B894767F9B75FEE6D0BF6F-wk-Fact-27AA9CB174B894767F9B75FEE6D0BF6F"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-268D10173B1BC33A61B775FEE6D24EC4-wk-Fact-268D10173B1BC33A61B775FEE6D24EC4"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-7A3DF061F3DB6F0EEF9F75FEE6D28DB9-wk-Fact-7A3DF061F3DB6F0EEF9F75FEE6D28DB9"
      unitRef="shares">304830706</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-E83BBD97B5576D19DE8475FEE6D0D7A2-wk-Fact-E83BBD97B5576D19DE8475FEE6D0D7A2"
      unitRef="shares">308886497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-BC7624A493AD84016F9375FEE6CFA59F-wk-Fact-BC7624A493AD84016F9375FEE6CFA59F"
      unitRef="shares">304830706</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-0139DB16EC1BFA5056C175FEE6CE9520-wk-Fact-0139DB16EC1BFA5056C175FEE6CE9520"
      unitRef="shares">308886497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-3BBAC7B5E97D7505FF5E75FEE6D277FF-wk-Fact-3BBAC7B5E97D7505FF5E75FEE6D277FF"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="Fact-0D4C66312D469C8D741B75FEE6AE816D-wk-Fact-0D4C66312D469C8D741B75FEE6AE816D"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="Fact-442F61FE2B6FD5F7A68E75FEE672BB2D-wk-Fact-442F61FE2B6FD5F7A68E75FEE672BB2D"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="Fact-1DBEF0613D1F9BBE22D075FEE6AA8D96-wk-Fact-1DBEF0613D1F9BBE22D075FEE6AA8D96"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="Fact-25C049D332909F59612675FEE6B7C23B-wk-Fact-25C049D332909F59612675FEE6B7C23B"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="Fact-80922E0FCC45C412175275FEE6A3F3C7-wk-Fact-80922E0FCC45C412175275FEE6A3F3C7"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="Fact-252CB8EF23D111C2926C9EFFDCD6066F-wk-Fact-252CB8EF23D111C2926C9EFFDCD6066F"
      unitRef="usd">413000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="Fact-2732A943E99E432B688F75FEE6A3CDC9-wk-Fact-2732A943E99E432B688F75FEE6A3CDC9"
      unitRef="usd">1346000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="Fact-94ADE9270AE804525B1F75FEE66B0396-wk-Fact-94ADE9270AE804525B1F75FEE66B0396"
      unitRef="usd">2287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-EDC2064FF1A46874E63E75FEE6D2CBFC-wk-Fact-EDC2064FF1A46874E63E75FEE6D2CBFC"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-11D3BE69EAEA4A93760C75FEE6D110A5-wk-Fact-11D3BE69EAEA4A93760C75FEE6D110A5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0E0E8B73370B39E5BEF575FEE6CED4AE-wk-Fact-0E0E8B73370B39E5BEF575FEE6CED4AE"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-F08091ECA925E51FEE2A75FEE6D266AB-wk-Fact-F08091ECA925E51FEE2A75FEE6D266AB"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-11BC3626CAF4F609F70D75FEE6CEE164-wk-Fact-11BC3626CAF4F609F70D75FEE6CEE164"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2020Q2"
      decimals="INF"
      id="Fact-D16D710714A5464E7F6075FEE6D3D9B8-wk-Fact-D16D710714A5464E7F6075FEE6D3D9B8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <dei:DocumentType
      contextRef="FD2020Q2YTD"
      id="d682038e417-wk-Fact-97A378DA99D33CBF574975FEE6C99C7C">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q2YTD"
      id="d682038e432-wk-Fact-8153E32E4695622263D875FEE6B79D6E">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q2YTD"
      id="d682038e443-wk-Fact-F04EFFCBC4E1410E26E575FEE6B82387">2020-07-03</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q2YTD"
      id="d682038e463-wk-Fact-16B6CAC910788EA9CC1875FEE6980BA5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q2YTD"
      id="d682038e473-wk-Fact-43D6C66160FB22FEA8A375FEE6890E3D">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q2YTD"
      id="d682038e495-wk-Fact-509928AF09A5FD9B1E3575FEE6AC3EDA">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q2YTD"
      id="d682038e516-wk-Fact-A8A23BC723E01347380675FEE6D3B50A">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q2YTD"
      id="d682038e521-wk-Fact-F689D07F834BFEE36CC975FEE6D3F6E1">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q2YTD"
      id="d682038e536-wk-Fact-51389F73B2BE1F8C6AAA75FEE67835CB">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q2YTD"
      id="d682038e542-wk-Fact-DFF7BCA75BDB92E5D5CB75FEE6895C3B">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q2YTD"
      id="d682038e547-wk-Fact-38ECDA7B2C4777A6774F75FEE68E8EF5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q2YTD"
      id="d682038e552-wk-Fact-673E1D5F9724DFC6FF9E75FEE692181E">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q2YTD"
      id="d682038e560-wk-Fact-FF4D3253E0698EF9F7B275FEE6B9BC85">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q2YTD"
      id="d682038e565-wk-Fact-51BD7D0936C139A2020575FEE6BADD09">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q2YTD"
      id="d682038e606-wk-Fact-0369FC7F4F51AB35A89275FEE6C80220">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q2YTD"
      id="d682038e611-wk-Fact-517F6D14AB7E4E1E4C9175FEE6CA274B">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q2YTD"
      id="d682038e616-wk-Fact-B6F2AF48762C029F9C7675FEE6C85672">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q2YTD"
      id="d682038e621-wk-Fact-1ECFF1A3F9967DCA52AC75FEE66A27F9">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q2YTD"
      id="d682038e635-wk-Fact-A50608FCA16FDE1F7DE375FEE6741497">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q2YTD"
      id="d682038e666-wk-Fact-AF41EFCDD72FE9B8998575FEE6B23103">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q2YTD"
      id="d682038e717-wk-Fact-17AD38345726C198B73075FEE6B4F8EB">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q2YTD"
      id="d682038e733-wk-Fact-E94D7EA43E6BB0D20E7175FEE6B28DCE">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q2YTD"
      id="d682038e764-wk-Fact-DA7EE7D81F61B2381A7075FEE670BAC3">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2SharesOutstanding"
      decimals="INF"
      id="d682038e780-wk-Fact-F9C6A1B6D1DC8ABD99A675FEE679D497"
      unitRef="shares">308995819</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e555-wk-Fact-A1BC98B7EF7C3CEC321D75FEE6A61235"
      unitRef="usd">527143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e574-wk-Fact-7FE412FB8DEB8D023E2A75FEE68E25BF"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e589-wk-Fact-8EA9C968D0775E56EE9075FEE6AA88F7"
      unitRef="usd">685895000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e608-wk-Fact-7D70645D98D7DF24306575FEE6A71499"
      unitRef="usd">585742000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e628-wk-Fact-726D61C5B7AA39AF4F6C75FEE6983988"
      unitRef="usd">121080000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e647-wk-Fact-D267F154A2367000C44B75FEE69B3AE6"
      unitRef="usd">119073000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e667-wk-Fact-9E0ACE578A8CAFF5511075FEE69718F6"
      unitRef="usd">16608000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e686-wk-Fact-659D1063D874253CF9C775FEE6AAEA01"
      unitRef="usd">12886000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e706-wk-Fact-9BEBE9EB865DA7731A9375FEE68F2F95"
      unitRef="usd">43937000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e725-wk-Fact-33CB26723913E330830A75FEE6917841"
      unitRef="usd">26988000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e745-wk-Fact-A56525C631E2A9DE7B6075FEE6992BD1"
      unitRef="usd">1394663000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e764-wk-Fact-962916F4D3A05E28A5FA75FEE6A6CBD2"
      unitRef="usd">1011190000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e784-wk-Fact-E99F48EF214B6EDB2D2775FEE694C2D2"
      unitRef="usd">327141000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e803-wk-Fact-123709BDA93A763239AD75FEE693F4F9"
      unitRef="usd">536385000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e823-wk-Fact-3F16181B17AC2617D95B75FEE6A99C7E"
      unitRef="usd">52323000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e842-wk-Fact-126DA19DE7968DD6BB4075FEE6968C69"
      unitRef="usd">48892000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e863-wk-Fact-0017258F1EF9928801C375FEE6AE8AAD"
      unitRef="usd">148235000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e882-wk-Fact-391D35AC6B9749C9457475FEE696F7C0"
      unitRef="usd">172374000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e902-wk-Fact-EBEB69FCDD20547F03BA75FEE68E4EA3"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e921-wk-Fact-3031808366C2A59AB31775FEE69A3A6A"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e941-wk-Fact-056CE590EDDF7FA621F175FEE69849CD"
      unitRef="usd">60502000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e960-wk-Fact-F6F6250876E1F16C133775FEE6A9439A"
      unitRef="usd">53145000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e985-wk-Fact-1E08E820C252EE2AE0DA75FEE694B2FE"
      unitRef="usd">2046548000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1004-wk-Fact-324C8C7F81D535E8DCC375FEE6AB36BB"
      unitRef="usd">1885670000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1106-wk-Fact-3760C39ED3F86A42220175FEE68F448F"
      unitRef="usd">9103000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1125-wk-Fact-37A7A0834A4B2442D5F475FEE6962BCD"
      unitRef="usd">11581000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1140-wk-Fact-423BB5F65BBAA6C0633F75FEE69407F7"
      unitRef="usd">33156000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1159-wk-Fact-484B2F7FFDD6045C957375FEE6AD3784"
      unitRef="usd">37364000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1179-wk-Fact-EA22433E5A4FF56702B375FEE698AA64"
      unitRef="usd">39940000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1198-wk-Fact-69E7B0F63573AC62CCB575FEE6AB53AE"
      unitRef="usd">38777000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1218-wk-Fact-DD643177FF5977EB8F4E75FEE6913792"
      unitRef="usd">16957000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1237-wk-Fact-21659537ED2F6B51D33C75FEE6A57CE0"
      unitRef="usd">18719000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1257-wk-Fact-7A70E94CB4F70781F48875FEE69BC2A5"
      unitRef="usd">10695000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1276-wk-Fact-E82A53BC12F4E0C7BF4275FEE6A33354"
      unitRef="usd">11856000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1297-wk-Fact-838E447ACDB39F68B25275FEE68DE7E8"
      unitRef="usd">32830000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1316-wk-Fact-00C652C57F4B0234EF6375FEE68C2456"
      unitRef="usd">24449000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1336-wk-Fact-3B1997B750DF626E721C75FEE6990A5B"
      unitRef="usd">142681000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1355-wk-Fact-946863AD77AC67770FF475FEE69C4294"
      unitRef="usd">142746000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1375-wk-Fact-A93B787849B3E949D31F75FEE6940F9B"
      unitRef="usd">15003000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1394-wk-Fact-6C8B22B96953215DDA0575FEE68C322B"
      unitRef="usd">6596000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1414-wk-Fact-11EA854E2FC2A219A9C075FEE6962530"
      unitRef="usd">48334000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1433-wk-Fact-CFA81AE458A42D0DB1DC75FEE6ACE3DD"
      unitRef="usd">48011000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1453-wk-Fact-B4E38DA5FC452561B80D75FEE6925F37"
      unitRef="usd">7206000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1472-wk-Fact-85F9A7631F241144FCBB75FEE6A465A9"
      unitRef="usd">2347000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1492-wk-Fact-F20AF102F9BF9F1120E075FEE6951E4E"
      unitRef="usd">213224000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1511-wk-Fact-A852081931270495BA6875FEE696A711"
      unitRef="usd">199700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2020Q2"
      id="d657361e1531-wk-Fact-E9A8755E38B85F07B2C275FEE69ABD66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d657361e1550-wk-Fact-3A18043265814EC1383375FEE6A1D0E5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1611-wk-Fact-D566DAEA28C18D00B8D875FEE6A40F8E"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1630-wk-Fact-E41C41AC20D42CB61D3575FEE6995EE3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1650-wk-Fact-6EB798595AE963D0B77575FEE6AC0917"
      unitRef="usd">309000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1669-wk-Fact-D84C1D33D7080277100D75FEE6A72524"
      unitRef="usd">305000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1689-wk-Fact-A675F4CB2955238197AB75FEE6A354DA"
      unitRef="usd">2269093000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1708-wk-Fact-63723B8BA9AA57909FB575FEE695A57E"
      unitRef="usd">2241947000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1729-wk-Fact-661E9F47367FD7AAB72975FEE690C909"
      unitRef="usd">7840000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1748-wk-Fact-68D0EA26568360F9C02175FEE68AF2D1"
      unitRef="usd">3069000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1768-wk-Fact-74DB45FBA64E3D67553A75FEE6A22C3A"
      unitRef="usd">-443918000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1788-wk-Fact-15708CD2EF4E8CA781F275FEE6A8EECC"
      unitRef="usd">-559351000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1809-wk-Fact-405EB66828E2E3705C8975FEE68FA624"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1828-wk-Fact-7276C7CE657618237BF775FEE68C3A2B"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d657361e1853-wk-Fact-7F8719D4C919EFEB115675FEE6925125"
      unitRef="usd">2046548000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d657361e1872-wk-Fact-F74093144AF9AFE4866A75FEE6998805"
      unitRef="usd">1885670000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d661138e684-wk-Fact-5A2214FE83685521E13275FEE66421F4"
      unitRef="usd">178730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d661138e703-wk-Fact-A72FA94CFA55F8922B2275FEE6756D0F"
      unitRef="usd">193675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d661138e722-wk-Fact-097C78DB144C18F7259275FEE691AFDD"
      unitRef="usd">372610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d661138e742-wk-Fact-699B1F7B1BA2FDD648FF75FEE68E5EDB"
      unitRef="usd">373256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d661138e757-wk-Fact-6497319F83CC3DF3C90C75FEE69CD50C"
      unitRef="usd">59234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d661138e776-wk-Fact-47C49EFE5D0D56E8685575FEE6630E63"
      unitRef="usd">37742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d661138e795-wk-Fact-DB9618FDB1571E3C9A6C75FEE68A0242"
      unitRef="usd">80113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d661138e815-wk-Fact-6128661D81D66A5B5C9375FEE6974202"
      unitRef="usd">63306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d661138e835-wk-Fact-9B99F65872BA5239ABE07602BC70F963"
      unitRef="usd">21515000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d661138e854-wk-Fact-899A8C5BB40BE0001A397602BC1564A1"
      unitRef="usd">8858000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d661138e873-wk-Fact-FABE9E85A8ECD171D56A75FEE69330AA"
      unitRef="usd">33671000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d661138e893-wk-Fact-C4E1C3CC83C7DDABA2EF75FEE6927942"
      unitRef="usd">19200000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e913-wk-Fact-44B7BE6FB321312F7E7D75FEE669CD36"
      unitRef="usd">259479000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e932-wk-Fact-3EFFF6A6BFF3B9030C2D75FEE6D03440"
      unitRef="usd">240275000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e951-wk-Fact-4696CD3398156FF3047675FEE6878468"
      unitRef="usd">486394000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e971-wk-Fact-6B39914FAAEB56AC401A75FEE696E280"
      unitRef="usd">455762000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1073-wk-Fact-9E27F2A0808CC315799F75FEE6A7866E"
      unitRef="usd">9221000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1092-wk-Fact-8622BF1E05F752B317E875FEE682C9FE"
      unitRef="usd">7539000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1111-wk-Fact-625C07FCFC01125B6CB975FEE68F2955"
      unitRef="usd">18510000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1131-wk-Fact-E83356C41307BE58712675FEE6894674"
      unitRef="usd">15040000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1151-wk-Fact-7333C5FA493FCB1F77FE75FEE691024D"
      unitRef="usd">114933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1170-wk-Fact-675F905CB9B96736DF2875FEE6788ECB"
      unitRef="usd">81932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1189-wk-Fact-DC501452596C90F137C975FEE696699F"
      unitRef="usd">216810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1209-wk-Fact-08DEBC41F956C6CFBE0B75FEE68810BF"
      unitRef="usd">145221000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1229-wk-Fact-B2FE5F35811885D0B6AA75FEE67AA348"
      unitRef="usd">59791000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1248-wk-Fact-263A5B76D209799EFBEE75FEE6B38F88"
      unitRef="usd">58815000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1267-wk-Fact-239AE749398E97D75FCB75FEE68C0B3E"
      unitRef="usd">122731000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1287-wk-Fact-6641CBDBC3058A0F984F75FEE688BDB7"
      unitRef="usd">118953000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1308-wk-Fact-3006363C2CE6A9500A0475FEE66DB08B"
      unitRef="usd">183945000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1327-wk-Fact-CF49A044B7BA64FE1A4F75FEE6C496E3"
      unitRef="usd">148286000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1346-wk-Fact-119BD0C532682CC94DE875FEE68B6007"
      unitRef="usd">358051000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1366-wk-Fact-441EE5DFFB2EE984B69075FEE68CFE02"
      unitRef="usd">279214000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1386-wk-Fact-68379E13562CC39B45A875FEE688B677"
      unitRef="usd">75534000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1405-wk-Fact-A17BCD475B3923AC655F75FEE6B50AC6"
      unitRef="usd">91989000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1424-wk-Fact-5EAE4C597C7E377BB7D175FEE6917C5F"
      unitRef="usd">128343000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1444-wk-Fact-880CD5AE7F89A9F25FE175FEE6939619"
      unitRef="usd">176548000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1464-wk-Fact-785AF6D3969505B038D575FEE6851F86"
      unitRef="usd">5162000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1483-wk-Fact-A72E29C8EE1E6CF96B4075FEE66A8B9E"
      unitRef="usd">6975000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1502-wk-Fact-ECCA051934A25BD46C0775FEE692197B"
      unitRef="usd">12382000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1522-wk-Fact-011C16CC181C6067369F75FEE693E65B"
      unitRef="usd">13062000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1542-wk-Fact-AB2CE9FBEF99724C556375FEE69B1D5C"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1561-wk-Fact-0C7C873D2145DF3AC32F75FEE6981B00"
      unitRef="usd">803000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1580-wk-Fact-070975B94B0C319114B575FEE6929B67"
      unitRef="usd">6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1600-wk-Fact-DBC663AB684CFF36214D75FEE68F2AA1"
      unitRef="usd">828000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1620-wk-Fact-FA3B7009E9448606CEEC75FEE697D8AF"
      unitRef="usd">80696000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1639-wk-Fact-5DF3282E546998A3A03275FEE6935A9D"
      unitRef="usd">99767000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1658-wk-Fact-300C48E7FC43A080E26275FEE69486CB"
      unitRef="usd">140731000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1678-wk-Fact-5EFFB8AE52851F00A18E75FEE6981051"
      unitRef="usd">190438000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1698-wk-Fact-7F0D96BDAFFF1885BDB375FEE6833EE9"
      unitRef="usd">13875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1717-wk-Fact-F70908986042DF91E8DF75FEE665A45D"
      unitRef="usd">20725000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1736-wk-Fact-21B7AB002913FBF6C5B275FEE69330CD"
      unitRef="usd">25298000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1756-wk-Fact-6C6FDB6E21072B966BC675FEE6975173"
      unitRef="usd">35621000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e1781-wk-Fact-B487DD23D99A668528F075FEE69990CC"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e1800-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e1819-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e1839-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d661138e1941-wk-Fact-F04F7BABEA56FDB5117F75FEE6AF18A3"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d661138e1960-wk-Fact-566FD1EE1C16BA6A763575FEE69BA939"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d661138e1979-wk-Fact-C28F37DC2381E7E89D3B75FEE6957C17"
      unitRef="usdPerShare">0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d661138e1999-wk-Fact-0CBBC6463637620FE6C375FEE6880911"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d661138e2019-wk-Fact-31596066A1892C4DB17575FEE6844845"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d661138e2038-wk-Fact-A98347421B831C365EB575FEE68DED9E"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d661138e2057-wk-Fact-CEB696DF869A2F41037E75FEE68AADD1"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d661138e2077-wk-Fact-CAB85F7EB403C6F9822C75FEE69349E8"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e2175-wk-Fact-59033765D73556484CE675FEE68A2255"
      unitRef="shares">307807000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e2194-wk-Fact-1927675C729F464ED63A75FEE6BA1013"
      unitRef="shares">302188000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e2213-wk-Fact-D67C673E55257A7E629B75FEE68DC8AD"
      unitRef="shares">306598000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e2233-wk-Fact-1B7FF6816B05CF8C6D3375FEE695C60A"
      unitRef="shares">301365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d661138e2253-wk-Fact-FDB4E707E9E9AEF20F9075FEE6B71B34"
      unitRef="shares">318144000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d661138e2272-wk-Fact-AA49B4BBB4C251F3D89B75FEE6935051"
      unitRef="shares">314911000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661138e2291-wk-Fact-A5A35B7E2FE8BFD7BE9375FEE69113AE"
      unitRef="shares">316992000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661138e2311-wk-Fact-FE1018EC5634CAFA582475FEE6978CD0"
      unitRef="shares">314786000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d686239e611-wk-Fact-B487DD23D99A668528F075FEE69990CC"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d686239e630-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d686239e649-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d686239e669-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d686239e766-wk-Fact-C325A05E25FA49873E8175FEE664573A"
      unitRef="usd">8062000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d686239e785-wk-Fact-F789BDB1F0539B01D15375FEE679B796"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d686239e804-wk-Fact-305CBE1D5242A6DB460275FEE6681873"
      unitRef="usd">4771000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d686239e824-wk-Fact-BA446023B0360A29E07B75FEE669989C"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d686239e849-wk-Fact-86AADDF31698EC3FFC6475FEE67A2EB5"
      unitRef="usd">74883000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d686239e868-wk-Fact-7324A1B2D18D7859833A75FEE668BB5E"
      unitRef="usd">80521000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d686239e887-wk-Fact-298FC67CD0C2D4AB5DFD75FEE668EBDB"
      unitRef="usd">120204000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d686239e907-wk-Fact-6F8F6A5AF21ED8F0D88475FEE668208E"
      unitRef="usd">157725000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e795-wk-Fact-B4C0B679A7B7426455FDB659D0305744"
      unitRef="shares">305780000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e814-wk-Fact-0C8B8C5BFEB941225EEEB659D19D5726"
      unitRef="usd">306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e833-wk-Fact-C0BB75657B31AD2FD51DB659D31D457B"
      unitRef="usd">2258307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e853-wk-Fact-B9597F3572FAE2D4A0D7B659D48AF7EA"
      unitRef="usd">-222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e873-wk-Fact-D806E132FA81CAC6D16CB659D60BC94B"
      unitRef="usd">-510739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d691634e893-wk-Fact-258819F3C2722FAFFCA1B659D779C447"
      unitRef="usd">1747652000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e981-wk-Fact-56BD2266AFDAAFAA478BB65B0D3D77B1"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d691634e1000-wk-Fact-B487DD23D99A668528F075FEE69990CC"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e1074-wk-Fact-6D1AE06B475D91D6F8B9B65B1250532B"
      unitRef="usd">8062000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d691634e1112-wk-Fact-D1FDA48D752AC68F0DC4B65B14B969C2"
      unitRef="usd">8062000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1133-wk-Fact-9F25E308761044CBBBDCB65B15605A82"
      unitRef="shares">3106000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1147-wk-Fact-B38294F59DC3F293888BB65B16DE8BEE"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e1166-wk-Fact-C2B5455AC650ADD9F529B65B184D0369"
      unitRef="usd">13780000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d691634e1224-wk-Fact-2115D271EA638DB7515DB65B1BC2C275"
      unitRef="usd">13783000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1245-wk-Fact-4C8B44EA6DEEF1EADC7A9EE7CF212C1A"
      unitRef="shares">0</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1259-wk-Fact-8E1AD2F59669937AFF419EE7F873E437"
      unitRef="usd">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e1278-wk-Fact-009AC1632BBB135A97B99EE7F884A657"
      unitRef="usd">19148000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d691634e1337-wk-Fact-0C70DB5CD61A1E2C7B859EE7F85BDC5E"
      unitRef="usd">19148000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e1392-wk-Fact-0D9AE55490B5D4E8A9C4B65B1E5DB06A"
      unitRef="usd">16154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d691634e1450-wk-Fact-03625A2251369A11D339B65B21BD9796"
      unitRef="usd">16154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1471-wk-Fact-3D89C39D3A864657343775FEE6887E87"
      unitRef="shares">308886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1490-wk-Fact-FC5A742D21DEC7EE36F075FEE682BCA1"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e1509-wk-Fact-7F3927A2BE560D1A923175FEE67A48E1"
      unitRef="usd">2269093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e1529-wk-Fact-E4281AB195516E124F8475FEE67A710A"
      unitRef="usd">7840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e1548-wk-Fact-DF3BD333F12A4B7156BE75FEE68A703A"
      unitRef="usd">-443918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d691634e1568-wk-Fact-405EB66828E2E3705C8975FEE68FA624"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1970-wk-Fact-218D16037F1B3E8181E5B659FD3B7B9A"
      unitRef="shares">301520000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e1989-wk-Fact-F56DCAA4B8574F43D935B659FEBB3339"
      unitRef="usd">302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e2008-wk-Fact-BA78C55E9180299F512BB65A0029FFE9"
      unitRef="usd">2188578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e2028-wk-Fact-511E863E0E7ADBEF2E92B65A01A7863B"
      unitRef="usd">728000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e2047-wk-Fact-70A348EA7E82AF20A00BB65A03168972"
      unitRef="usd">-804588000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d691634e2067-wk-Fact-41A07C2AC2CEA25D52F0B65A0498AF25"
      unitRef="usd">1385020000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e2155-wk-Fact-3142823932FCE325C8D6B65B4A3C24D6"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d691634e2174-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e2248-wk-Fact-B6E7E8A1CC192AEFC735B65B4F4186CF"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d691634e2286-wk-Fact-BBE51ED4AA7E3E987220B65B51B9BF50"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e2307-wk-Fact-35E2848AF6BA65E69C7EB65B5260DF32"
      unitRef="shares">1265000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e2321-wk-Fact-1E1377C11F37A4F5A5C9B65B53CF7278"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e2340-wk-Fact-035C141CB9DA20C5DAF3B65B554F40C4"
      unitRef="usd">8865000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d691634e2398-wk-Fact-9D166AA500BDF049A144B65B58AFB3B6"
      unitRef="usd">8866000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e2419-wk-Fact-6CB68A99C8376082B1299EE7E2E716A2"
      unitRef="shares">0</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e2433-wk-Fact-485A07A121F13B53C29A9EE8193F55E0"
      unitRef="usd">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e2452-wk-Fact-357A548E93BDB23817BA9EE8193FD60B"
      unitRef="usd">854000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d691634e2511-wk-Fact-49BBE17602BC9604D9149EE8193F720D"
      unitRef="usd">854000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e2566-wk-Fact-AF05BF8F2FF8A5BB7D3BB65B5B4BFCA3"
      unitRef="usd">15079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d691634e2624-wk-Fact-FFCA155468DA4C6FA5A3B65B5EC4E659"
      unitRef="usd">15079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e2645-wk-Fact-E5115665AAAEDE9296E075FEE6B10BE8"
      unitRef="shares">302785000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e2664-wk-Fact-9B8AF0765E1D87F21B6975FEE6B8A98C"
      unitRef="usd">303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e2683-wk-Fact-2A3D92C80FA735850DBC75FEE6AE3441"
      unitRef="usd">2211668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e2703-wk-Fact-EB9AB94CA6D92BF0BDD275FEE6B484D3"
      unitRef="usd">2207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e2722-wk-Fact-6306400E31582A2FED1C75FEE6B81248"
      unitRef="usd">-725546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d691634e2742-wk-Fact-1105B74DA3A2AD822BFD75FEE6B17D02"
      unitRef="usd">1488632000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3158-wk-Fact-1C3B2610812AB3CE318775FEE681A350"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3177-wk-Fact-3D87CD4DE7CD8DBCD19675FEE6829032"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e3196-wk-Fact-E577F76ED347B8629C3A75FEE688A9FD"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e3216-wk-Fact-25E427EF73470D6CB0DC75FEE6867160"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e3235-wk-Fact-5BA18EF013E36644574275FEE687E145"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d691634e3255-wk-Fact-7276C7CE657618237BF775FEE68C3A2B"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e3343-wk-Fact-B82192C24AC3A41B7E2E75FEE6897CC9"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d691634e3362-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e3436-wk-Fact-02700DE730381EADD1D775FEE6855919"
      unitRef="usd">4771000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d691634e3474-wk-Fact-A85282254684D990D90E75FEE686360A"
      unitRef="usd">4771000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3495-wk-Fact-B2DDE578212311C9D9C175FEE68543AD"
      unitRef="shares">4055000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3509-wk-Fact-9B9C1BFBD4007AD78A9075FEE67CCD8A"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e3528-wk-Fact-D7146D53383F37431B4F75FEE682D810"
      unitRef="usd">17951000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d691634e3586-wk-Fact-05099D82C87FA23D3CA575FEE685C7B4"
      unitRef="usd">17955000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3607-wk-Fact-FA5F0ABE32011CB381509EE9217E0C01"
      unitRef="shares">0</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3621-wk-Fact-8A0C1FB852AD6BC30D939EE923664E65"
      unitRef="usd">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e3640-wk-Fact-E9FDBB9A72AFB14CFC679EE925602AE2"
      unitRef="usd">20941000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d691634e3699-wk-Fact-38F2389EA67A4125C4D79EE9293C2DE5"
      unitRef="usd">20941000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e3754-wk-Fact-385EB6884712785BE5F175FEE678C668"
      unitRef="usd">30136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d691634e3812-wk-Fact-C54A906E7E2D8E17743875FEE684D8CD"
      unitRef="usd">30136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3833-wk-Fact-3D89C39D3A864657343775FEE6887E87"
      unitRef="shares">308886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e3852-wk-Fact-FC5A742D21DEC7EE36F075FEE682BCA1"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e3871-wk-Fact-7F3927A2BE560D1A923175FEE67A48E1"
      unitRef="usd">2269093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e3891-wk-Fact-E4281AB195516E124F8475FEE67A710A"
      unitRef="usd">7840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e3910-wk-Fact-DF3BD333F12A4B7156BE75FEE68A703A"
      unitRef="usd">-443918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q2"
      decimals="-3"
      id="d691634e3930-wk-Fact-405EB66828E2E3705C8975FEE68FA624"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e4332-wk-Fact-1BC96CA04031D1CFF45275FEE6AE9C13"
      unitRef="shares">299876000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e4351-wk-Fact-B234DBB445107B0D8A6175FEE6B4D7FE"
      unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e4370-wk-Fact-295FFE3155019E88E2E775FEE6B33867"
      unitRef="usd">2168217000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e4390-wk-Fact-BB2A01826E7DA494B81775FEE6B5D43F"
      unitRef="usd">-701000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e4410-wk-Fact-B57280CC7A1EED3D828575FEE6B6BA05"
      unitRef="usd">-880363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d691634e4430-wk-Fact-E8B7D75A367A1A71EC2375FEE6B1AF5B"
      unitRef="usd">1287453000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e4518-wk-Fact-AB75BED4FC69972EBC2375FEE6B66EB0"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d691634e4537-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e4611-wk-Fact-4686E9A491BCAA41609D75FEE6B32C79"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d691634e4649-wk-Fact-541DC41C260972EFD16175FEE6B002C7"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e4670-wk-Fact-8236F8316BCD44CC6CCB75FEE6AF3E7A"
      unitRef="shares">2909000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e4684-wk-Fact-5AB4604EDB02A9FCE74975FEE6B4681E"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e4703-wk-Fact-732AE455D54E231F72FF75FEE6AE8A1F"
      unitRef="usd">18277000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d691634e4761-wk-Fact-0FA11B37558E207C03A375FEE6B03559"
      unitRef="usd">18280000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e4782-wk-Fact-125AEA6C263F523D62979EE9C43C541C"
      unitRef="shares">0</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e4796-wk-Fact-71BE5E09C6C91EABF93E9EE9C626DE25"
      unitRef="usd">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e4815-wk-Fact-86709CE7D8D68FB725B09EE9C81C99E0"
      unitRef="usd">2434000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d691634e4874-wk-Fact-AA5C4579FD4719E85F8C9EE9CBFF0086"
      unitRef="usd">2434000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e4929-wk-Fact-B8B93AAF005A45CD366375FEE6B92BCF"
      unitRef="usd">27608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d691634e4987-wk-Fact-B37872B58E6399998EBB75FEE6B6C11B"
      unitRef="usd">27608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e5008-wk-Fact-E5115665AAAEDE9296E075FEE6B10BE8"
      unitRef="shares">302785000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d691634e5027-wk-Fact-9B8AF0765E1D87F21B6975FEE6B8A98C"
      unitRef="usd">303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d691634e5046-wk-Fact-2A3D92C80FA735850DBC75FEE6AE3441"
      unitRef="usd">2211668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d691634e5066-wk-Fact-EB9AB94CA6D92BF0BDD275FEE6B484D3"
      unitRef="usd">2207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d691634e5085-wk-Fact-6306400E31582A2FED1C75FEE6B81248"
      unitRef="usd">-725546000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d691634e5105-wk-Fact-1105B74DA3A2AD822BFD75FEE6B17D02"
      unitRef="usd">1488632000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e513-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e532-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e588-wk-Fact-2867C45E0F7D32BA9A2275FEE6AD3B68"
      unitRef="usd">4376000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e607-wk-Fact-72AE9A4E1ED39B055E0B75FEE6ADDF85"
      unitRef="usd">3998000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e627-wk-Fact-84CD633465686252ABC975FEE6C49DF3"
      unitRef="usd">30136000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e646-wk-Fact-EDCB7A8EEA52903BCB8875FEE6C33A78"
      unitRef="usd">27608000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e666-wk-Fact-B127A796D9184C3DDF4175FEE6B640DE"
      unitRef="usd">2383000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e685-wk-Fact-B63118B38A666723131D75FEE6C770DF"
      unitRef="usd">1099000</exel:NoncashLeaseExpense>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e705-wk-Fact-62E271D638856DD3B83375FEE6B0A894"
      unitRef="usd">22793000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e724-wk-Fact-3E92D433FDDF4B1508EA75FEE6B4E3A6"
      unitRef="usd">33067000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e744-wk-Fact-EA0357F0016266F1BC3D75FEE6B0C29B"
      unitRef="usd">-726000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e763-wk-Fact-EB651914D0400B9C1F9875FEE6BAB97E"
      unitRef="usd">98000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e825-wk-Fact-681E3EB2D89B5788167A75FEE6BB7A93"
      unitRef="usd">2014000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e845-wk-Fact-C81C1F12249EDCBF576075FEE6BD0135"
      unitRef="usd">-65230000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e866-wk-Fact-F2490184CE0585C2AA5F75FEE6B49A91"
      unitRef="usd">7049000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e886-wk-Fact-AB4878DCC3FCE045CE5275FEE6B9F15B"
      unitRef="usd">2514000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e907-wk-Fact-94C36D8D2BC2491A9F7775FEE6B2977B"
      unitRef="usd">18954000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e927-wk-Fact-AD898E5268074456DB2475FEE6ABB86B"
      unitRef="usd">9278000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e948-wk-Fact-F422F64CF4DB8271E99F75FEE6B51332"
      unitRef="usd">9659000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e967-wk-Fact-EFF19C1CEB4A6FE2CE0075FEE6BA1922"
      unitRef="usd">4656000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e987-wk-Fact-92906DE47483F15357E675FEE6B1BA2C"
      unitRef="usd">262000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1006-wk-Fact-06C348DE70749FEA6FDA75FEE6ADE1D3"
      unitRef="usd">14736000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1026-wk-Fact-552353194C69765A7AD175FEE6C3D6AD"
      unitRef="usd">157751000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1045-wk-Fact-EA2EB4DFB70B0FF0773075FEE6B72986"
      unitRef="usd">293321000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1106-wk-Fact-93080FAE74AE1DB9D2B575FEE6BA06AA"
      unitRef="usd">9925000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1126-wk-Fact-6D5611278612A329A86A75FEE6B88077"
      unitRef="usd">3516000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1147-wk-Fact-77804806D993831C079675FEE6B54562"
      unitRef="usd">433154000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1167-wk-Fact-11DB8924C128ED4887F775FEE6B8BDCC"
      unitRef="usd">518268000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1188-wk-Fact-35C6563D3912C9A7707275FEE6AB016D"
      unitRef="usd">548973000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1207-wk-Fact-F194CA637E6D4899AF4875FEE6C67FBC"
      unitRef="usd">271198000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1227-wk-Fact-AD5A54CBBCB48DD2E61B75FEE6B33CC1"
      unitRef="usd">105894000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1246-wk-Fact-F23066B63799EB104F5F75FEE6C41D77"
      unitRef="usd">-250586000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1309-wk-Fact-B3EFE5E5911E04384D7875FEE6AAE75A"
      unitRef="usd">17938000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1328-wk-Fact-26123195C5ED29D9426775FEE6C213B4"
      unitRef="usd">14735000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1348-wk-Fact-2E814D669175F3608CD375FEE6C53C2B"
      unitRef="usd">20941000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1368-wk-Fact-9D0BB365892EC5B6BDE575FEE6BB6207"
      unitRef="usd">2434000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1389-wk-Fact-8009644C420177F2B5C275FEE6AA88DB"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1408-wk-Fact-2276CAA793549BE3C4BE75FEE6B7B1A3"
      unitRef="usd">-22000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1429-wk-Fact-4471F5E935DEDFFF524775FEE6B9B10D"
      unitRef="usd">-3003000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1449-wk-Fact-D94EF118E322220ABEA575FEE6C37E05"
      unitRef="usd">12279000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1469-wk-Fact-57544DA839DB28C3B3C375FEE6B90B9D"
      unitRef="usd">260642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1488-wk-Fact-B7D88E01470A1E2B405D75FEE6B35EEF"
      unitRef="usd">55014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d661133e1508-wk-Fact-8769E5B4758910A379EB75FEE6AF4BC1"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d661133e1527-wk-Fact-60C7BA94A95E2D674C3075FEE6AFD6CE"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="-3"
      id="d661133e1552-wk-Fact-894D15D3C93C47AB426A75FEE6B2B28C"
      unitRef="usd">528779000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-3"
      id="d661133e1571-wk-Fact-E24C8F0479AF9D312D9C75FEE6C6CEF0"
      unitRef="usd">370889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1632-wk-Fact-DCA8B3292C61567AC8A575FEE6B58F71"
      unitRef="usd">1824000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1651-wk-Fact-EE7BC74EF03E442D4A9875FEE6B0D0BA"
      unitRef="usd">11338000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d661133e1671-wk-Fact-FFE7FE04BA0A0478D98D75FEE6BCB3DA"
      unitRef="usd">804000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d661133e1690-wk-Fact-8911D45121336B390AE675FEE6ACF1F3"
      unitRef="usd">1350000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E72D58CE998F817F398C75FEE6E37340-0-wk-Fact-FB8CF658B3E8F386A16975FEE67965A7">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Since we were founded in 1994, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;Two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma and previously treated hepatocellular carcinoma; and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The other &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, included in our Annual Report on Form 10-K filed with the SEC on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&#160;25, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended July 3, 2020 and June 28, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended June 30, 2020 and June 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Such reclassifications did not impact previously reported total revenues, i&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ncome from operations&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, net income, total assets, total liabilities or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines for difficult-to-treat cancers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In March 2020, we received the 2020 preliminary fee notice from the Internal Revenue Service for the Branded Prescription Drug Fee for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accordingly, we recorded an adjustment to increase selling, general and administrative expenses and our accrual for these fees by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$5.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the three months ended March 31, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. T&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;his adjustment resulted in a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.02&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; decrease in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;basic and diluted earnings per share&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our total accrual for the Branded Prescription Drug Fee was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$15.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, of which &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$4.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was recorded in other current liabilities, and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was recorded in other long-term liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2020, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Accounting Standards Update (ASU) No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2020, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2020, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#x2019;s impairment &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;is due to credit-related factors or noncredit-related factors. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Credit-related impairments on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;debt securities available-for-sale &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;are recognized as an allowance for credit losses with a corresponding adjustment to o&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ther income, net in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the accompanying Condensed Consolidated Statements of Income. The portion of the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;impairment that is not credit-related is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded, net of applicable taxes, as a reduction of other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Trade receivables, net&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; contain amounts billed to our customers for product sales, and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;amounts billed to our &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;collaboration partners for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;development, regulatory and sales-based &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;royalties on the sale of licensed products&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;profit-sharing arrangements, development cost reimbursements, and payments for product supply services&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to estimate credit losses and consider our historical loss information, adjusted to account for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which happens at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from non-refundable, up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and clarifying and amending existing &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember"
      decimals="INF"
      id="d691997e438-wk-Fact-9C5CC1732F9F0614737E75FEE6774DF1"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember"
      decimals="INF"
      id="d691997e442-wk-Fact-3784B82218A19C9524E375FEE6740E97"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromOtherCompoundsMember"
      decimals="INF"
      id="d691997e449-wk-Fact-1A698DE9C304102A077B75FEE67655D0"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-B43C0B9BBBA3FB25235475FEE6E310AE-0-wk-Fact-DB0B7BEBFA3374C3C6EB75FEE67BEB14">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-2C7E747566A77499FC6B75FEE6E37F97-0-wk-Fact-79243E4F60C28E51FCFA75FEE67B9DD8">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, included in our Annual Report on Form 10-K filed with the SEC on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&#160;25, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="FD2020Q2YTD"
      id="TextSelection-72C474DCEBBD9FBD33EF75FEE6E3AA1C-0-wk-Fact-36720F4A2C497AD73E9D75FEE679B2D7">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended July 3, 2020 and June 28, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended June 30, 2020 and June 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="FD2020Q2YTD"
      id="TextSelection-8B8007B3123F17EA899175FEE6E35F3A-0-wk-Fact-219CDB6211F635D012FE75FEE677B23F">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Such reclassifications did not impact previously reported total revenues, i&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ncome from operations&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, net income, total assets, total liabilities or total stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-1C5A2E293DA56F48C67675FEE6E3FEB8-0-wk-Fact-5BDB206604242C87ADB875FEE68316CF">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines for difficult-to-treat cancers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d691997e563-wk-Fact-64E029CDD110273079E975FEE67B5A8E"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="FD2020Q2YTD"
      id="TextSelection-8559EF33B190F463711E75FEE6E33283-0-wk-Fact-C28E5E089C795F811CD875FEE677B993">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;In March 2020, we received the 2020 preliminary fee notice from the Internal Revenue Service for the Branded Prescription Drug Fee for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years.</us-gaap:UseOfEstimates>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q1QTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember"
      decimals="-5"
      id="d691997e607-wk-Fact-1B054492DA4DD702CB8175FEE675880F"
      unitRef="usd">5400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="FD2020Q2YTD_us-gaap_ChangeInAccountingEstimateByTypeAxis_exel_NewInformationMember"
      decimals="2"
      id="d691997e616-wk-Fact-1D65A425E4CB610BF9FE7D6FF0B2E54F"
      unitRef="usdPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <exel:BrandedPrescriptionDrugFeeAccrual
      contextRef="FI2020Q2"
      decimals="-5"
      id="d691997e637-wk-Fact-B8FFA6959C9F6232263275FEE677F626"
      unitRef="usd">15100000</exel:BrandedPrescriptionDrugFeeAccrual>
    <exel:BrandedPrescriptionDrugFeeAccrual
      contextRef="FI2019Q4"
      decimals="-5"
      id="d691997e641-wk-Fact-CAB34890CDA6827DB85175FEE674151B"
      unitRef="usd">6000000.0</exel:BrandedPrescriptionDrugFeeAccrual>
    <exel:BrandedPrescriptionDrugFeeAccrualCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d691997e654-wk-Fact-56588E269F039B43358275FEE676EC68"
      unitRef="usd">8600000</exel:BrandedPrescriptionDrugFeeAccrualCurrent>
    <exel:BrandedPrescriptionDrugFeeAccrualCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d691997e658-wk-Fact-002E2771CDE0E27F247A75FEE67BEA46"
      unitRef="usd">4400000</exel:BrandedPrescriptionDrugFeeAccrualCurrent>
    <exel:BrandedPrescriptionDrugFeeAccrualNonCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d691997e662-wk-Fact-F31E39E882E70FC4CA2C75FEE674DBA9"
      unitRef="usd">6500000</exel:BrandedPrescriptionDrugFeeAccrualNonCurrent>
    <exel:BrandedPrescriptionDrugFeeAccrualNonCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d691997e666-wk-Fact-73D1050FAFCAFC195D8275FEE67A0030"
      unitRef="usd">1600000</exel:BrandedPrescriptionDrugFeeAccrualNonCurrent>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E0919F35E5DBE4FFE51C75FEE6E3DB35-0-wk-Fact-7C353960A80A09DADB1E75FEE6732258">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2020, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Accounting Standards Update (ASU) No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2020, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2020, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Investment Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#x2019;s impairment &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;is due to credit-related factors or noncredit-related factors. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Credit-related impairments on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;debt securities available-for-sale &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;are recognized as an allowance for credit losses with a corresponding adjustment to o&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ther income, net in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the accompanying Condensed Consolidated Statements of Income. The portion of the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;impairment that is not credit-related is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded, net of applicable taxes, as a reduction of other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Trade receivables, net&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; contain amounts billed to our customers for product sales, and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;amounts billed to our &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;collaboration partners for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;development, regulatory and sales-based &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;royalties on the sale of licensed products&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;profit-sharing arrangements, development cost reimbursements, and payments for product supply services&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to estimate credit losses and consider our historical loss information, adjusted to account for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t recognize any impairment charges in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Up-front License Fees: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which happens at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from non-refundable, up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Regulatory and Development Milestone Payments: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Product Supply Services:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Development Cost Reimbursements:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Profit-sharing Arrangements: &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Royalty and Sales-based Milestone Payments:&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and clarifying and amending existing &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d691997e968-wk-Fact-64E029CDD110273079E975FEE67B5A8E"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d691997e972-wk-Fact-46C10B37E848520AFF7D75FEE6725F2B"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-FC50726AF4826ADDE44875FEE6E45034-0-wk-Fact-8BFF7CE42D60DBBCF35075FEE68A44BC">REVENUES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;229,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;482,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;464,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(46,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(109,854&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(90,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;178,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;372,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;59,234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80,113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;63,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;113,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;82,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;259,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;486,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;189,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;362,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;364,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;178,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;372,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen Pharma SAS (Ipsen)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda Pharmaceutical Company Limited (Takeda)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;377,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;378,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;259,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;486,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(72,169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(29,592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(110,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$13.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. The current portion of the contract liabilities totaling &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanying Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Significant changes in contract assets during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; include the impact of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; development milestone from Ipsen we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;determined was probable of achievement, which was offset by the impact of a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;milestone from Takeda which was recognized as revenues during the year ended December 31, 2019 and was achieved, invoiced and collected during the current period&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$3.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$62.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$82.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues for performance obligations satisfied in previous periods as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$36.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$61.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the comparable periods in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Such revenues primarily related to milestone and royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$71.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price was allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for information about the expected timing &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;to satisfy these performance obligations&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-4429EF402FC218E899BA75FEE6E400E0-0-wk-Fact-D0D788419C6B7C881D3975FEE6624E26">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;229,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;482,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;464,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(46,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(109,854&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(90,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;178,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;372,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;59,234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80,113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;63,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,858&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;80,749&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;113,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;82,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;259,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;486,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;173,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;189,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;362,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;364,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,784&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;178,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;372,610&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen Pharma SAS (Ipsen)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda Pharmaceutical Company Limited (Takeda)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181,231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;377,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;378,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;259,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;486,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d672417e689-wk-Fact-75E61E4155457B9DC64C75FEE69B34A3"
      unitRef="usd">229898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d672417e708-wk-Fact-42E7E3EEBEF51004554175FEE68959B1"
      unitRef="usd">240418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d672417e727-wk-Fact-5A2437E9F723431F06EC75FEE6678C7E"
      unitRef="usd">482464000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d672417e747-wk-Fact-B87648C5D2A24F19289475FEE665F257"
      unitRef="usd">464168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d672417e762-wk-Fact-0F9A4F27D1484F2E3B5475FEE668AE8D"
      unitRef="usd">-51168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d672417e782-wk-Fact-0775568DC09851F9E65375FEE699D081"
      unitRef="usd">-46743000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d672417e802-wk-Fact-AE57CEF1BB0D51041CFD75FEE666D129"
      unitRef="usd">-109854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductSalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d672417e823-wk-Fact-9715B9A42CB5D82101B875FEE66C6211"
      unitRef="usd">-90912000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e844-wk-Fact-5A2214FE83685521E13275FEE66421F4"
      unitRef="usd">178730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e863-wk-Fact-A72FA94CFA55F8922B2275FEE6756D0F"
      unitRef="usd">193675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e882-wk-Fact-097C78DB144C18F7259275FEE691AFDD"
      unitRef="usd">372610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e902-wk-Fact-699B1F7B1BA2FDD648FF75FEE68E5EDB"
      unitRef="usd">373256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d672417e1004-wk-Fact-6497319F83CC3DF3C90C75FEE69CD50C"
      unitRef="usd">59234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d672417e1023-wk-Fact-47C49EFE5D0D56E8685575FEE6630E63"
      unitRef="usd">37742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d672417e1042-wk-Fact-DB9618FDB1571E3C9A6C75FEE68A0242"
      unitRef="usd">80113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d672417e1062-wk-Fact-6128661D81D66A5B5C9375FEE6974202"
      unitRef="usd">63306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d672417e1082-wk-Fact-9B99F65872BA5239ABE07602BC70F963"
      unitRef="usd">21515000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d672417e1101-wk-Fact-899A8C5BB40BE0001A397602BC1564A1"
      unitRef="usd">8858000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d672417e1120-wk-Fact-FABE9E85A8ECD171D56A75FEE69330AA"
      unitRef="usd">33671000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember"
      decimals="-3"
      id="d672417e1140-wk-Fact-C4E1C3CC83C7DDABA2EF75FEE6927942"
      unitRef="usd">19200000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d672417e1160-wk-Fact-00F23BF2710148220E7075FEE6D15EB4"
      unitRef="usd">80749000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d672417e1179-wk-Fact-5AF0D8107730A50AC5C075FEE678CE8C"
      unitRef="usd">46600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d672417e1198-wk-Fact-1CDB4277CFAC2A3C75BA75FEE66689C3"
      unitRef="usd">113784000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d672417e1218-wk-Fact-CB45989127F561E2BCDF75FEE66ADCB5"
      unitRef="usd">82506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d672417e1243-wk-Fact-44B7BE6FB321312F7E7D75FEE669CD36"
      unitRef="usd">259479000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d672417e1262-wk-Fact-3EFFF6A6BFF3B9030C2D75FEE6D03440"
      unitRef="usd">240275000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d672417e1281-wk-Fact-4696CD3398156FF3047675FEE6878468"
      unitRef="usd">486394000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d672417e1301-wk-Fact-6B39914FAAEB56AC401A75FEE696E280"
      unitRef="usd">455762000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d672417e1528-wk-Fact-C7291BDC3630B3E636E875FEE6B6B113"
      unitRef="usd">173610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d672417e1547-wk-Fact-608EB675A72BD98355DE75FEE6BBE1B2"
      unitRef="usd">189015000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d672417e1566-wk-Fact-B3ED997AA6070DE474F475FEE69B5C5C"
      unitRef="usd">362826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d672417e1586-wk-Fact-7B05A6D1DF4E8FC9C98275FEE6A4D3A9"
      unitRef="usd">364905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d672417e1601-wk-Fact-0A4D89824AB9D3007F1A75FEE6AD0E17"
      unitRef="usd">5120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d672417e1620-wk-Fact-38DDBA319CE1E0513AD575FEE6B39348"
      unitRef="usd">4660000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d672417e1639-wk-Fact-BADB79FD50BA1104E87575FEE6A4C355"
      unitRef="usd">9784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d672417e1659-wk-Fact-62C105BC4367E6AFE18375FEE69CC773"
      unitRef="usd">8351000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e1684-wk-Fact-5A2214FE83685521E13275FEE66421F4"
      unitRef="usd">178730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e1703-wk-Fact-A72FA94CFA55F8922B2275FEE6756D0F"
      unitRef="usd">193675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e1722-wk-Fact-097C78DB144C18F7259275FEE691AFDD"
      unitRef="usd">372610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d672417e1742-wk-Fact-699B1F7B1BA2FDD648FF75FEE68E5EDB"
      unitRef="usd">373256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1906-wk-Fact-73F4F9EC40D81B245F5CB6E621622607"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1921-wk-Fact-5A87E05E90D0F8DD8D5FB6E594293242"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1936-wk-Fact-992EB9D518267292FB9D75FEE66A7E05"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1951-wk-Fact-629862386B35A299BCFA75FEE66C0345"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1968-wk-Fact-7C41E6F3F433DECAB421B6E618084B85"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1983-wk-Fact-64D3DB69D4036A80073AB6E58BCB5ECD"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e1998-wk-Fact-17011D27505146DCA7F275FEE66AB6A3"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofCVSHealthCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2013-wk-Fact-F2B147D8F15FC5F9AAB075FEE66E995C"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2030-wk-Fact-C6F11659D7622EB4C412B6E61C9DE5F8"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2045-wk-Fact-24C57E65741E2669935FB6E590110263"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2060-wk-Fact-B40C04F4998C26C1DD9D75FEE66B4C4F"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2075-wk-Fact-21530D242669368BA8B375FEE66B8BE2"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2092-wk-Fact-B02F2C735D1A2E13D99CB6E6264424D3"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2107-wk-Fact-034604E54968694AE36EB6E59929A280"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2122-wk-Fact-17C87D592ECE51A9532D75FEE66CBB37"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesOfAmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2137-wk-Fact-D7FFB89A07ABCEB83A1975FEE66EF5AB"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2154-wk-Fact-226A55FA2D1C9054A9ADB6E62B3DC38E"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2169-wk-Fact-3011228E6ECB93D7CE83B6E59E11A966"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2184-wk-Fact-86627013F6F488312E0C75FEE66E1F14"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofOptumSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2199-wk-Fact-E914B700CB52FCF8EFB875FEE66DF0C7"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2216-wk-Fact-2E27ACAA1DCE958559EC7127B40A5BDC"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2231-wk-Fact-0C46E8DB283DA678A1727127B939291A"
      unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2246-wk-Fact-EB63B154536F992518837127BDF70F0B"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_TakedaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2261-wk-Fact-73D87BD7444A314069F97127C32C0FFF"
      unitRef="number">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2278-wk-Fact-491986CA0FB6D5FE5A7CB6E62F9A993F"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2293-wk-Fact-59008AAD1210BC7B343CB6E5A2D0426A"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2308-wk-Fact-7728904BB5841AF33F0275FEE669152A"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d672417e2323-wk-Fact-5925AAB94F01AE3F29C375FEE66A097F"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d672417e2537-wk-Fact-802622B63D75BC86F0427602BC275A14"
      unitRef="usd">181231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d672417e2556-wk-Fact-E335AF4C229A771EDE757602BC78CF58"
      unitRef="usd">196347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d672417e2575-wk-Fact-CB53EEEA8D62B629A1DA75FEE6B934FC"
      unitRef="usd">377827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d672417e2595-wk-Fact-8698FB9433CE2968B92975FEE6C51C7B"
      unitRef="usd">378473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d672417e2610-wk-Fact-42583925A711EBAFAB247602BC779FE5"
      unitRef="usd">52917000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d672417e2629-wk-Fact-0B47D60139C0F7244C3E7602BC72874F"
      unitRef="usd">22249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d672417e2648-wk-Fact-953C134494B206A765E275FEE6C64ED1"
      unitRef="usd">81953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d672417e2668-wk-Fact-6A36C21C6478349FABE575FEE6BBFB60"
      unitRef="usd">44117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d672417e2688-wk-Fact-E78BDE53A1E2E01465267602BC7106D7"
      unitRef="usd">25331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d672417e2707-wk-Fact-9BFC4A3D44E7A13034537602BC23CD76"
      unitRef="usd">21679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d672417e2726-wk-Fact-C196CA27E2956B283DCE75FEE6B23111"
      unitRef="usd">26614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d672417e2746-wk-Fact-23B245A4374FE791348375FEE6BBCC6F"
      unitRef="usd">33172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d672417e2771-wk-Fact-236CCC5F43B92BD94705B6E7A291E7BE"
      unitRef="usd">259479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d672417e2790-wk-Fact-EFD8537590A7DAD43966B6E7A296CDC2"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d672417e2809-wk-Fact-F61B0DC327BA39D1D716B6E7776BD6AA"
      unitRef="usd">486394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d672417e2829-wk-Fact-CBEB745D5F61054F7843B6E7776F4C91"
      unitRef="usd">455762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-D7F1FA9817065AEE5E9275FEE6E4DC89-0-wk-Fact-9E3CB1E3CB7397A3165575FEE6640823">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;109,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(72,169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(29,592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(110,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d672417e2986-wk-Fact-4C33FA0B6F44D99A977D75FEE688DD58"
      unitRef="usd">7514000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d672417e3005-wk-Fact-F8DB20A18B45811488DA75FEE678C699"
      unitRef="usd">3497000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d672417e3024-wk-Fact-956C44DBC52F0650D9C675FEE6A4A664"
      unitRef="usd">15222000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q4"
      decimals="-3"
      id="d672417e3044-wk-Fact-F30A7CB458CA47BB8C1475FEE6833337"
      unitRef="usd">26233000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d672417e3141-wk-Fact-AF0586EF9D952068642375FEE67B2BF2"
      unitRef="usd">72874000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d672417e3160-wk-Fact-FBF024E0017D4875C0A875FEE682DB46"
      unitRef="usd">8339000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d672417e3179-wk-Fact-48470B330B8AF551CE0475FEE682E4FB"
      unitRef="usd">28226000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d672417e3199-wk-Fact-6986BB2B477994842F7B75FEE685F690"
      unitRef="usd">109439000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d672417e3219-wk-Fact-92CD814550C140EF98DC75FEE67664B9"
      unitRef="usd">39000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d672417e3238-wk-Fact-FAEB27FDE4001533B40C75FEE678E8CE"
      unitRef="usd">-364000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d672417e3258-wk-Fact-D397191DF0E6D703AD0675FEE69A3B46"
      unitRef="usd">740000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d672417e3278-wk-Fact-48F7B70CE4F1DDB6F08875FEE6784C0C"
      unitRef="usd">415000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d672417e3298-wk-Fact-65C4463DF48EE688C77C75FEE698F929"
      unitRef="usd">72169000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d672417e3318-wk-Fact-DB7ADC8B8B06512E83F275FEE67B8493"
      unitRef="usd">9111000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2020Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d672417e3338-wk-Fact-78F1254141F8543F9C8075FEE6845AA5"
      unitRef="usd">29592000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d672417e3359-wk-Fact-FAC6EDC04EFF5ACDA60C75FEE67AB6C7"
      unitRef="usd">110872000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d672417e3385-wk-Fact-3B9D9EB536D5B082C2A675FEE6744954"
      unitRef="usd">8258000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d672417e3404-wk-Fact-A343E52FFBBFB89CC07675FEE6875F6A"
      unitRef="usd">2361000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d672417e3423-wk-Fact-02894ED3950D6EF07EDA75FEE6737386"
      unitRef="usd">14596000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2020Q2"
      decimals="-3"
      id="d672417e3443-wk-Fact-9AB781BD067B5554A2E775FEE6756C06"
      unitRef="usd">25215000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-14D21D02B533E7C39F9C75FEE6E4F742-0-wk-Fact-C92EC76FF3DB2E67AE2175FEE686B4CA">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$13.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. The current portion of the contract liabilities totaling &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanying Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d672417e3567-wk-Fact-AF23E46A4E7C9C8DB37575FEE68FC5BD"
      unitRef="usd">13800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d672417e3571-wk-Fact-77BCE6DAF10BF973718775FEE6D4C5C4"
      unitRef="usd">1100000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2020Q2"
      decimals="-5"
      id="d672417e3584-wk-Fact-051DAEBCD80A3B8208A275FEE690A87C"
      unitRef="usd">16300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q4"
      decimals="-5"
      id="d672417e3588-wk-Fact-ADA8FFC71BA8EDE6101A75FEE69045B2"
      unitRef="usd">6600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2020Q2"
      decimals="-5"
      id="d672417e3600-wk-Fact-3931015A0044A1825C3775FEE6901E64"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-5"
      id="d672417e3604-wk-Fact-8222D7D29C15113E983C75FEE68E943B"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d672417e3632-wk-Fact-79B5D9AA426F6193E4D1713526BBAE4C"
      unitRef="usd">20000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2020Q2_srt_MajorCustomersAxis_exel_TakedaMember"
      decimals="-5"
      id="d672417e3638-wk-Fact-A27FE51E00A2DDAAE58B75FEE68B3986"
      unitRef="usd">10000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d672417e3662-wk-Fact-7D871297CB30BDFFC03B75FEE692B52F"
      unitRef="usd">3400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d672417e3666-wk-Fact-95A5F89B7247B542AE5F75FEE68ED916"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2020Q2QTD"
      decimals="-5"
      id="d672417e3681-wk-Fact-A4E20AD0A1DE7AB7B09BB6FF7B94FE70"
      unitRef="usd">62000000.0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d672417e3685-wk-Fact-FB02B8E130BC88D1747075FEE68F7BE2"
      unitRef="usd">82200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d672417e3689-wk-Fact-F19C96A3D191E8B5494BB6FFA6CEA868"
      unitRef="usd">36100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d672417e3694-wk-Fact-AE55E14EE8D6124BB31275FEE68BEDB5"
      unitRef="usd">61400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q2"
      decimals="-5"
      id="d672417e3709-wk-Fact-94336A19737899D6278075FEE695ABD0"
      unitRef="usd">71400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-813C4703E5DED57EF68475FEE6E594B7-0-wk-Fact-93113978F0181E8FCC2175FEE698CB77">COLLABORATION AGREEMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib. Additionally, consistent with our business strategy prior to the commercialization of cabozantinib, we entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 2. Revenues&#x201d; for additional information on revenues recognized under our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have also established multiple collaborations with smaller, discovery-focused biotechnology companies to expand our product pipeline. Under these collaborations, we may be required to make milestone and royalty payments, and for certain collaborations make payments for development cost reimbursements and/or option exercise fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for a description of each of our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. During the second quarter of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2020, Ipsen opted into and is now co-funding the development costs for CONTACT-01 and CONTACT-02, two phase 3 pivotal trials of cabozantinib in combination with atezolizumab in patients with previously treated, metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively, and the four remaining cohorts of COSMIC-021 it had not previously opted into.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues for both the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; included &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$18.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenues recognized in connection with a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; development milestone from Ipsen we determined was probable of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$46.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration agreement with Takeda. Under this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues for both the three and six months ended June&#160;30, 2020 included &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$23.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in revenues recognized in connection with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$31.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in milestones we achieved upon Takeda&#x2019;s first commercial sale of CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma in Japan, as well as royalties earned related to sales of cabozantinib in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$25.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. We are required to pay a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$15.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$15.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the comparable periods in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with Zelboraf and Tecentriq (atezolizumab) as a treatment for BRAF V600-mutation positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-7F2A7A999A3A402563E475FEE6E565A0-0-wk-Fact-CC59790D422FCE6DA2F975FEE6A4E250">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;81,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,783&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration services revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e638-wk-Fact-236F4CD7C50BF08900E7B733B2565510"
      unitRef="usd">33597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e657-wk-Fact-E9C12EFBE451B2E5CA5AB733D544993C"
      unitRef="usd">14946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e676-wk-Fact-97233F1C6784D56BF8DB75FEE6CAF7B4"
      unitRef="usd">51546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e696-wk-Fact-4348C8FC48872EB376E475FEE6CF0832"
      unitRef="usd">28909000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e711-wk-Fact-E8BEE20B3434CDFD10A8B733B521618E"
      unitRef="usd">19320000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e730-wk-Fact-BD006F0DC9B1E0A5A00CB733D81173DD"
      unitRef="usd">7303000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e749-wk-Fact-A67B020A145596D6D78F75FEE6CA5DA6"
      unitRef="usd">30407000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e769-wk-Fact-DCF4118497FE7209D96F75FEE6CB92DD"
      unitRef="usd">15208000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e794-wk-Fact-CB1AE47A1FEFA1B8426CB733B84F4270"
      unitRef="usd">52917000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e813-wk-Fact-488E6C9DD40914687CB1B733DBA59952"
      unitRef="usd">22249000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e832-wk-Fact-098BEA423A0767D1F04375FEE6CC26E7"
      unitRef="usd">81953000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d671000e852-wk-Fact-D58292963F600DFBE23F75FEE6CAF4E9"
      unitRef="usd">44117000</us-gaap:Revenues>
    <exel:MilestonePaymentsEarned
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d671000e954-wk-Fact-2664B31718BB44FE1E88713DBEB70CDD"
      unitRef="usd">18800000</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d671000e958-wk-Fact-79B5D9AA426F6193E4D1713526BBAE4C"
      unitRef="usd">20000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d671000e969-wk-Fact-9C225FB6B01EA36ECC6B75FEE6BB86F6"
      unitRef="usd">46200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1192-wk-Fact-070652DFABB9D3B000A8B735CAF63CD9"
      unitRef="usd">22946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1211-wk-Fact-F927F2D3C3403A793A19B735F06565F3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1230-wk-Fact-5115172E19E1139DEA5375FEE6AD461E"
      unitRef="usd">22946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1250-wk-Fact-4C6385FE23D3E0867C8275FEE6ABA1F6"
      unitRef="usd">9056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1265-wk-Fact-0821F0E7BEBC77113983B735CE68B0F6"
      unitRef="usd">2195000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1284-wk-Fact-C01FACEEE068E24B8674B735F4348A06"
      unitRef="usd">1565000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1303-wk-Fact-B612B993545C92F473DC75FEE6ACC097"
      unitRef="usd">3264000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1323-wk-Fact-ABC63BC52127D185094B75FEE6AB0593"
      unitRef="usd">4002000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1348-wk-Fact-3AA94C98BBD9F24123DAB735D15E1E13"
      unitRef="usd">25141000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1367-wk-Fact-37BF683D908401969BE3B735F8159904"
      unitRef="usd">1565000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1386-wk-Fact-AD688E69561EEE8C08E275FEE6BCF812"
      unitRef="usd">26210000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d671000e1406-wk-Fact-8FD3AC0A737A995406AE75FEE6A98524"
      unitRef="usd">13058000</us-gaap:Revenues>
    <exel:MilestonePaymentsEarned
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d671000e1500-wk-Fact-836A51E6DDE5F0540E2394579215BBD6"
      unitRef="usd">23700000</exel:MilestonePaymentsEarned>
    <exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d671000e1504-wk-Fact-B84DCEB143503652D249945F27D4540C"
      unitRef="usd">31000000.0</exel:EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2020Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d671000e1515-wk-Fact-E1D193D86111CB838D8275FEE6CBE5A7"
      unitRef="usd">25100000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2020Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember"
      decimals="2"
      id="d671000e1534-wk-Fact-FFCBE57EB6DE16A8452475FEE6C23818"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d671000e1538-wk-Fact-C3DB37C4ACE5C379BF9EB7373B47FA63"
      unitRef="usd">7600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d671000e1542-wk-Fact-FDBA1E4750D1B4587D5875FEE6C928E6"
      unitRef="usd">15700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d671000e1555-wk-Fact-7E20911B4AE9D8FE3BDFB7376DF5D69C"
      unitRef="usd">7800000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-5"
      id="d671000e1559-wk-Fact-2C6311766A03F8F380D075FEE6BCF063"
      unitRef="usd">15100000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1787-wk-Fact-2C5B94634F128DB4465175FEE6C7F5EA"
      unitRef="usd">1376000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1806-wk-Fact-AF5C10BE8DCD35C4416875FEE66923E2"
      unitRef="usd">1349000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1825-wk-Fact-7DC52CD6A38341BEB70975FEE6C98853"
      unitRef="usd">2783000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1845-wk-Fact-478A121F079D8B7F82E875FEE6C423D0"
      unitRef="usd">2404000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1865-wk-Fact-A1387856281B23C89A4B75FEE6674BBF"
      unitRef="usd">1125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1884-wk-Fact-412ADF46147D0C06674775FEE6D4D715"
      unitRef="usd">1323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1903-wk-Fact-80D14B879D0E64134CA175FEE6BDBAB7"
      unitRef="usd">2434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d671000e1923-wk-Fact-29AD9E28F3F4F8B3418475FEE6CA5EE7"
      unitRef="usd">2813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CashCashEquivalentsAndInvestmentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-6F622559253FBC73838975FEE6E50CB2-0-wk-Fact-ACBD627D7970321673E375FEE6A644AE">CASH AND INVESTMENTS&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;527,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;528,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;long-term &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;classification of restricted cash &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;equivalents is based &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;upon the remaining term of the underlying restriction&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;663,491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;672,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;89,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;90,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,021,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,529,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,540,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;752,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,308,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,384,510&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,388,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Interest receivable was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$5.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Realized gains and losses on the sales of investments were insignificant during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All securities presented have been in an unrealized loss position less than 12 months. There were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;720,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;789,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;311,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;522,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:CashCashEquivalentsAndInvestmentsTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-72B5EA6D9452E6D9BB2175FEE6E58B1C-0-wk-Fact-474B42617C7BDACBC56975FEE6A88447">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;527,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;528,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C55BFE0AE9248AD788E375FEE6E589CE-0-wk-Fact-DCA608C1BC1F3223123A75FEE6A4A019">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;527,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;266,501&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash equivalents included in long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;528,779&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;268,137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e489-wk-Fact-A1BC98B7EF7C3CEC321D75FEE6A61235"
      unitRef="usd">527143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e508-wk-Fact-7FE412FB8DEB8D023E2A75FEE68E25BF"
      unitRef="usd">266501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e523-wk-Fact-6315AEEC1175E1B551CC75FEE66753AD"
      unitRef="usd">1636000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e542-wk-Fact-01EEDAED8C68CD6B172875FEE66B14F8"
      unitRef="usd">1636000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e567-wk-Fact-894D15D3C93C47AB426A75FEE6B2B28C"
      unitRef="usd">528779000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e586-wk-Fact-8769E5B4758910A379EB75FEE6AF4BC1"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-9F8D83C8086EB7A2D38575FEE6E6D907-0-wk-Fact-5CF740AF1BD7925998A575FEE6A67C72">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;663,491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;672,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;89,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;90,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,021,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,529,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,540,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;752,295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,308,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,384,510&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,388,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e912-wk-Fact-522319E133BEFB42A34275FEE6D46867"
      unitRef="usd">239685000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e931-wk-Fact-2FDFC0A79414F3015A7D75FEE6CC3AD2"
      unitRef="usd">245000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e950-wk-Fact-526A594F51DE740DCD7C75FEE6C6CD35"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e970-wk-Fact-A9289102402F99BBD8FC75FEE6D287B0"
      unitRef="usd">239930000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e985-wk-Fact-D1A191D0DBF126F9395675FEE6C61F0A"
      unitRef="usd">663491000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e1004-wk-Fact-609F3016527D90BF439A75FEE6CCBA69"
      unitRef="usd">9527000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e1023-wk-Fact-8D3E7D5281419F153BBC75FEE6CE7F80"
      unitRef="usd">150000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e1044-wk-Fact-F864CE890E543E5D356E75FEE6C7791A"
      unitRef="usd">672868000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e1064-wk-Fact-8E434C861C3724B0594E75FEE6D373F1"
      unitRef="usd">89890000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e1083-wk-Fact-C62B7925DF1C9E7B021F75FEE6C937C0"
      unitRef="usd">462000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e1102-wk-Fact-D4F1C1F5C7BE1462416775FEE6CB9025"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e1122-wk-Fact-6B916479768C857B084975FEE6CBD745"
      unitRef="usd">90352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d666062e1142-wk-Fact-AD9D9FC35CA82786238275FEE6D1A08D"
      unitRef="usd">28229000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d666062e1161-wk-Fact-20F8CF00BAC242D2834175FEE6CB3A3F"
      unitRef="usd">152000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d666062e1180-wk-Fact-83A37DF8166B4AAA47BA75FEE6CFBEFD"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d666062e1201-wk-Fact-51AFEF564A2F2C64983F75FEE6CA8FC7"
      unitRef="usd">28380000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1221-wk-Fact-24361C94A361CB748C8A75FEE6C51006"
      unitRef="usd">1021295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1240-wk-Fact-779F1992EEEC7861261775FEE6D0C8EB"
      unitRef="usd">10386000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1259-wk-Fact-893951962E32BE8AA7F475FEE6C9B8FA"
      unitRef="usd">151000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1280-wk-Fact-CBDF93617CF02EC0310B75FEE6C46ECF"
      unitRef="usd">1031530000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e1300-wk-Fact-9C8120DDAB01467C86EA75FEE6CBD4DF"
      unitRef="usd">52053000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e1319-wk-Fact-4025C9BA6044667C982875FEE65D4ED4"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e1338-wk-Fact-7B7E2BB280260F833FD575FEE6CD922A"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e1358-wk-Fact-0B978933754D9005F5C975FEE6CFEC6E"
      unitRef="usd">52053000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e1378-wk-Fact-5638AFEDA9FC1947E80875FEE6D0BE99"
      unitRef="usd">404313000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e1397-wk-Fact-724D6570DEC463C8089175FEE6CD3CCF"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e1416-wk-Fact-C5F22A645179C190AD1175FEE6C9AA42"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e1436-wk-Fact-87A97E1FC14D82524CE675FEE6CE82FE"
      unitRef="usd">404313000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e1456-wk-Fact-208CD45C8B650A2ABA0075FEE6CDD683"
      unitRef="usd">52283000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e1475-wk-Fact-60AB8C6C821B2255302475FEE6CB28B7"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e1494-wk-Fact-846CC78D18B633711FEE75FEE6C485BB"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e1514-wk-Fact-B39C6E6E332DBD04F71275FEE6C34EC2"
      unitRef="usd">52283000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1540-wk-Fact-E3DAD595D38E376B4E6975FEE6CF5621"
      unitRef="usd">1529944000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1559-wk-Fact-ED6DFE1107D6002210E475FEE6C76E61"
      unitRef="usd">10386000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1578-wk-Fact-27B857BF84BFD62FAB9575FEE6CEEF62"
      unitRef="usd">151000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e1599-wk-Fact-50AADC7571B677170AF975FEE6C8D039"
      unitRef="usd">1540179000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e1890-wk-Fact-BE5DFE01A9F0F4BDE1B975FEE6ACFCE1"
      unitRef="usd">389573000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e1909-wk-Fact-85BE5F5E344F56DE712475FEE6705688"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e1928-wk-Fact-492917F91EE9FC4DC65C75FEE674DD30"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d666062e1948-wk-Fact-608C28D4C198B91A279275FEE6714490"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e1963-wk-Fact-E6D71E200005A7F3E90475FEE6A827DC"
      unitRef="usd">752295000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e1982-wk-Fact-D1A6C2F458D59606B50F75FEE6B6AB05"
      unitRef="usd">3934000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e2001-wk-Fact-82A47A2197C40469FA8A75FEE6B27A2F"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e2022-wk-Fact-B330E7B6AF4FCE3AD75D75FEE66ED0C1"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2042-wk-Fact-1E5BAB7E975018F1097E75FEE675AFDF"
      unitRef="usd">166483000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2061-wk-Fact-9BD712EFC41785EC4D5275FEE6B45BF9"
      unitRef="usd">187000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2080-wk-Fact-C070A0CC46FA79D8CB3075FEE6B894B4"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2101-wk-Fact-3D065C56B42EB437494775FEE6A67AE4"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2121-wk-Fact-DD4A4B26EC4806DBD7C075FEE68563D3"
      unitRef="usd">1308351000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2140-wk-Fact-E1A5DFE664CBEB8F823375FEE66F6B10"
      unitRef="usd">4121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2159-wk-Fact-4D4E82AAE923E302229F75FEE6B58C31"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2180-wk-Fact-D262D005796EFBBAE4FF75FEE6D2519D"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e2200-wk-Fact-C895ED58202C82F3D5C275FEE6723B92"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e2219-wk-Fact-C94B1BEF441EFDE0F7E075FEE6AAD45E"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e2238-wk-Fact-2ED04B3BBB3BA7752FA3B7449F9DC9FB"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CashMember"
      decimals="-3"
      id="d666062e2258-wk-Fact-8E6760AB9067DE2081E575FEE6735E35"
      unitRef="usd">40964000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e2278-wk-Fact-CA3F66DEBBFD1B6632A475FEE6A405FF"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e2297-wk-Fact-B94C8449ECAEBBAE8D4FB7449FC5BF31"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e2316-wk-Fact-8D0D881263380CB8F17875FEE6B1F72E"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d666062e2336-wk-Fact-EA73B8314FC1D183E63775FEE686B658"
      unitRef="usd">2467000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e2356-wk-Fact-4D2F41E1F1653617E97175FEE6ABACBC"
      unitRef="usd">32728000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e2375-wk-Fact-74BBDB6A392F2B7A2B8775FEE6AF31C1"
      unitRef="usd">5000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e2394-wk-Fact-4E5531F7AED76CC282F675FEE6ACD50D"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d666062e2414-wk-Fact-6C3CAA0539565CA81EE875FEE6AD436D"
      unitRef="usd">32733000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2439-wk-Fact-73273A70EE388A9C48E875FEE6A7871C"
      unitRef="usd">1384510000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2458-wk-Fact-5DA3DCB03553435904FD75FEE6726762"
      unitRef="usd">4126000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2477-wk-Fact-0640331C6C335518AF9975FEE6B2899A"
      unitRef="usd">8000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2498-wk-Fact-695F3CBC631EB1B2146575FEE6BB107E"
      unitRef="usd">1388628000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="FI2020Q2"
      decimals="-5"
      id="d666062e2510-wk-Fact-A00F9C87F7650FF141D375FEE6A8AE3F"
      unitRef="usd">5300000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="FI2019Q4"
      decimals="-5"
      id="d666062e2514-wk-Fact-71B0079E6F0878E93B8C75FEE6A3A851"
      unitRef="usd">6200000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C05F5F5A88BB450AEDDE75FEE6E6C3A7-0-wk-Fact-40BCD2CB9ED99DE7B2E175FEE6A7B12C">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,377&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e2662-wk-Fact-ECDA02EE5E2AED64853775FEE699A15D"
      unitRef="usd">27850000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e2681-wk-Fact-94E7FE489585CE0E98B675FEE687667D"
      unitRef="usd">150000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2697-wk-Fact-C8D0841065C2977EFEA375FEE689C374"
      unitRef="usd">4997000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2716-wk-Fact-9F2FD1B22C2540A2D33FA5A44C0D343A"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MunicipalBondsMember"
      decimals="-3"
      id="d666062e2736-wk-Fact-DB027AC591108761DE0C6CA39DA73425"
      unitRef="usd">2471000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MunicipalBondsMember"
      decimals="-3"
      id="d666062e2755-wk-Fact-3B593206F6A55C2089FC6CA3E2D2C082"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e2781-wk-Fact-A09D3FDD7561C74BEC6F75FEE6A8F3F8"
      unitRef="usd">35318000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e2800-wk-Fact-CB242F77ED5B9ECF8F8175FEE6AA3A6C"
      unitRef="usd">151000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e2917-wk-Fact-A5557C7EB3CEEA2AD0C975FEE6D38A01"
      unitRef="usd">14529000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d666062e2936-wk-Fact-EEB2C1B70061D493F27F75FEE6D3831F"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2952-wk-Fact-1CDD464FF29C3DAD026575FEE65D2411"
      unitRef="usd">2848000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d666062e2971-wk-Fact-7EBAA6779541C97F482275FEE6CF8A91"
      unitRef="usd">5000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e2997-wk-Fact-AA5BABF804E923AC245F75FEE6645FAF"
      unitRef="usd">17377000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e3016-wk-Fact-DF6A8B8F4A75FDBBAFC275FEE6D0270F"
      unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2020Q2"
      decimals="INF"
      id="d666062e3032-wk-Fact-09AF54E7B491B6819D4575FEE6A4A914"
      unitRef="investment">17</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2019Q4"
      decimals="INF"
      id="d666062e3036-wk-Fact-7B2E081106AB6D160EB075FEE6A75091"
      unitRef="investment">9</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="FI2020Q2"
      decimals="INF"
      id="d666062e3061-wk-Fact-35BF21AF06F6C41D8B7875FEE6A5F8B1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-44BC1A95F65F002E272575FEE6E50C27-0-wk-Fact-20CE14E41C04EE186F6075FEE6A33F57">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;720,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;789,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;311,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;522,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e3179-wk-Fact-83FE0C0ABB89050C5F3F75FEE6CC4E7E"
      unitRef="usd">720089000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e3198-wk-Fact-D40D400B1EDCA3AA826375FEE6CD289F"
      unitRef="usd">789913000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e3213-wk-Fact-BA73B5A9D7D362829A8375FEE6CCAB79"
      unitRef="usd">311441000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e3232-wk-Fact-B51294B9051F1D2DFFCC75FEE6CE6034"
      unitRef="usd">522551000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666062e3257-wk-Fact-CBDF93617CF02EC0310B75FEE6C46ECF"
      unitRef="usd">1031530000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666062e3276-wk-Fact-D262D005796EFBBAE4FF75FEE6D2519D"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-CF5FC8BC1AAF9DF36C3675FEE6E6A406-0-wk-Fact-9F1E5CB48DC847C25A3675FEE66391A8">FAIR VALUE MEASUREMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;672,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;672,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;90,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;90,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,083,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,488,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,345,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,347,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-0AEF4FE31E0DC582C97C75FEE6E69B3C-0-wk-Fact-F346AB19B3D3573D35D175FEE66A6AFF">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;672,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;672,868&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;90,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;90,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Municipal bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,031,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;404,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,083,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,488,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;389,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;756,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,665&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,312,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,345,197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,347,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d662808e592-wk-Fact-FBA3730362021F175EE875FEE6743A35"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d662808e611-wk-Fact-217BAB2D3FB9F82E6EA975FEE6A738F1"
      unitRef="usd">239930000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d662808e630-wk-Fact-991AE4FAE1C81744A16275FEE67A1B4A"
      unitRef="usd">239930000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d662808e646-wk-Fact-41382F81375D635FF23C75FEE678DD31"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d662808e665-wk-Fact-59A7E6F192AFED6DF71075FEE672EC0B"
      unitRef="usd">672868000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d662808e684-wk-Fact-9F85996B929B619A241075FEE665CAAF"
      unitRef="usd">672868000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d662808e705-wk-Fact-957B3417FFD97B6A721475FEE6730A74"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d662808e724-wk-Fact-E5BD91EE03AE7CC4B3E075FEE66D0505"
      unitRef="usd">90352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d662808e743-wk-Fact-524DE3EE3FA03A981F5575FEE674E99E"
      unitRef="usd">90352000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d662808e764-wk-Fact-F18EE73CF8D28A02B5EB75FEE6729A32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d662808e783-wk-Fact-0F7B538091424A947D3C75FEE67713F9"
      unitRef="usd">28380000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="d662808e802-wk-Fact-55A6BD2DE1C733DDD4C475FEE69A73AA"
      unitRef="usd">28380000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e823-wk-Fact-846FA02778A45020A3B675FEE69B8118"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e842-wk-Fact-E7D296C81D8D1451E4B875FEE66DDE1B"
      unitRef="usd">1031530000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e861-wk-Fact-91DF7F8BD29700E78BA875FEE66E7E55"
      unitRef="usd">1031530000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d662808e882-wk-Fact-5A3311DD9A4B1171074975FEE6AA60A5"
      unitRef="usd">404313000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d662808e901-wk-Fact-B2338375F149F905908875FEE665145A"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d662808e920-wk-Fact-2B6649E6DFF13969599C75FEE667502B"
      unitRef="usd">404313000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d662808e941-wk-Fact-C999D1340B443C70CCC675FEE69B6B37"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d662808e960-wk-Fact-A7B2ECF20443DC233B9E75FEE677A1BF"
      unitRef="usd">52283000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d662808e979-wk-Fact-A849D1DDA04A8BD6098375FEE678A91C"
      unitRef="usd">52283000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1005-wk-Fact-E92575B29AF2FC3E044975FEE6A53B2D"
      unitRef="usd">404313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1024-wk-Fact-330B015285238FD7AF0F75FEE6A1A95B"
      unitRef="usd">1083813000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1043-wk-Fact-9C5B4EC9062BEBB51D5775FEE675C0DF"
      unitRef="usd">1488126000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d662808e1269-wk-Fact-D3E35149A5453AA2AC9375FEE668F5BB"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d662808e1288-wk-Fact-DD1E70CF50A64C419D1875FEE66632E0"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d662808e1307-wk-Fact-B650C507BFC0D22F3A8A75FEE6676121"
      unitRef="usd">389573000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d662808e1323-wk-Fact-5663214468CA148FED1775FEE66BFCFC"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d662808e1342-wk-Fact-382B2C1225137C212A8F75FEE6B0FAF5"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d662808e1361-wk-Fact-60C3F07ED9CBAAB06E1175FEE65DB390"
      unitRef="usd">756226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d662808e1382-wk-Fact-2232F6ADBB069CE5776875FEE66A9230"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d662808e1401-wk-Fact-B96B213267C510A7810C75FEE66475E0"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d662808e1420-wk-Fact-E3036C46B25C388E280B75FEE66C1BF8"
      unitRef="usd">166665000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1441-wk-Fact-D19A1AE3F80DD4030EAA75FEE6719219"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1460-wk-Fact-F2150D2F6432AACF1DC475FEE66E6F52"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1479-wk-Fact-E2C2AD428866AFC0B60675FEE65D89FD"
      unitRef="usd">1312464000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d662808e1500-wk-Fact-4CBC4BEB7AEEAB6744CA75FEE66AE43A"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d662808e1519-wk-Fact-38AD9C580B3BF901606175FEE6666692"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d662808e1538-wk-Fact-BDE2CE7BD1341B99DE2F75FEE668CEE4"
      unitRef="usd">2467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d662808e1559-wk-Fact-B7AC88D92D4A95C416AA75FEE669FCFE"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d662808e1578-wk-Fact-FD828F0DB5F9328D38E7B757D43B95B0"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d662808e1597-wk-Fact-FA3CC24B4CD7727E8B3E75FEE6B16D25"
      unitRef="usd">32733000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1623-wk-Fact-64B264FE4E92DE12EC5F75FEE6D30444"
      unitRef="usd">2467000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1642-wk-Fact-5BBBB3B11A07E359821175FEE6678C4E"
      unitRef="usd">1345197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d662808e1661-wk-Fact-3DD47DFA974B0CC5F3D675FEE6706488"
      unitRef="usd">1347664000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-08480ABB0B373849A4FF75FEE6E6B37B-0-wk-Fact-FAF156D68E16C90A17C375FEE6C4D50B">INVENTORY&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,086&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,886&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Write-downs related to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;excess and expiring inventory were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-E1EFC0655D560DBE63CB75FEE6E669BB-0-wk-Fact-7B656871401920BCE5F975FEE6B71BFD">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,086&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,886&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666504e493-wk-Fact-3A07B3959FCD48891A0175FEE6715001"
      unitRef="usd">1876000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666504e512-wk-Fact-9CC01F0F7082CA3D4B3675FEE667629A"
      unitRef="usd">2709000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666504e527-wk-Fact-DCB91F09B342EE00993A75FEE66E9EFB"
      unitRef="usd">15275000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666504e546-wk-Fact-1EA81E3131047A513EC675FEE66CAE56"
      unitRef="usd">9447000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666504e566-wk-Fact-FC9F58DF0A74B591654675FEE684152E"
      unitRef="usd">5086000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666504e585-wk-Fact-6255D2AE2B449C0A2B2A75FEE6825E11"
      unitRef="usd">4367000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666504e610-wk-Fact-9BD5C314F7A28689FDAF75FEE686265D"
      unitRef="usd">22237000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666504e629-wk-Fact-574B21D606C0F130D38975FEE67BC4D1"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d666504e690-wk-Fact-FBA75F3963AE7DFE494C75FEE67A6817"
      unitRef="usd">16608000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d666504e709-wk-Fact-0F78892AA805ABF0720475FEE682125B"
      unitRef="usd">12886000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2020Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d666504e724-wk-Fact-62DB2C29A725FA51AD1975FEE6764809"
      unitRef="usd">5629000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d666504e743-wk-Fact-9F4BAA84BB0C7E708EC275FEE67AA7CA"
      unitRef="usd">3637000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2020Q2"
      decimals="-3"
      id="d666504e768-wk-Fact-9BD5C314F7A28689FDAF75FEE686265D"
      unitRef="usd">22237000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q4"
      decimals="-3"
      id="d666504e787-wk-Fact-574B21D606C0F130D38975FEE67BC4D1"
      unitRef="usd">16523000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="FD2020Q2YTD"
      decimals="-5"
      id="d666504e804-wk-Fact-F63B735B9D5A211DA8FF7602BC05B29D"
      unitRef="usd">1300000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d666504e808-wk-Fact-417B36FD2579903FD7D27602BC057029"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-82719FCA92319853ACAD75FEE6E6A24A-0-wk-Fact-B8D7E0041F077D2C88E675FEE68671C5">STOCK-BASED COMPENSATION&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;25,749,356&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; share for each share issued pursuant to a stock option or stock appreciation award and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares for full value awards granted in the form of restricted stock units (RSUs). On May&#160;20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (the Additional Shares)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval.&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Additional Shares will be registered on a Form S-8 prior to grant&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we granted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;839,318&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; stock options with a weighted average exercise price of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$21.40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per share and a weighted average grant&#160;date fair&#160;value of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$9.74&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per share. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;16,655,274&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; stock options outstanding and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$30.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; unrecognized compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we granted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;889,023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; RSUs with a weighted average grant&#160;date fair&#160;value of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$21.43&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per share. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;4,774,852&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; RSUs outstanding and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$75.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Stock options and RSUs granted to employees during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; have vesting conditions and contractual lives of a similar nature to those described in &#x201c;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Note 8. Employee Benefit Plans&#x201d;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;"&gt;year ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;308,365&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; performance-based stock options (PSOs) to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of our Common Stock is equal to or greater than &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;125%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the three months ended June&#160;30, 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there were&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;4,343,852&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; performance-based restricted stock units (PSUs) outstanding with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$79.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. Of the outstanding PSUs, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;237,945&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; relate to awards for which we achieved the performance target during 2019 or had determined during 2019 that it was probable that we would achieve the performance target during 2020. During the three months ended June&#160;30, 2020, we determined that it had become probable that we would achieve an additional performance target for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;98,653&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; additional PSUs granted during 2018 resulting in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in compensation expense during the period. For more information about our PSUs, see &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Note 8. Employee Benefit Plans&#x201d;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-C6AD1E98381ADCBF1ABF75FEE6E66902-0-wk-Fact-56D735F1F79ED8463A6475FEE68D6CB1">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30,136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d667668e618-wk-Fact-65E58CF88A0998C7491C75FEE6BA7417"
      unitRef="usd">6112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d667668e637-wk-Fact-9587BB59E8B50646AE0075FEE6B37789"
      unitRef="usd">5138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d667668e656-wk-Fact-BE68106A723F728B0C0375FEE666481A"
      unitRef="usd">11198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d667668e676-wk-Fact-80118899E2371525F70675FEE665022C"
      unitRef="usd">9444000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d667668e691-wk-Fact-7ED48AADEA2D5AD6995E75FEE6B03EB7"
      unitRef="usd">10042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d667668e710-wk-Fact-0EEB62A3EF06F9ACF8E975FEE6C43447"
      unitRef="usd">9941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d667668e729-wk-Fact-B249BD08CBCDEB10E35375FEE6B63D3F"
      unitRef="usd">18938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d667668e749-wk-Fact-9B66E76EA68AB7846EC175FEE6B4D2A3"
      unitRef="usd">18164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d667668e774-wk-Fact-D25B80EC9080863D585075FEE6BB1ABE"
      unitRef="usd">16154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d667668e793-wk-Fact-5ACB6E99A5B073C6942B75FEE6B0DC25"
      unitRef="usd">15079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d667668e812-wk-Fact-2B88BA7C117BE0CC098975FEE6BD04F4"
      unitRef="usd">30136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d667668e832-wk-Fact-5347209DC38252E73DC675FEE66436D0"
      unitRef="usd">27608000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2020Q2"
      decimals="INF"
      id="d667668e858-wk-Fact-189C0A55FD4710CCC7117602BC886F37"
      unitRef="shares">25749356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d667668e862-wk-Fact-8500CD7AD98CD0354214714BBE9323CF"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d667668e866-wk-Fact-D78721E0C429A57DAC6F714CC88ACD14"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="D2020Q2May20-May20"
      decimals="INF"
      id="d667668e870-wk-Fact-8076BE195FB5B6795343BBFBC950D7B4"
      unitRef="shares">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d667668e894-wk-Fact-CC4705F6D458C04FA0A275FEE68B0C88"
      unitRef="shares">839318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d667668e898-wk-Fact-0B968784B8E9EE3CB98775FEE683E26F"
      unitRef="usdPerShare">21.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d667668e902-wk-Fact-9FAF301FD6204C9A9ABB75FEE6896455"
      unitRef="usdPerShare">9.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2020Q2"
      decimals="INF"
      id="d667668e911-wk-Fact-A46C846BBA9CC0A7B34775FEE68A07EC"
      unitRef="shares">16655274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d667668e915-wk-Fact-3D4D2433AA02308B681F75FEE6894675"
      unitRef="usd">30300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d667668e930-wk-Fact-DF4847989CDA7BF655C675FEE68447B5"
      unitRef="shares">889023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d667668e934-wk-Fact-A15D92602F7A76707E5475FEE685FA8B"
      unitRef="usdPerShare">21.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d667668e943-wk-Fact-28DAE5087FF6A203952375FEE6757145"
      unitRef="shares">4774852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d667668e947-wk-Fact-6648BA04E87099E5BE2C75FEE6838A92"
      unitRef="usd">75100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember"
      decimals="INF"
      id="d667668e1050-wk-Fact-491F01DC44A6631698E67602BC5BF7EC"
      unitRef="shares">308365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_exel_PerformanceShareOptionsPSOMember"
      decimals="INF"
      id="d667668e1054-wk-Fact-FF4223E6E2378F069D227602BC67AF89"
      unitRef="number">1.25</exel:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d667668e1065-wk-Fact-34B3AEE8E214A35F0C5A4761B58DCDE8"
      unitRef="shares">4343852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2020Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d667668e1069-wk-Fact-E49C7C84240546B7A60E71663A4F6E5F"
      unitRef="usd">79700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d667668e1073-wk-Fact-0BC1D6BBE60620B72ED47165B7FB12E8"
      unitRef="shares">237945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d667668e1077-wk-Fact-2A89C4AB55E6496DCFFA716A8945E80B"
      unitRef="shares">98653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d667668e1082-wk-Fact-2189ABB5E339AA87ED817602BC510A89"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-23CEF12B4BB978669A9175FEE6E6C1D5-0-wk-Fact-53B6C221B82C3871533375FEE69062AD">INCOME TAXES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our effective income tax rate was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;17.2%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;18.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;20.8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;18.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;comparable &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;periods in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The effective tax rate for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2020&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; differed from the U.S. federal statutory rate of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;primarily due to excess tax benefits related to the exercise of certain stock options during the periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2QTD"
      decimals="3"
      id="d671637e409-wk-Fact-352A482271A9B1D8E2ECB75D0DB287B3"
      unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2020Q2YTD"
      decimals="3"
      id="d671637e413-wk-Fact-F0472657DDE5E9D7B9CF75FEE68F043E"
      unitRef="number">0.180</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d671637e427-wk-Fact-E5583659DD831C57581DB75D35AB173D"
      unitRef="number">0.208</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d671637e432-wk-Fact-E6B2E9E59D1C241DD3DD75FEE6870BA5"
      unitRef="number">0.187</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2020Q2YTD"
      decimals="INF"
      id="d671637e461-wk-Fact-F3DF6470589172FC3B0B75FEE679059B"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-58EC83A226D55110680275FEE6E66A35-0-wk-Fact-5791CBC86BCE4AAD577175FEE68CEC31">NET INCOME PER SHARE&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66,821&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;154,817&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;307,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;302,188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;306,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;301,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;318,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;316,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Dilutive securities included stock options, RSUs, PSUs and ESPP contributions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSOs and PSUs for which the contingent vesting condition had not been achieved. These excluded potential common shares were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,812&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-662D20F65E54626B555475FEE6E7F935-0-wk-Fact-79F364EA440FBB5288C675FEE686A376">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;66,821&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;115,433&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;154,817&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;307,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;302,188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;306,598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;301,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;318,144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;316,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share - diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d673815e699-wk-Fact-B487DD23D99A668528F075FEE69990CC"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d673815e718-wk-Fact-07E0A20C6BFF333372CF75FEE6CD057A"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d673815e737-wk-Fact-6206BC955D3C09B3A57375FEE68E4C6F"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d673815e757-wk-Fact-2567D8071804F3CC0A2075FEE695FDE1"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d673815e854-wk-Fact-59033765D73556484CE675FEE68A2255"
      unitRef="shares">307807000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d673815e873-wk-Fact-1927675C729F464ED63A75FEE6BA1013"
      unitRef="shares">302188000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d673815e892-wk-Fact-D67C673E55257A7E629B75FEE68DC8AD"
      unitRef="shares">306598000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d673815e912-wk-Fact-1B7FF6816B05CF8C6D3375FEE695C60A"
      unitRef="shares">301365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d673815e932-wk-Fact-850D667D436AC0D5043175FEE6734D32"
      unitRef="shares">10337000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d673815e951-wk-Fact-0CBE8B0943D10CB66B3375FEE671FE85"
      unitRef="shares">12723000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d673815e970-wk-Fact-CC684BE0DB67ED87D59375FEE6B990AD"
      unitRef="shares">10394000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d673815e990-wk-Fact-68DEEABC2496D31B657175FEE6B49E3C"
      unitRef="shares">13421000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2QTD"
      decimals="-3"
      id="d673815e1010-wk-Fact-FDB4E707E9E9AEF20F9075FEE6B71B34"
      unitRef="shares">318144000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d673815e1029-wk-Fact-AA49B4BBB4C251F3D89B75FEE6935051"
      unitRef="shares">314911000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q2YTD"
      decimals="-3"
      id="d673815e1048-wk-Fact-A5A35B7E2FE8BFD7BE9375FEE69113AE"
      unitRef="shares">316992000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d673815e1068-wk-Fact-FE1018EC5634CAFA582475FEE6978CD0"
      unitRef="shares">314786000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d673815e1093-wk-Fact-F04F7BABEA56FDB5117F75FEE6AF18A3"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d673815e1112-wk-Fact-566FD1EE1C16BA6A763575FEE69BA939"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d673815e1131-wk-Fact-C28F37DC2381E7E89D3B75FEE6957C17"
      unitRef="usdPerShare">0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d673815e1151-wk-Fact-0CBBC6463637620FE6C375FEE6880911"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2QTD"
      decimals="2"
      id="d673815e1171-wk-Fact-31596066A1892C4DB17575FEE6844845"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d673815e1190-wk-Fact-A98347421B831C365EB575FEE68DED9E"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q2YTD"
      decimals="2"
      id="d673815e1209-wk-Fact-CEB696DF869A2F41037E75FEE68AADD1"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d673815e1229-wk-Fact-CAB85F7EB403C6F9822C75FEE69349E8"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-8CA8D5E7B9185639DD0F75FEE6E7CDAC-0-wk-Fact-FEC7702D1B48562C243875FEE68C4A3F">These excluded potential common shares were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,812&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d673815e1496-wk-Fact-9DC9A83B8D4B74D4FE42B7625625E65E"
      unitRef="shares">8812000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d673815e1510-wk-Fact-E77FD60FC27D3DF65452B76256291C68"
      unitRef="shares">5935000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d673815e1524-wk-Fact-9748BFEA7DA37B2B20CD75FEE6D081CF"
      unitRef="shares">10413000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d673815e1538-wk-Fact-E71148913890CB91990D75FEE6C2FDEC"
      unitRef="shares">5625000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2020Q2YTD"
      id="TextSelection-73C6235F7931B31A6488F0A6A056ECB2-0-wk-Fact-6CD2338B0EBE87975DE5F0AB209A1586">COMMITMENTS AND CONTINGENCIES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Orange Book.&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998515912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  03,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,995,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154999015992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 527,143<span></span>
</td>
<td class="nump">$ 266,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">685,895<span></span>
</td>
<td class="nump">585,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">121,080<span></span>
</td>
<td class="nump">119,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">16,608<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">43,937<span></span>
</td>
<td class="nump">26,988<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,394,663<span></span>
</td>
<td class="nump">1,011,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">327,141<span></span>
</td>
<td class="nump">536,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">52,323<span></span>
</td>
<td class="nump">48,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">148,235<span></span>
</td>
<td class="nump">172,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">60,502<span></span>
</td>
<td class="nump">53,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,046,548<span></span>
</td>
<td class="nump">1,885,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,103<span></span>
</td>
<td class="nump">11,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">33,156<span></span>
</td>
<td class="nump">37,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">39,940<span></span>
</td>
<td class="nump">38,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">16,957<span></span>
</td>
<td class="nump">18,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">10,695<span></span>
</td>
<td class="nump">11,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">32,830<span></span>
</td>
<td class="nump">24,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">142,681<span></span>
</td>
<td class="nump">142,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">15,003<span></span>
</td>
<td class="nump">6,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">48,334<span></span>
</td>
<td class="nump">48,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,206<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">213,224<span></span>
</td>
<td class="nump">199,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 308,886 and 304,831 at June 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,269,093<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">7,840<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(443,918)<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,833,324<span></span>
</td>
<td class="nump">1,685,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,046,548<span></span>
</td>
<td class="nump">$ 1,885,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998822760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">308,886,497<span></span>
</td>
<td class="nump">304,830,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">308,886,497<span></span>
</td>
<td class="nump">304,830,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998779880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">259,479<span></span>
</td>
<td class="nump">240,275<span></span>
</td>
<td class="nump">486,394<span></span>
</td>
<td class="nump">455,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">9,221<span></span>
</td>
<td class="nump">7,539<span></span>
</td>
<td class="nump">18,510<span></span>
</td>
<td class="nump">15,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">114,933<span></span>
</td>
<td class="nump">81,932<span></span>
</td>
<td class="nump">216,810<span></span>
</td>
<td class="nump">145,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">59,791<span></span>
</td>
<td class="nump">58,815<span></span>
</td>
<td class="nump">122,731<span></span>
</td>
<td class="nump">118,953<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">183,945<span></span>
</td>
<td class="nump">148,286<span></span>
</td>
<td class="nump">358,051<span></span>
</td>
<td class="nump">279,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">75,534<span></span>
</td>
<td class="nump">91,989<span></span>
</td>
<td class="nump">128,343<span></span>
</td>
<td class="nump">176,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">6,975<span></span>
</td>
<td class="nump">12,382<span></span>
</td>
<td class="nump">13,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">80,696<span></span>
</td>
<td class="nump">99,767<span></span>
</td>
<td class="nump">140,731<span></span>
</td>
<td class="nump">190,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">13,875<span></span>
</td>
<td class="nump">20,725<span></span>
</td>
<td class="nump">25,298<span></span>
</td>
<td class="nump">35,621<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">307,807<span></span>
</td>
<td class="nump">302,188<span></span>
</td>
<td class="nump">306,598<span></span>
</td>
<td class="nump">301,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">318,144<span></span>
</td>
<td class="nump">314,911<span></span>
</td>
<td class="nump">316,992<span></span>
</td>
<td class="nump">314,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 178,730<span></span>
</td>
<td class="nump">$ 193,675<span></span>
</td>
<td class="nump">$ 372,610<span></span>
</td>
<td class="nump">$ 373,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">37,742<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
<td class="nump">63,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 21,515<span></span>
</td>
<td class="nump">$ 8,858<span></span>
</td>
<td class="nump">$ 33,671<span></span>
</td>
<td class="nump">$ 19,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140155088082984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains on available-for-sale debt securities, net of tax impact of $2,287, $413, $1,346 and $807, respectively</a></td>
<td class="nump">8,062<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
<td class="nump">2,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 74,883<span></span>
</td>
<td class="nump">$ 80,521<span></span>
</td>
<td class="nump">$ 120,204<span></span>
</td>
<td class="nump">$ 157,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140155179403272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gains (losses) on available-for-sale securities, tax impact</a></td>
<td class="nump">$ 1,346<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140155077420056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 28, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 2,168,217<span></span>
</td>
<td class="num">$ (701)<span></span>
</td>
<td class="num">$ (880,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">18,280<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">18,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(2,434)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">27,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 28, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,785,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 28, 2019</a></td>
<td class="nump">1,488,632<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">2,211,668<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="num">(725,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 29, 2019</a></td>
<td class="nump">1,385,020<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">2,188,578<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="num">(804,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">79,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">8,866<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(854)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 28, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,785,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 28, 2019</a></td>
<td class="nump">$ 1,488,632<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">2,211,668<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="num">(725,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 03, 2020</a></td>
<td class="nump">304,830,706<span></span>
</td>
<td class="nump">304,831,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">2,241,947<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
<td class="num">(559,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">115,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">4,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,955<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(20,941)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(20,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 30,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 03, 2020</a></td>
<td class="nump">308,886,497<span></span>
</td>
<td class="nump">308,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 03, 2020</a></td>
<td class="nump">$ 1,833,324<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,269,093<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
<td class="num">(443,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,780,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Apr. 03, 2020</a></td>
<td class="nump">1,747,652<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">2,258,307<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(510,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">66,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">8,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">13,783<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(19,148)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(19,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 16,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 03, 2020</a></td>
<td class="nump">308,886,497<span></span>
</td>
<td class="nump">308,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 03, 2020</a></td>
<td class="nump">$ 1,833,324<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 2,269,093<span></span>
</td>
<td class="nump">$ 7,840<span></span>
</td>
<td class="num">$ (443,918)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998303384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 115,433<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">4,376<span></span>
</td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">30,136<span></span>
</td>
<td class="nump">27,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,383<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred taxes</a></td>
<td class="nump">22,793<span></span>
</td>
<td class="nump">33,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">726<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(2,014)<span></span>
</td>
<td class="nump">65,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(7,049)<span></span>
</td>
<td class="num">(2,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(18,954)<span></span>
</td>
<td class="num">(9,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">9,659<span></span>
</td>
<td class="nump">4,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">14,736<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">157,751<span></span>
</td>
<td class="nump">293,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(9,925)<span></span>
</td>
<td class="num">(3,516)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(433,154)<span></span>
</td>
<td class="num">(518,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">548,973<span></span>
</td>
<td class="nump">271,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">105,894<span></span>
</td>
<td class="num">(250,586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,938<span></span>
</td>
<td class="nump">14,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(20,941)<span></span>
</td>
<td class="num">(2,434)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(3,003)<span></span>
</td>
<td class="nump">12,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">260,642<span></span>
</td>
<td class="nump">55,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">268,137<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">528,779<span></span>
</td>
<td class="nump">370,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">11,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">$ 804<span></span>
</td>
<td class="nump">$ 1,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991957976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our drug discovery and development capabilities and commercialization platform are the foundations upon which we intend to bring to market novel, effective and tolerable therapies to provide cancer patients with additional treatment options.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>four</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>Two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, our flagship molecule, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Our cabozantinib products are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma and previously treated hepatocellular carcinoma; and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. For these types of cancer, cabozantinib has become or is becoming a standard of care. Beyond these approved indications, cabozantinib is currently the focus of a broad clinical development program and is being investigated both alone and in combination with other therapies in a wide variety of cancers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended July 3, 2020 and June 28, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended June 30, 2020 and June 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Such reclassifications did not impact previously reported total revenues, i</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ncome from operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2020, we received the 2020 preliminary fee notice from the Internal Revenue Service for the Branded Prescription Drug Fee for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accordingly, we recorded an adjustment to increase selling, general and administrative expenses and our accrual for these fees by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$5.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the three months ended March 31, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. T</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">his adjustment resulted in a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.02</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> decrease in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">basic and diluted earnings per share</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our total accrual for the Branded Prescription Drug Fee was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$15.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$4.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was recorded in other current liabilities, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was recorded in other long-term liabilities. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Accounting Standards Update (ASU) No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Revenue from Contracts with Customers </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investment Impairment</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#8217;s impairment </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">is due to credit-related factors or noncredit-related factors. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Credit-related impairments on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">debt securities available-for-sale </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">are recognized as an allowance for credit losses with a corresponding adjustment to o</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ther income, net in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Condensed Consolidated Statements of Income. The portion of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">impairment that is not credit-related is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded, net of applicable taxes, as a reduction of other comprehensive income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade receivables, net</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> contain amounts billed to our customers for product sales, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">amounts billed to our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration partners for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">development, regulatory and sales-based </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on the sale of licensed products</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">profit-sharing arrangements, development cost reimbursements, and payments for product supply services</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to estimate credit losses and consider our historical loss information, adjusted to account for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which happens at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from non-refundable, up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit-sharing Arrangements: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Royalty and Sales-based Milestone Payments:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and clarifying and amending existing </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993397160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>229,898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>482,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>464,168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(51,168</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(46,743</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(109,854</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90,912</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>178,730</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>372,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,742</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>80,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>63,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>80,749</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>113,784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>82,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>259,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>486,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>173,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>189,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>362,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>364,905</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>178,730</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>372,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen Pharma SAS (Ipsen)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of CVS Health Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of Optum Specialty Pharmacy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda Pharmaceutical Company Limited (Takeda)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>181,231</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>196,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>377,827</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>378,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,917</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,679</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>259,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>486,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,233</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>109,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(364</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(72,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(29,592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(110,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$13.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The current portion of the contract liabilities totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanying Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Significant changes in contract assets during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> include the impact of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> development milestone from Ipsen we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">determined was probable of achievement, which was offset by the impact of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone from Takeda which was recognized as revenues during the year ended December 31, 2019 and was achieved, invoiced and collected during the current period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$3.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$62.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$82.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues for performance obligations satisfied in previous periods as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$36.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$61.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Such revenues primarily related to milestone and royalty payments allocated to the license performance obligations for our collaborations with Ipsen, Takeda, Daiichi Sankyo and Genentech.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$71.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price was allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements - Cabozantinib Commercial Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for information about the expected timing </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to satisfy these performance obligations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991727880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib. Additionally, consistent with our business strategy prior to the commercialization of cabozantinib, we entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations receive payments for product supply services, development cost reimbursements, and/or profit-sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for additional information on revenues recognized under our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have also established multiple collaborations with smaller, discovery-focused biotechnology companies to expand our product pipeline. Under these collaborations, we may be required to make milestone and royalty payments, and for certain collaborations make payments for development cost reimbursements and/or option exercise fees. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a description of each of our collaboration agreements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. During the second quarter of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2020, Ipsen opted into and is now co-funding the development costs for CONTACT-01 and CONTACT-02, two phase 3 pivotal trials of cabozantinib in combination with atezolizumab in patients with previously treated, metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer, respectively, and the four remaining cohorts of COSMIC-021 it had not previously opted into.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51,546</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,208</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for both the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$18.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenues recognized in connection with a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> development milestone from Ipsen we determined was probable of achievement.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$46.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration agreement with Takeda. Under this collaboration agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,210</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues for both the three and six months ended June&#160;30, 2020 included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$23.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in revenues recognized in connection with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$31.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in milestones we achieved upon Takeda&#8217;s first commercial sale of CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma in Japan, as well as royalties earned related to sales of cabozantinib in Japan. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$25.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price was allocated to our research and development services performance obligation that has not yet been satisfied. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. We are required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties earned by GSK in connection with the sales of cabozantinib are included in cost of goods sold for sales by us and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$15.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$15.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with Zelboraf and Tecentriq (atezolizumab) as a treatment for BRAF V600-mutation positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,349</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998125480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsAndInvestmentsTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>527,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>266,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>528,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>268,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash equivalents consisted of certificates of deposit with original maturities of 90 days or less used to collateralize letters of credit. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">long-term </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">classification of restricted cash </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">equivalents is based </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon the remaining term of the underlying restriction</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,685</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,930</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>663,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>672,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>89,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,021,295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,386</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,529,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,540,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>752,295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,308,351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,384,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,388,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Interest receivable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$5.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Realized gains and losses on the sales of investments were insignificant during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,997</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All securities presented have been in an unrealized loss position less than 12 months. There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>17</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>9</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>720,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>789,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>311,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>522,551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsAndInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsAndInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991696392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>672,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>672,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,083,813</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,488,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,345,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,347,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994452136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">excess and expiring inventory were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154992012120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,941</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30,136</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>25,749,356</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> share for each share issued pursuant to a stock option or stock appreciation award and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1.5</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares for full value awards granted in the form of restricted stock units (RSUs). On May&#160;20, 2020, at our 2020 Annual Meeting of Stockholders, our stockholders approved the amendment and restatement of the 2017 Plan. The amendment and restatement increased the share reserve under the 2017 Plan by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21,000,000</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (the Additional Shares)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to adjustment for certain changes in our capitalization, which became effective immediately upon stockholder approval.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Additional Shares will be registered on a Form S-8 prior to grant</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>839,318</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> stock options with a weighted average exercise price of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$21.40</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share and a weighted average grant&#160;date fair&#160;value of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$9.74</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>16,655,274</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> stock options outstanding and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$30.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> unrecognized compensation expense. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>889,023</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs with a weighted average grant&#160;date fair&#160;value of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$21.43</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>4,774,852</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs outstanding and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$75.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> unrecognized compensation expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Stock options and RSUs granted to employees during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have vesting conditions and contractual lives of a similar nature to those described in &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Note 8. Employee Benefit Plans&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;color:#000000;">year ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018, in connection with our long-term incentive compensation program, we granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>308,365</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> performance-based stock options (PSOs) to our President and Chief Executive Officer. In addition to the standard service-based vesting conditions included in our other stock options, these PSOs contain a market vesting condition such that they may not be exercised until, at any time after the grant date, the closing market price of our Common Stock is equal to or greater than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>125%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the per share exercise price of the PSOs over a period of at least 30 consecutive calendar days. This market vesting condition was achieved during the three months ended June&#160;30, 2020. The stock-based compensation expense for the PSOs is being recognized on an accelerated basis over the service period of the award, which commenced on the date of grant. The achievement of the market vesting condition did not impact the compensation expense recognized during the period.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there were&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>4,343,852</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> performance-based restricted stock units (PSUs) outstanding with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$79.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. Of the outstanding PSUs, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>237,945</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> relate to awards for which we achieved the performance target during 2019 or had determined during 2019 that it was probable that we would achieve the performance target during 2020. During the three months ended June&#160;30, 2020, we determined that it had become probable that we would achieve an additional performance target for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>98,653</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional PSUs granted during 2018 resulting in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense during the period. For more information about our PSUs, see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Note 8. Employee Benefit Plans&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994446008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>17.2%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>18.0%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>20.8%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>18.7%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparable </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> differed from the U.S. federal statutory rate of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;primarily due to excess tax benefits related to the exercise of certain stock options during the periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991775336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66,821</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>115,433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>154,817</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>307,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>302,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>301,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>318,144</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>316,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities included stock options, RSUs, PSUs and ESPP contributions. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSOs and PSUs for which the contingent vesting condition had not been achieved. These excluded potential common shares were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Anti-dilutive securities and contingently issuable shares excluded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,812</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991969928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets.&#160;MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets&#160;prior to&#160;expiration of the two previously-unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284.&#160;On May 11, 2020, we filed a complaint in the United States District Court for the District of Delaware for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These two lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The sale of a generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140155077151784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;25, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2020, which is a 52-week fiscal year, will end on January 1, 2021 and fiscal year 2019, which was a 53-week fiscal year, ended on January 3, 2020. For convenience, references in this report as of and for the fiscal periods ended July 3, 2020 and June 28, 2019, and as of and for the fiscal years ending January 1, 2021, and ended January 3, 2020, are indicated as being as of and for the fiscal periods ended June 30, 2020 and June 30, 2019 and the years ending December&#160;31, 2020 and ended December&#160;31, 2019, respectively. Similarly, references in this report to the first day of the fiscal year ending January 1, 2021 are indicated as being as of January 1, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Such reclassifications did not impact previously reported total revenues, i</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ncome from operations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, net income, total assets, total liabilities or total stockholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div>In March 2020, we received the 2020 preliminary fee notice from the Internal Revenue Service for the Branded Prescription Drug Fee for the 2018 sales year, which resulted in an increase in our estimate of such fees for the 2018 and 2019 sales years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Accounting Standards Update (ASU) No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as part of revenues under Accounting Standards Codification (ASC) Topic 606,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Revenue from Contracts with Customers </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(Topic 606) when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 precludes entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic 606, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. Upon adoption of ASU 2018-18, we have presented revenues from performance obligations associated with our collaboration arrangements that are within the scope of Topic 606 (license revenues) separately from revenues from performance obligations that are not subject to Topic 606 (collaboration services revenues). The adoption of ASU 2018-18 was applied retrospectively, and prior periods have been restated to conform to the presentation prescribed by ASU 2018-18. The adoption of ASU 2018-18 did not impact total revenues for the prior period presented in the accompanying Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-04 simplifies goodwill impairment testing by eliminating the second step of the impairment test. The amended guidance requires an impairment charge to be recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value under a one-step impairment test. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The adoption of ASU 2017-04 did not impact the accompanying Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2020, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, we will recognize our estimate of current expected credit losses </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as an allowance on financial assets measured at amortized cost, including accounts receivable, unbilled collaboration revenues, and investments classified as available for sale. Current expected credit losses were immaterial as of the date of adoption, and the adoption of ASU 2016-13 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Investment Impairment</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Quarterly, we assess each of our investments in debt securities available-for-sale whose fair value is below its cost basis to determine if the investment&#8217;s impairment </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">is due to credit-related factors or noncredit-related factors. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, issuer default on interest or principal payments, and declines in the financial condition and near-term prospects of the issuer. If we determine a credit-related impairment exists, we will measure the credit loss based on a discounted cash flows model.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Credit-related impairments on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">debt securities available-for-sale </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">are recognized as an allowance for credit losses with a corresponding adjustment to o</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ther income, net in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the accompanying Condensed Consolidated Statements of Income. The portion of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">impairment that is not credit-related is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded, net of applicable taxes, as a reduction of other comprehensive income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have elected to exclude accrued interest from both the fair value and the amortized cost basis of debt securities available-for-sale for the purposes of identifying and measuring an impairment. We write-off accrued interest as a reduction of interest income when an issuer has defaulted on interest payments due on a security.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accounts Receivable</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Trade receivables, net</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> contain amounts billed to our customers for product sales, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">amounts billed to our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration partners for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">development, regulatory and sales-based </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalties on the sale of licensed products</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">profit-sharing arrangements, development cost reimbursements, and payments for product supply services</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our customers are primarily pharmaceutical and biotechnology companies that are located in the U.S., and collaboration partners that are located in Europe and Japan. We record trade receivables net of allowances for credit losses and chargebacks, and cash discounts for prompt payment. We apply an aging method</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to estimate credit losses and consider our historical loss information, adjusted to account for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">current conditions, and reasonable and supportable forecasts of future economic conditions affecting our customers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Goodwill</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recorded goodwill amounts as the excess purchase price over tangible assets, liabilities and intangible assets acquired based on their estimated fair value. We review the carrying amount of goodwill for impairment annually and whenever events or changes in circumstance indicate that the carrying value may not be recoverable. We perform our annual assessment of the recoverability of our goodwill as of the first day of our fourth quarter. The assessment of recoverability may first consider qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of our reporting unit is less than its carrying amount. We perform a quantitative assessment if the qualitative assessment results in a more likely than not determination or if a qualitative assessment is not performed. The quantitative assessment determines whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognized for the amount by which the carrying amount of a reporting unit exceeds its fair value, limited to the goodwill balance.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment, which is also considered to be our sole reporting unit and therefore, goodwill is tested for impairment at the enterprise level. We did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t recognize any impairment charges in any of the periods presented.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaboration Agreements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We assess whether our collaboration agreements are subject to ASC Topic 808,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;(Topic 808) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic&#160;808, we apply the unit of account guidance under Topic 606 to identify distinct performance obligations, and then determine whether a customer relationship exists for each distinct performance obligation. If we determine a performance obligation within the arrangement is with a customer, we apply the guidance in Topic 606. If a portion of a distinct bundle of goods or services within an arrangement is not with a customer, then the unit of account is not within the scope of Topic&#160;606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and the recognition and measurement of that unit of account shall be based on analogy to authoritative accounting literature or, if there is no appropriate analogy, a reasonable, rational, and consistently applied accounting policy election. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We enter into collaboration arrangements, under which we license certain rights to our intellectual property to third parties. The terms of these arrangements typically include payments to us for one or more of the following: non-refundable, up-front license fees; development, regulatory and sales-based milestone payments; product supply services; development cost reimbursements; profit-sharing arrangements; and royalties on net sales of licensed products. As part of the accounting for these arrangements, we develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract. These key assumptions may include forecasted revenues, clinical development timelines and costs, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Up-front License Fees: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license, which happens at or near the inception of the contract. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenues from non-refundable, up-front fees. We evaluate the measure of progress at the end of each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Regulatory and Development Milestone Payments: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until uncertainty associated with the approvals has been resolved. The transaction price is then allocated to each performance obligation, on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development and regulatory milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Product Supply Services:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Arrangements that include a promise for the future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Development Cost Reimbursements:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Our collaboration arrangements may include promises of future clinical development and drug safety services, as well as participation on certain joint committees. When such services are provided to a customer, and they are distinct from the licenses provided to our collaboration partners, these promises are accounted for as a separate performance obligation which we estimate using internal development costs incurred and projections through the term of the arrangements. We record revenues for these services as the performance obligations are satisfied over time. However, if we conclude that our collaboration partner is not a customer for those collaborative research and development activities, we present such payments as a reduction of research and development expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Profit-sharing Arrangements: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of our collaboration agreement with Genentech for cobimetinib, we are entitled to a share of U.S. profits and losses received in connection with the commercialization of cobimetinib. We account for this arrangement in accordance with Topic 606. We have determined that we are an agent under the agreement and therefore revenues are recorded net of costs incurred. We record revenues for the variable consideration associated with the profits and losses under the collaboration agreement when it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Royalty and Sales-based Milestone Payments:</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> For arrangements that include royalties and sales-based milestone payments, including milestone payments earned for the first commercial sale of a product, the license is deemed to be the predominant item to which such payments relate and we recognize revenues at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2019, the Financial Accounting Standards Board issued&#160;ASU 2019-12,&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and clarifying and amending existing </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">guidance. ASU 2019-12 will be effective for us in the first quarter of 2021 with early adoption permitted. We are currently assessing the impact of ASU 2019-12 on our financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The allowance for chargebacks and discounts for prompt payment is recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenues in advance of the contractual billing schedule and such amounts are recorded</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> net of any allowance for credit losses, as a contract asset when recognized. Contract assets, which are presented in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$13.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. We may be required to defer recognition of revenues for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenues upon receipt or when due. Contract liabilities were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The current portion of the contract liabilities totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, are presented in other current liabilities and the remainder of the contract liabilities are presented in long-term portion of deferred revenues as of those dates in the accompanying Condensed Consolidated Balance Sheets. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and license revenues are recorded in accordance with Topic 606. License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with Topic 808 and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid to GlaxoSmithKline (GSK) on sales of products containing cabozantinib by our collaboration partners.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. License and collaboration services revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993158376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>229,898</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>482,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>464,168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(51,168</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(46,743</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(109,854</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90,912</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>178,730</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>372,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59,234</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,742</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>80,113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>63,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,671</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>80,749</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>113,784</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>82,506</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>259,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>486,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>173,610</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>189,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>362,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>364,905</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,784</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>178,730</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>372,610</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen Pharma SAS (Ipsen)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of CVS Health Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of Optum Specialty Pharmacy</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda Pharmaceutical Company Limited (Takeda)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>181,231</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>196,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>377,827</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>378,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,917</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81,953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,679</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>259,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>486,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,514</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,233</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72,874</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>109,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(364</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(72,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(29,592</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(110,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,258</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993358296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51,546</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,909</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,208</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div>License revenues under the collaboration agreement with Genentech were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,349</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,783</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,946</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration services revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,210</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994556200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>527,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>266,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>528,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>268,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>527,143</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>266,501</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash equivalents included in long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>528,779</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>268,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,685</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,930</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>663,491</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,527</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>672,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>89,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>462</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,021,295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,386</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,529,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,540,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>752,295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,308,351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,384,510</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,388,628</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,997</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross Unrealized Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,848</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,377</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>720,089</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>789,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>311,441</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>522,551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991918072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,930</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>672,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>672,868</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Municipal bonds</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,031,530</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,283</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>404,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,083,813</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,488,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>389,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>756,226</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government-sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total debt securities available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,312,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,345,197</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,347,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154997808808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,637</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,237</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154991937608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,941</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30,136</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993257720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 03, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66,821</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>115,433</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>154,817</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>307,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>302,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306,598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>301,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,394</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average common shares outstanding - diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>318,144</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>316,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.22</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share - diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.21</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.36</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">These excluded potential common shares were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Anti-dilutive securities and contingently issuable shares excluded</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,812</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,413</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993996472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 59,791,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,815,000<span></span>
</td>
<td class="nump">$ 122,731,000<span></span>
</td>
<td class="nump">$ 118,953,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_BrandedPrescriptionDrugFeeAccrual', window );">Branded prescription drug fee, accrual</a></td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_BrandedPrescriptionDrugFeeAccrualCurrent', window );">Branded prescription drug fee, accrual, current</a></td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent', window );">Branded prescription drug fee, accrual, noncurrent</a></td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products derived from cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember', window );">New information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Decrease in earnings per share due to change in accounting estimate (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_BrandedPrescriptionDrugFeeAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Branded Prescription Drug Fee, Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_BrandedPrescriptionDrugFeeAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_BrandedPrescriptionDrugFeeAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Branded Prescription Drug Fee, Accrual, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_BrandedPrescriptionDrugFeeAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_BrandedPrescriptionDrugFeeAccrualNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Branded Prescription Drug Fee, Accrual, Non-Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_BrandedPrescriptionDrugFeeAccrualNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=exel_NewInformationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998501192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">259,479<span></span>
</td>
<td class="nump">240,275<span></span>
</td>
<td class="nump">486,394<span></span>
</td>
<td class="nump">455,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">178,730<span></span>
</td>
<td class="nump">193,675<span></span>
</td>
<td class="nump">372,610<span></span>
</td>
<td class="nump">373,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">229,898<span></span>
</td>
<td class="nump">240,418<span></span>
</td>
<td class="nump">482,464<span></span>
</td>
<td class="nump">464,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="num">(51,168)<span></span>
</td>
<td class="num">(46,743)<span></span>
</td>
<td class="num">(109,854)<span></span>
</td>
<td class="num">(90,912)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">80,749<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">113,784<span></span>
</td>
<td class="nump">82,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">37,742<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
<td class="nump">63,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 21,515<span></span>
</td>
<td class="nump">$ 8,858<span></span>
</td>
<td class="nump">$ 33,671<span></span>
</td>
<td class="nump">$ 19,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998433960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">178,730<span></span>
</td>
<td class="nump">193,675<span></span>
</td>
<td class="nump">372,610<span></span>
</td>
<td class="nump">373,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">173,610<span></span>
</td>
<td class="nump">189,015<span></span>
</td>
<td class="nump">362,826<span></span>
</td>
<td class="nump">364,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 5,120<span></span>
</td>
<td class="nump">$ 4,660<span></span>
</td>
<td class="nump">$ 9,784<span></span>
</td>
<td class="nump">$ 8,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998675560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Revenue - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS (Ipsen)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited (Takeda)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998171528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">181,231<span></span>
</td>
<td class="nump">196,347<span></span>
</td>
<td class="nump">377,827<span></span>
</td>
<td class="nump">378,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">52,917<span></span>
</td>
<td class="nump">22,249<span></span>
</td>
<td class="nump">81,953<span></span>
</td>
<td class="nump">44,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 25,331<span></span>
</td>
<td class="nump">$ 21,679<span></span>
</td>
<td class="nump">$ 26,614<span></span>
</td>
<td class="nump">$ 33,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998238328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2019</a></td>
<td class="nump">$ 26,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">109,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(110,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2020</a></td>
<td class="nump">25,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2019</a></td>
<td class="nump">7,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">72,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(72,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2020</a></td>
<td class="nump">8,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2019</a></td>
<td class="nump">3,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">8,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(9,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2020</a></td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2019</a></td>
<td class="nump">15,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">28,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(29,592)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2020</a></td>
<td class="nump">$ 14,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140155077248072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customer, liability, current</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">$ 36.1<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
<td class="nump">$ 61.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">71.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Reduction related to a milestone</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998635928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">259,479<span></span>
</td>
<td class="nump">240,275<span></span>
</td>
<td class="nump">486,394<span></span>
</td>
<td class="nump">455,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">52,917<span></span>
</td>
<td class="nump">22,249<span></span>
</td>
<td class="nump">81,953<span></span>
</td>
<td class="nump">44,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">37,742<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
<td class="nump">63,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">33,597<span></span>
</td>
<td class="nump">14,946<span></span>
</td>
<td class="nump">51,546<span></span>
</td>
<td class="nump">28,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">21,515<span></span>
</td>
<td class="nump">8,858<span></span>
</td>
<td class="nump">33,671<span></span>
</td>
<td class="nump">19,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 19,320<span></span>
</td>
<td class="nump">$ 7,303<span></span>
</td>
<td class="nump">$ 30,407<span></span>
</td>
<td class="nump">$ 15,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154995255960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Ipsen Collaboration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 71.4<span></span>
</td>
<td class="nump">$ 71.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 46.2<span></span>
</td>
<td class="nump">$ 46.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154995016840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">259,479<span></span>
</td>
<td class="nump">240,275<span></span>
</td>
<td class="nump">486,394<span></span>
</td>
<td class="nump">455,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">25,141<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">26,210<span></span>
</td>
<td class="nump">13,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">37,742<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
<td class="nump">63,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">22,946<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,946<span></span>
</td>
<td class="nump">9,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">21,515<span></span>
</td>
<td class="nump">8,858<span></span>
</td>
<td class="nump">33,671<span></span>
</td>
<td class="nump">19,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 3,264<span></span>
</td>
<td class="nump">$ 4,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998993032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda Collaboration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 71.4<span></span>
</td>
<td class="nump">$ 71.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_MilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement', window );">Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement</a></td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 25.1<span></span>
</td>
<td class="nump">$ 25.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_MilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_MilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998514232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998779128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CotellicMember', window );">Cotellic | Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">2,783<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 1,323<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154997703832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 527,143<span></span>
</td>
<td class="nump">$ 266,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash equivalents included in long-term investments</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 528,779<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
<td class="nump">$ 370,889<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994979048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">$ 1,021,295<span></span>
</td>
<td class="nump">$ 1,308,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">10,386<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">1,031,530<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost</a></td>
<td class="nump">1,529,944<span></span>
</td>
<td class="nump">1,384,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized gains</a></td>
<td class="nump">10,386<span></span>
</td>
<td class="nump">4,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized losses</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities</a></td>
<td class="nump">1,540,179<span></span>
</td>
<td class="nump">1,388,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">239,685<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">239,930<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">663,491<span></span>
</td>
<td class="nump">752,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">9,527<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">672,868<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">89,890<span></span>
</td>
<td class="nump">166,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">90,352<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, amortized cost</a></td>
<td class="nump">28,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, gross unrealized gains</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, fair value</a></td>
<td class="nump">28,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="nump">40,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">52,053<span></span>
</td>
<td class="nump">40,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</a></td>
<td class="nump">404,313<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">404,313<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost</a></td>
<td class="nump">52,283<span></span>
</td>
<td class="nump">32,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, cash equivalents, restricted cash and restricted cash equivalents</a></td>
<td class="nump">$ 52,283<span></span>
</td>
<td class="nump">$ 32,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154997762568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2020 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gain (loss) on sales of investments available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154995236344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 35,318<span></span>
</td>
<td class="nump">$ 17,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">27,850<span></span>
</td>
<td class="nump">14,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">2,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993176728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 720,089<span></span>
</td>
<td class="nump">$ 789,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">311,441<span></span>
</td>
<td class="nump">522,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,031,530<span></span>
</td>
<td class="nump">$ 1,312,464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994676504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 1,031,530<span></span>
</td>
<td class="nump">$ 1,312,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">1,031,530<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,488,126<span></span>
</td>
<td class="nump">1,347,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">404,313<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">1,031,530<span></span>
</td>
<td class="nump">1,312,464<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,083,813<span></span>
</td>
<td class="nump">1,345,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">239,930<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">239,930<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">239,930<span></span>
</td>
<td class="nump">389,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">672,868<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">672,868<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">672,868<span></span>
</td>
<td class="nump">756,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">90,352<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">90,352<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">90,352<span></span>
</td>
<td class="nump">166,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">28,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">28,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal bonds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">28,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">404,313<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">404,313<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">52,283<span></span>
</td>
<td class="nump">32,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 52,283<span></span>
</td>
<td class="nump">$ 32,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994953256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">15,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">22,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">16,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 5,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140155077249480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 16,154<span></span>
</td>
<td class="nump">$ 15,079<span></span>
</td>
<td class="nump">$ 30,136<span></span>
</td>
<td class="nump">$ 27,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">5,138<span></span>
</td>
<td class="nump">11,198<span></span>
</td>
<td class="nump">9,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10,042<span></span>
</td>
<td class="nump">$ 9,941<span></span>
</td>
<td class="nump">$ 18,938<span></span>
</td>
<td class="nump">$ 18,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154993954344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 20, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,749,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,749,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in share reserve under 2017 plan (in shares)</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,655,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,655,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,154<span></span>
</td>
<td class="nump">$ 15,079<span></span>
</td>
<td class="nump">$ 30,136<span></span>
</td>
<td class="nump">$ 27,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,774,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,774,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember', window );">Performance Share Options (PSO)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises', window );">Share-based compensation arrangement by share-based payment award, options, percent of common stock share price triggering PSO exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,343,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,343,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceShareOptionsPSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154994019032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">20.80%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998232312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">307,807<span></span>
</td>
<td class="nump">302,188<span></span>
</td>
<td class="nump">306,598<span></span>
</td>
<td class="nump">301,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">10,337<span></span>
</td>
<td class="nump">12,723<span></span>
</td>
<td class="nump">10,394<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">318,144<span></span>
</td>
<td class="nump">314,911<span></span>
</td>
<td class="nump">316,992<span></span>
</td>
<td class="nump">314,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140154998199592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Anti-dilutive securities and contingently issuable shares excluded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">10,413<span></span>
</td>
<td class="nump">5,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&;EV?S#H])W!T'HIPRK\G^*N/8;UB9^N46Y#5O;V285 980*5Z>X*>>KI=M
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M;].&XC@3YP+<-WTVW/3_R!?U/N55P>W;*1MNIS\;7('L!IFW04!@/(Z]/HO
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MB%0NTSJI&BKK]FR2 ['JV,QVH-NOW[$3,MH"J[87[&.?[SL7'[X,ME(]Z0+
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M3+)-43'HRE^=9*1G)O(2,YTZOE"JAH.X<3;TMWL8X)5I>5$-PY^TJ:<?S50
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MM=C;KSL.<[TT O#[1@C]]& .Z/X]<?4_4$L#!!0    ( +B!!E'Z#5^4S1P
M ,56   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULY5QK;QM'EOTK#4\P
ML &2EN1''#L)("NR1S.QY;'LR<PN]D.QNTBVU>QB^B&:^?5[[J,>3;9D9X+Y
ML%@@<$2RNNK6K?LX]U']_=8UU^W*VB[[O*[J]H=[JZ[;/'_XL,U7=FW:F=O8
M&K\L7+,V'3XVRX?MIK&FX(?6U<.3HZ.G#]>FK._]^#U_]Z[Y\7O7=U59VW=-
MUO;KM6EV+VWEMC_<.[[GOWA?+E<=??'PQ^\W9FFO;/=Q\Z[!IX=AEJ)<V[HM
M79TU=O'#O=/CYR\?TW@>\(_2;MOD[XQV,G?NFCY<%#_<.R*";&7SCF8P^-^-
M/;-511.!C%]USGMA27HP_=O/_HKWCKW,36O/7/5+672K'^X]NY<5=F'ZJGOO
MMG^QNI\G-%_NJI;_S;8Z]NA>EO=MY];Z,"A8E[7\WWQ6/GS- R?ZP G3+0LQ
ME3^9SOSX?>.V64.C,1O]P5OEIT%<6=.A7'4-?BWQ7/?C9;,T=?F;$1;5178E
MIY.Y1795+NMR4>:F[K+3/'=]W97U,GOGJC(O;?O]PPX$T#0/<UWLI2QV<LMB
M3[,WKNY6;79>%[88/O\0A ?J3SSU+T_NG/"O?37+CAY-LI.CDZ,[YGL4N/&(
MYWOT%=R89&>N;K'7(C+G76-;6W?R!3CTJJQ-G9>FRJ[PI86P=FWVWZ?SMFL@
M;O]S!T6/ T6/F:+'MU'T_O7IVXO_.OUP<?DV.WW[4W;U\<V;T_?_RBY?95<7
MK]]>O+HX.WW[(3L].[O\^/;#Q=O7V;O+GR_.+LZOQL[G/[98-A"D\\^V*C^7
M[22[J/-9=C]^WMI)YOHF<TW6MP^RL@5?,U=#C-UR-UTXB+PMLGGI.INO:OXV
MR]UZ8^I=UJU,EX&U4.,VZQPT.H=V-V \?K)94;:YN['-;@*UO(&YV=!Y\+EA
MAK5MZ* \A3B\&B9C;0O(<HWY8-\PPP+B#GV>=F[:P<9U&80_MTT[RRY!=-'T
MR[@,SYRNE)N-F9=5V4$Y;EEV4YF.+&EF&B%Z :T2 6NS?H,1VU69K\"FK*P[
MBSFPSWE#:H<_H)C7L-,UEJ\FF5TL+-LT7JMSQ(IYQ=,V9E,*CS:-NRD+J_O(
M-EB*A71;=JO,%$5)2T-^>;>\"[=A:F90?SQ"E&QMHX3B:,HZ._[NN\<3^J*A
MZ8L^QWQ0#/"-Z%PT;LU''!D%2EV#02L#8O'($J/IF+M5X_KE*LLAB# S5<K-
M":;,+797X(]E#[XY8OF&-H21M&7;=MAP">-79"9A-I8@-<V)A]F-:4K7M]G2
M8EFS6?'9-+09YC]\1E7,L@];QT=2V(:7Y$WD9NY^,V3TRKE([:(RRW95;K(U
MN U!@3!#?,MZ5<Y+T$=2M28V;.@8=HUK(5K9-8Q$BU7!SJHOB$5OSC],LM-_
M_CS)_G'^^A5O=(/'16C>GW\0:4N7CXP&E<^SL].7EYCD7__\\Y^.OWW\(KN?
MCGV0$5LLC65NT79 FREN2 :(G73@4!W\8\"PVJT-KPRVW1"OJIV( \:N+"3&
MT5B<0!/'O^ 'SHB(]Q=_'Z<"Z@"9L'MD^.,'FR=0O\ZT9$YSTL2^JLCS="MP
MKBQ49&<9O"\=54LLW6 Z,%E^F@Q9M#)M-K<0 TO6I=0/Q&\#JP%Z35/(PXV=
M92_MSHD,8.) 85G#'H@Z[LV.^?*^ >\Z8@]K+FP5S6>@H,X4HU(LVS5K9A>3
M1/24-2Q85RZ9Q7-'FEBY6O08(@NJYY 9-ABLIXY4.M%KC#&$$RQ+M^UVD2?0
MVP\@3I_8NM^IH2)=EQ_.?X99#\?JYL!A<JJ' O_F_&^3R$"<P<8TW4 3TOU
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M4"<ARZ4H+.50AH(0]-?;IW;$0#$!C.+G)K]6#K'E])8T\&F]"=+)ZQKF&!G
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MLB7F-4H?%.AOX44P)MP D,!C%$[@Z=;IE6Y:^*"EUO>HW2:XLX$#.",;^'X
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M?%TC6VTJHI)HY,%UW:O2)^-R(:I6B>K! ^.^*>RC2M$;!2Y' X0WA?P&1W:
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M>33>@=]OB=S#Q0<8_CE6_P%02P,$%     @ N($&4;]B];4@"   HQ0  !D
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M1D^"_+K2'LGW,/O%P9_[2MS)+5P,4$="^B:A@?ME5=6(YQV8$DE!TCBS5Z8
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M[ @;/HF%"V_6_!EJ;KPW)2]72N+M@3;@^<( HN:"%.R_2U[\'U!+ P04
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*U6WV_C-@S^5PCC'C;
MC7\G3I$$2-L,UP/:"YJ[W<.P!\5F8J&VY$ERT_[W1\E)F@Y-@1OV(DH6^>DC
M*9&>[*1ZU!6B@>>F%GKJ5<:TET&@BPH;I@>R14$[&ZD:9FBIMH%N%;+2&35U
M$(?A,&@8%]YLXKXMU6PB.U-S@4L%NFL:IEZNL):[J1=YAP\/?%L9^R&835JV
MQ16:[^U2T2HXHI2\0:&Y%*!P,_7FT>55:O6=PI\<=_ID#M:3M92/=G%;3KW0
M$L(:"V,1&(DGO,:ZMD!$XY\]IG<\TAJ>S@_H?SC?R9<UTW@MZQ^\--74RSTH
M<<.ZVCS(W6?<^Y-9O$+6VHVPZW63T(.BTT8V>V-BT'#12_:\C\.)07[.(-X;
MQ(YW?Y!C><,,FTV4W(&RVH1F)\Y59TWDN+!)61E%NYSLS.R>\GXK"MD@+%'!
MJF(*)X$A9+L?%'N4JQXE/H,RA#LI3*5A(4HLW]H'Q.A(*S[0NHH_!/S2U0,(
M$Q_B, X_P$N.;B8.+SF#MV!*<+'5KT["7_.U-HINQ=\?X*='_-3AI^?"N/@&
MM_?77^\6L%P\P.KS_&'Q7AA_'05LAGB?H9;(:T?^PEY%7@ 3)92\[@R6/NR0
M=DBQM4M@&C:RID>GX3<NP%2RTZ2N?<#G EMS@L8:V0FC?[^$;Y5"?)-,^-()
MA"3T8<6?S^S8)-$0C4]F]UV#BAFI+D\]^ 3#H9_'$4U&8S],8YI$4>:G26)G
M6>KGT0AN4$BZZ[WU#_>PL+Q@3P2X=1XV])X==0U4:+0AORB[QZ@DX<C/PQ')
MV(_RG.30S\961GXRS.#&1HR* 6@L.L4-)YPH])-D!%'LC^+$K<8I1(F?$ME?
MHK!/!R11[D=I2C+UQU%$<NB/Q[%;C_+AQWG]!.$@CGLQ="+)G<BB<X:'<YU-
MU(NL-^T1TO&[CA-4W=ET4JTI'D&VMEK2+7E8?:=Q2:.[98O5<DE^"Z/XNG,J
M [A&9:CN0RL-"L-9_:_ N M)MZW'WRC94*P4%*PNNIJYJBPWI/4?HKO&@G6:
MT+FI* @TO%#][^H2*H*A@1X U7QB=5$>G,;-AGH!$+1X+X3R &-9*R2"=(Z1
M!QZ._G+UM0^'BPOU1-A5O*BLH0L.D:1(P!-J.[6?2N[\M(2$-,0;;2NJ.#YA
M.:#WAOHD1!\&\MR#_E^?[?Q-Q$ZNB77ZU</Z!;C6'5O7>.!X="*G-QQ#YH^3
MS+ZC-$IH,8RS]\IL<-*YJ%YL77_6=!#5H[Z)';\>?P'F?>=[5>__'^Z8VG*A
MH<8-F8:#4>:!ZGMROS"R=7UP+0UU53>MZ#<&E56@_8VDZ.\7]H#CC]'L)U!+
M P04    " "X@091H$<>,,(&  "U$   &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q."YX;6S-6-MNXS80_17"!8H64&U'<=;)-@G@7-JF0)R@SO:"H@^T-++8
M2**6I.+-W_?,Z)*DNS$6VY>^Q))(SIPY<V9(YGAKW;W/B8+Z4!:5/QGE(=1O
M)Q.?Y%1J/[8U51C)K"MUP*O;3'SM2*>RJ"PF\73Z9E)J4XU.C^7;K3L]MDTH
M3$6W3OFF++5[/*/";D]&>Z/^PR]FDP?^,#D]KO6&5A3>U;<.;Y/!2FI*JKRQ
ME7*4G8P6>V_/9CQ?)OQJ:.N?/2N.9&WM/;]<I2>C*0.B@I+ %C1^'NB<BH(-
M <;[SN9H<,D+GS_WUG^0V!'+6GLZM\5O)@WYR>API%+*=%.$7^SV)^KB.6![
MB2V\_%7;=NY!/%))XX,MN\5 4)JJ_=4?.AZ>+3B<OK(@[A;$@KMU)"@O=-"G
MQ\YNE>/9L,8/$JJL!CA3<5)6P6'48%TX/;=E:0)8#E[I*E7GM@JFVE"5&/+'
MDP 7/'&2=.;.6G/Q*^;>J&L8R+VZK%)*7ZZ? -J +^[QG<4[#?[<%&,UW8]4
M/(VG.^SM#_'NB[W]+XE771B?%-8WCM2?B[4/#J+Y:X?7V>!U)EYGKWF]N;Z^
MNKN^7-ZMU&)YH<YOEG=7RQ\OE^=7EZM/L?P?S*FK2JVH#E2NR8&VO:-(;0D%
ME!#TGRJM*AM,0JJ@$###T4:[%!R #[58KQT]&!TP<8F2NG#-1BWJNC")EBKZ
M!OX6WZ*&UZ"19P6K0D[JAXN%6C^JZ]52W>8:Y9)0 R^Z\!$ )6/U#8:^C>#M
M?4,^B+NZ=O9!%VP"#>$>'4@K9(*<2=0#.:E[FZGSQ=G-]>7='[^KH-< [<?L
MYNNO#N.]^?=>F<H$ RLOHS)54C2IA'NKG=XX7>?JZE>5D LFZZ/9FI #DJ_1
M(QB&;9QZ-UZ-L29 (FIIX>PP.IS/H_G\3:2.HGD\B_9G<:3VIM%T?X:A?=&1
MO&+X8 ZV<Y/D2D-$A?',D:F$HX4$C'=A]=;9M$D@0P%QEQ,@"F?J\GUCP LT
M2>H2#XV !9%@TW(G).=:YK47PS=.0\+J#+WO<[A)3<I?%*,Q*>VF2&_0V7WX
M%RUC-8\.YD?1;([29 B)+6OK3>ARAG;)GFJ9'RG[;UJ9U=G1/(H/9PA+E11R
MF_+"QE.W:JQN*G63!"LR/HJ>I)R90A++/@N@"SW![Q N1E8!!J28 Z044..-
M"PH;F$P:/L/;!15ZRXGBP=8M;&6..P+WB"%ZUK7VGIF!<C^.I5,(DFX\S\B<
M+5]D@LN&@?.@)+PK&HER"55TU=J'R0[;. TDPA*% JBOMB%RUD1!&[8:<OUQ
MEIZ0&58#Q(3<LUXY_WVDJ8"XUH_JH.VS+QM&)YX^I-:1"2K7, 66T@ZDA"BB
M9)Z43E.1 ^3WNKQ07G=<&;RTXI[:M@?_Y<T!JC:<::OH0VV<[A7)M(6MQ3#Z
MFVU\\?A=4[50@?_)3*L"__9UP0M_K\IYX')O[QF9_SO)?F8TKPNZS_Q.83,/
M<=SS\(6:)HUNBLB_-(3=RE\20*/TX("[_X#"MRC(OV3W(QQ0\.?L"F/>EE\Z
M$&%P)CW1/1P@[M(B:"MX'!6&LH@W9>M2<BT73!1E&<E95J4 P8AT]2@;\% T
MG=XE-UO;%*E:<YN7^14J0SL8%Y.M"E^6"@+?R7>T2R^?3,6P@;*S@J4N3+8;
MI3@'S_:IW1^R9/:GD9A#2S!2W!TGBJJ_+78V4"6*8F5V.6HU0\,>TK87WU8^
MZL8WK+SG%9)K\+@FJI"8REN(A,\^K6.-@0H 47O@-,=F*Q/Y8I0V+&,N09'X
M-(Y5V\D\]FWA<'>S>I$!QM15\K-$))(W;S:5=,LJ%(^X;B2X>2$>5A(:&57H
MEH*5-4,X@&'C)8:+R7P,DXGK!B5,'H++3*5QTD4TB+9MS[(:].,6XZ4(:G)]
M:[X*7#QR5+#>&TZ!:! ? VYF7+DIP1_N)=2FUMPC1;EM]W*$UE29?K!.LH<K
M(<1/?!C@$V#9B9?70?@-%Q>"DI-,I^G:,BD,%X=RX/F-$-]C>PR2M/<HY'=-
M8EZ#2Q<>V1A.J7]W)[L'-#)T_:ZX4-@PBF))B/CHVW*8H"Y+L-1UA&%S@*6G
MK>+I>&>0AZZ+6SY XT[+27->\/>DC]5*@LYZ83YS*N)#;[+%0Z\YCJ_[TAO/
MFH +2=3!:_N M(VGZ/#H@VZI:BK>8;G#F$X;#+[[)HE(=8G[MA]_ZF(S>7:5
M+,EMY,+L.:XJM+?*X>MP)U^T5]&GZ>V%_EH[%*0'V1F63L?S@Y%R[26Y?0FV
MEHOIV@9<<^4Q)XU>QQ,PGEGDOWMA!\-_*D[_ 5!+ P04    " "X@091?:4K
M]'H;   >6@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6SE7/N/VT:2
M_E>(N<7!!B1Y9AP[CE_ >-;.YK7Q9IS+'0[W T6V),846VF2(RM__=975?V@
M1&DFSMX/AP,6&X]$=E?7\ZM'Z^76NH_MRI@N^[2NF_;5V:KK-L\?/6J+E5GG
M[<QN3$/?+*Q;YQW]Z9:/VHTS><DOK>M'E^?G3Q^M\ZHY>_V2/WOO7K^T?5=7
MC7GOLK9?KW.W>V-JNWUU=G'F/_BI6JXZ?/#H]<M-OC0WIOMY\][17X_"*F6U
M-DU;V29S9O'J[.KB^9L+?H&?^(_*;-ODWQF.,K?V(_[XIGQU=@Z*3&V*#DOD
M])];<VWJ&BL1';_IHF=A3[R8_MNO_HX/3X>9YZVYMO4O5=FM7IT].\M*L\C[
MNOO);O]F]$!/L%YAZY;_/]OJL^=G6=&WG5WKRT3!NFKDO_DG9<1]7KC4%RZ9
M;MF(J?QKWN6O7SJ[S1R>IM7P#SXJOTW$50VD<M,Y^K:B][K7/[IEWE2_Y\*B
MILQN1#R9760WU;*I%E61-UUV512V;[JJ66;O;5T5E6FS!_Y?#U\^ZH@6K/BH
MT'W?R+Z71_9]FOU@FV[59F^;TI3#]Q_1&<)!+OU!WER>7/#;OIYEYX\GV>7Y
MY?F)]1X'QCSF]1[?@S&3[-HV+1VVC'QZ[TQKFDX^(&:]JYJ\*:J\SF[H0T.*
MV[79?U_-V\Z1YOW/"8J^"!1]P11]<82B-WE;M=AJ0,P8ZT^O\V%ER!@*N][D
MS0X"I?5*LC-3)BO3'Z,GJIJB[DN3=;I(CP^)IK>?3%U](OK FVYE6X-/;>^R
M[<K6]6YJMPVMV?;SMBJKW)'6S#*BA)ZC=:N._O[W?WMV>?'EBVS1-VRQM''1
M.V>:8I?1PMCQY]G-+"MIO=S-LJNZ)G(ZX_0H9)TU$6R4!I<W;<X+M=DJOS79
MW)@F(RK)BG"^V0F1/ DB>7(_D:3:,":1T\L<2*1O\KZL.I'(O6433TD.>I,[
M>JYJ>&%7@C'D6KJ5EQJVV3@29[6IB65+TQB7DZ#PO=ET\F[@.;E_X76USA9A
M[ZJ1L.!M8M.[MH>WZ&P&GYE=G$__P=]<N:XJ:D,?@%L_F65?RVLWT__$)]CH
MQI"X61/XE;>?BE7>+ T=?+VN6@X##V[>7C^<L3-R)9V@WDWPZHYT(FML%[23
M#N)7W:=Q86U'C](FSOS65V#2?">''.'!.+/ #4BK-IU)V-$&4<RR;QI6?KNI
M&G8@H"@O?R6'+K)Z4) XJY97MDW-_K8!H371!;7'%\D+#S-^H30@N#&DY2V\
M-"C)LT5>.<A\X)"P_1AM_ XXLR%IVK+U+]*Z48&4D>4L^Y$>RYE,>HQ"77R_
M6SECF*=M]2E;BSLW<.?9MWUCLL?GXHPSTD26CB>[HN-634F!!1'9"\HOWZWR
MCB(<F3.YAD\;BMZF#'ON3.ZP!^CY*RVWGAN7/;[0C>@A9@CY@D7?]<Z?D3W-
MY_L\'/'OK#)$@C.DW.W*]G4)"H&$8"DDG5_5;XF9@?V?L_3^2>G-O8->?)5-
M@H"P-[:Z:IJ>EO[);*SK2*."_7U'2E#3<TP4F]G;:_[>S%T/%;I\HMP[Y1"?
M!H?X]*0G>U>U!9'QGMD^Y@A/O_Z+$1W,2ROFESVYG$*L3QY/M\9\I+/P^LR<
M#=#'3O0EFBZQK,7Y<-1WCGB_RXJ:PE'+7BEA)9E$-LO>)0N""Q.*5U6Q0L#A
MS?=WI>\K,F7:!9M\FS?,0U' "W$P@Q4OOO(K;G->\O @$Q5SLI["F!FD"-6Z
M-4U%<=!, (0-0J)IQ3]7\&,L\YP#D;@X42'=P]NY-\TZK,]/LZU>/ILHL?CH
MZ%(@M_7VMW=X>54W&9YCPBY 3=[P^G/##NZ^- _<23/XA,Q!,(<9DG?H'B)]
M!Q8%QK;P->20ZMV,H.^Z(I"!^'*<XZ1/0K(C58*BJ2=+-6"<5Z?Y,7SX_)1=
M?AGL\LN3AO63*>J<8NB"G2ZYI3';/+W$M7$=97F(@R0K$5"6KP4!*E;X;!<;
M(X\+E-*SQ&'2?@1PSVQ!A)W?/PUZ)+6>[,SM'S4KJU+0 9%6='CGMK)]2W8@
M@N2-.HZ\9&B]:<F]9@V=A$3I[)J".(= +#6A(,8P@[Z<Z%NTF>E:_U==Y?.J
M%A@#G>8/*8TK/A(.IO =8"[01[<[)=QG0;C/3DKFQBS!1<(< >J,B??D(LC^
MG[?$'_/JC)GJ;LT9_+$<WG"<(9N;]RV]V+99JYNR^UU82E5-\+LE&8"]-8ZL
MIR26UG;#C\+^B'%K0NPD?I]T OA0\KXV9 U8FEU!62U(?H0'IIV==A1DNZP
MA"7S)DB"T+JJ#&<=1<\@XD<\;\B7YI(I%/R]#>"E-$4%"#E=YQ_QV#IO\J4B
M38H;%H8(PVXIF,+42=T$OP71 S^J.(M4G^?( 6:LXX3G<$X-M>0HTET%0UI
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M&/&15"L0S;-P,2;D/'E3B\'"61G0"Q#<,3J2*38& &FO(K3_15T/&P\\ X5
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MH?_Y/$Q*,!!.U742<6&>K'$AJY:&#K-2>@Q)#JU 3%AVB#(#6DK?/]X?FZ@
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MOE'N6!X?L KM%(QC<3Z'VD8/5<>5##_K"?- VAAK>U=^,F6/ R.3T.+4>)K
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M#F^C:N._<.AMHP VK;&JZ9V)05/);A6/?1W^C0/O';CGW07R+'\25BQF6AU
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MH74N]3LI415YB?[=7W9EM*3U"UHS1)ZF>.(\=5CBUY;X5DM6NL?K;_82Q<!
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MS0A[15]H2LV=ZJJ<9CLJXR9;XM%%B,AK,JOGGD]$'5SM(NH"MHFH ]=Z^NG
M'<E^A^%KC@&>/1].PU! Q*N#LGFO896V[)?8)DMZWF4HILFCGOTN>9IB[%P6
MQ=B!K=M.!Z[M:A:<CBO#Y^S5<U)S<#&%-(E"GC-5WL_KT;I8-RU*5#^-S_#=
M'!\97^"[H"S%-?1E9?"1B#5E$B40:U/N]:W.E:(LMI4=Q;.BFO3,E>)IT=P
MB4"8"?IYS+G:=8R!NN0Y^0]02P,$%     @ N($&417#Y@1( P  [PL  !D
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MOP>'2%:#<W6CQ=8.>DNAH=G:Y09^;!!I#.#Y6@A]N#$!FI\OXW\!4$L#!!0
M   ( +B!!E&#EDDA"P0   82   9    >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;,U876_;-A3]*X30AQ;8(I+Z#FP#B>UA&5HT2-KM8=@#8].64(GT2,KN
M@/WX41^1+(E6W'8!_&*+TCF7]]YSQ2MR<N#BBXPI5>!KEC(YM6*E=M>V+5<Q
MS8B\XCO*]),-%QE1>BBVMMP)2M8E*4MM#*%O9R1AUFQ2WKL7LPG/59HP>B^
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M+ZCVM!U@+MQWNW-^&9[/PI[S.0X\]7SRPWP]+7V@:L6$)AR6Z"H8C+!%JIY
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M(DJL8+L44M>!ZIQ $TY%46+^3OD*C07/H+V;*RJX$HQFV$#G&G[UK6\N.7J
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M&WZYNP&O7[T!KT!:@,]KOI%Z,CD9*>U;M<)HOO?C_<X/U.'''YOL$@3X J
M!8[AUR>&TZ)K^$A'Y! 6= @+JN?#'?/=L)EZ1)TR>0'>;35B.LO84%-G*&G&
MP#]_ZD'@@V*Y_->S)#XLB>LE2<>2C9!? &HMI[_+N5#I?VP!YEPJ5XAW"T3U
M A5_MU,8((B2<#+:-F/IL,-!C$-XL#M"0 X(R+D(G !6@DL)-H5.-UF-8Z73
MC'.O[-8)CX#@.&K!L*T(1!T8P@.&\'DQ9/J:.4&$EGM#V CQ#H/#*'8CB X(
MHB<A6-)4@"W--LSE=.2*/ QQT/+;88<A(A%Q.S\^.#_V.E^EHPLPKY(2^[9)
MM9L[/@@-2:1S56W^QXS5_JXQH/[=!J_SNZ:U;-#Z-*?&-M 0)0DAK8 X['!,
M0ABX Q(? A+_4@$YGZ/Q61RUK31'(W=,DD-,DE\[)MV<3\[AO,.H@_,P,#(>
M_$(Q<>I[X& *"> X:<%W&>(XCE!7$!JU#/0'@><Y$_.49J"D)1,>58:F$H"]
ME0+0U +PQ8N!_0K-,".<1'&[&'#8X3@)Q[CC;IAJ /95#D!;Z1&Q<-A&';D7
MFF( ]E8-0%OIVYKJ-3E&8(H!^)+5 +1E7N^AQ*H&'';>/63* 7BB'N"BY((J
M!F;<ZBN.YS2*"N/>"&TD"_HUZSD(;>M&%&&2M.7%83<.4;,+.&Z)C,8@O\8\
M'Z&1+0%)B,8M( XKG."."A,9E4!^E7A&4N]7:NE]FQTNJPYFH$:#BEZ0V/O)
MC_;2&,51W';=MAN'$>JJX) 1..07N"^7=Y?@LPZQW(B'NNI8\2T3105H*$M>
M2"YTZ/45$Z5(K?@?+VLT"9&^N(^,BJ"S5>1GN8]L:8B3.+%VFFT&HXC$7;O-
MR AZFHS\ /5MJ2 1:N-PM)?QN .$$1/D%Y/G)+[=[EGWPC89=J5@HUW(WPX^
MD?5V-Y8$.+2B[VCM(OVORWLC@L@O@K>;(IVGI2[/3ZDY-J*$@]Y.ZHR$X+,E
MY*?/ZFQ10+%6:7>,L=$%_#1=.)^IV,[]L+%7COUKG'*>W=D\E838[ER&'<=_
MV"@$?EK7XF<8=G0J,8X[RGAL) 3[):1J[WT[UR1R'/5&%Y-X<2^G>F?1RLZZ
M(0I"W$IQ#C,2)%VGE]CD9]S+<5T'39V [63=5B*OR3%0D\IQ+V=P'7QW K7;
M&@NHS^3XD8;1%]++P9KS*8?=W[CVJL/,LU>)$3'B%[%;7K 'D%/QE2FPW/@%
MF1@!(KV=EQ&C*L2O*CUF&&*K#@D(AM9M<YR_D:BCB"6-9VQ^?>H_PQ#?P=H>
MZ]EG;\1('CDM>?UF&'+ZB,YK<@S42#+Q]U8OF6$<S99SKSK.^;KWJM%]<D+W
MF>;2,IU3Q23@2[!@)9>I\C'>*"WI[12/&-4C/:G>&6G&UK(0H=BZ<[891N.N
M1RFAD;VP%]G[@303VC+79I_#I*,G#8T*AB>>&?6>9D*[\[. ^DR.@1I=#OV-
MX0NFF?W*T8F]ZC#3>Q6W#Z=&C;>9JE?);JE8Z1859&RIQP678QT6L7L[:W>A
M>%F_X#3C2O&\_KAF=,%$9:!_7W*N'B^J=Z8.[\A-_P=02P,$%     @ N($&
M455XMWH= P  ^@D  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULK59=
M;]HP%/TK5]$>6JEM(('0(D#B<^ND5E6K;@_3'DQR :N.36T'VFD_?K:39I1"
MX*$\$-LYY]Q[KAW;G;603VJ!J.$E95QUO876R[;OJWB!*5$78HG<O)D)F1)M
MNG+NJZ5$DCA2ROR@5HO\E%#N]3IN[$[V.B+3C'*\DZ"R-"7R=8!,K+M>W7L;
MN*?SA;8#?J^S)'-\0/VXO).FYY<J"4V1*RHX2)QUO7Z]/6E9O /\H+A6&VVP
M3J9"/-G.==+U:C8A9!AKJT#,8X5#9,P*F32>"TVO#&F)F^TW]8GS;KQ,B<*A
M8#]IHA==[]*#!&<D8_I>K+]AX:=I]6+!E/N'=8Z-(@_B3&F1%F2304IY_B0O
M11TV"&%]#R$H",$6(=A'" M">&R$1D%H'!NA61":QT:("D+D:I\7RU5Z1#3I
M=:18@[1HHV8;;KH<VQ28<KNP'K0T;ZGAZ=Z0J 40GL U7Z'29LEH!>=P2Z0D
M=L[A9(2:4*9..[XV\2S+CPOM0:X=[-$.X49PO5 PY@DF._BC:GY4P?>-S])L
M\&9V$%0*?L_8!=3",PAJ0>WQ800G7TYIZ7M'@L-#>OP"@DNK5[\J]';9_.2L
MQI^2U>2 "N%'9_5N,L)RY84N0+@GP,:".X,13K5;AN/GC.I7>, XDU135/"K
M/U5:FAWH=T701AFTX8(V]@;5*$U8LR?&2%=DRG#7NLY%(B=BM^95KQG6[*_C
MKS8G]DC<Y",N"M[CWKEIEFZ:E6Z^FH,#3IA0ZA3,+JT(,_42,Z ;WS)9F:_7
M^CPWI]"YA>PRW/R0X):%X4'$Z"!B7(5X5X"H+$!468#;+)VBW+9LBD(X9-P<
MM(S^P01LA6 I%'6'V5^H_+H&><CF1I;UUI;5PY#)1\C5;J^MTFNKTFN?F4L
MX3&"F4B()294.V>H=KEH'9S1@XC10<2X"I&[]#?.IA3EW-TB%,0BXSK?+,K1
M\J+2=^?SUOB@WA[6=XR/ZNUQ?@_Y+Y_?BFZ(G%.N@.',A*I=M,QLR/RFD7>T
M6+J3<2JT.6==<V$N9R@MP+R?":'?.C9 >=WK_0-02P,$%     @ N($&48H4
MK %$ P  "PP  !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULS59-C]HP
M$/TK5M1#*RTDS@>!"I"VK/JE5EHMN^VAZL$$ U8=.[4=:/OK.S;9D(6$K=0]
M[(78\;SQFYF78<8[J7[H#:4&_<JYT!-O8TSQVO=UMJ$YT7U94 $G*ZER8F"K
MUKXN%"5+!\JY'P;!P,\)$]YT[-Y=J^E8EH8S0:\5TF6>$_7[#>5R-_&P=__B
MAJTWQK[PI^."K.F<FKOB6L'.K[TL64Z%9E(@15<3[Q*_GN&!!3B++XSN=&.-
M;"@+*7_8S8?EQ LL(\II9JP+ H\MG5'.K2?@\;-RZM5W6F!S?>_]K0L>@ED0
M36>2?V5+LYEX0P\MZ8J4W-S(W7M:!918?YGDVOVB764;>"@KM9%Y!08&.1/[
M)_E5):(!P'$'(*P X;\"H@H0N4#WS%Q85\20Z5C)'5+6&KS9A<N-0T,T3-@R
MSHV"4P8X,YT1O4%$+-$'L:7:0(&,1CWTEC"%OA!>4G?X3DFMT9T H7#VAR[1
M)]A3C>3J >YR2Q@G"TY[H*_>G'"*&%1*'"/1M=3,5?'E%36 T:_@SKOY%7KY
MXA5Z84&W&UEJN%J/?0-A6K)^5H7T9A]2V!'2QY+W41!=H# (@Q;X[!$X$5UP
M'Y);9SBL,QPZ?U&'ORNZ,&A.LU)!R%1?'&5)0Y8N.A,$UEE6YB4GYO[HV^5"
M&P7R_WZ&7%23BQRYN(/<H<YM>=YC!PYK^\%V&B41'H[];3.=IU8XC=*TMGI
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M;F!:I\H:P/E*2G._L?-@/?]/_P)02P,$%     @ N($&44G[@Q>< @  108
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MFB)^6=*<1^T"Z'VAE'W;N%'2_7,,_@)02P,$%     @ N($&4?D[]-**!@
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M=Y4[KLP1P#(9I%E# .;D/'8-<7T8QTOSA>RG"V@G?K2W*=>WRA%@,8D'J1R
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M!=]BII^LN2B0TD.Q<>568)1944%=Z'FQ6R#"G/G4WKL5\RDO%24,WPH@RZ)
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MT&9,<<O"S*H@+<"\7PJA]QMKH)E^QS\ 4$L#!!0    ( +B!!E%T?JZ0E@4
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M0X9,A6!#;0*?4+*V\X#[#G0;NWW+^LD4G%(9L%D9&CEIT@E<Z@1^)3J!2YW
M_X-.X!8!&/D-G>@TJS.7.H'-.G%2P6OJAD,<TE+PN@WK^*7"8+/"?,="^%W>
M574*1X<FD)2*0<R*T4QO] ^ZGB]#MF&!Z0"F+.K$?AV93DH-(.9E^"E9DW==
MVZ(3?^2X^R<YG79U^,J)EEDM6B,V%7RFCZ1,TU-6?N*\DHB559B8J_!)$7,;
MD1@-/9?L!ZS++$,?5$[-]=<N'ZA8A"#>$7L&/ZOO0P<B^R8CNU%\E1ZDS[A2
M/$XOEXP&3&@#^/R9<[6[T6?SQ?=)DW\!4$L#!!0    ( +B!!E&64,S*<@(
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M+;F]5=N/4.?C!6:*&_]+MK5O%)"L-%:)&HP*!)/5ES[4=6@!D&<_(*D!R4M
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M.=K<TTH7]3&?M7^@IY]02P$"% ,4    " "X@091!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( +B!
M!E'HB/W.[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( +B!!E&97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ N($&4>54BY\X
M!0  8!4  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( +B!!E%\SC/PGP8  '$:   8              "
M@7L-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "X@091
M+T)%4*L"  #>"   &               @(%0%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ N($&42]1:@08!@  _1D  !@
M     ("!,1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M +B!!E$V+5#+/ ,  %,)   8              " @7\=  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "X@091M4>7I*@"  #D!@  &
M            @('Q(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ N($&48TG)@*?!P  'RL  !@              ("!SR,  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( +B!!E'RG2@GA 8  *H8
M   8              " @:0K  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "X@091^@U?E,T<  #%5@  &               @(%>,@
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ N($&48%PTB*X
M"P  HA\  !D              ("!84\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "X@091%TYCD7@*  "K'0  &0
M@(%06P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( +B!
M!E%R3[>'_ <  )H5   9              " @?]E  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ N($&4<[',5;'!0  W T  !D
M         ("!,FX  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "X@091:E((HP4#  !%!@  &0              @($P=   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( +B!!E&_8O6U( @  *,4
M   9              " @6QW  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ N($&45S)_3*V @  [P4  !D              ("!PW\
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "X@091:0%1
M>^H#   D"0  &0              @(&P@@  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( +B!!E&@1QXPP@8  +40   9
M  " @=&&  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MN($&47VE*_1Z&P  'EH  !D              ("!RHT  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "X@091_CDZ1QT&  !W#@  &0
M            @(%[J0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( +B!!E%C(ZT<7P,   4(   9              " @<^O  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ N($&4?NB+"H$!@
M5Q0  !D              ("!9;,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "X@0918<4*), #  #U"   &0              @(&@
MN0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( +B!!E$,
MH&Z2L0(  *P%   9              " @9>]  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ N($&44)<!#/= @  (08  !D
M     ("!?\   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +B!!E'7:^RQ(P0  /X4   9              "
M@1K4  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ N($&
M417#Y@1( P  [PL  !D              ("!=-@  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "X@091+:>FHH@$   >$P  &0
M        @('SVP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( +B!!E&I9K4&P@,  ,H,   9              " @;+@  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ N($&48.622$+!   !A(
M !D              ("!J^0  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "X@091>SO[>/4"  #T"   &0              @('MZ
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( +B!!E&D3^H4
M_@,   $2   9              " @1GL  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ N($&44,-*>[T @  ]@@  !D
M ("!3O   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "X
M@091=)1QK\\"  ">"   &0              @(%Y\P  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +B!!E$*,I?H,P,  !(*   9
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M970T,RYX;6Q02P$"% ,4    " "X@0912?N#%YP"  !%!@  &0
M    @($V"@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M +B!!E'Y._32B@8  ,<Q   9              " @0D- 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ N($&4:;SU9<] P  D@H  !D
M             ("!RA,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " "X@091DP45$$L#   )"P  &0              @($^%P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( +B!!E%T?JZ0E@4
M %L:   9              " @< : 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ N($&4990S,IR @  5 <  !D              ("!
MC2 ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "X@091
MK38*G*,#  !X#   &0              @($V(P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( +B!!E$?6B^EX (  ,('   9
M      " @1 G 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ N($&49;H+-A) @  N L   T              ( !)RH! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "X@091EXJ[',     3 @  "P
M@ &;+ $ 7W)E;',O+G)E;'-02P$"% ,4    " "X@091P5HHNB($   3(@
M#P              @ &$+0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MN($&4:&7ZI3) 0  H!X  !H              ( !TS$! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ N($&42BT:!/# 0  B1X  !,
M             ( !U#,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #L
,.P 4$   R#4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>251</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Ipsen Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Takeda Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsGskDetails</Role>
      <ShortName>Collaboration Agreements - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel2020063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel2020063010-q.htm">exel2020063010-q.htm</File>
    <File>exel-20200703.xsd</File>
    <File>exel-20200703_cal.xml</File>
    <File>exel-20200703_def.xml</File>
    <File>exel-20200703_lab.xml</File>
    <File>exel-20200703_pre.xml</File>
    <File>exel20200630exhibit101.htm</File>
    <File>exel20200630exhibit102.htm</File>
    <File>exel20200630exhibit103.htm</File>
    <File>exel20200630exhibit104.htm</File>
    <File>exel20200630exhibit105.htm</File>
    <File>exel20200630exhibit106.htm</File>
    <File>exel20200630exhibit107.htm</File>
    <File>exel20200630exhibit311.htm</File>
    <File>exel20200630exhibit312.htm</File>
    <File>exel20200630exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exellogo19q4a03.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel2020063010-q.htm": {
   "axisCustom": 1,
   "axisStandard": 16,
   "contextCount": 251,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20200703_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20200703_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel2020063010-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20200703_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20200703_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20200703.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 370,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 23,
    "http://www.exelixis.com/20200703": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 30
   },
   "keyCustom": 27,
   "keyStandard": 255,
   "memberCustom": 29,
   "memberStandard": 30,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20200703",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Collaboration Agreements",
     "role": "http://www.exelixis.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashAndInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Income Taxes",
     "role": "http://www.exelixis.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
     "shortName": "Collaboration Agreements - Ipsen Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember",
      "decimals": "-5",
      "lang": null,
      "name": "exel:MilestonePaymentsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
     "shortName": "Collaboration Agreements - Takeda Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-5",
      "lang": null,
      "name": "exel:MilestonePaymentsEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Collaboration Agreements - GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
     "shortName": "Collaboration Agreements - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
     "shortName": "Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_srt_ProductOrServiceAxis_exel_CotellicMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember",
      "decimals": "-3",
      "lang": null,
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InterestReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2020Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "INF",
      "lang": null,
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2020063010-q.htm",
      "contextRef": "FD2020Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accredo Health, Incorporated [Member]",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_BrandedPrescriptionDrugFeeAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Branded Prescription Drug Fee, Accrual",
        "label": "Branded Prescription Drug Fee, Accrual",
        "terseLabel": "Branded prescription drug fee, accrual"
       }
      }
     },
     "localname": "BrandedPrescriptionDrugFeeAccrual",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_BrandedPrescriptionDrugFeeAccrualCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Branded Prescription Drug Fee, Accrual, Current",
        "label": "Branded Prescription Drug Fee, Accrual, Current",
        "terseLabel": "Branded prescription drug fee, accrual, current"
       }
      }
     },
     "localname": "BrandedPrescriptionDrugFeeAccrualCurrent",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_BrandedPrescriptionDrugFeeAccrualNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Branded Prescription Drug Fee, Accrual, Non-Current",
        "label": "Branded Prescription Drug Fee, Accrual, Non-Current",
        "terseLabel": "Branded prescription drug fee, accrual, noncurrent"
       }
      }
     },
     "localname": "BrandedPrescriptionDrugFeeAccrualNonCurrent",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsAndInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Investments [Text Block]",
        "label": "Cash, Cash Equivalents, and Investments [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsTextBlock",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents and available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized gain"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents, gross unrealized loss"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EarningsPerShareDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Denominator [Abstract]",
        "label": "Earnings Per Share, Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDenominatorAbstract",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EarningsPerShareNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Numerator [Abstract]",
        "label": "Earnings Per Share, Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareNumeratorAbstract",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "label": "Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement",
        "terseLabel": "Reduction related to a milestone",
        "verboseLabel": "Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement"
       }
      }
     },
     "localname": "EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS (Ipsen)",
        "verboseLabel": "Ipsen"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_MilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone Payments Earned",
        "label": "Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "MilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NewInformationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New Information [Member]",
        "label": "New Information [Member]",
        "terseLabel": "New information"
       }
      }
     },
     "localname": "NewInformationMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceShareOptionsPSOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Share Options (PSO) [Member]",
        "label": "Performance Share Options (PSO) [Member]",
        "terseLabel": "Performance Share Options (PSO)"
       }
      }
     },
     "localname": "PerformanceShareOptionsPSOMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products derived from cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Percent Of Common Stock Share Price Triggering PSO Exercises",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, percent of common stock share price triggering PSO exercises"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsPercentOfCommonStockSharePriceTriggeringPSOExercises",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited (Takeda)",
        "verboseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20200703",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r165",
      "r240",
      "r246",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r165",
      "r240",
      "r246",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r162",
      "r240",
      "r244",
      "r369",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r162",
      "r240",
      "r244",
      "r369",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r240",
      "r245",
      "r401",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r240",
      "r245",
      "r401",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r51",
      "r53",
      "r54",
      "r389",
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r54",
      "r55",
      "r101",
      "r102",
      "r103",
      "r314",
      "r403",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r280"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r261",
      "r263",
      "r282",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r263",
      "r273",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r145",
      "r154",
      "r160",
      "r184",
      "r310",
      "r315",
      "r330",
      "r372",
      "r387"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r47",
      "r90",
      "r184",
      "r310",
      "r315",
      "r330"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Investments available-for-sale, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Investments available-for-sale, gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r168",
      "r191"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Investments, available-for-sale, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r173",
      "r175",
      "r384"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r173",
      "r174",
      "r383"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r167",
      "r169",
      "r191",
      "r376"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Investments available-for-sale, fair value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total investments available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r265",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r83"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r83",
      "r87"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r331"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r109",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r109",
      "r127"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r303",
      "r304",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r213",
      "r377",
      "r394"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 308,886 and 304,831 at June 30, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r64",
      "r379",
      "r396"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r328",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r328",
      "r329",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r328",
      "r329",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r328",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r165",
      "r328",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r218",
      "r220",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r218",
      "r219",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r218",
      "r219",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract with customer, liability, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r218",
      "r219",
      "r241"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r67",
      "r369"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r133",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r170",
      "r191",
      "r197",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Gain (loss) on sales of investments available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r179",
      "r192",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r180",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r178",
      "r195",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r181",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r143"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r240",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r380",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "negatedTerseLabel": "Decrease in earnings per share due to change in accounting estimate (USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r380",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r289",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r128",
      "r185",
      "r216",
      "r217",
      "r277",
      "r278",
      "r279",
      "r293",
      "r294",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r321",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r320",
      "r321",
      "r323",
      "r324",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r253",
      "r254",
      "r259",
      "r260",
      "r321",
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r253",
      "r254",
      "r259",
      "r260",
      "r321",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r325",
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r176",
      "r177",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r195",
      "r196",
      "r199",
      "r200",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r203",
      "r205",
      "r371"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r81",
      "r204",
      "r206",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r92",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r295",
      "r298",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r112",
      "r113",
      "r144",
      "r288",
      "r296",
      "r299",
      "r398"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r90",
      "r155",
      "r184",
      "r311",
      "r315",
      "r316",
      "r330"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r90",
      "r184",
      "r330",
      "r373",
      "r391"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r90",
      "r184",
      "r311",
      "r315",
      "r316",
      "r330"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r56",
      "r59",
      "r63",
      "r82",
      "r90",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r117",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r184",
      "r330",
      "r378",
      "r395"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r2",
      "r100",
      "r139",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r37"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r57",
      "r60",
      "r308",
      "r309",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r51"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains on available-for-sale debt securities, net of tax impact of $2,287, $413, $1,346 and $807, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r49",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized gains (losses) on available-for-sale securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r74",
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r93"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r208",
      "r393"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r19",
      "r26",
      "r392",
      "r411"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r285",
      "r423"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r87",
      "r413"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash equivalents included in long-term investments"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r217",
      "r280",
      "r390",
      "r406",
      "r408"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r185",
      "r277",
      "r278",
      "r279",
      "r293",
      "r294",
      "r403",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r239",
      "r240",
      "r369"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Revenue from contract with customer",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r134",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r230",
      "r243",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue not from contract with customer"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r62",
      "r90",
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r184",
      "r330",
      "r381"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r263",
      "r272",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r263",
      "r272",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r12",
      "r87",
      "r370",
      "r388"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r265",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Increase in share reserve under 2017 plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r267",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r262",
      "r266"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r16",
      "r374",
      "r375",
      "r386"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r128",
      "r185",
      "r216",
      "r217",
      "r277",
      "r278",
      "r279",
      "r293",
      "r294",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r128",
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r216",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r17",
      "r18",
      "r217",
      "r264",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r90",
      "r166",
      "r184",
      "r330"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r176",
      "r177",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r253",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r253",
      "r382",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r94",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at June 30, 2020",
        "periodStartLabel": "Balance at December 31, 2019"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL108322424-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r424": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r425": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r426": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r427": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r428": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r429": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0000939767-20-000117-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-20-000117-xbrl.zip
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M9<LOV)5UNAR=PYT,BJ#X82)>*!Z>M\GO97)065E\/\6#8;1LR8@8JQ@'41B
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MLQ##F_DUXF\2W1UJ#$1G<DJF@K#?"MM1;23BWK='=E[_<V5%S\.GLY,3VUZ
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MC)3! ?$D(BCWA C,#(Z$'KI#?.B4-5/ 5%)RK+/J[XQFO%$4S"_LM#$*T:3
MGB.&(JM%5J),<EQ2$\P [:&,C!AY\D? J-@Y2 A=SDP[^V#K_(Z"/:V7WQ^F
MVG0 LKE&1:71L"UR%)GE,#S&$8F*(1^$=I8&87VO%%;[% HC\\%X4!4\%KN\
M*M,92AL>,,MW9M[%Y?NT(S?2_5JJF!#)8ZT19CJ THX%*-B:(T."PP&HM6K
M;:LR1LC8[#,YA.7"FY>VGL?PTK9S4)"OWLAZ$5/MZ^W1S;LJ5T2GA"D,E6M8
M1C(FC+*.#>+5*8D%\9@,<'^5\:V/S#R3H%9L&^I>?]BVNW0%JJ"U,Y@ -BZ
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MA 0"1Y#6W#('M/)"0"_6"[X!]1>MSMP1W0K5<?$]CLQMT @ZD;P-STF<1YY
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M)4W>@8$F5#9G4:74^GK@O W&#\JO.Q!^'\=P+>:[U[/_K%V".*>"6(\P-1X
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M]XO[\&7TYZ=1F/1D-*UDSSQMGV!-+)+<B( 60]PAJ<TC;1A@BP>8%-.%\M\
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M'/M)#P @FJBD@P;-6L[N]DB=O.U^->]^'%NFEK:9Y%E.PR:B6$W2#NP>B9O
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M(QJ:^%^0C"%,*$TCQ &2O'UVM=&F. D #F'LHB!,*0E!%.QG+#Z(H/*40M7
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MSE.A[1H76W&@/MNN\JPZO &_?S[;];F8)2Y.0>*F&+(PB1 +$H#\""=A\MI
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M36>ZHA%VY]'QS+A26&A]:IT*K?^^J]J>?5-\S(3WXA7,K!9O1MUG;XN*_[D
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M_C#(;5'^V)5$>&GI:+KT78).R83<9&!F(JBVO#N3-)MGT?SB_(*E8E.5^0
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M)QDZHT$&:)V'")EPY&GQ05/<R&?T5<9_5CP)07BZM2F:VJ*=!BXH2 ,4)4F
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M.Q@ 1ZG2=,ZX<<L:\Q2D<@%\TUS+:=&D-*OIU5-\%WPV??^P+)>?\HVXNW+
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M0NRL!A=3/IV:ZQAD3&I N5G^EJV7_8 5X$B\R>5C1J+4QR#T7/[].(:N&]%
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M7Y\V.?_^#(C.T?PPS9?YPTU> =\5_^JB,\!M/.;+;?$]7RN^!J4>-?D"S%K
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M>W!5W&V*VV*9\=*&\$'475F)/VL5N'L66WS&G@6%*G.T6$M4^W,,LYI\O_0
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M75'Q+85TOEG EL,2F<$JU_ML<=ABO_"O_OV?^G_A_R=VWOW[/_U?4$L#!!0
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M/I]!C,7+;E9DP9<B['QF:\_.V_"+3?G8[ME'FM<?EGY=I+-).EF=F2X_+BR
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M;#:LJ;07!&Y%,WUG=3P"W2:KG[2?<*L-,- 1QA$$PE-J2AL].AGJL+JZX_%
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M*$]-O#VZEIH+7><EJ#Y/88U1K#EL.V;4H:6N+)(88I%5P9Q77$-JK'%<;B6
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M!"B]L9K[4O(PQ >6$Z-I.IS$MK,0/_NHG[D=%3?IY]'XS_GJN//&F@D&SU6
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M&M46C9KD6%^IF<+5-&R8L;Y2Q[T&,$[JP*CL69PTL'MVK>9'W_(%MI:\* 0
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M#?O&Z.VF>PB,=Z-,DWT8%L?'>]%MFL=]\YK7S/$@6&Q\YD-@LXF ]Y7-CXJ
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M5HPG:=1-S]4-7QPHQ0.?0!0XPO/5_P.$?63/U(WP$76"EM0-E+^0%M0-8FQ
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M"C0:R6(=E2#L.#1@U'%LF[F 81Q4ZQ: KYY64-+7O[D=IW=1Y)14W;71QW@
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MF(% N@!5!V[: ?)6*M>>C=.VHL<!8/U.X_0Z?ERRM:/H,A[&$[/11$__N_7
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M \&A](@KH?0#WX&0LGD7&HA6]AXM;8.UD]$+>B1H  @;4+*[5$0-<SOK>?3
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MI - ^@W+/N\U^ASE49@-KXMS[D?1EVB<WNH359\)TEY@<6F5E6.,71K81.+
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MKO(AQ^0&K05:)9FC%4K$%3Q=CF1 &/$]ANT96AT; KA2:_Q,M*[FZI^%5C2
MHM7^<0:M!JT=0RN">'$:&>,NX]BG%%%N<Y\AZ51K:*ZP5WHZMF!;?VL/K6Q
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M<JCM\+Z/ O10.KQ;:K/49JG-4INE-DMMEMIV;%E!2MOI") @CK# * XBC&C
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M&3QOPJS>9+N%ZWS$K:2US/M.W3B6VBRU66JSU+:_U+:.8B+:&)8(H>MZ'@7
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M4DU:*(<04)^1T,,>\D*.I&(=UD$\%H+5+6[7@/)A.E1S/G+QD$/8#DT!UED
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MJ*OG+%!9XME$Y-WDB]F12CG[?/;Y]O;YCJ^%P%+3@# =ZX1!!\/-&P<<8E^
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MSUN>/S">?[J[CDM VVI1Q*'O"X\A+_8A">+ 99KIJ0N0%_5:R^X!TV_;;XC
M2)#];<.S2P7;=MHY.@"Q*6.65"VI6E*UI+ISM4RT21:8QPAS$7DN\PA$-""A
M4<L$#E 8[<06LZK4ME6I \Z+U#;YR:4B-EV:6U/;)F>^RW'G>R:GGGGTO157
M1R65+'U:^K3T^:9^;$9)1W>BD>]R3AA$C%,_HG&51\YXX+K\"=WI(G_$N:15
MI\N'JM,7%4LLLWEZGA;?LG%J0ME?TG'^=::OHJ/:[\7OA<$(8G=(9<VB@T4'
M*[TL?5KZM/1IZ7-/Z7,-[8K#MHM;0(DG@!NQ"(4\@HP1S*M\/Q+RH%>E]V;:
ME=6(;/;@NK.Z_[*8I8X\;4=1SZO/%<MSG>2+RVG:'.SQ#O+F&'?GV(H BQ![
MW"4N99C@NN4,9Q%GKQODK?A^/^IX,> CSK<''"\AL/T<?+%7,+-/XWJ>/>B-
M .,PY_F\&G0/!F-IJY_% ?4802&"812P*,)N#.KZ3S_P^EG;:PS\&1A9-U?'
M!IT/:2'50JJ%5 NIJR&5M8GQ+,8",0_Y$75!"#V!<!U0\(BT@7<$J5O/>QTA
M5XR &+(1N@59"[(69"W(/@*RH@79B" ./1\*2J$;041B3FJ09;#?T&];(+O#
M]K)LQ,F@PR\MV%JPM6![O&#[='ZQ@&W95QAC/\08QQ!YQ&>0NG[=/M5C .\*
M;;<_5)T0/!*0[P7*;I2CO#?<9VO!+$);A-ZF.BQP"] $J"1&ER,>H0@S0 ,N
M*H"./1>M;JNS!D /,K>=8SS":,A6F(>FNNIX^A]U"_'F??UO9SE3*?E.KE.-
M9A"!/SRD7_  %=3KSB.HCM)IL0PDS5>RF41 \WI@,NX_\."/U+]IYQ;//F]W
M#3-%Q=.E6T)@!(<^&V><3J?5I__] 7S0K^6SC>O7*W;I(KM)2^<LO7.^Y#=)
M3\S<),77;&:6ERSF>?V&D5KZG;ML,K^6WY;[4U&O).EI<ENF/]5__/R05C\T
MZ1EM9A+^\'CVAKD'D;?XT&-!\QE__",X]$?L0.]UW'OXIN5K;Y8/N%<)@3W$
M%*^ >/7;2KA6:S6?J<O44*K?N3/H>BG5#0-44C?("YVTI_2!5*[@//ON_"J_
M>UTZD<3F23?%"HI]JX5\*V)R+2VM04LFE\#1*NZ19R-+S;S([]XN,[F_+YOI
MWWM+:VV0U5%15JE8.E6<]<TH[P4[;,GR4,FR#4LY9M[U4F#*,9$IYP<USFH3
M1YVE5$NIPU-JF%YEXVQNZ='2XYO1XT4N9;?3=8_J@CSVLV/<I-84V2?B>W_T
M90I3K%EBB6<387F3+V9O)Q_W-WYJG\\^WUL^WY'7PX;I6&?BF/W!4'MM^5LG
M@+RG8#[!N*W)@GX@W, #!& 8PB"."44FF.]%(H#X=76OD/^5[$?=*Q)BQ-F@
M=:_O*^R_5VCQWN7!@:8['4DV$\$4=D9[8Q+Z/B$4 N:#D'MN54'EDY#%T2;9
M3 /#WN9%J8.F\%N\LWAG\>Y=XAUKLS>1H'$<84@I@"+B*H>S:G3B8\S=7J.3
M+>%=&\S<5L4H=/D(0681T"*@1< C0, G*XP(%BT$^C[R)&8A-V*A1P3Q.:PA
MD(8$Q[N"P*'K.=<I.F)@?V<>[ TKV7HBBZ8639] 4]*IU_0I0QP$ ?-@%(4X
MY(A74[9]U_= ;Q[,EM!T^_6:G(,1=@=M06+AT\*GA<\#A,^GT;-33!EQGX6,
M>MB5^.DQ& 4(5^@)O9CZFZ+G(,64B+,1H3M!O/TTH0]X"M99.G<R;63L"+1V
MRH6;=[;?6W?- 0C"M3/Z+'U9^K+T9>G+TI>E+TM?[Y"^UK""*.2-%>3YC/I1
M2.+ %8*AR&^M(->-?/#0"I+*JW&0JZ*R_I@5*#898O<Z#])3AA0E(SYH)-(R
MH67"89@0LS8S@+HLY(!!#DB,@P!XJ&K/+V@<]GM)K\>$EG^./7G;% 6/EXJ"
M-_8\#+HO[T3E>O29]U8,'+(W?_VR1$NJEE0MJ5I2M:1J274]==R%;6$"<;D;
M"8\(Z >>1^36B;!.U$4!$P_5\<=RR)1V+E7U3U<7R??/>:%NZLWG17:YT'TF
M+_+/22%MX:&LZ%U.*4 C 0;MGVTAP4*"E5Z65"VI;B2]B&BD%R4P# @,D!1;
M#$5Q")NR.@"D^-J5]+)2YKC37$[+<J%;!^17R@6EFG66*H5*DL4D+9Q4JS+*
M'26)2#FFDMFD^L+MHAA?)V7JW$[E]0\Q268=ENY4CG&$W9ACZ/I!2$@0N$'@
M5ZT"8ARQU8-9U/ZGDW!1R ?]+)>13TS; /VO+[=WHIA><KQN/C.4$KJM)@(2
M"8:<\[JWLOJ81/)!L"DGK>3U?.("$H4^0)Z(@X@141>TNQRN+FCOL^G?DNDB
M?3LNW;CFW;*G9<]]8T\&<#NQ%R,O(I2&E$0(PYBA.*X;[G /KBX^?!/V]";;
M+=&&?(38041U+;^^(WZUJ6^6OBQ]6?IZK_2UCK[AMF$D$'L0^IA1RB,$6 "P
M5Z=6 DQI+XPTH+XQD([ A^QBM?\^M@/*_-*TY,P+^15S<*63E&4^SG0+_KML
M?NW,D^]IJ?^\3J<31U)RY9)+[I)BLHG;[:!=[(QW6G<BZD6>&R 7QQ3AT$6"
MB2@2 <$!)3#H<;9V?"E=/LZ+B^3[W]6FYU/UR/*-]^&0^T]:Y).DO.Z(V0/V
MR^\55.RKP#YL?A=NZSF ?D0C( (W$##R_%C@2/.[B]PP0KU&&][DWXMRKEBS
M_)+JA(R+?(_8?FV5P/*\Y?D#X_FGN^MP2-N@F\LDQT<LY*'+8Y\AZ@/-]!P&
M0D2]RJ@]8/IM^PW1B.!!!WP/VH5GE_JU;;1S=/AA,\8LJ5I2M:1J277G6AEK
M<RP\CP:$,A&'A*DNVC3F@=;*_#@&@+N[T,JL)K5E3>J LR*U17YRJ6A-%^;6
MQ':(68XV'O>NA8JE+TM?1TU?:WB)!6H++WSN"^QY4@VA'J%!B%VWCO<*Y >]
M_+*.:G*1/^*ZT9K)Y4/-Y(N*U)79/#U/BV_9.#6!XB_I./\ZTU?1,>-WXU5B
M(W?0,@_+W9:[K?2P]&7IR]+7X=+7.MH);WN,^9AQAGS*(Q<+^3\>^7[=Z"^
ML-?N_,VT$ZM1''GN6F?D]%\6L]3!0$^:%INXQ4QO^^K1\.UW9Y(O+J=IT]_^
M:$=14P#:)J 1A9"Z+O4\+PHC:=.X$:A'(0 _XJ\<12WY>C^J2#% (\;ID'[7
MC0EL/\<N[!7,[-.PF&</>B/ .,QI,J\&W8/!6-3J7\+G7@R82R,8<A8CZ+MU
M<3#W!._G#*\S;F989-U\VO6@@VHLI%I(M9!J(74UI)(V+1MY.!0HX"#V&*:<
M@M /ZH)N3$BO;?:6('7[69<(PI'K#MH)R8*L!5D+LA9D5X.LVX)LY O/%R3P
M7(FU?@S\,$1U4QM.0KPKD-UI<U,$ANR.8<'6@JT%VR,&VR?36RG@;=&1BX%+
M (@PI!QY*(Y"&-1> HA(SQ.[);3=_DAOANB($G<O4':C'-F]X3Y;BF01VB+T
M-M5A"%J AO*%STCH80]Y(4=2):YG T 6 K0I0 \R-9QP/G(QV@M0W4_55<?3
M_Z@;6#?OZW\[RYE*R7=RG6HT@PC\88F>H:+>SH)5]^*T6(8-4'\EFTF\,Z^'
M)-IJHYN]O+A.G62LJ@F2V;U<A3/+YVGI)(5JJNQD<H%?BV3JW";%7#5CEN93
MF3I!KA:GRA#D7_IT=&N8.)LELW$FO]YH"N7'Y8W4_YC]?;AU_8WY\+ZWUGU
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M(AQ_,3_+Y_],YY\E:6U3[>%@2*5G;W4;J\)8--@%&@C0B5Q!&!(*D?S$];$
M7E2-O_&"&,:]XKW-T6! 362$*3@$/-#ZQA_GR>4T;=[7_W:6,Y4JW\EUJKD;
M(O"'AP3V4/E0KSN/H!H=I<4RYS5?R682$<SK@8FP_\#K/-*>K+_21IL,CHOK
MU$G&X_Q&7O%>9?W-\KF:SU&HQGU2BYJG7XMDZMPFA6[L,[].R]0)<K4X53,H
M_](Y(;HA4%6_(K]^/I=OZ.+7C[V=JC?PX<[U-^;#^CL+T?YM+7O %?K?ZZ*^
M^&WR-3VY+-+D]Y/D2B[VIV1ZE]R7<@E_O"ZJG4HTN)7<Q9[O!X3$A- H<+V0
M^Q[&&"#(W9 !]9MD:8O7W3?T@"0U*CR^2=SL4?+B#=(_=*X+!8W_KXR)B+GO
M^C%U,8TY](4$T2#R.8O"F#*RZ3'PJE65"DM)8@T42G>'RB0])'J,&'N;UJ>M
M(4E'O[PSM[O,IQ-YM>@?T2^G_S@]'SFG9T&?B_9GH6>?+J)SY^*3$WPZ"Z.S
M\RA4?YU_^N4T]"[DB_CTS#L+3KU?G/,+^<:OT=G%^1X_S@^+6;*0TC^=_+@"
MNBJ&# 3T 2>2):5^(6T,CV(>,.IYV ]]ALA#AMP(PS0OOB&"F0_5=:0N(A66
M:7^[]&*D[I(7.NJ@=):T(@D'?G0J3>UL<2/O-G[<AEI6PSX57Y-9]A]]Q5:^
MR!?>;/)9ZF0JZ*E>?KIJ!$XK;\(F JKZ'\IMS*ZD4C2;>U+&+6:JM_IG>;UQ
MEI87<BG^-!___D&?J7IYGE:#6TXBAD+*@T@(+O&)Q5CP*@L@P@P3<-)JF;'/
M@]BEW,<1CS%W/:F#FJ\RX5*/&6TQFRW2B3=_\7W@!R>5BN.M$I#%(OWPIT]?
M_NR=G?Y_WL7IIS/'.PN=\]]^_=7[\D_G4^R<G_[Y[#0^#;RS"\<+@D^_G5V<
MGOW9^2QY,3B-SFNULCJ/!TJ,_*Q::-*HU2]?[&N>%;U"X+]?9NF2^\O5RD<T
MY9=O#^%;5H>B[^DT^YZ54J#-QA^=']K7=^G(R1>%DQ?.HOS1R516JY//U 6^
MWI]<Y6/=GN(RDYKI^'JFWW4JC54JI,G<4=DUWZ36.L^5+BL)3NYPJG15G1"A
MO 3W(VF,?4NG>3O$7?6N3@N%'M7F*Y5AEMXY-^E$ L1,7D_Y#B?9E420Q70N
M]_5D+M4UU3-C-DZ+\J/S22YZ4BR^MK?15^[>2;)NZY1<?=O;:3)7%J%6NM6B
MKY3?V(1QG<6M_,;==3:^EMND]?&9[KPI]UXJZ_*/FZ3X/9U+M5W><^2DNA:L
M;KL]S]56*&U(]9^1UJW9HZK)1_4<4K>7BU.YQ'?9_-I1-*)N+;5X_;2FI:?I
M#_L"->3]T>>Y:EFN-ODN+:HS,(%V* 09.?6C#W?#I[P90MZ4I01W&A$&- @@
MPR@6,7 A89A5G8@8(V&\'-B5"'^9%OG5YR*?+,;S,I."M":[7S7!/.K1_%=9
MS/]5_>Y3<9X6W[)QZDD^_9>Z\K^^I*7D!7E*JL-16)-]="4)>%[^FJK;=KP@
MM^8Z74_(Z5G<N$+ DBM$[MI8N4/N\F(BA?R'/\DS*)YSA0QW'$ZUV%+ETYMG
M- WO%32U#)Z:1S5^PNM$<IK\W5?Y$X51\^LB7WR]=L:2'Y0OI@L%(WG=<2I9
M4R7L?UU(IL\57MPJ;I3?U-&(4OE+LO):?B?I((6\A5)[QKJ0_UM29/FB=+ZF
M\K;)[;4&%AUJTN A=V\Z^?@VY$K:/ 3,I'K,D310/2@"01&)JM)X1D DV([(
MM;YBF"H),5%$&R27^7\2I:5DEP,3[,5=OD-Z5>)B8I[+$.JX\V1&HEY-DZ_E
M=7;KW$A)((68%+3:JW.=76:2_)3$NU&D?JM$Q'V1RYU/G=^E5EV:$)HI-G9^
MC2Y&CO>/7T;.WZ(_QYJ.;^7/C4#[$ET82=B]?<M,<I4_.8'G?Y(7^><_)-LP
M\K/S0_>[/SK:2ZB^JYFA"MHEDV]*/BEN4<)(BG65Z2AI8I;?)/K.DBN^*5:8
MWAM1);][G4IIEJOO2@8KVN__K'\0J$5\.?VK685AX0=+D?):,G_Z8"TUB\N]
M'DG]8)Z4R@09*U5A,94W4GJ(W+YL4LG4CTXL?V6<9?/[6Q-X-!^-EO?I.BF=
M2ZD3WJ1*_<FJ%VK3E9-%+CHI)N;'1?K1\=/[W/"YR@FK5R@EI 0;+:$?7%U>
M3_NO9W.U1UJUD,J4NEXB-8@\F:Q$*O.XR8W>,[TDM9YJ!N%7O<]2K$M582HU
M6/.EF4*K2TDX&A2T(I$KG:.C>,CO)/(3J7<H!$OG]^V>'+9BH5RL9C/>!I3;
M?B70<P4/(Q%@0"! 'F"LJDMF+J4A>#M0U@T253]D)<>&UB/F.X7E%ZD1%3Q^
MNHA^D39Z@X[Y92911B-2'[%_C?YWU#)_4C;.^0;*N[PH=0UYK9E6_(WY4M[*
M390VC=XS P8UU-ZDTZ2!5V-9R'?-8!^ED$BLNZS,5\/D?TYGRBLWOJZMND1>
M0QU>%2QPON1C^>^?I7YR^Z/S0_/U'PT@_WIZ=A;Y7S[5#YZ6R7>I?2O+V#RX
MO)FT:N1K:5NG"F#5R]*X%*3J=:G\-^W-)&Y*M)'OY2H4ENM9!494C9;Q7'VY
M8]U<.=?W*B=$;I-FGYGSET01A%KB5)*N#G7(_0N33!IBF7.>S'Z_SYW V* C
MYY?L1CD,G1^6O_#C!K!V6+X-/RDS36%=OUW/[?1R%^&26U [].Z?=.?Y! ?
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M.KBA7<VJNTFI/C: ,=4[T,&>CXY4>2]U.U&)H^VRY)9**3K/"YTNKBY3Z!"
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M_?2Z'E25+5>0M3U5NO5W[=&_H *OD\LE5W"J"[L>FAQ6:7R=TBB/M:L6LA-
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MG,)81"[%E4M4A(#O@1=CI]A!W!$CV&*'Q0Z+'2NQ@X,6.[R(LB"*H>^#D$)
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M?^Z-^3W;--@+&D Y0.!-,W9[AP8O(Q,[C!K#S[-5-DF&=Z;:Q3#BDY" -4@
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M,Q0D PE.V!;LZ0%Q)U'!$!/\Y<?_?&DSEWTDK>Q)_UFK) -X-1=>YXG2TF(
M>%J79"@+'.3[C(@%[5^,_]D=P]\ HK?L1]I;8^<(;)JHT&V%;C48Q\):K3"4
MQD$'*,3*5NQ_&DM,[JLY?9/@3M<*30:,186."GU\"HV;5J1:6<UE:BG0"D)
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M'?L/7N6K;+GR[PZ]K$_]Y4/+XV28^7M-9U=9NZ]X&*M_S_^[F%UGDZ*Y>%X
MBO_JI.:A",-;/M ]_)B;S$=RF1>@&6PJ:QRT4&(K&(30:(&%K6OSC'94W9>]
MNP]VF:ZW.GJVG:=R,O0R1PP*Y9OA.L]EZ/CAT]^.=UH*0HZ/P]7,JX\'-(!*
M0HYEV)?&RTLO<UF@)PO9N#<D+4C>-GO&@QP&?A[/DO_VN^PB-(K[YWJ\*"5Z
MGEWOD&KO8<S#C067I@';N-/,.LB4(!15G#4&80'%#0ONAK6U,;8\[(5NA1\O
M?BGVY>N/TP_YZI-'G8=K%W[*_F>VJ!.CEPWL_3#)?I]]NO)S][<@9UL8YZ&K
M>*&!.;1!N??H88MK"^/^N#MP*ZV4Z[#67@9JLI.IAY^-C9)-KS=BYIV\V6)>
MS.WTRTWKY=S;3<M"]@(,WI2V0' R]?-WEOQRVRKR7PLWOL-Q" .YVU *4KIQ
M-XMO+@LNEB^SV6@9C@E&A7U7?KD95V$">L%>;\A7A@_7]-Z\RD./]6GM$;^Q
M^ HND#V9"KA)7378:LP-4<91@[G4J72:8XXUX:EBVZFKI3"XW^>AOGXG":S+
ML+2/*<]+#01^MEUZOWO[((C6GM::-$T:4ZL5=!X5@86:4,&M_Z^$2(F$VR[1
M?,):OS+:L=.UAG0O<8_1>A&0+])![\T#\P;V/&P3P5,O'&YOZG@@+NV5/>DA
M;=PS[A"0T*N@<M**U&%MTX"YS*;4,FF>JX<=9+;N&'/W012]1\RE#=$K,@Q#
MR!E3 *<BL*19L,FR \_?7SM("-DUYN[# 6]A;JGK15S.N]'C8.YY^Z_[>[;[
MAW=WU9?X\"_S3'?+[]KRUY_9E_V'?!I:QGMC^91(-6T^+%0P./&L<.)GZ]7[
M2=G&JB2B?-Q_+]R5\_%57OI P6';3&;)5)@EWV:+R>C;>'0O8^%9\N.TW*(_
MS+X68RK_\O).!\5 ?CW[=):DWI$JAF$7ZR^)&EWY6Q;\E>%B?TJM^G-),1GB
M\:U!#5J4B>>+\/V ?XGY^-G]_>\_FD'IJUV=CZ=9X^9MGF(3S?__\TD8^47R
M)S_$M?\E]]?^\^,1?/V+2I/_8@"X$+0/O_PMN5JOBGN]G\^6XX(I,QM]#:&W
M47*53[(0OC_;#/#.\6U&<UF$^Y:S,C"W>?YQZ3*[]6(VS[W0_#JM&3^OUMX;
MG$_"+4?C<,%P<C!;3U>+<>5;KI=Y_?UEF*F&K#0L5/+7]>2ZL*/*I?'S7@Y@
M<^_-P%L7N_\!PI@^YR$*LAC_,_E3MLK_-?/BM;[*[I[=S7R^KV<QN7\6PZWG
MWG$>S];+X@BEN);_0+U&'OP>IQNE1@$C$&7$:<N%HTALZ$8MUO0]*'=-?XE\
MI%;/_CK<YD-X*LUGHVV/,GUN90L\DW3U"8_QT"SLA;-U&T);=WATK]HS 6ED
M%^W@9I%=-/+P17;(R"X:V44CN^BQHEH_^-B.CB)RCSQ_SYC+TR8!/#JAB[RD
M4:XBF$6A.PJABW2GU9=_7LPNQJMER&0J0ME;@?1]LZ'TONK_%47]?:O;YX*W
M#FNIEH1ADD(DK":$45@ER/"4.G5?#N&-X]4?IUZ>\K_/ELM0&')?)<=3N FJ
M4]Q5/IF,A]WT2]U$J#ML8(7YF["9Q#XI>]B3(^8=(^:)5J\2E5(#@7;"&HNI
M(02R*BF0280=ZA;S'F5P.!3,(S)B7L2\B'F'@WFHE8!I#47&,H4%)E [S8&L
M$Z&%H+A[.^_!SO@'@7EHP,5VV4G$O(AY$?-ZBWFDP3S"A8*!<(]+*S1/!7)U
M\0=!V(+N[;QCP#P"NB3WZ1_F]?3 MPO]J#+IFR0^KQWY[^^+B%]1L/=&2-AW
MP#M$7&NQB"J(!1>4(0$UPD9(57,;!0)"G>Z,V?T8W%B((A/AB1IH$9:ZAZ46
M'2J!2-F4,$BX!08$,.(E+%EB.:0[HT<_!EC"J$M/,\)2A*53AB79XG45P$*B
MA?<!@6,$8F)4=<*IK5;ZOLY0K[>6CL(9Q)'I-<)2A*6.8*E%4(NDLM(AD>*4
MI$)C D7=O$E1YW8#2\<2HQ+P**RE?;1HOK-I<_W5VX7FVUE^3ZR1O*L@LKK"
M'BOT0Z^&6_-3_+Q<U%>?9U_R]^>+//OM?7;A1_M=-OF672]#"=SEHIJJK%#J
M)4=<(6FE=HQ3 L*9&I*(:V<)=YB0\)VL-:=/GS@$YMN5I/?/DB@G*7OV#!5?
M3"X701?_L$R)]#C$=$I9P36HI4<,X[SEY&Q*.7GI.I3#^UQVC;U( GB%PN?-
M.F0WU^(!:3R1;A ?/GYV"2D+P_U+']8>WL?#^TS,FX<8V?(R_.?^N1Y_]4CJ
MYUE-1S].O^;+HH!]&4JB]60V_.W='076+&4(42H1Q:DV' LL9%TA#8Q&[YM>
MXLIHRQ"W7'* $60<.US1_3!"E'NP$OO1^\!W2>YW@GE H,4Z?_<?1GWZWXGZ
M8),?/_R7^_3Y)_?A\Z=Z ZCFYQ;P/5Y._I11O.8AT"N@\G"%-TC?( D_DY80
M%DT6?O%"Z!<J=#_8>O^86YT\4Y%K@^_3\#(?K2?>Y&HF+LR;5^A;*OZ@4G.D
MJ5/,2D*1\_]HC>"F[8&&IJ74A!--$(/<<&V]AAO**I%60A#"']2'1^^SI=2O
MG99[)B-L- _.B*%4IPXH)Q$1RG(A:NSR(Y7&M6;$&L6 ,% ;F&*$,$1853-"
ME+>F'YR11^^S-2.J( V8#L>3<=/=IE"H\#/)FZ<<%!JU:#3J]@?\>_/98M5T
M8LF&19>HZ;57A+ )C\HN._ZWHLRC:$JBLTG1?_G399[[2ZQFY3>O0G>6YH+!
MJ'_&13^M_#_%YE-L_V&<:=$@I&@4_7"_D!OP_CJX?X)\/N4R3UC45^$7N--F
MWH:G VHC<I4MOHRGY?"R]6I6OU &3HI7.NHT(AYH55'>@O&7=<@@;]F.XVDW
MZQ7AWHZ#6SVKDSN\4KC[FY">5I0T"M(K!:ENVE<)$PS"%*LLJR\7QDW1I_"6
M-;;O#-3#)EP^>CYEQ@!#.1&RE>*EC12:NY0;;)S!"-HZON*=D*U<BKM](;4R
MV6(1C//_RB;KVZUU*SJ;#@+R%/$!)&^2*M]/\N->8=RA'SQ&%#MD%*.@8=K@
MJ2,0I5I8Y_\#H;:R"I\(A^AVHNH+40S*_R1='"LR-J!@NY7WR:#8,6?&/Q I
M:W/F3&;A*?+%E?]C<VCRB"N!^M23;T]*WTIL8!A2Y9R!D%,'-:70F#H[G6*U
M%="]&=UNZ?V'V72X7BSNI03M).^2X4X[.3RRU+TU4([ #HGZV-+'%@42@,Y9
MY:PP3!C+-.2H[G:@(4E%)_K8T19\,OK8=73D]C%"+S=A\\*CK.QEIUGW'3R]
M6HZPEZ/1;!U.2UZ#&4?JYSPV52?C"+&FRY:0Q$)JL9'8$*["*7OE"&FDD=BB
MO[HCCV<K">!>G-YAF$<,..^T"\R+A:6?'E2, T4 C0#:%8"*IF67X$PZJ@FG
M0D*@, ^4K64\/"7:P!T#:&<1)C& >)N@,P)H[S+BCRC_\*'8EW_NY7@9W@JI
M9D'$+@+55LDN/<H+8JN2Z&GF06 <N+J\<*_]FH[+STB0C++K9: 6F^3+9:#;
M*BA'B[2=5;[PH_U7[M]:^=]+RNI%/AJOSG; 3OAY)^RS342P^VL/)]ER6<YX
ME>UWVPWJ_IXW(I_+Y#P+"];];=;SBC1]D5]EXVEPTXI)],\87BW8Q2:%]U8_
M<JL)<7?#.#MU:LE-2L*/]\6S7Y2%^^MTD1>J/?K!KV[HCO1QVBXS>#0)5Z;"
M"FP$$,SOY I9+&B51\FL!+R5A$M-R@E0*=262T2E%(K69^'<<+255WQ<\+U9
MP=:)Q$W<#@I59M$&?=K*H^THLSYFINZ8 T\>#5/<\=[L))-N0^N6_IRH]#8U
M\DDYMB<I0#'9]F42I:YF?KK^51QL+%<G?JP;A>B%Y/(+;YTGC<&>!(O]K3*2
MHS =N3 %U^_-^HH>NS0=E3F49N-%4F1LQNJ0XLLV/U\ERWQ81T^SK]EX$CS;
M]Q>SQ?O0G_>[U\K9;B>KOSQZ_1&AWD)0%(TH&E$THFCT233V-PDO#,,<1IKE
MAMLSF6?S?!'[11Y<O\@R 4;")HN;ANXSTD&,M4LU00H35#?79H)MM8M4M7&9
MSA:?O&D9C,]/&]MS$U@*<26=+<?W) UN>C^FXVDV#2+UXW2Y6JPWW1_K]QN9
M^SF(7'>M'K$<,!$[]A\ I$9,.0A,P;!I09O:U #%)8$DQ0!2Q:LB<V.PLNB9
MF#(<KJ_6(>EG5$2);J8(Z-QK>;[=E+8W0$,BR$20B2#3#<C05O8.8HI*DE)H
M'2? &LNK<E## OUN5R 3 M&] YE_Y8O9*%M>!HD6"*+O(\9$C(D8TPG&\%8W
M8HE"60 B *52:FU%6F&,18)K\!C&-/AR$VWZ B-W.$42@V/ DM.L@YTMYN&P
M+$_.9]/1J]M+=!FCZYN2BX;UT$(%);3 ZA0BEDHL*:L-"9@"M?<(2+6HVJ]I
M<Y_.E)XQ/"#R3;K3]-:R.-IP=-3W4M\A  V?( ,R1"481=Q*H%."I:K#$UHQ
MV<_PQ&Y10 [\;$0,B!APV!CPIX=!H-5-2ECLN*5(0 )E"BG6N@X?.)Z*1TW[
M_80/=@L"D'9I^S\J2XUR],S1_7.$C].$CX?1@S0F1"H8,4Y(X"C!CEI,F:O0
M@W,)'_49=A88V+&OP-% ,''4=L(Q9W#\>O;I+/GLMZ;E>G%=U'Y^"5 R#8+T
M?CD/3:X6^2@I,G_GB_&]"=A/!H2CT'O6Z+UP!!,C&#28(Z(!E:32>XLY3K?:
MA;QQK.#73_7BJNGHA\W2=J;_0@X\YAU#?/ $SAI.2TE%8]H;AG0HZ+<I--)Q
M#1!,J\U98FXZ,^V[].]WK;F$H:BV46W[IK;>)6_B\,3K*TRIX=I!+Z\$,EZI
MK98 ]?) OW.UC0?[46O[K[6HT5JF)62$2\Z$$=1OMH+(6FLM)X]J[8X\X5WO
MIQ(,,#V*+?4D3\I_\@(P',^S23<GY8^4X1YU6 RV6L(K*ZU,#:9&"<0%0UC4
MQ010 ;'5[>O-W>.B=7>@+O_9+U"QDI_6YWXZQTO_7-W%R9 8(+2[?L;/D+#>
M[ODQ7G[RP,%:%0,@%28%0"N#"+)(8 )K*P(KO$7HU ^7_8W0!'9J:$0HB5!R
M@%#R\,D^%$W2KO" P6TJ(&.:**4(UW5Z3ZI=^EPCY(WB"&^%)7U DI@ $%'H
M,%'H01!"H#%H*%2I2RDC"J7(,"(%KL\@5"@BV%M8Y.T\("PZS28Z.+/E98D$
MF!U"_.3S;)5-O%P\UG@J!DLA0BTWAV &C20J_*,Y$4;4I@F% +#=Q$<ZX<\#
M" Z0C+7,1[9A'X6&D<;XYURF4$KDG#-<,(@8K X1+3#"Z3<,)'2A=L#OHEWR
M5D:=BSK7C<>-J&RQ$&))H63(8:2=4(JGI$ZXT2)];@7=:SSN3L)M73K)1^GK
M1FWMG;8^K*RM\)C1-I7>_N0F!<@9@"&H&.\,8<X\&FI_GF?:C>V)X8#&NO1#
M[4\<B(9B8<G]VHE!HYW2"(B M4H#2!@W@CFU2:<A=J.=^>_YY'5DE#>\Q]?6
MG?A+=Q8ZHF@ *#[J&I->*7]?-][CUGG8F,\$(.H-9<4 (<SKO!1(E#I/+7&6
M=*?S=SBQ>]7\76:[1JV/6M\[K<>BB51I[I#6WC1'#*0"X]16[)/&2H34SK0^
M>-%1ZZ/61ZU_*ZVGC=8#+;F0&'-*K 2 IG[GKY-3G&&N.ZT/-#D%2XX=+X>3
MV7*]R*.5WT]?__!<^I]FT_PZN<H6O^6KY&+]^A3ZH]!SWN@Y95BHU%DE4P,E
MX4X 49]#:2=E/_WX8EE_*E8U#8O:7?DI( ,,NU3WWN[GI[1M'X762M[8Y(A8
M1CFPSA!6D,C+.@W=8F,ZC+YU[XEWI[NQ!C6J;>_5ED#6'&G1U#O,C%#(I=]M
M@;*P5ENI%$%]=J6CVD:U/26UQ8W:"JXD=] ;R,0*1!$QKFZ\[ 1*>^T+1TLY
MGG7?>=8='O#"/^(J7R:S"R\!\]ERO(IE%:^ #,I:=:+"6$*-T(P"A916 -0&
MNF4"]].M;@O%QPM;BD27D30D.HVD'5RI1:\ IJ_FPVF#"*>M_N]*"\.,-Y(U
M0I1B@.IT58V$YGWV\CN&DIT>Q448B3!R;# B6[U@"3.&"PN],8(QA] C2)U(
M*ZC6?8XZ1!B),!)A9&\P0F$#(QI+PQQS&".K+2 IAU7/+(.),QT&+W>0$1 =
MFYZ$4&YH!3V(4$E90S[T,EITHA]/OWK!#2)V3R[!,Y86^Z4=S=;GDWRSMIW"
M1D_(-9_\T(<$C:UB7H>MLE12BX7#G&GBV"99BC($.XSV3$<]JK6G2 XD(3M#
MOCLDI;?&TA'81!&X3@*X6@71SC*;.@@!MPP A"!P=82)>UOO38'KV%H81"B+
M4!:A;+?-'6@KDQ5Q'?JZIX+HU#*4*BWK.A7G4M:A?_H*+#O$SA!/EIS8.B*"
M8 3!-[?G9&//4:"4-9QRJ!GGD .5UHZHL !WF<W_& ;NTNTD8 #Y[MK6]\E6
M*P)K?UF%::Y?;PWDAHX&0HMB9..I!Y?R[\EXFK^_S L\FH8YG=P0<0A*@2ZN
MGPSSR:1Z]]_?@7?%WWY P_KO.Y[G\_@J7R8?\F_)+[.K; O1KK+%E_&T'%ZV
M7LWJ%TJ +%[Y-AZM+OVGP1_K51C.)I-LOLR_JW_Y_O9\O]O$&C=A?,C>W1^*
M+.]!Y!^_?[<E$-7]'W@+O.QK\68ON=E>:]'V=08%Z2L/H3K=JX<%K6KK4>0K
M]K'PW>J,HAIK^5ZX3(U(Q2O?2I ZGTU&I;Y[P \4P1[8 \CG?@0V'Q9'-@F&
M@P0!*/M6R[@O^<%[$)_MN:CN4NPK6[<X/&G;1-*3$$K?FP?QC%F-XG=$XE<$
M#I(F<I"$,.A+3ARC&$8Q[% ,0P3K/KKU*(==RN$#\W)D0A82?I(BXR=6YQ1?
MMH\2%GSW6B'<[63U5TW[(T*]Q:<H&E$THFA$T>B3:.QO$EX843H(>FDSN[K*
M%R%Q.IEG\WSQ1F9]WX\)#_ 44,@F'54[:E,'H)(I2(FV#NKJ%%"9U#C8/7L3
ME/])GIZ,OQ&ZGX/,=9:&CX4<4'X4'0E.('@=0:7_H")!BSN'>EA)J<.$I)19
MQV%=C,P!94*\$6'5?I FMBR*(!-!9D<@@YH<3B*1A#R5T#F9&F(-HZ8"&6(M
M!F]$T!5!)H),!)FC ADB6FU5A$'"$@.ET!(JQ&55R,PA(?)1D'DZL5ATB_K=
MJ.U 8C2+>3@ORY/SV>O[EQ]UNP+)<%/:QBR'#H70,54\Q4Z"RE]1 G%K]AX$
MJ595^T5M[M.9UO/0E*!3&NS^-1V(<?F35WB!-@IOH6(&I80*2Z5_6U.0E@JO
MF=* ]C- L5L4P .).RW/CQ@0,:!G1:!^BX=-E!(IPA6"DAL"").I$A4MJ4;^
M]4=)@_<30-@Q"+P% &RK1L\<W9?4@$;P. +P>!@[$&HU.,/ <6\LI"0U#BO+
MJ2VQ@SD+S*/'ICN+"^S:4V #A#KM?-$[*^&8<SA^/?MTEGSV&]-RO;@N.I1]
M"5 R#8+T?CF?39=^EQHE1>[O?#&^-WF[LXZ(1X$+I,$%Z*A6FCO)*8 BA4#R
MJG\JIRJUS[4INHXD_/JI7GPU'?VP6?K.\ $R-B!OVMZPM\[$26W[IZ#EK/$<
MI+8<(I<: KF@SA!+JU,!3:A.91_#!SM7?<&CVD>U/T"U?R1B()ID20,X4, 8
MPE+%I15&XXJI10M)-.ECQ&#7>M_IL<$3!>JH @<1,0X.,1X$#-@*,6(+&#74
MFP7(:8(YD817!XN,*_<H8.PH3/ 6;@!C;XD,_8\6/"TTAMDAA!'*+N>C1PM/
M8S3Q 9A #4Q82Q31B'E/0@!FO7=A*KM"4(8MWDW4H)/^:AB( >ZVA63O(H(Q
M]'_RRMINX ]5*)EBC!CMM$@%PK@*_:=,P\[RCI_@_'=!S3KP0!2U-VKO86OO
MPSX\;+6Q)Y8X@91R$F&' 4)(UJD_5!C\W(+'U_CP':BOB.?U\;S^=-7^8:UO
M1>XL8L@"0+ED+M7:N]YII?4642AMMXYX-Y8U1 /"CCLC;Z\=.'><BI\M+U^I
MG<>@A BTPN="4F>I0  9@5)LJ:F+:1#6LDO6A8>)SI^74^,OW5EDC("![%2G
M>VM6G](V>A2*"AL;V4BBH78I(="EUH&4NRH>I90EU+TQF?@;JFNLJXVJVG]5
MQ2TF(V<!T5AK_Y_BG*)48<T)D:FT1J9O3=@=536J:E35EJK21E6%MW,94%H"
MQJU#0$!7D8YQ3!VF;TR*'8W@WIW^'H1C^]-LFE\G5]GBMWR57*QCF?G# -!B
M'30*IXQ9IW5JH68,AP*TTJPF@*9I/_W?8KU_*I8[#:O=&0R$\%:G.:.]"V_U
M"A7ZNLT?M_I+WM2,26*$M\R=42Z$H(4E:6FJ&ZI3W"&!<O=>=7<@L$NS/2)
M1("^(0"&K/$ ++!"0,0P%L!HD4(NJK-GF'*TN[A:!\YZ1("( !$!7H0 N$$
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MXKMMWWS $^]WO]_]?O??Y\3[W7^B-6;97[.?YW[M^7HA ?LE)_>?SYC34Z9
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M=XW C<S ,2,SB4T]<&S=@O_&MK42^_E,4Z(_A07?W%GB_\1K_N^9KPENUS_
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M&) ZD'%S%"36$NI:T197C(VPR&]SSB:1+US?5_+P:OR_S0$)ARSIG;A2W *
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MO9^ QK#"?^&PK,'BPAFTDZJB>6,'GHTY="'\M6!4"KP<N6H/)6$81[#&  D
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MA U\7090@UBCG,IT9ZVL&WD['/-E*<4C2OH2V-LT/^% F\ZHSB[#D15U67
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M'K2+ZD8H8@TG?+4>CFO;'\E (, H(WH<-U4(<0_K,M"2%79Y>KX/H>0<ZUR
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M189"$N8_GN6@2?ZLK"Y/5<#_1O+Y-]FH&O_DX-JC'E2-\$?QQQ_ITL[EZ.]
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MKTJFYD/20G=(CAB@P\2)U[-@##KG 3J:@MQ!30+JO>BG^\I)0"6K?S\[+3V
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M.&NK;%]4V0+W8V5S #)GV4#56P=+4",^JPIZG!-:@Q31:1K[ 2GLVR";T:Z
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M](4W%2<CL)N^GW@3F.UK+[SUEBEB.\T2N57W77^W7</,ZQ<[X+5Z#UXH/>@
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M4IRLM*&3BU4JA]Z?2IJ]<QFE#>FT'$.3@=2&H4^ $[\+VF)DKB!;:RF0G;+
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MYIH)0 PC(I!!X N%&BJ<]PJ"[ N6W,.\OC+<N^8&>BV_;0D,V7(^E#6\5O_
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MF9.*** 9:#6/ -MHO.4I249*4M= \2ZJ3,%J5Q:12"M/AJI288@Q+E^ $2Y
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MD"$!?" 6LSB28-PW04+)EL3^GHRQD(8W_$[304Y5(&0UR$$<C<DZJ+9TFF=
MC5BD;-=UCU3:+Y,[-'M@IPA9BQ*CB/*EP% N<A'=W32Y<4 ^_JQHIAUKT+?B
MVKS9=NJ%T@L%[(<J.ZF%8Y3Z[$:4%(2T.K@7I0*S5IU1R0BK<!&)4CF";*-
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M,"/0$*V!-AP-V@_KE8?<6VR,H[Y?CZ_!QSP"WUBZV#4(2D5 H4[SF1@X=U!
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MMV)*'$4A^K-9!,*7DH+[28@?'IY\D4]3EKZR6R#90!K8O2RKN<),>XEJ'D;
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MJF\@XCSSP=A,6^HKOG[5%3*J2=HDQP:3C'K&-:C21M3K6FV#HK#<8!MDB6U
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MX;>A$V:63ZF11@I=--I^N/P#2P"='A7W$M?CY;QQ_(!%-O[@6[X&6ZZ*MKI
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MH/T@""[T7''I*<&B%LUW>2+<A&\AQ^?:;89-D RMRYKX7(WOKMK N!D407=
MI#SJBDOL"/94RL L_=(J>\#'3N$'M:!CYM3^W4C$@5BPL\#KF"U'CN"0T0/
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M\268-M*-K$&ZI&A1%D#5C*(5[M$7YI!&&^3+[IQ^+25N/@&L*"T'4JC9F[<
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M"C,T64&]NI[&'(9Y"C^_>_U/W:/[HU5SL]Q^T>'$N.XB730<*$B%1."KP&\
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MB)(;C<*:0%#21*DA'P/U;XIV?CS4W^VAUC!>6.^%*(:#-2FJMI'">)2F!J?
M?@SL(O>!>"3BD=B*(Z& +F8F*]K9& )'A+:@X#UT[OQBF4\0Z[U)\8,Z&([9
M]-K7=_RMJB;)+T%MX%NH%\P!X0K_>"J1X\[O7VJ"8OD;)<_ASV\I_UY=YA=Y
M :6@[C/Q(,6#]/5B2 +"[<ISL*+N$K,BT 8K]15"F=*+\G)XV!X7D[=$4Z&?
MA>9<Y^6>\BJH]Z-1XHL 4B1>4?%D?4LGJU>\@4$;:D/1@-.A2:9X,,2&@]+
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M<J^0RT*T!U"G@"K#\?NB7ANB!;8;6& PZ\(T5\2*[#7K*G'J'LAV+[HA3U>
M29X$!,\.+C?/Q7$UW'!M$0UIH/H Q4SXX/+:GGA,LU'8)E2<0PXA;AE8K(H*
MU7J&+;HRI6=(L<X(G'.8 27GN+( IQ30T3E:6Q^'*M9B 822WL4I-Y,(6CT$
M6OU:M>N_5VC!+\'1?%OGEU"&!#O\6G??O^7N^^VU?VYD_^$B49P(#N)X#>#
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M/AL\QUQ11N(H $Q6Z!WX"Q>FV7G8I;9F>HL!H*#'?TW1T"YPX1#^O3;ELRO
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M-N:@DJ]E$A5:'X<+A!)$*^?6K+,TSO$=65_;<#C@^L=AN5)M0.-WG^AV95H
M/1\"$ 3 -*R_F<_>,0T2F $4R(CUIR&D74B 0Q4_A%M*EN386@^\&7]]L/<
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M>/KBU='3PZ-7S_=?'+]Z>7!Z]N+YL[.7KXZ>/?G<Y:3AO0?Q078+^P<[AV;
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M__6O#_8>X+_MQ,?R[X$U?Y_/39.\,:OD737/>F*YRB?MS/YHYSZJZHFI=\9
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M\U[FL+YBFHK_0:J0S-15OA]M!%=I3=+6TB@^KN8=U"Z/!;MBYFYC.>^9OTD
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M!EQ2Z3/PE#R#V-S9+$,TCX[G3(0:J\?9.T"UAZC[S=(Y::4NBZN.GAX\!=Y
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M[::"%(4A]@E2;;'$AC15"B1OP[RV:12,.@>6EU$RA@/77V/D;6FGQLCBI=5
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M&0<]&V&,A#J5U*LER4Z,QTMW$T&,ZFA!%0H949#WG[DVN%1U$G:=+KI[C01
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M/@9V4U@-+K("D^5^DP2U6Q2IA [1T9.C7J5A/&H*Z7%L[^!@8)D3'X>D!*V
M )@6[J1]FVF=@Y8F:-GO;!';Z>%)*];NLMC2CVDUS3C]N&ZJ[$,JC":K73HI
MQH@,J77*ZA8'#%KO^+,)V"/U:1X ]5X/B'I_0=YT0ND2.RIV75M @'H?^06:
MY$/:@K4.*TAU<Z:NPKGT(QJB==C<^T'_O^'4JG2VLMG@O66)E5QCB[)!6:BZ
MR;J?V9J9DK\VLA^<,ZO. JVZO_=7YVWS:OO$>^!>B!A:Y,22/-8<NTDU*W)I
MLU.%V[,R.A:6OZ"# M:7S@:1N+Y30@ E)<<V77 &HBDC $,R_9!PDZ^K-)_C
MYFJ/8"TN)K[!%%R]NBAS5W\=>--,_K&,(4TI$(O19EVW$L! 1NE"!M=-)-V<
MYD;:F[NNP04(Q\F*53 I$*R2K$YG 67:9AXU>7PKKK'-%AC<%1TP W%-<TWK
ML?&42L;U33 [.,FK<I7/$%D'$]@Q<,VWK'?N?I,5+"LANN__@3T"X_-UZ7=T
MLH.X,+NN]%"5TKV<$Q0R3 ^@P"XYK2W0']P;)&ON>T#%N[6D&(H380;7I5@9
MUF?JQ6(&-26;D*V5K+:8II3Q5%)-G[1AL<F2;'\027$1+%,C%9K0_84W3A)C
MK1A5LTKQCMT,#H7AQ65#E(JLW?3Z0,L:Y@X#G6>7+.45"$J;R!ZRJS;-KGIQ
M?[.KAE)=]*]56O<(%734E5-!30.I6%8?X/:JYJ<J5(*E^:F@+/0S>))O9ASK
M&%67"=4>$'+RF;R?>(?KJC, KK[K8[5-I)QFC*R8FE,-8?MV+1.-'DDZR'Q5
M)[E1EUS-ZU0!A]0U>L]1M-RB]X\-5#L0A<Z&4,,HE+S<?<FJ(7H4#+"%-PC[
MTFM<:']L<=X-2N,-IW//_$$; -9UM\$2MX[RM^BD4%3?\#_4+*V&U0C79B2[
ME]$HD<-OR1A4LN8$+>>G,* /A"8D*01/]GB &<AYU?[:[T1)OIJYOR0&>1C5
MXSAL4F:^\#N<J16Z/GX7['>D2A]0/&=L]5EL++5\SCHA>L'.86#@9\9+\&0O
M4K-GZ]*V>V5E\U4TFLA.Z?V8E2D[3*?(E>AY[,[&B !=&^0\5&@>J4;@ZEWL
M2<7X'[ B!&&Y++G*R.V^B/K&38"73TR/NV7B/SMFQ5WA1E.U&%^S0"(1?4%M
MV?JUT*$5,W/$4GLDOVD7/&.C.&UVDQEP+2X9LWN]9X\5T2@'^+>S,JK+>W;7
MN]CPOW?L^WUR\.IN'<!OX.H7E _$#GWVX.\BA1]T4**8<ZD6TTE>)J/IF56.
M^:(P\4S2V+$2AC"C+J%UK'+M,[L02<):*M"*:'TBU? B;$DRH"#%V[)X9''G
M=E"IO*5E[#8#5B'G790&AQ933$TL,&))WKC$3>M3"G/MVH"55D"1K+OTG>ZQ
M>5U?>B")H77*(B7@&#Q%AE@T0+Y3#_I3"GPM^*CJO^;5[5AW+G?[C))%N6)0
M-QOU1,"^O*Q1MK(G51KO6L T-B#>@!B.GNX]!16+$'ULNGQT^NB_O8QYS;""
MQ'S,!A[=[:7P)[K%VS >*W)8EG7-'8H9N# E;[>"#=0P(BXQI;7WM]SWV$"Z
MXQP,-#TE3MA6SH1:AG8&IMYN^&9]@OA^9H@XB4G')%Y9#,1,YQ!U ;L7P*'L
MM3,X]7U57PP:]7SRZ,D !,UD,BQ!X]JH[UH?NKZ%0F3OHP_@VJV\#8"JIM,!
M4=4[EL&[2 P2KZ_T\>!2B2YYOU;]Y7W=?]Y50#  6IK-AD1+NS//NID)X['W
M,D8*QZ\J()BZ%_RLB[\-J/(Y30='7]&A<=KN@FF9]"SG&>Y EB8%T.8W<JF6
M@:$QOBS&5L8'K3_*>)W?*='Z.(J.T:$=KLWF[@9)C'W##HAFY_/!T2R3R Z%
MK&W2:*D+,QK6\+8(X26P#XT%]!;0?PVX3K(;Y\[B6Y6]#4:9.S\?$K'1V:F$
M[)W(XH12O2=)S68O)=2)>P2SO!CC;)YRX,;U75'%4P9:J8] ^YB<,3R>CV9#
MZ")Z,:2VQRW:VXF<OJ<( ;=1*R+1)T17:&WK+?2,UF]]E:/_Q+:G?3SDRVTX
MNX.]^YLO=S<]O8?4U/L=Z%*8?KY+:-M/B,ET!6)D8Q(3+YEIH*@;P"#.,/-\
M!6;Y20_0#[O;?3!F'>T<QVZZ"/)MDS ^:[:X(1)+JOT*#G*'4R:CC0B-5)@G
M3$J/FN3C(Q/T13BC)JN8@6*.^CB:K2K+IY./A.QZG2:@>2,B*X=\4"CTNL8V
M6%-L%H5<N14I@]FLBE1PX'LB89L-?T.4;=/86'QSW,+.J)1+<E/,HI]\!J D
M_G-(O>;?715;ZNQW+[7!.]_L=/:PW7>YW=OJ6_FPW9MM-\;7O[X=[]C?K6WR
MH7'-@0P4?"Z'\H YD&BJR4D@MS4RTW3D=%\!;U!?"MZ'^MJ*VW(>2X=,&H$:
M5J&@UL_B0;CG-1Y7-O=J0.RT^_&\FHNJ7)U?2 5CT50)MJ<B(/?SE,&Y2?TR
MSLC83[?0+5]8T:+L7HK^:(@O"_'-B'B<I,S@7Z8?%:^:9\;@3J7+6]90!@'P
MVP#4C@\?!J1VJ.SDN_'!LSMEMRYXY;@9 +WE^9#H+:W06,4&$]$1MJ':M3,>
MD0_P/9_N4,?&'-D0G.J+Q5 )B=!)LV0W0,X:"64J;XI,;WH*WZ #.T7D.6):
M[&0036 N)7-YEA2F!7V_4=[1 MN./V9MIJ86D"U#WT+W&:>*WI]?RB2OI8F-
M_OP]59)@8^[@!T?>,HT6M1(T!?LNJ0IKO4GP%S@.)MB"7*-D>FE.,E,J-8]#
M;)FNGNS>+BOX-R<@QB^CT?X8*X_0PU9'(]=*VWZV3$7=H?M>I(W]:OPJ&AVH
M7T]2+*2RN;,(D_%1@+EG")LZS:29(S;RN>%7L?<3CF0L$(_VWV:,IV/85FQD
MI/!MT6.VJO#;9V/Y-VXETA4#SX+"62&^A_J-0]2AI^"WS_5ON1,M.J2PXS:K
MB]3T:(G7S+9H@)]]-Y9J#,*:@@^^'R/*VGE6Z'T]K\JZEL]Q U^,46,L%W!(
MLA,X3:Y9PXW 9_;W@."7Y'8CH 1\'#_>;W^L?XJ/P/G -CZ"O]%/.L\:_/")
M_ATQ^CG0$7X#F\I @%3->ID6*_0T5N>P!?CUL[&&_RCL(^3E++%\V'R$3\,^
M8E.HHDZ-K*@;565\CF2/S\'&90MJ64.NSHSSL)HFR0K3J@+KP'FRO.TYO(5_
M#)N<@A J%]E4L%)!D, =&+$SDFK58$4PS")MX&!H/U^,#;PE43;2,6RQWHF#
M??6WNP/X#6PIWP?&%%NZFXS?PM[.THE:)W[XE%:8T_HL8@EQN-2B750E1L9J
MV4LL'*83/( ]GX+P*]%7C5[E>I[8<9^/-2770LJ.D@^^&SM*Q:, 6;VJ>-SO
M9:)V*P]>:+)@:L'9X)4//\<[##N&QP*+GZ)/%9%;^*U/8.^ S*^P8]B<?BZT
MB:94FXR?P(9.,L*#K*44\,F3<0L;*6D\3=@5&#)_I=V\OEE6L#*\H#@"2P%U
M@"(HNEBHX: #4&F*(?6<;PG2'> R]RD!<4O5(9[F00)WR>+=:CP&T;,]7U$N
M5DL!*^S27D"QV4 W,2&?1U<84*$^>FTOAMX86\J"L!PHW3.IG(]=Y51-DM4^
M6:?GR"_KV"")2L@HF=1EOFJ,%4*2"OTUES8[2-]H4^EM=%'7DIQ!&3(6=C?\
M#-Z07A(Z%[!0;/,718*WRW7B&*UST:>[/W.*P_*AAJD7HG(WF:!.M'P)-H!6
M:'>!Z5P'Q] T KTD2-!M^@C?T?$$;**Z%O&F"BKKT=31#L0M0Y\MD@\HY9%_
M$H%$-E#<7)1BO.93B@^+7N\K$YMK^1I8G31E5.0_<L<+5%8K$/$<D@42_=;V
MG"C*HD+G'7TSO4#]J69=6?W>8FT3UB"C"C(&O';@X,RPX.J/QZ>/X4QR1),#
M25$RF,"LO1;6KM5[2(CRZ+0U]%(J'3Q/,92+5?R,I(/!TND4:PL%FKF89J"A
MU$;9[AN2L$YLQKP^&)++'/NEB#6MU0CY9S>-*8($Q&.5$+XAMMP +K6H;8S:
M,WLXB+[IJN *WW]17@ZI@W?[_NW&-^'ZT!+#ZM?Y=LZVL66Y J/PV926/VV6
M9?P+HLG.K-@WR'@*HYT85#=:'^X_=Y[A7EI>>\"'[+M/SK[;OU_9=]M=O:96
MG0_:DK+.F1VHG7S]K>()U'@)S%\$+5V;'*0D=0E8F1:#HH1@YTNJC*ZL;;VA
MKC$ TVZY'*@\V&T10CNIV>OPO5FX8PCT\Z]_#8E^\F0G0.\9-J=,\^PC&KUO
MBNECZL8=';.7V966#J1^KAI20_@3M-HR4O?NIJX)LU>Z2X6W4+:4#('GU$/J
M"]Y-7U]-C;$N!HIZYKII05#?[[VBH)OVXT]<E]P,J8UXZYS_*+)FZ\SUOJ6P
MFAMJS6Q31[$[D3 9@DA8#:EK^IJK\5#3^ODUK6T1H_;WTV69&F2]0.LZS3^Q
M5+L<4GMZAUZW?;W-C=U1P1A"4YF..@Y2'BC*C1#[O:FX,(^"<27]=P!T=36D
M9M)T<D_WGNV(JF#D'IKR83P'$0+[.*0&F_[Y[";\%4"Y@OC9?_&$64BRH'RJ
M ;"+ZR$UKA3+>:D28D_P^VW2!XB4.U[4X<F#TMNV#"D.K$^Z+'P;T8#&?ZJ)
M^&P M_O?NVY-\#7<[J_3:=@[VXU-K=X1/#OKYEWY$QM9R:!:'NPX$'/=9K*=
MD*U.2T8JB2-7L]$+&!NO@XN-U]!ZW.L^[_S&^1CB((,B3*^ U;9PN 9 \)-!
M0:]_E9$AW7+IMKR\[29["/:$(.]#0GD_74WJ;)8EU?4.JBW",@)%JC$ENC.0
M@X64HOHP"ISH)J-_-02D:]Q-+137Z5TDEX0K9E*+-9H#I293T2@V"_PG]2\V
M(TY*">P;(*G:=DO3TQIEE:P"Q09-,D76'.MT^5CF8CH,$N^>YDE-50GTC[1[
M>-=N#Y-$2<+17]XJ"#N56I3)W"_ MD@-G)I!Q( _X;9?$X:6-[<^2 V"^PB:
M)G*9!E42X+@(W2I 'G&49XL,I5F>)=07^MIVQ+0Y\RF#CW0V9[L@R"_!S5!3
M<6U:1K*WIA0 Y2-E#?)F8$V=US <L66ID*W6Q9RZ(3IE\7H$-0 N-!M4?X S
MD&.@"Z%BQO)FY[#8")X!M%]3#FE6*X@<^+2SI\G3@Z>CF0]!:*J$N=L0DJ<C
MLWW'M[BXF<N^X1W>M<:["[=?LP?#15IX?->NP.H!3O73$[H/;I/0_1_FCTDY
MN_[Q/W_X]J)9Y#_^?U!+ P04    " "Y@0915:S-5OQ7  #(7P( &@   &5X
M96PR,#(P,#8S,&5X:&EB:70Q,#(N:'1M[7UI<]O6ENWG[E^!EZ[N(JO@09YN
M8N>EBI'D1-VVY"<I2=^/('$H(@8!!H-DWE__]G0F#"1ED[+%J*K[QI)(X S[
M[+.'M=?^\?\<G1U>_O/#<3"KYFGPX;>?WYT<!M\]>O+DC^>'3YX<71X%OUZ^
M?Q>\>/ST(+@LHJQ,JB3/HO3)D^/3[X+O9E6U>/WDR<W-S>.;YX_SXNK)Y?D3
M?-2+)VF>E^IQ7,7?_?3O/^*O?OKW?_MQIJ(8_OMO/_Z?1X^"HWQ2SU56!9-"
M196*@[I,LJO@CUB5'X.#X-$C\\G#?+$LDJM9%3Q[^NQI\$=>?$RN(_V)*JE2
M]=/QIUDR3JH?G_"/\+(G\K8?QWF\_.G'.+D.RFJ9JO_[W33/JD?3:)ZDR]>7
MR5R5P:FZ"<[S>92]H;^5R;_4ZX.GB^H-CAZ^^=./49!%<_AN>7#XP^'!VV??
MOWUU_.P?;P]?/G\^>C%Z]?+X^Z,?OG_^C\/GW_WTXY,(_I^^I?]'OSE-,O5H
MIG NKP^>/?W/-Y7Z5#V*TN0J>TTS;+__1_Q-U\@/X6OC(@E+V)9'I2J2:?/+
M].,-OVV<IS$\398I.'CZ^-F/3_ #SE W&>6?=5DETZ7[JF>KQYED,QA<U?&-
M<?&3/P9GT>AO:P>VB.(8A.;1.*^J?/[ZX-7BDSO8"8B7*G:^IO][_.[D?T\N
MPN#D]/#QYJOZ30S^V=.#5S#NH]\.C]\?GUX&HS]&YT?!AW>CT\\2C[L9].CH
M[,/E\5'P\S^#RU^/@Y_/<,QG;X.CD_/CP\NS\XO707!Z]OOQ^Y^/SX.#[\,
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MB\3B/5SG'T%V\#:07US5J6@GO'Q66!/VI:XQ$NIKWTHI?:<4W0B&!IHKD[S
M^Y;L;[ALX9\@7O.D+.DMZ&O@G-'FR29+SY*@/[+=3B=K=%4HNA;IS7CI9QE>
MISQK'DF%MV92\7&*X>-P$-$C $L$GP?J5\5HS.,WYM%'Y;V-7S.M4[C,P;-
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M"3#3 H\1CESSLGX:78%E^MC34L$=A3I:/X?'7G;3=>V^.O !H'(KJ>N'03P
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M6=1S![&NVR?VVO5UMHY/-QAU),/V#Y:$F>%JYN21#BNT.D4W198LEG;"ZG-
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MQ,&UN4Z385DDU_1HA#6)]FK)+=&8(T='8$K;ZY+SV>L?-E@5&0OULYRNN+0
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MW?/!D)8X?\/P)V;(5"23T35/D8;JAZ;A,&-Y2UL.UT.4KO["TBK;@5/G=C&
MK>/4(8YQ,!(1($?%[4AIT*W-K!IW8:&[WQ"D=["RN#76O6"'6T6H'.X.79#8
MUQT:KXPZ$\A')^/>,.1.:8.?90'P*XV>GKKZ6I=8R];V1??UM[$_24YX:.RQ
M$W*Z55==R,[]2Q6Y=FVZEQV^P[N("*G"Z2?J+3,-%%XHY]4RO&CL1.G@-:@A
MO++Y'$SWN+51;OVFEP7R&HDT<S].SV,W'=/-%=%C,9=F; V><P4;G"-QBZ*N
M+34:@C@,A$F7?N+8N$^31.U#H\)^KF1+72J>X%TC!N+-$0/-H3Z@!39 "^R6
MY?XKPP6V(:LGW;)%]1>EH;)%@JA,!52!)M"DD-N2A)I.FNL,BPHE1BK5R.(+
M5X;!6B_NYO7M2-D80P4T'E_,$08,KO.TSBJJ\71PK ,T&6PBGVK+<.!'"/0B
MNI*A*6VC8A-BBY#'!MW/)$W\"]:&G%-MB+CYWW"<LEG-Y0YU+?TL-<Y(5A0:
M=J;58B>&0>QK-RJ]5L'*4L;U_>RQP3:,0H_=3-.DJTE\-0%'SW-O,1$2<I@[
MLABU!-HM9&S+\Z#-^KQY!;T^AIZEUWK'7D0L=Z_EB#K0-$48JTQ-DP:/N A/
MX1$F&.XOYZ*R-]3 %/?N(G;4L53/OG_ZR]:,E#L:L]C4VQDVI\O%>3*WH],0
MS>P(5CQ/9O@KV7A=E&?N*T4<<J*JM56&*^S7?FON77X5NIG,)(G5V=A\)$,5
MX=?1BI=(]871)RGR).O%U%;_\,,/7FWUP$$*W-'&'/,(+Z-/V]P;N0D-.SDM
MJ(Z#W/F!V8GPR05K_$K<NG.A2!\1#X!@KF2N_M^L',IC$C+!!Y^<$ +XO%?(
M6M\@9M?+R#E:.@/BXX% 9WG?QP>Z:;#PQ"/ G'DT/(FU\D"D:,O^\2 E$1M=
ML6-8D9&25U@KY \@Y$0.AL$U3\*..I8EC]66.I;A\&6L?GAHDI*)B(T-F)Y2
M_V(Y'.KVS-(!G5H2&3IL<?3$O&H0:.)*,H.FT]JEPHZS5)V-E0KRD^D+87=K
M$%'+F_F"TT,20(-C@%OFO',.NXBU7 $:A<-09,?XF]T]-> >7" 3+Y6:T_0>
MH4XC5DBST> V1M0?$#1Q/D\FYH9M)PBB2G-445U&C\AJVKT^":5NV&Z'!3)Q
MS===%H(FIA;-:R7$3:R^S9KZ!Y7C*6;OW>>X0C#M>2K+D!V@8YOJZX?;\WX%
MU7]N1O6>F ZWJA]ICQNRQ0("XMB2D XZ>=[<.9? 1.)],B,C58-Y*VH5H W&
M-=[!.Y%42(/L=+.P'<3YYT61X\F(OL:&?(!WG^.[=[DS]RR:]]U/'3Q'3CC6
MD ;K1@!H\ET5T6+6Y$$R\)?FZNK2P][E;]VR'>U2M-)I7ZJHL3L+V%O4.LZ-
MCM$*ZV(TE.#&3W0"$JTYZ;X;JR;>U<C*-DF8YS%3*I6Y)F<WC%ID[1H2^5NL
M0:1C DCK/!IR#'N:%&AWH \L60#]]HGC\E-K">K>EC?4C3 Y2C_Q\/;**(B\
M6Z#S'GRC6>HC+-S.L]@9L$DI&,B&7Z8WK:EPD(*]]Z"3*PNY Y7V(F?#L*55
M$8JCL&C&KVUL+PO*_8JED28HA[+.&&Y<O<R;T(BM]@4["+"^8&Z= [GE".Z=
M!B<CS3U-$E@I'6,-#YU%>C5LL)OH%D:8* MS#72E7(AZ01M\)QGQEZ7P5A"R
M6IG8F\=JJ$!?2+,P;!FQPFQ-6APFUF1M=^>B; MI3[C4YHN*>F6#R)M,H>G
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M8)_96!:NU(.G_VD#PU[=FL0+[ N16)SBK0+43+$_5553]H7C?XRM8[HKK._
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M<OVBRRS/HW&:U"D*-BR'F\_.66QP)YSSI.$VH-_CSR:X6> 6>/TI+I(9;C2
MJ9\N*_BBBL#A&U?9""[-BN@4YQIF_A$H [@'2-&0[@FW@XMA&\[GZ22#A<BO
M.I<9K\WJ>IG WHH6RPK_U> 83DG,#EG,VO(EHO6JL*(91].JG-,-DRD<8'UR
MLB$AZ#C--K&HG4(<1[!YHG+9U V\'NX8;Q.NV'UQMT[;V^O6:3%N,?";66O"
M3,(^;6C/?I%M!,/<M++KGY"W9?'@>+[(RZL49CVK8/[+JI8M+.+X;D'"_N74
M_[7CO*7YVM__J@[%_2V\-XI_][L_A7]-EN.4HF&DH;[DNWNCV?0T\-G )S6<
M&J,_0=K,"0$Z=EX;LRG0.';OJC^O%UQSL:QG5%IMUGI)UE2+!<P+GB@OHFU,
M^'<_+ZKR(@-E&$?GY65ZD5:;F%Q\S02/OBMC"JF9_70MO_4YYV$/LF&4?ES
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MA/!M?7]+,=E5.*D#66@\I,8-8M_ME6A0@X*M.7$T[(="[<(*7&QU <*HYHJ
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M;^BU>].^D*K@S+-I:C!@X3%#H&D9H_H<W30_I.?$'J%$LRI9G,=JBZ+L2F;
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M3PI4^O?@DQO)W=.[!3[9[,L+#6\[.6EUMA_%8[V'&XA"YU[(=;6C8I7%6CM
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M]"#ZL7T0M:;R5N.3W2M\H_,&O[^'2MQ(3__P+4,E5NRTZZT$GTQ3.(#N38_
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M"G6F*S]@W*ZZXBD(>- Z<IF.L4QL,B+D466LNCDSWJ-G,'FRJ%,7:)4">J-
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M!08L9K2;ARW3/%QY/MVZWY69CL-.=?@0[F%'C\+"?-NP2_P74SR->'Q$;4U
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MZ6%6I#T=ZPZFQ-E?G=<&0:RCW$X0%RX<:64_>9^WX ]^!YS&T,T0]<Q&(1O
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M3QA":^]_*@#LM!W0J:*9%+@G."$XC4SSZID!.N(%K&3(G^0EC@);0^@ SYK
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M [$%_]!3 NI990&=(W,T]<0XE69.!H-A\3D\R*MSZ/D(L"N^4^P"@8TROJP
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M!4OG7HG*.*=$-,9Z$'00)P(#9<AUPM>9C: PE2*AP<S:,D VG4-'"9'>2(\
ML^\V]-D6G *)*<]S^-00;G1@';5E#="&PZR)ZXK-4U1&:>QY#BBT\%&7M$_Z
MUFC,G-,$>@28/-KW")@,4H4RJ$J9NIA2A@FI->D!L3;U=>(;H$&27^ED,AQ9
MY4E)FV$UN26"WHD!?SA#.&7E^I[SH0D*F\RAZ[8=DXA28#S;]=Q37SOBGO=Z
MA$OX,G>*QT93!SE<DI$6/@-,9G\':HJ(4O#E/!6Q4>')N.1ZB$SS1GI?H"(R
M8273)0/8%Y'-._=ETR;EG$P"?>"LIUHLD[^!J!RF&]TJ+C0QSNLQ !9-D@O)
M_GDO[-8:HF<LL&R9G46:NYJL6&"6/R-Y]*10YV@W1H>^$H@)LQO.)T76=; %
MMIYDB9/',:J+S#_PN.>RP3\TXS!L),R-H)3[0L,-L<;JJ AK9_XWF5;[,<=\
MS"4=<_L1ALX,ZZ_!C'4.I$MI\IX; <=3S"7L[8V?;_>\P.G@.IZ*[!SS]*IN
M%,8Z&^Z%%?F*GS4[[[S;8FB6QJ@6&G0&O P<\DF8R $\988/*<F"T-&+6[1S
M4$1+3.3G\;'/M-F-XBN@5J>_A*U.=[K"X'4+D_E/\$YK4T0(S%S8J==1:BO
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M?S(?QGFR>/OG-[O3:I:^_7]02P,$%     @ N8$&4>"#8S?6'0  #Y   !H
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M0Z;Z3*:9S&&O.8&8K0XF.97G)2 %G),(IF51 MQ#I'Y\+B[G8^"1<+9P]#"
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MU)+PW!Z%K&<F#Y]6GC;2RO#RPW'_'(7OQ?ON>?]B*T1SK_#Z]<7]PZLE=IH
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M3<1!JXMUVC6Y0S4<*C XTLX##5('R<3U ##>G6\\,%W P:4 ]3&Q6D)3LVU
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MB;K".C0F:N8#U!_,6HY2ET+G7EC,6**/X+#E_=Y601Z_KV@5JY;$QN@Q5FP
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M-/=;Z+T_PX+RL[=XZ=86.RU4-=,V.G$I#AOK:[^UNW5NG9L;T(2Y)Y4EFD-
MS$,UF?J%OF05EPHSQ$JL*81DDZWPC][HH\28Z5H@4I\?6-;$LY]9$W\-@KNC
MG0/8I"=;M$LW\H9YE]<1LZ247>*>G-_N-2!P=V6)2F]]%S8'6<,Q"]-.+V:E
M<^5*"'L%O<!X^MH<K+N#T!ON#.,H>B_HD^>R5QR,+ZR@M9F0/ZMFE>+MG(/M
MW(68\EEI-%O3^]6$,- @HT27UP(C29=.S33F.&OHU38^ZV[*B)/ZB^:^N8BL
M/J$RZV#6<M %NC0LR)M@F!X]68LF >@_ZY^I[+(A 8"A9T5OM023/)IM:KJW
MTGJ?]K;.-M_@/'4AXP+;QQ6ZY[Z<5R,QZ)'/3;1P;8#%X!K5(/.Y> XYM(ZX
M.27.5KME$&\>]0QJ<\LGE\W#$VWO9_*Q$+S@L=_+D*^(P)R(G(7>^@O%].36
M!^DM@>*"Z$K@L_7K<VB,6G&/+C/AK"0ZHKCJD/!NR?5[8K%GYH$)M^?KA-O?
MS(=Q$B[?_/WU_JR81V_^'U!+ P04    " "Y@0911GC@(5L7   7E   &@
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M^HO'#JSED.O8^ R]1 N>. 3U9&1H[*HD<*6/S9A8U2U8#!W@"] F?%(K%/+
M$$ @7!%%Z)KD(#;%C3#](.ES-X9NG.+U!+,=\'@$-#=!+J"SE[@Q*A/.;@&4
M!NRO1,L(^(TD>!$Z907E#5NK\8.JJ_(55V6HL6A"4(V !)R#9@HSVQG6S-UI
MA*">9X$3@AEC^ERS<D'Z&M"$"U*Y]SB1^^9*6';+$7'Z&([7&+:BI=O?73U&
MWJONS9,'4-LV]7#>B!:KZR5AL$L5(\@"!1J0WA:25!\5G61Q/#4* '@-9(@J
M:UUN4 0'8_. C+HV,']VV9I!1QTC7FRK6E_G&ZCWUB6\75#/:86J#01%D0(U
MB<XS(;_R;AR6!#[FDTE+CP#@&YR>E<W\WFH2[;3H^S""'!@:M\ ?I\_C@T,9
M)+&PQC%,=)2D#AO:EW2<4=*S=H*1 12WXX/5BN;^[JI%<^T8F#)/$E&K9(F:
M/I#"5=JS0 =01X@6$/^>RTLTBF39Q8@,7@9[P HB+(%K"%*H2">.2B0<>= #
M925]#.QA:[/28/EZ*H4/D NL)HHP!0%+'J8\G74[YDV-G(-0RR':=2WH,=GS
MR?+;Z'[1A>A+'<4FB@20(B:7 :\K>.765I/ -' .]/H0W$X*0:U[$OJ-010)
M.VB5W Z(#IZ@$C"Q0=0E2+:0Q)1:*\,[L-2J I!3]A#"FUA3AP8X;= ]ZJ((
M%Y?'$'P&FT(ZVFH%K+V!<7@91BY!YOB"3TH U[>(U>%*TDEKQ]B=]*@?OJ1X
M[?;6X?JG#2,#N2*=%ALC,$!.+>XDK \DQHPVF:HT?K0AKG^-GJ@O%_BMOLKY
M=0#/(0[F<Z#3%D-^*RH]<+$^5G@_%OJ ^R,^CM:^3I*71[LO*N?_*@N^7(--
MGB0F1H+</!10"JAFZ#U" Z9,J04^8*Y2[&HD,"P1D4>:!#:B8.L 2HP(NA2I
M<2)@U>Q4/KRCEC3:!<SH@3('-9<CO9WUWL:ZO /[U0/WV6'KXPVK_L#@"2IY
MQNX!#,1PMR_1R7<5F XPQ8O-W9Q9@>Y<_[Q1KF++;7)NDN\UL? _M&"8J^X)
MZ*&/P6,WT1J>,,8;HP$ <TS2$>T5"?Q7)$>^&7#86P@.4Y?3A,@I*C)3/%6(
M!QD_IH $&GWD8)8ALT$F$:6<),Q"[,1O>;#EAAB+"4"MHJAR(_H":T\-OC(V
M-\_J(>H$9\0P^1XDFBZ>A5X71N+R*>4KPW:Y(#;,OJ)(X!MV9??GR4A3J= F
M;);DJK91(NQNB*\0+(OZX!4>*5.XANFEQ(_S:@1P1"6ZQ*Y(*W4+:(XR4@92
M<PSG(<P%QS%4F&DB+49"9P=GO27K#!@A,ZY$[E):O[6(&*&=A;A_"GE+.ULS
MQ32;CH-/I[MHCEZBL]$"^95G_**L>P-32Z(%J=K?JVZG^CXNZ(;'L6G"XH"'
M/I*^;PI(3/G(K8(!]CG:+$]&;D(TM$E\3"=A&>!]SKM16Z9J$;P:H'PVZ#2:
MRT%-@(7$1TK<G#0<#T0YZT],VE-D<HQ>1%K?-Y2TPP6].$:#P73#A(HJ@2(]
M%&%0?MJ4.%"$_)-P$Z+N%5#7Q619G]R]2/D),0JCS"[ZN\3WK(0!K1=J(:K1
M3YE:WZYNK_.-%Z"YUHX_F.)[DCYK_DG9(P6LJIZLVE"!CPN]GQ<:/8B78/R0
M^1K5 Y:[(!8PO!.1R_TT)# 0 ;5M%SLZ_5I8BP6-&L"R  A1_,4KXV:^(O<P
MY&87)0A!$M(&,T0S)KNTR#NW))F1R!['-*LIQ\470:%D^]<Z<>*-K: 6O5Z@
M![!\5HG2EJQ<I:=QAX)>2)69,21&%?./%K;%(HQR'3XN((2\()G&DK,))/D4
M)NWZW"2$1H\3BN*@43B0;P<,J9WJVEF;0:4(8>P\U.ID*_,!UF.1J<C:*4?W
M13AC!D_MNTA*BH$2;,]HC*!?1$@0;Z(7XP/D=,D#QWJ*IVE),5HHK7R#&X=\
MC-HLYZ"B?'X_\3/=6"##_8Y",=L*'[ZH@#N*IR"D1>:P$KAQ8B:FAO[,QJ'Q
M*'H;F9="5$@G'!6(4&*V2UK,HVSS!NQ0#_>JYBQ<E55+Y*I)+PJ&F[4F37):
MW.$+-!XBOO' YM)2$I4\8Z6L_&5C*YC(TA"D74AT),*+,",3ZD,E,18EE5;]
M+0,'#6&6#X<10-\/Z'ZRR?)81CL R-V=.Z;[$/-2-?#5 JJ9&#GN!T'RR#XN
M5C\+*D_5,DY.)\U\YM[H/9:Z"!W--)4+CGU)O,-Z^:N)07./#92[E.K;H:""
MBP@UFU6IDZH@<]G3^K9'&,09)DR9\&+=W+19_%O;0& W*'$ABM=?J%TL;^&Y
M[2"M99!X-A&]\B-55!K!_0[NO$4R;X%@(&PR\F >,1G HJ!ERX?\N_1I?'_V
MV7E".3^WGH7'<I859!:$)]^Y8VN8,U'-0V*EANLQPCO9 >8>\_UF4T*]T!<J
MIWJ5=<CG^N0.>'!KPC)?1)G%%H$<JE7:@Z4E(V=,P7Q;\+VCL]+P9'US;@P[
MU2<%8/HUY"Y$)]-T!P;-;/5?$!OK1BEN 9JX7P#/&Q-5H]Z4KV^5'? --\R:
M'LH<S$+I2B<MZ]JK[E&[>]5]H[XF('E:Z$R(BQ(8<D9S9YX.3_UV4N&^@F6E
MTVCAI,(O!1T(-1*-X\46>G]9Y3E_I!/(8E)_FN!#.K:'H8F"E7>RM) OA]+L
M$'**IC^8\>/*#'Y98+A(75.'8E-TU,03TWMY)07/<5S9O4-89A'I\U8ZEFBN
M[!1!NV4-)+LO46]B$;$,<#>=D<)\+TN*AE(I=4P--@E&3W/WH\#TU0!DIR?
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M85M01YMT7:ZU%*30K4F8/+;@52@6#&=WKE"TZ00=- JPX/"H6+ )LZ<R9"%
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MW4EF#)A+VI30S%#B;IG);0EYVWX4MHPUD2VO)$/HK]]S9)LX@:1)D^WR9B:
M+D?G_IPC3/^WH[/AY-NY1R(3"W)^^?%X-"2U>K/YI3-L-H\F1^3SY.28=!MN
MBTP4330W7"94-)O>:8W4(F/27K.Y6"P:BTY#JEES,F[B4=VFD%*S1F""VN'K
M/DX=OG[5CQ@-X/U5_[=ZG1Q)/XM98HBO&#4L()GFR8Q\"9B^(BU2KZ]V#F6Z
M5'P6&=)VVR[Y(M45G]-RA^%&L$/O.N)3;OK-? C,F@6W_E0&R\-^P.=$FZ5@
M'VJA3$P]I#$7R]Z$QTR34[8@8QG3Y,"N:?Z=]5IN:@Y0>J \[%.2T!AH=7NP
MW^WLN^^&7JNSM]\=OO_4';I>N_M^K]MZ[PT[M<-^D\*_I2I?2LZ")ZP>,=2E
MUVJ[OZ^SZ^/,)D%Y$C'%S0:*J0)V.%URK?"V:S^4PK!K4Z>"SY*>M?,3Q!H"
MV51Q1T-PU#5(&-XEML-%SFTJ10"G%<XBG5:C=5OTAZ1,:1! A-2-3&$BO:Z*
M[4,@,?5ORSWTQI/1I]%P,!F=G9*S3^1\/#H=CLX'Q\3[Z@TO)Z/_>3 -.[SQ
MX_7ZY6J<7XXO+@>G$S(YVV(IO:_#SX/3/STR&$[(^/+8NR"M#JVWNCMTE] D
M(*V](!\Y6ZS%X((,CL[.)]X1^?\P^X4WM-'=<=L8X9//'KD8C#\.3KV+^MG7
M8^^;]0>LM%VW_8SD?4DU:H<CAYQP/Z),D),&.9%*<:W9TB'G4>.HX1"?*</#
M)3$1-;WG0@Y/ G!%K]U]<35:#3(B$9TSHMB<LP5411-Q33Y)%9.66_^+R)!X
MUTSP:ZX=,DK\QL'V:M-ND(]4@PXR(?&27"5R(5@P8TZNE&*I5(8$$@IP(J$/
M 'K*$\CM)<D2HS(&C*$SL$T"Z$U)#"/%J2 A]6%*$1E#%3$RW[>V(6$^TYJJ
M)6Z)Z14#OI4S-<P%( RP%+:[ !ZXP><*.A/8E@ Y2!(P11811!?1&;[<T"^8
M8L4AJ$#,M8"> [N8!3<1**A3YEL!\=P41),!J#D'LH!,EU4S;+$;.P^XD9&0
M)V HM/F-81R+SQ*6566=)R&$,<4.$C[[(@O@3#!^Q0H..(XKL20IV [=CN$@
MQ(U?"Y/J.ZPA= +;FCJX(Q.P 9PIP>*6G;;R^%1')!1RH4M/*S;CVD!?:PC%
MR5QND-*I.$R7PJQ)N\4^ZS;(Y):"?[S9;[?>'>C"*P4>8JC*,.0PW-%Y51T1
MJIBU,]B-3P5#>Q &SIT*KB.DP&TQ9"IF*XX#KGTA=09TF,-*BMS@J9(^"V!:
MDQVP;\# 8;D1O6O ZF3&R #28YP)V&%K^]X.J]1V'.5#CI4OR1V-YQ/,H8K_
M<W^@+(]F%-YB% (CU/-N5, .A..?+!EO[SBZN__BCL9FZ(AIZ ] 88M//_:&
M@]#ITTP_G@0Q;,K L@6G'!5EIN  2),YUS;Y8!=+[#E8:&_2MIKZB@EJ757
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MS \,-M.Q]$_]#.+=<F!_!?*^;7^><OD_4$L#!!0    ( +F!!E%V$0"8[ 4
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M4%7@"EU)@BX3)<.E$'Z%T"57"^PMP!$-PNTD@AFB9;@9(I0@4,,M$>$$83.
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M1+ @M4KN(!%$F7;;S9A#M(00[F0YQ!-HV,TJ(<.P"+T];E$*DX:U[E:4<);
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M2LR<K(62?J?>LL(1$@G'S=ETIPY/(4T^K3I2630/#+E6S:6P1L821?@2;Q5
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MR U W9^6VWY7"W)2M@P)XI.0 MXQS(@PX2J$2V <S,%MO^@B/3*,N1F;&*A
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MPZ+.F8@B^]7!0G6R IJ.<J 9G2;&O2)VY9^2#"FWP9YZ@JUBQ+6HH?##C[A
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M>_R(QC'HJ^U'8G;A/'LK3X9IG=&&SA0;K$*-GH=5F^B'@NS[-:20/K.(([5
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M*?41LL./?(<>KV8Y<65UD*J7OYH_&1T3M6QR^'(D[8)J@##UZ\AYW%?3&29
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M2A#DU$<$%W*PP KP,8QKGE:P3KX'P/+ W]WCV)JM7-FO]V&7!@BAA*R#87#
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MP0#!XL/I3YR-!%IC6KX-?$<*+42._^[IW1R*RI?1,\E-JT-N'(?%H11*$''
MTRI]5<\BOW(S0 ^XN%0/IU9L60,4]OS[OW.JX8YZ>B]XQ1%R"((WZ\6LQ9C3
M/8#=H /^JCW[ICPJ$$4Z,P_;TI5 *@+/==3^_/9/JL>..4P!E)JD50^C\!<C
M:9+/,<E!].W (&I3.?P9AG3>E@':LF!%JG/YZW78X?]4IYG_,#Z^?4&4 'PN
M@A6RM01,]/LYKI3%VDR<FK0,>/9\EK@6^@*RVMX7BO 96..:P++,T<\3/B>G
MVO<76,[%IU<-C][X*%VDB<L1VWJ*B"8'4V#TCH<!^"QBCS$AKRO201ABU[TT
MB&SYEAKU#4-IV'WC_=W[KD^1L=1;. 8H:Z+?U3]\:1Z#&!7%=@/"%43KHM6M
M>1'W4[1 9"\^J;$O)N^PPQDC_>Q00HFS?Q(,$(X)F[4/?UE+HV56[TA*W=B)
M@K[BJJQ<#PEI]\J2\L!Q7#2/]/N-74R&MMG/TGG%-(92["_*!#_KZ^G**+((
M_PH;'" EO*?ET'?;(43*5F[WOO*--2Y69X $8VWW$)@W;AP?0%5.*OM9HF&A
M,()>Y_ <QAH9]CX_W:5U',S!6=C7BXK!HD:_3M+CBOB3$)J(#"Z*T(%V5Y96
M/O'4S+O6YXV9D_=@BI25)OJ2OME[@)>SAF4LL#H/=1P6/+XP0 I4&(%^4R+I
M<B(7O=-XY1U%\OVZG^=RV\18;F30*70M1.SG&Y2+XO?&7B8[CK-J60Y()?>X
MAXKLJ:BL>$4M.$'Q$%X#W8V\ (K<K7$YXMG-:7Q,7LUABZ'TTP8Y<I?C'[R*
MUY&XX7PI<GZHE=X#*7;RHTC"16N)5VM$OCWV,?8,_*"+='$K%-XXUPJI?YO4
M1P;V;=*IAJ(.U^NEFDSHIKIFVDM;7^/X9MZH.G4V?%R#?T?ORE4=X0W(C[49
M.8A!R!'A/I%5//7\NQ@_S9XXS.38F56A)RWQY-WAY\;5CJNAN=%3T,/GYLVF
MQ>?)]^AH/0IF#/F) 2+U=3E4V6RQXSK]WX_#F0?.%D!YS1Z-^@A5/O7=:LT;
MBT]+ /"5VD@K_C&V:U(G>*"W]@2Y1?>+^Z-[U7URP:\7)6[#)B,&3VVQ^:B
M6A?-C+;8 6MI1HNN[?+PW6X4H71;VFX8Y$'I>%KTE?VMR#$MMU.+,)UZ.,1$
M\=,<3FPVH1IEFX>=K1[6:B9N<%\;SXTL=3#N:#(_1+>K.5%+@]F^VP+?IW=
M=JQAA]"X?'\<3>9^</H'U1X7;KOJ<N=X,R@RKO7889<JK0OBU2E!=%S]N-WM
MS!9VC0?U8L*QEZ(C(9^4/15K93@,N%]$15\.;=-;&O%RGJX/.I7O]^IGD>N_
M38V Z?W22&0KO86P?H\W<^=_.S+(],LB![?M# L %I%3!61=>H,\<DM%; <-
MK*_!U>;^/0B  P$"8RX5Y$@4(A$&\/T72;4<125=;\]/?H,J0MMTTL"$HYNZ
MP.]C20E$'_(3BI8WY::TCY\QD8LV_&;*\=$+W@L+'W;MP(L';M;D9"OQJ/S)
M2@0F/(HL%(M7LJ% X;<KB28O\HP7ZNC[O*?DNP^T9%F6=7!>@03)@JK"&* 3
M+XWB,39<%R690>Z"T:LPZF'(N#MD/\!\.W?O"KV^T'BV/6^TG &*02L_2X9H
M&P.<^/% =W2'F$6"AAGPD=>O_2U^?&. BI%X9\(,*;\+T3X)8QV:YS[[KMU7
M\_@4=AA9(4T=9$[,. 4UDMMLH>@"L+4'[HA+R E>?OZP!!WB7KT4#JV).+-^
M*F##2_YX%'CLT]T9?W1_V^E7\2>;9#9'B!OX1*+2^/T5T4!5,+E!]Y"-='NZ
MWM2;G3J'=Y]J *WLXS_Z[3Y=<&$KM*W!.7F!X]/F<,20]J=!WG,@FW<.6U=3
M<H8Y\)T?EI^A"'J04,")0 OI*8POU62,5$POFP90Y'?!EN\YI@=0GH07 .8#
MX+3DX^'^=&Z8^0**4VZ_\U'[+^\C9!/<K;N3;]-6!A^%M1PX](CK-@S>I=-[
M/YTS$+]XO"?O1%E9T#G'<35^U^;DZW),.R[P@YA!+)%!IUE^%K[!OH#L@TL1
MPR\HPH*HD%1R,'0J4([O4KFA*#G61>G&UUM!FYW-@ AIH!ZK2I5'.B!9Y^,/
M1-XM(SGE2>=#70KC.'U!3,.U^2F)PTR3&'9D'6LMTVS9'=T$")=]&QL\I^9F
MMF U8L[*>:#DT4P=;(AY/!R/5R?+U"FR!;ASVPQWL\L3T,E)%[LC\.8U)X+.
MO\Y]&G0J[8>_MT/__]5.Q[;-:&6 [G<.B:O1"FOWP;RAIB/.GI!NV;Q+(G.R
M(V_9AIBSDXQBR='AZD]5[@2!Z,[T'^!" [6[X)?[J*(3#B(]ZWE'W'8W:D6K
M] & =%CZ9=LHR\M' W( 45N$4+D"Z/N64"49#5"R#E7&'@.P;2DF/@^USP7W
MI3OLD2/,$KQTHO@'.'JBKZDZ)O:PNJSS@:ZS6EI\9CPN:@*!^:_;9IOUWV._
M6Y/,E[^;TKEN0]_;\+]3LP-2S*DGB-&DQ4>ZS] !SJ+(A&ME&L(C9U7NOE 3
M7S@ZF6V-$:MUMB\;7SX(\]:U+.R3;<_">TC( \A?\:1-Q_GT#W<]A%[6/3ZV
M%12G.=^D:6RS5J(!!RCLK@%:]7VD(])O?J!0S6$RG#U%/6]8DO.R=OVH)F;U
M\Q7^)QM\XCUVJHM$CHDCX034AV'T"V4U7[:$5-O210\OU^.;5AKTNP00?^0%
M7F$3E5S\?8 )+J92;LPB"S+JE):Y[)N5$J8[:J,RG$=$4MW5AOW*]3?BJDZI
MZ(#H^ZDP<@D:[D&.SO4N:ASHS'0P'ZTK+W]%Z_M+HUG^W=>43-(08Y!2SP**
M ]6I8F!9>4&/&3KJD&R77GM#W!'K$P"5O[+'<T9T?V+V6^^,CL4;]?*]S=?_
M[@X,,'M %H\C<4FBI&CB!'FUJ5^IFGF\*OQKG;2U1U53W2'<NO\YR8=GZ]UB
MA]_D94I DP%V&((B7%TE8"^5DBLF=5EKC_4=%VWH-\CHR+BA.+EXAEWGY/6+
M&Z:M2U-2LWHLR=Q,CQ79+XO'7W<<34B_E1(D]@L1_]<=UF*N &\[JHKBP2P!
M@%#!0OT$R-=:)YVU9XX83,=A*"\SLPC1 IT]IT^E5'0\_9-Y//\]SOLG'N?]
MZ 5U !AA !XZB.@%[TRKZ%Y\EB1)R'PT*F6[N13%U '0RR?^NY$C&KR@$M_C
M&CX5S48!G]Y[_' NW5O/;-/3H4/%)%XE2;"SP$?26DNV3LDP77C 9A0B)OZN
M\EWG3'17ZH/<=+.K>X5>VI60F*E<#20UP+*($6]Y3VJ4K%!E)L6&,@QOG@S=
MW)VH$G/A0/"2, ^(A4S'!+CA8P^]FIR_=1;"*4@[.CL098Z:6V9QE>> M&5.
M#RHL]9J4F;;;:6PVC?HL%=\&O)$PWX-__:3Y@.T!W@!^^%<0FFK!"[&6-H'5
M0B *Q\>A1^V@B^B^E)/7&*!"JX4.A,F "4%W@EY X)A("I[H8(-)Z7<M[6I+
M&Q=5;VC$XBN/&. =%LA"0:?OFJ6==2 [C\8O<V,ZG&HDBFQF:D4(<I*G/\[?
M$H@VI?1^&W:PGI/RWU1:BJ!,:CQ [:)+V8$%:X_,UDI\^;8J2[/_>B5;6X)I
MS3L!W!C""RV7ZQL@U;"L+1B$VE\E1NK)%4$-Z3:;J4'U?0W&28+5-VWV3 IO
MZ"G)4K?SRTO/_T6\]NB<:.!3*LS.;#][#O0PG@IHP=.WB+%0B@:YB2HP_@C8
ML&?@BV\VHS2QDD4NU3[/-EZP760+B)WY-H*'$(R1(\L4P?[5<:B?,[)[Q@ <
MN)SLO+X7^:V#?>,U,E?HK=+YD_7T!R:K <'\OHO6VTWG*HNS3O8!IL W=GAI
M;7:9%H%C]Q>L_V$B9$R0&CW;E!?% ,6&>B&M"C?*[+>'_3T!]_^UG,V: H$?
MZ66 ;)$AYNQ^:Q&E"V85AZK+VT8NJ=I9.]^]T+$<XB%'221@QTFQA(P/YEK/
MUVYXE':OZ1H6EZD-V(?<W2KBCWP4"7VXR4[?.[J=BEU?1K9Q(_*9E@[E>E="
M1/785!T>@3XLD59O[F& / Z&5SLL!@&[&>Z/+'J 10_ :M VT\DDD\X)I&0+
M =+-' XI=4/C<\^@U5F&>^P,*5#Z*-DD/LH<X"WBZT6;U%_8Q_\HE^#38M^G
MV++K>N*\)^."JP1S&Z>BKFS69 T<63&_J<,9U-7*Q^EQ^VF:B]H[ZEA?_^\'
M*O[G!HS!$*YV( 8:,>\'ZD>"97B?0]AOF)?%7%7^:-(:53$#=T3!UV954C!2
M2%P K$PU8=Q6A*PT$3R([U^9RZ?*N2DMAJ:_#)?N%/4_@U5DG[CWTL;U O):
M3OSE3\.2LW^;B/&OO/Y569[T)T@<"K-R%\*"P9L6;.?36-990@ F0P,PZ#@9
M(*YWFL+I+\Q)+%,*8=M%$W\O#?[KA6Y?)DLH4#G*Y[A-D+S*W%8)-P)&)X)Y
M.&BZ2;OG,^E'E'5F&R''*F"]1]'9=IY;TPFNUC[.K'V)4WJ["%>>3,;+[S8S
M@^[^L8JQ3]/XCOW,JL9/R3V]2((A=)!M@21#+J$EIS;(CH&(LFB1:,B9,R>_
MQ7=TWLS\MH_2.F]$7)GI6+38][7AUN_5\W\7FANC=X"+30*1ULB0>&BHLH)\
M^Z@<J</I$SR!XMD2M\NO\AS8Z+CI[5>'UD2IG MT%B_1Q3C!B'',_A;?-&^1
MME-HJ6.H_?+)#Z\=%FZA%CV+S%:4V>.&BG)NP?[([R6-'H4M]?^LSXC?'Y><
MY@>/B]8G>DW&-H:"ZQ%'"Z*N]9>T/W%V9%EKG:H"CVM<,WM-R$Y+VGU,A8_$
M00OU0(^83/JB ^[#%_38VAW[*[)V;]YW+/HBF.2 RY9RB]HP"J2-DYT)"YID
M+9R*:(.JX':/'_<;'B7%9>%IMK4967<>Z IN3RC6 [@HWH0B9 LK0-6)@_?/
MB0LT)XM(ROEJW1/N=0K<\69CK^J\%"%S29=C(;I3[.;P6<#UX#KYJQ-B_QL&
M_O]G&/C'$D-L.')W<?@PW[A(R;B '?)+2> !A]/YEOWZJUK2R.(0)K86'N7#
MXH29B8WZ&BM<>&.-57WE&MBF3_;&\[+7[%7'Y@O%EL+2S: N'P:6F^"Z +SX
MTUXBQ^_"56$OS 7R%YWK"?B^Z[*;Z#-NB3-,,<\BW6CU0Y2W)I-T"4(X*8R9
MHGL \TC#8>S:*-J4JMNVX!D^ZPR0X4#8X!":)"EMW#!A7D(*U8M:2XI P-&7
MXC8? 9*R$D>;^KYYC"\@4[O\:>\AX_K4*\X!PXMCG6SDRMLD[HC:[5(X_=8/
M9IH'&:!BH;D8N:UD6*>LC%QUCO#]KE;> [D9N[6G#CZZ@[D+^!%OP"7=]#[D
MSF1Z5[D)T>OY4S,'%F@'A+FMHB7MR=6'\'GJCB#Z2X)S,"U=(>).^K+F4H*O
M\1)$8B!Z2QC)YRM4K4*2,^'$62U][LJ-U7'D98!&L >J-RU7;+[TZFL@R,A3
M/RH<?#OF<(I6=9P6H[Q[>^";$'G9\AGMY0$%TEW18U_+YY+V:JB8<GR\SIZ.
M& 27. 53A.#"%<0]Z:4+U\NW'<X]PQL;/+A')P@656QQ)]6H9N14HI(YN75R
MT:!Q[$0-8(7D[$(&.!28OIP."PKZ(3OU,>>.;LQQHGJXL8$Z18E)BO0BSYQR
MR!?92.^T1CLP0&ID\+AN)]'AW*=Q>JO.+(I:'3\WLY>6OSPZ,%8JL8@?CIX:
MX.;0=75U610N_-B4I"EZ\J<AH%-1U[HTD&+R(U60FNLZ9G^ME:CQ(@G1XO(A
M]NAA)AW"="ND8-RY=(%#1"O*]ADWKP!OZ]Z,HG,J.] GT(/LY).H[22I PL4
MU89L>^,Q6)#R78YK-6.JCVS/4@)5WN=:/)F2#6$?Y=I($B 4?5ZU[<[$>$#'
M4"G#$-)J3_=R\J9-,-6]W.I8XD/)OGG**\J[_D(&J.Q(346%P=<M@RL]CFL6
MBF.?NWD6\QQ/;)?NLT2<>,QER/88!!)\FJNO@;1I%A,7HHZ\>I,X-J[!:7#P
M/UQW(6]0PWSU>3A8^-BY+EYX:1=5#7G7T'-E21AJ,#>//#H%_-"6%9UEG=!*
M/XH8HTNKPF(=)ICVE-QW#9VPC?T$V=BT%B2CX^@_DA.EGV'>;].W_9QYN[)G
M/X6%\)I=Y=6>55M'?UD>=*#O]\_T9FOK; !SIU0/R'XL;6 .S&N)\W6J81X6
M8H!BVLYM#FR\9CYQT6'U)ZZ:?BJCO*> )@@_21X9!X?1>2VLZL9.=,,U,OCW
MQ+2Y'G\6\;)0:BRT@"K)Q'YYWF&SB,#>&'X0?IK(K]CRW"//0*WO."76F%O*
M^10O,]^KIX:XNX+L+@YXJ2=@@D5X$);MR'X8MYDM7;EGLKXX2G30.2CLAY.!
M]Y6];%]'8?-=W;'J&G*]M*"46ADRX!OO;B/+$ ]9!32RYI,%UQ^SDBCJ;@[E
M)+-;8ZY+LT]KWY(=B"-U,-X\Y>5]Y**&VA-Z58$]ZWOS!9@IEW/-H 6@WG,E
M%5Y:9AJ<U__E(T;_W0',2>R'9;(D=U M,U60,."W"&<=IRPXL]I]F>NZJ>LE
MW2K=G*S^ _].U^%*-#D0U@Q;NTJ5 9SX(L ;=EN1,1)&Y.G#7F&(!S$AF-E$
ML@T#Q&2SG1<^<1S)B^Q2(G32]W32.2MX-B.V2C00UQF@QHMT:08HQ6L<165%
M;2>$!_I3K1F@2\L-$#(?A*S_L2$.G&-H\DV*>DEJ4FI+% $8UP]#@*<6_K>/
MYP\Y_W_[CXHO+0\RD3)Z(?>=A\9&FN-CHFQ2+?1\76T=\]+LA';*@_C+SI]/
M;GI['6HU\D>.#YO"Y,8'-#N]&[FO)'P/.7Y@4=$2?:2^O3&FF^VZ;2>A4GZO
MZN#Y77YD48HQ_5/2,5H$778^B95XP#J]1-4C>CA_L(3/6+0]425AUZ&HDNA7
M*^\PR?.;&W06<0J;';:TL\[NC-6-1S >V]M+LGP;..%GK%_.;_<3=00Q0.[^
M3IZXKR>WFY$0W'Z:#T,_0WB7CH-QS!^5+[!V?3=?:=$P/#K\N>KN4\.39J8/
MG[)>VZS)>=OX)U(U_XX;TQ2[;X8:-EZWLK.E39,>LYO3DK=KB  BJF)"TB>[
M,4#[8$%G>N%J1+GRU>L:NXL=#)X?:>C6'$_;8,'4ZVPNT/=6 0QCF0%Z%J5?
M1&Z9U 638X=:,0U'##*H\"L98,=;2/^])Y37;V/(AJC>H.:T2B'MEDR <4>\
M_4U"^"O13]HQ= <#1#X70+_4Z8]9W\QD@&:/K.M_C;N/L/@9LMSYW>K>OZ78
MFW$ $_^">6]#Y90RH_DAQT_3/Q*68M'(>B,25&'1K1JA-42E57FN=R8-=6YH
M7(GN"PJ;6=[-M0G0N4/[R>WT%]CG2((\DI!*/\%-C*5Q8+;S2@& &C=]('/U
M[I]2]0<_3&O-]_V)G]028OM_[A<),U0.#)T%,P$>@4Y.C;'W*8NFVI9VV<G,
M0VQ+*B*U)/@:DUV^WMI$I?NVZ.0X7?<"8/[E]SX:O]2O]OQ SZ)_/3YMW!LR
M_SUZF\?]-A413/BUB#-Z!O5K/4),#;_V)]5I<!I;^_^:*_G]]2LQ9_&Y[%_V
M"#'2<F<>S_C>IQ0]]YNNV?]QC[_M*]/)T:JV-)(W-<SVWO5(S7E>"^VZ78)[
MA4*.Q@<=K0WAL!L%!R,)USJ'I)V'U"<[^A+?2#% >_-K*BD:KZ:R-:&=3M"-
M%*NPM,53T#$T,WH$/1),,B^AY=8RS1]E&[0:.+/Z*/5F.5-KQ367-)+.'OV:
M':Q/#4TF$"6I%F0WLZJ>Y<7IHMKW<8M+QZ(]6P\$-IGQ>!Y_LNMA$%V)*/,,
M6>"FH+A_@\OY% F:B[!0CE^%=$%WPR_>U(L\[9T%X[C8A?*1*H)0?,0ARZ*%
MMCF .S0]@W_REY89EF@*#[W'"UL8T.(KU?AEL\C."=&:8P[8N_ <+2%O)DK;
M!0\&R XTJ^>CP37PI,6X;N)X4$-[C(M=QC0F[]$;WG=FSS^Y>/S \W'5((N;
M5W)N;H/T*",;\G:9E1S4TBP(+N@K;G^]+$N[O*NR-$EF18\OT_HV7FT/VF0&
M0SV40*JAZ.5B]WDLH,<N"E<3UB(5QF[&Q/?Z2G=+%;STU(<E<]$P]=4:6DKM
M=I.SLV.1L/:3E303]Q[()R=E'!5Z8$;N0:YFMB0A=E6-*DT#VXE4[G9#'D&<
MML7L5A683SI%Y)H8LE.\(F*'RCD_F^E'3GSMK_\UXD:E/U7Q*DJNK[=K9'A$
ML[M#-H3KA ;OO3O>()".: GB(K).&^D$6$7[Y4#DT%'^U0:<WL[K9U+/PQ;%
M*EC=%Y8_7O Q$B98/%X]-QEB>Y>'V6RH+[I7:'0#.6J!T,U:](:-CXD&NQD%
MF(2R>'K8#"%/SW5(Q#I:Q!LKCY#*:5ERZ.'.B<6!P'7-R+%FY;KT.<J&5L:(
M7WU84[BQ\X3J8Y!R99 XN5T@#!V"5C86N6J04.6<@QQHMZ(=:W_P51[V+.-)
M7=W%1-E4SE(=I'E9SL.:B]N#L\I_"@^_>U^08%C[O'^85U)24N!.T*G>HH]X
M%\X=K<(OS^J)C+Y\$VEBTX4B7&$?@M*/0DE^3U>OETE[P^IWRPEH/?@F*=RY
M)-%)P:<'+D643Y[ W,EI@=P.'XH$#QF0X-W5D!.:'E5U)-H]ZYE/E2X*IU3Z
M0'M5+LYDR>$]:(GC RRY46*ABL$;)2IS6S6 7^Z4I^*TA9K>"%%V)R= $LVE
M:P6CQZ%%.@L0BN\"7="0M-VE9HV:]JMGV/]10>X$),'%Y$.<U!K[+JIV<8 7
M"1[^UEZ2^\RA5;D*U2">JS(+)\*H=-AV@2,'O1>V\S[&+ORQH!A!9558!VTF
M>^U*PXGA<6UOZQ;*X6QYI<=:#^D/X3;CK+KC&\$E*OM-2R);C+J6T@JKRE["
MO[3S<5E#+K(Z7C4W;7.X$8?]OK7XA3_1%.S7K*!$-'[8\:O;2(=$-:%T+5+^
M]*RO&K^?_O^.8"U!6)"X=# _@FWO9#?BA$/9D0*"Q+J6Q>5CF-&=+M^T*&DF
MW<C]$!P.Q6\;RFGY P$: %=C&3>W4/1QG^ND:'G%/Z/LUE];@*&0/PWX.&WM
M)D."C9M0N;5P96'QYSPZR3K*?"Y?96"FM'=?P39EDH,;=V$+,!VX."V#+D!U
MU@9PDH-8]KQD[B[O$5(9L:2> :HY=$*#:FBRFO<KY=WV*O&S$-O.N<@@Z@ZR
MVG9R +F+H))JP3S!'7BT7WEW<:_(4?_WL*7 &39.9)7?,LR(RL, ^3VEZJ6]
MSJ/ZXA+%S0-OFZ]J)N9.,X6_;A%9\USX<.K\H@%^"#Y+,TBIM2,+ #_J2!8@
M-J4\A7!)^:^+N=(#)GB:7C#W= A_@+Z/4NU;\_>G'DU_XW6D2-W563H@S/2-
MHG9&\BX7K>ZB(@V.OS,Z^:<BF%3J;S1:1,-^P]^ST!_\_7;8_Y_<P(HQ!'74
MY@^C$'J#"7;KZ,#$P"__V.\A+YDT,\BIKW'+_H_Z0</W [L5!:R!%^ YX0A?
M&2 N9;Z,):)QL!.D-.\8-,&X1(U>O&/CW0M-%?.S89EOZ9>W555Z8'*#>H2/
MOF^< 3I FSRO*N2MVM).@ 8Z07H6;T%'9\O"'NW8N/URI2;ZA>4.M1L&L9HV
MI]95^;X[A,@Q^.$?ZXN;,X<EBX#Q^STHMO ;%.,\UD;5'82O69)H%VF4(X+W
M?M=SMAG^ N;3;PAF;E/(PF7\P 1XN&52,A:'96L)#I[&NKG/7U'TK9S\E 0E
M&0HFF@5E3@71EFA)M3N]O4CWR#IIW@H-1S V/>ZO2^-XV!57#-H[Q4!.$2.1
M#[=KY?>X11=K:"HH+HI>+OWBGN/ Q^=]'X^?,)7 ^>_4VF6_,_MTV,['() +
M*(=3WY3O=ZG;O_!$X-]_PSR,)*AA-U7:,90CSI UQQI$J\FD,_6@%QWZ8)G>
ME-!)XW.&%1IU&KB9/P*^_MKWH?S_GC#\'Y\P_'A1AP%-;D=\A!'"%]Y33;XX
M>@[9WX^II+KF[U+@/V,"UMESJ)SI0=94!;K;O)G( #V1Q;P88^E35LHSSYN.
MSKVADO=)@JK=P/_PA_F]4P?WSL'.-O,KZ"JWBS[)2BOSHYM)H#*TIH9(=$%B
M.H+[\]P]]_QQ0F\XP"%U^VPG:5.5X,YO7+.P$F[\9C;B$X1/+GSO_*.T&V+*
M[4J1Y3=&;*;/:_6Z7)AM:RCQ640>ND,H<2G)"$ +FC45]\SVAS! >@^HO@><
MCB;)[#]YVN/P*_.A=_FO 4;QV?,O&G/4DIWHF8H#<\T-CT5YG(S)2OMZLB^7
MB(H7.^0G1FVY^LQD<08?3-&Q8X!*H!]&19N,$3<5(J6&UI4TSE,$AG=,BU(R
MCK_:,+'<Y");6<81.$B%1!1^Y*UW#I20GW(_A6C]LB01$S14-^$=3FCCK'R^
MB%$QTJ9Q-]2>@T."X]$^^O$;D=@X*0^T:G@K-@4B2/1KX&HJ9W%FZ765C?\6
MU76N]%7*<'_KHW9?H]C&SAS(=FU:&88JO#& 8J&"O;%#_84^B..U_N3*:*A\
MD!9!C,F'+L+W4&R4H'(NL45T6J*WQV':.S:PP&Q,U11OT#<;J]V29I(QL;2%
M<JR#@Y^,YV8GF3PQUS+3S9W:B%KUY;X4:7X,D(D/JKG_T["0 2(+9?Q8#ZT^
MT8@]6.+@NP7VL]Y_1P!Q(_%"2!9XO4D;><^VTPHF#(<01-*)2LU;)@'N#IZ5
M?7():<6E@4B.B@^=*6%I:R".88P;Q ;Z9-@&_XU@I4Y O,K^,B<_?N^-).O7
MQ55=F4=%D:Z#M]A Z'[XR7'HXIG.A;Z^N6M%*VX4\6]$R*6D&1P"0IPA2>K0
M8OVC<R:BPA*:42.(FUB6]2CSQB7@;>E%D,>_F6KUGY=B93(-I7(+D7A?WD36
MSQ(ZWDVY"J!?X$(1<SS:SF?G0@LP[X3.?0NDR6?'3[^PF7 \LJS7*W&[YCW&
M?W')<?H"L9/O:6X(^ZZ#VL>V^C2-O3A,(/&P'\E%;?9V;S=DW;D2R""VY<'"
M0X&:IHV&T'MNI/VY<7Q7(BHH9UI*SP^V+)^:-Y6#YP!O>]%K\,\>Z?\S;OIF
M44Q(!^@+<)'C2@<.P^-P](S]2'S7R=7[4RH(6[#[%=^VF?A5S(\?$X-#Q-([
M8 38@'%93ZVXMX69MWKNK/HN=][(H<X),_Y'HO84"@ZY>!SG/*S>H)M-%FT<
MOH=Q*.8]O$_^ZPV;XO>EPB$4Q2"Z>ZVS_0!!-'R]\[G@J9)^JE*._5&1O+LC
M;ZL*$Y/C(; X[7,J>V>UF.7>9.7[9Q5M74W!_("T@I E1_M>Q52R-]^ E*@W
MVDWH*8(*156<''MO!U#T01? KB^$$:^\^5KBI1JQ+&8+28)]9SP2P=?"/Y55
M%;_6Y<S!:[E^\?MX[.D.KC<I_=-!.O&]^AK:?Y@.^!_1N.S?<D/+ &15L+Z+
M7A?O(%V8&]^T*B:TS(J[^W!E+U6<: 50:BR4+(*M-ZME033"V-V5,H?Y9GJ0
MQ4[ZSP6$*R.6+I=1+I_<OUC&%:T7G%&Q)*NO<></62I7U&3GSCD(!YPWVQMI
M61!PO6L]V*NDJO25];W0YWO7F<N%=AW<6P?J+_%A7RR@6,XB"P+J^)8Y[9,L
M^M,E'8M]%1 #O4Z!)TUZ3]!FG-J4"JY=@' CG:%#TLZ#/:07O=5"I-EU 7GM
M?@9(%_7)0,9<V_18M-9HQ.7"))!CU>,=C]%'MZ/EY#RB[DWR )'#F&CR0BJM
MMR3/'O?UYB=ZQN-LB+_1!2/]^NS'BB800#NO_\R9?O>[#,I@T7%X9?J<@=.F
MZ8FE6SF1+M)708)3C\5^ZN$)0BP"'!$P?K=K9$@29+$#TKXQ&\V"QRY5]J_O
M?=]V@_>&=T*U_A2. >(XXB0-VCJ-462 <,%8@CX[6<\] >9'EZW]7)#15-9@
M4@11>'^JM?@.\EN:_3YUJC8+X9H3C3/?SG(K0<L1$,ZL4[^;&?__4#MJU1Y
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M6W;#K<<3PD6O]< .7VS<5'C_QN>E-K/A;?+3'3S'#AW^:0!L81 .>0\VK-2
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MW8 !JCKU\X=';UEK\*^P&2+N :+_W6M )@0@6[FP37ODAC4B3E_K%Z^$LF.
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M"^$*]6.<V R[1WQGO\HO8V^R;\VV@52Z.&H=<'#-"33^RCN#- ;HD<%H@#O
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MDPJP$!^,;0"6-#<EB=?6\$;D(=4ZJBLM1MF2;-.\8U&?IP"7922%HPSTF29
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MPZ'85*J4^TXYWU.7EDBE=>3#+]OOKI&XB7"\I#'Q*WZ_'EXM=#6]IZ3:=:+
M<85_8<D+<#PL!Z![MRX+\  @T@ER9!H^94(NKI$Q\TK467=XDN@W;%UA8U\
MMSVNK!@1N954B02ZWV?BI0'2%.;/EUX7_-SS&OX=? 3Z(W"<&IPH%$*28HK
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MN2A(Q2!KVWVQM&CX&+!.B;/(;M3<Z+W*$:9*CH4N60J+ZL&WA"/6^[NH@ ?
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M4$L! A0#%     @ N8$&49D3V=-,&@  5A(! !4              ( !"Q
M &5X96PM,C R,# W,#-?8V%L+GAM;%!+ 0(4 Q0    ( +F!!E&0"I)L4SX
M 'H/ P 5              "  8HJ  !E>&5L+3(P,C P-S S7V1E9BYX;6Q0
M2P$"% ,4    " "Y@091X[!7PH6:   (_0< %0              @ $0:0
M97AE;"TR,#(P,#<P,U]L86(N>&UL4$L! A0#%     @ N8$&4:K#6/HA8P
M*/0$ !4              ( !R ,! &5X96PM,C R,# W,#-?<')E+GAM;%!+
M 0(4 Q0    ( +F!!E%DRX,W EP" ) J'0 4              "  1QG 0!E
M>&5L,C R,# V,S Q,"UQ+FAT;5!+ 0(4 Q0    ( +F!!E%2J9$GK6H  -S:
M @ :              "  5## P!E>&5L,C R,# V,S!E>&AI8FET,3 Q+FAT
M;5!+ 0(4 Q0    ( +F!!E%5K,U6_%<  ,A? @ :              "  34N
M! !E>&5L,C R,# V,S!E>&AI8FET,3 R+FAT;5!+ 0(4 Q0    ( +F!!E%2
M]DQH=VX  +7U @ :              "  6F&! !E>&5L,C R,# V,S!E>&AI
M8FET,3 S+FAT;5!+ 0(4 Q0    ( +F!!E$570WVOB(  )RU   :
M      "  1CU! !E>&5L,C R,# V,S!E>&AI8FET,3 T+FAT;5!+ 0(4 Q0
M   ( +F!!E$;%))KR2   (:I   :              "  0X8!0!E>&5L,C R
M,# V,S!E>&AI8FET,3 U+FAT;5!+ 0(4 Q0    ( +F!!E'@@V,WUAT   ^0
M   :              "  0\Y!0!E>&5L,C R,# V,S!E>&AI8FET,3 V+FAT
M;5!+ 0(4 Q0    ( +F!!E%&>. A6Q<  !>4   :              "  1U7
M!0!E>&5L,C R,# V,S!E>&AI8FET,3 W+FAT;5!+ 0(4 Q0    ( +F!!E$I
M1E$#3 @  +\B   :              "  ;!N!0!E>&5L,C R,# V,S!E>&AI
M8FET,S$Q+FAT;5!+ 0(4 Q0    ( +F!!E&2RJKZ5 @  /DB   :
M      "  31W!0!E>&5L,C R,# V,S!E>&AI8FET,S$R+FAT;5!+ 0(4 Q0
M   ( +F!!E%V$0"8[ 4   ,C   :              "  <!_!0!E>&5L,C R
M,# V,S!E>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( +F!!E%AT2J161$! ,+&
M 0 3              "  >2%!0!E>&5L;&]G;S$Y<31A,#,N:G!G4$L%!@
0   1 !$ G@0  &Z7!@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
